

Single Audit Report Year ended August 31, 2018 (With Independent Auditors' Report Thereon)

Single Audit Report Year ended August 31, 2018

Table of Contents

	Page
Independent Auditors' Report	1
Consolidated Financial Statements:	
Consolidated Statements of Financial Position	3
Consolidated Statements of Activities	4
Consolidated Statements of Cash Flows	5
Notes to Consolidated Financial Statements	7
Supplementary Schedule of Expenditures of Federal Awards	29
Notes to Supplementary Schedule of Expenditures of Federal Awards	87
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	89
Independent Auditors' Report on Compliance for Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedule of in Expenditures of Federal Awards Required by the Uniform Guidance	91
Schedule of Findings and Questioned Costs	94



KPMG LLP Aon Center Suite 5500 200 E. Randolph Street Chicago, IL 60601-6436

Independent Auditors' Report

The Board of Trustees Northwestern University:

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Northwestern University (the University), which comprise the consolidated statement of financial position as of August 31, 2018, the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the 2018 consolidated financial statements referred to above present fairly, in all material respects, the financial position of Northwestern University as of August 31, 2018, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.



Other Matter

The accompanying consolidated financial statements of the University as of August 31, 2017 and for the year then ended were audited by other auditors whose report thereon dated January 10, 2018, expressed an unmodified opinion on those consolidated financial statements.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated December 19, 2018 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.



Chicago, Illinois December 19, 2018

Consolidated Statements of Financial Position

As of August 31, 2018 and 2017

(in thousands of dollars)	2018	2017
Assets		
Cash and cash equivalents	\$185,535	\$92,623
Accounts receivable, net	273,954	263,424
Contributions receivable, net	311,458	318,780
Notes receivable, net	151,666	151,679
Investments	11,287,087	10,717,787
Land, buildings, and equipment, <i>net</i>	3,258,035	2,933,679
Other assets	12,051	9,495
Total assets	\$15,479,786	\$14,487,467

Liabilities		
Accounts payable and accrued liabilities	\$204,237	\$298,891
Deferred revenue	302,709	277,853
Deposits payable and actuarial liability of annuities payable	154,743	156,179
Government advances for student loans	19,077	30,559
Bonds, notes, and other debt payable, net	2,555,136	2,040,602
Total liabilities	\$3,235,902	\$2,804,084

Net assets		
Unrestricted	\$7,654,713	\$7,338,857
Temporarily restricted	2,887,890	2,720,408
Permanently restricted	1,701,281	1,624,118
Total net assets	\$12,243,884	\$11,683,383
Total liabilities and net assets	\$15,479,786	\$14,487,467

See Notes to the Consolidated Financial Statements, beginning on page 7.

Consolidated Statement of Activities

For the fiscal year ended August 31, 2018, and summarized financial information for the fiscal year ended August 31, 2017

(in thousands of dollars)	2018				2017
Operating revenues	Unrestricted	Temporarily	Permanently restricted	Total	Total
Tuition and fees	\$1,071,402			\$1,071,402	\$1,008,586
(less scholarships and fellowships)	(451,121)			(451,121)	(419,944)
Net tuition and fees	620,281			620,281	588,642
Auxiliary services	83,907			83,907	80,812
Grants and contracts	648,008			648,008	617,448
Private gifts	216,935			216,935	199,630
Investment return designated for operations	482,747	\$164,454		647,201	604,534
Sales and services	209,690			209,690	183,999
Professional fees	38,448			38,448	34,929
Total operating revenues	2,300,016	164,454		2,464,470	2,309,994
Net assets released from restrictions	207,762	(207,762)			
Total operating revenues and other additions (reductions)	2,507,778	(43,308)	_	2,464,470	2,309,994
Operating expenses					
Salaries, wages, and benefits	1,420,531			1,420,531	1,343,723
Services, supplies, travel, and other	614,019			614,019	587,686
Depreciation and asset retirement obligation accretion	150,732			150,732	143,471
Maintenance and utilities	205,253			205,253	178,038
Interest on indebtedness	68,648			68,648	44,378
Total operating expenses	2,459,183			2,459,183	2,297,296
Excess (deficit) of operating revenues over expenses	48,595	(43,308)	_	5,287	12,698
Nonoperating revenues and expenses					
Private gifts and grants for buildings and equipment	2,853	40		2,893	512
Restricted private gifts		41,994	78,289	120,283	169,641
Net gain (loss) on annuity obligations		574	(1,126)	(552)	(3,808
Investment return, reduced by operating distribution	258,375	168,182		426,557	482,832
Change in value of derivative instruments	7,419			7,419	7,732
Other expenses, <i>net</i>	(1,386)			(1,386)	(633
Excess of nonoperating revenues over expenses	267,261	210,790	77,163	555,214	656,276
Change in net assets	315,856	167,482	77,163	560,501	668,974
Beginning net assets	7,338,857	2,720,408	1,624,118	11,683,383	11,014,409
Ending net assets	\$7,654,713	\$2,887,890	\$1,701,281	\$12,243,884	\$11,683,383

See Notes to the Consolidated Financial Statements, beginning on page 7.

Consolidated Statements of Cash Flows

For the fiscal years ended August 31, 2018 and 2017

(in thousands of dollars)	2018	2017
Cash flows from operating activities		
Change in net assets	\$560,501	\$668,974
Adjustments to reconcile change in net assets to net cash used in operating activities		
Depreciation and asset retirement obligation accretion	150,732	143,471
Losses (gains) on disposals, retirements, and sales of buildings and equipment, net	41,907	(362
Amortization (accretion) of issuance costs, premiums, and discounts, net	(174)	(2,369)
Allowance for student loans receivable	467	317
Realized and unrealized gains on investments, net	(1,036,599)	(1,040,580
Gifts of contributed securities	(35,376)	(51,886
Proceeds from sale of unrestricted contributed securities	19,053	46,886
Change in value of derivative instruments	(7,419)	(7,732
Restricted contributions received for long-term investment and capital projects	(61,873)	
Private gifts and grants for buildings and equipment	—	(512
Changes in assets and liabilities		
Accounts receivable	(10,347)	63,022
Contributions receivable	1,282	(55,357
Other assets	(2,719)	(789)
Accounts payable and accrued liabilities	(47,424)	(3,439)
Deposits and annuities payable	(1,436)	15,343
Deferred revenue	24,856	(11,230)
Government advances for student loans	(11,482)	(7,207)
Net cash used in operating activities	(416,051)	(243,450)
Cash flows from investing activities	(4, 6, 47, 70, 6)	(4 705 600)
Purchases of investments	(1,647,796)	(1,786,688
Proceeds from sales of investments	2,127,728	2,439,081
Acquisitions of land, buildings, and equipment	(556,940)	(667,350
Proceeds from sale of buildings or equipment	(22.157)	244
Student loans disbursed	(23,157)	(21,345)
Principal collected on student loans	23,317	28,113
Other	(13,430) (89,981)	(14,154 (22,099
Net cash used in investing activities	(83,381)	(22,099)
Cash flows from financing activities		
Proceeds from issuance of notes, bonds, and other debt payable	615,000	232,000
Payments for debt issuance costs	(2,522)	
Principal payments on notes, bonds, and other debt payable	(97,770)	(89,715
Proceeds from sale of restricted contributed securities	16,323	
Proceeds from private gifts and grants for buildings and equipment		512
Restricted contributions received for long-term investment and capital projects	67,913	
Net cash provided by financing activities	598,944	142,797

Consolidated Statements of Cash Flows (continued)

For the fiscal years ended August 31, 2018 and 2017

Increase (decrease) in cash and cash equivalents	92,912	(122,752)
Cash and cash equivalents at beginning of year	92,623	215,375
Cash and cash equivalents at end of year		\$92,623
Supplemental disclosure of cash flow information		
Change in accrued liabilities for construction in progress	(\$39,648)	\$40,952
change in accided habilities for construction in progress		+

85,382

67,663

Cash paid for interest

See Notes to the Consolidated Financial Statements, beginning on page 7.

Notes to the Consolidated Financial Statements

For the fiscal years ended August 31, 2018 and 2017

1. Summary of Significant Accounting Policies

University Activities

Northwestern University (Northwestern or the University) is a major private research university with more than 21,000 students enrolled in 12 academic divisions on two lakefront campuses in Evanston and Chicago and an international campus in Doha, Qatar.

Northwestern's mission is to provide the highest-quality education for its students, to develop innovative programs in research, and to sustain an academic community that embraces these enterprises. Activities supporting its mission may be classified as either operating or nonoperating. Operating revenues include student tuition, research funding, investment return designated for operations, educational sales and services, private gifts, professional fees, unrestricted private gifts, and auxiliary services. Operating expenses reflect support for all functions of the University. Nonoperating activities include unrealized gains and losses on investments, annuity obligations, and derivative instruments; gifts for building; all permanently restricted endowment gifts; and other.

Basis of Accounting

General

The University maintains its accounts and prepares its consolidated financial statements on the accrual basis of accounting in conformity with US generally accepted accounting principles (GAAP). The Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the source of authoritative GAAP. The University prepares its consolidated financial statements in accordance with the Not-for-Profit Entities Topic of the FASB ASC. These statements include all wholly owned subsidiaries. All significant interentity transactions and accounts have been eliminated in consolidation.

Net Asset Classifications

Net assets and related changes therein are classified in three categories based on the existence or absence of donor-imposed restrictions. For further discussion of the classification of donor-restricted endowment funds and disclosures about both donor-restricted and board-designated endowment funds, see note 8.

The category *Permanently Restricted Net Assets* applies to gifts, trusts, and pledges whose donor-imposed stipulations neither expire with the passage of time nor can be fulfilled or otherwise removed by the actions of the University, and primarily consist of the historic dollar value of contributions to establish or add to donor-restricted endowment funds.

The category *Temporarily Restricted Net Assets* includes gifts for which donor-imposed restrictions have not been met (these may include future capital projects), as well as trust activity and pledges receivable whose ultimate use is not permanently restricted. In addition, the excess of the fair value over the historical cost of permanently restricted endowments is classified as temporarily restricted net assets until appropriated for expenditure.

The category Unrestricted Net Assets describes funds that have no donor-imposed restrictions. All revenues, expenses, gains, and losses are classified as unrestricted net assets unless they are changes in temporarily or permanently restricted net assets. Net unrealized losses on permanently restricted endowment funds for which the historical cost exceeds fair value are recorded as a reduction to unrestricted net assets.

Revenue from temporarily restricted sources is reclassified as unrestricted revenue when the circumstances of the restriction have been fulfilled. Donor-restricted revenues whose restrictions are met within the same fiscal year are reported as unrestricted revenue. The expiration of a donorimposed restriction on a contribution is recognized in the period in which the restriction expires. All expenditures are reported in the unrestricted class of net assets, since the use of restricted contributions in accordance with the donor's stipulations causes the release of the restriction. Donorrestricted purposes primarily include instruction, research, library collections, scholarship and awards, and building construction.

Fair Value Measurements

The University makes fair value measurements and disclosures about fair value measurements as required by the Fair Value Measurements and Disclosures Topic of the FASB ASC. For further discussion, see notes 4 and 7.

Cash and Cash Equivalents

Cash reflects currency and deposits or other accounts with financial institutions that may be deposited or withdrawn without restriction or penalty. *Cash equivalents* represent short-term and highly liquid investments that convert readily to cash and carry little risk of change in value at maturity due to interest-rate changes; original maturities of the investments are three months or less.

Contributions

Contributions received, including unconditional promises to give (pledges), are recognized by the University as revenues at their fair values at the date of gift. Private gifts, including unconditional promises to give, are recognized as revenues in the period received. Conditional promises to give are not included in revenue until the conditions are substantially met.

Investments

Investments in securities and financial instruments are recorded at fair value. The University values its investments using a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the reporting entity; unobservable inputs reflect the entity's own assumptions about how market participants would value an asset or a liability based on the best information available. Valuation techniques used to measure fair value must maximize the use of observable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The following describes this hierarchy and the primary valuation methodologies used by the University for financial instruments measured at fair value on a recurring basis:

Level 1: Quoted prices in active markets for identical assets or liabilities. Market-price data are generally obtained from relevant exchanges or dealer markets.

Level 2: Inputs other than Level 1 that are observable either directly or indirectly, such as quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially all of the same terms of the assets or liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers.

Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based on the lowest level of input significant to the fair value measurement. In the event that changes in the inputs used in the fair value measurement of an asset or liability result in a transfer of the fair value measurement to a different categorization, such transfers between fair value categories are determined and recognized at the end of the reporting period. The categorization of an investment is based upon its pricing transparency and liquidity and does not necessarily correspond to the University's perceived risk of that investment. As a practical expedient as permitted under GAAP, the reported net asset value (NAV) of investments with external managers is used to estimate their fair value. Such investments that use NAV as a practical expedient for valuation purposes are shown separately from the valuation hierarchy. For further discussion, see note 4.

Equity securities with readily determinable fair values and debt securities are valued at the last sale price (if quotations are readily available) or at the closing bid price in the principal market in which such securities are normally traded (if no sale price is available). The fair values for these securities are classified as Level 1 because the securities have observable market inputs. Certain fixed income securities are valued based on dealer-supplied valuations; since these securities have significant other observable inputs, they are classified as Level 2.

The estimated fair values of equity securities that do not have readily determined fair values, and of other investments that are generally less liquid, are based on valuation information received on the relevant entity and may include last sale information or independent appraisals of value. In addition, standard valuation techniques, including discounted cash flow models or valuation multiples based on comparable investments, may be used. The fair values for these securities are classified as Level 3, reflecting significant unobservable inputs that are supported by little or no market inputs.

Investments in certain real assets and other investments are recorded at acquisition or construction cost, or at fair value as of donation date if received as a contribution. The University performs a periodic assessment of these assets for impairment by comparing the future cash flows expected from the asset to the carrying value of the asset. An impairment loss is recognized for the difference between estimated fair value and carrying value. In management's opinion, no impairment of investments held at cost existed as of August 31, 2018 and 2017. For further discussion of such investments, see note 4.

The methods described above may produce a fair value that may not be indicative of net realizable value or of future fair values. Furthermore, while the University believes its valuation methods are appropriate and consistent with those of other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Investment income is recorded on the accrual basis, and purchases and sales of investment securities are reflected on a trade-date basis.

8

Derivative Financial Instruments

The University uses various financial instruments to obtain equity market exposure (e.g., equity price risk) of an underlying investment strategy; if applicable, these have a reference index (e.g., S&P 500) that is the same as, or highly correlated with, the reference index of the investment strategy. Such instruments are not designated as hedges for accounting purposes and are recorded at fair value.

The University enters into swap agreements to hedge future interest-rate movements. It may also add various interest-rate options to hedge the overall portfolio and use an interest-rate swap agreement to hedge variable interest-rate exposure. Interest-rate swaps are valued using observable inputs, such as quotations received from the counterparty, dealers, or brokers, whenever they are available and considered reliable. If and when models are used, the value of the interest-rate swap depends on the contractual terms of and specific risks inherent in the instrument, as well as the availability and reliability of observable inputs. Such inputs include market prices for reference securities, yield curves, credit curves, measures of volatility, and prepayment rates as well as correlations of such inputs. Due to significant other observable inputs, the interest-rate swaps are classified as Level 2. For further discussion, see notes 4 and 7.

Accounts and Notes Receivable

Accounts receivable are recorded at net realizable value. Those generally expected to be collected within one year are carried without an allowance. Accounts receivable deemed to be uncollectible are written off at that time.

Notes receivable are recorded at net realizable value and are predominantly student loans with varying maturities. Notes receivable deemed to be uncollectible are written off.

Contributions Receivable

Contributions receivable that represent unconditional promises to give are recognized at fair value as contributions—either temporarily restricted or permanently restricted—in the period such promises are made by donors. Contributions are discounted at a risk-adjusted rate commensurate with the duration of the donor's payment plan. Amortization of the discounts is recorded as additional contribution revenue. Allowance is made for uncollectible contributions based on management's expectations regarding collection of outstanding promises to give and past collection experience. There were no significant conditional promises to give as of August 31, 2018 and 2017.

Land, Buildings, and Equipment

Land, buildings, and equipment are recorded at cost or, if received as gifts, at fair value at the date of gift. Significant renewals and replacements are capitalized. The cost of repairs and maintenance is expensed as incurred. Purchases of library books and works of art are also expensed.

Depreciation is calculated using the straight-line method over the useful lives of the equipment, which are estimated to be 3 to 20 years; of the buildings and land improvements, which are estimated to be up to 40 years; and of the leasehold improvements, which are estimated to be the shorter of the useful life or the lease term.

The University reviews long-lived assets for impairment by comparing the future cash flows expected from the asset to the carrying value of the asset. If the carrying value of an asset exceeds the sum of estimated undiscounted future cash flows, an impairment loss is recognized for the difference between estimated fair value and carrying value.

Charitable Remainder Trusts

Charitable remainder trusts are classified as permanently restricted net assets if, upon termination of the trust, the donor permanently restricts the remaining trust assets. If the remainder is not permanently restricted by the donor, the charitable remainder trust assets are recorded as temporarily restricted net assets.

Annuities Payable

Annuities payable consist of annuity payments currently due and the actuarial amount of annuities payable. The actuarial amount of annuities payable is the present value of the aggregate liability for annuity payments over the expected lives of the beneficiaries.

Self-Insurance Reserves

The University maintains a self-insurance program for general liability, professional liability, and certain employee and student insurance coverages. This pro-gram is supplemented with commercial excess insurance above the University's self-insurance retention. The reserves for self-insurance, postemployment benefits, and postretirement medical and life insurance benefits are based on actuarial studies and management estimates. See notes 9 and 11 for additional discussion.

Revenue Recognition

Revenues from tuition and fees are reported in the fiscal year in which they are earned, including pro-rata adjustments for educational programs crossing over fiscal years. Fiscal year 2019 fall-quarter tuition and fees, billed but not earned in fiscal year 2018, are reported as deferred revenue in fiscal year 2018. Similarly, fiscal year 2018 fall-quarter tuition and fees, billed but not earned in fiscal year 2017, are reported as deferred revenue in fiscal year 2017.

Revenues from auxiliary services, such as residence and food services, represent fees for goods and services furnished to University students, faculty, and staff; these revenues are recognized in the fiscal year in which the goods and services are provided. Grants and contracts revenue is recognized as expenses are incurred. Professional fees arise from faculty and department services provided to external institutions such as hospitals. Sales and services revenues represent fees for services and goods provided to external parties in the course of educational activities. It also includes revenues from the provision of physical plant services and goods to external institutions contiguous to the University campuses; trademark and royalty revenues arising from licensing of innovative technologies, copyrights, and other intellectual property (these revenues are recognized in the fiscal year in which they are earned); and other income including revenues not otherwise categorized that are also recognized in the fiscal year in which they are earned.

Federal Grants and Contracts Revenue

The University receives funding or reimbursement from federal agencies. In addition, indirect cost recovery on federal grants and contracts is based on an institutional rate negotiated with its cognizant federal agency, the United States Department of Health and Human Services.

Income Taxes

The Internal Revenue Service has determined that the University is exempt from income taxes under Section 501(c)(3) of the US Internal Revenue Code, except with regard to unrelated business income, which is taxed at corporate income tax rates. The University files federal and various state and local tax returns. The statute of limitations on the University's federal tax returns remains open for fiscal years 2015 through 2018.

The University makes an assessment of individual tax positions and follows a process for recognition and measurement of uncertain tax positions. Tax positions are evaluated on whether they meet the "more likely than not" standard for sustainability on examination by tax authorities.

In December 2017, the US president signed into law H.R. 1, formerly known as the Tax Cuts and Jobs Act (TCJA). The University continues to evaluate the impact H.R. 1 will have on its operations pending the release of further guidance.

Uses of Estimates in the Preparation of the Consolidated Financial Statements

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities; the disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and the reported amounts of revenues and expenses during the relevant period. Actual results could differ from those estimates.

Newly Adopted Accounting Pronouncements

In April 2015, the FASB issued Accounting Standards Update (ASU) 2015-03, "Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs." This ASU requires debt issuance costs related to a recognized debt liability to be presented in the statement of financial position as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The University adopted the provisions of ASU 2015-03, which require retrospective application, in the accompanying consolidated financial statements. Accordingly, the August 31, 2017, consolidated statement of financial position reclassified \$8,478 of net deferred financing costs, previously reported as other assets, as a reduction of bonds, notes, and other debt payable.

Recent Accounting Pronouncements

In June 2018, the FASB issued ASU 2018-08, "Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made," which includes guidance to assist entities in evaluating whether a transfer of assets should be accounted for as a contribution (nonreciprocal transaction) within the scope of Topic 958, Not-for-Profit Entities, or as an exchange (reciprocal) transaction subject to other guidance. The guidance also clarified that a contribution is conditional if the agreement includes both a barrier (as defined) and a right of return or release. The standard is effective in fiscal year 2019 for the University.

In August 2016, the FASB issued ASU 2016-14, "Not-for-Profit Entities: Presentation of Financial Statements of Not-for-Profit Entities." The guidance addresses net asset classifications, and reporting and disclosures about liquidity, financial performance, expenses, and cash flows. The standard is effective in fiscal year 2019 for the University.

In February 2016, the FASB issued ASU 2016-02, "Leases," new guidance to increase the transparency and comparability of lease reporting by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing activities. The standard is effective in fiscal year 2020 for the University.

In January 2016, the FASB issued ASU 2016-01, "Financial Instruments—Overall: Recognition and Measurement of Financial Assets and Financial Liabilities," affecting accounting for equity investments and financial liabilities under the fair value option and certain presentation and disclosure requirements for financial instruments. The standard is effective in fiscal year 2019 for the University.

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers," a new revenue recognition topic in the codification that provides a principle-based framework to replace earlier industry-specific and rule-based revenue recognition standards. Under the new ASU, revenue is recognized for the transfer of promised goods or services to customers in an amount that reflects the consideration that the entity expects to be entitled to in exchange for those goods or services. Additional disclosure is required to enable users of the financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The standard is effective in fiscal year 2019 for the University.

The University is currently evaluating the impact of the aforementioned standards.

Summarized Comparative Information

The consolidated financial statements include certain prior-year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with GAAP. Accordingly, such information should be read in conjunction with the University's consolidated financial statements for the year ended August 31, 2017, from which the summarized information was derived.

Reclassifications

Certain prior-year amounts have been reclassified to conform to the current-year presentation, with no effect on excess (deficit) of operating revenues over expenses, excess of nonoperating revenues over expenses, or net assets.

2. Accounts Receivable and Notes Receivable

Accounts receivable as of August 31 are summarized on the consolidated statements of financial position as follows:

(in thousands of dollars)	2018	2017
Research and other sponsored programs support	\$84,711	\$85,760
Student receivables	120,393	117,739
Other receivables	69,510	60,566
Accounts receivable subtotal	274,614	264,065
Less allowances for student uncollectible amounts	(660)	(641)
Total accounts receivable, net	\$273,954	\$263,424

Notes receivable as of August 31 are summarized on the consolidated statements of financial position as follows:

(in thousands of dollars)	2018	2017
Notes receivable	\$155,939	\$155,485
Less allowances for student uncollectible amounts	(4,273)	(3,806)
Total notes receivable, net	\$151,666	\$151,679

3. Contributions Receivable

Contributions receivable as of August 31 consisted of the following:

(in thousands of dollars)	2018	2017
Unconditional promises expected to be collected in		
Less than one year	\$53,615	\$57,821
One to five years	185,228	181,136
More than five years	114,416	130,727
Contributions receivable subtotal	353,259	369,684
Less unamortized discounts	(41,345)	(48,976)
Less allowances for uncollectible amounts	(456)	(1,928)
Total contributions receivable, net	\$311,458	\$318,780

Contributions receivable are discounted at rates ranging from 1.7 to 6.5 percent.

4. Investments

The University's investments are overseen by the Investments Committee of the Board of Trustees. Guided by the policies established by the Investments Committee, the University's Investment Office or external equity investment managers, external and internal fixed income and cash managers, and various limited partnership managers direct the investment of endowment and trust assets, certain working capital, temporarily invested expendable funds, and commercial real estate.

Substantially all of these assets are merged into internally managed investment pools on a market value basis. Each holder of units in the investment pools subscribes to or disposes of units on the basis of the market value per unit at the beginning of each month.

Fair Value Disclosures

The following tables show the estimated fair value of investments and derivatives, grouped by the valuation hierarchy as defined in note 1, as of August 31, 2018 and 2017:

(in thousands of dollars)					2018
	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	NAV as Practical Expedient (NAV)	Total fair value
Cash and cash equivalents	\$83,132	_	_	_	\$83,132
US equity	561,412	\$68,609		\$1,026,835	1,656,856
International equity	261,213	14,382	\$66	1,635,779	1,911,440
Fixed income	56,736	580,417	-	266,423	903,576
High-yield credit	_	_	_	301,826	301,826
Absolute return	_	_	_	2,123,246	2,123,246
Private investments	24,086	321	17,633	2,409,604	2,451,644
Real assets	244,976	17,687	91,052	1,429,307	1,783,022

(in thousands of dollars)					2018
	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	NAV as Practical Expedient (NAV)	Total fair value
Other investments	-	30,879	25,799	-	56,678
Interest-rate derivatives	2,500	(1,742)	_	_	758
Subtotal investment assets at fair value	1,234,055	710,553	134,550	9,193,020	11,272,178 ^(a)
Interest-rate swaps	_	(13,410)	_	_	(13,410)
Total	\$1,234,055	\$697,143	\$134,550	\$9,193,020	\$11,258,768

^(a) Investments held at cost totaling \$27,657 thousands should be added to the subtotal investment assets at fair value, and beneficial interest in charitable remainder trusts totaling \$12,748 thousands should be subtracted from the subtotal investment assets at fair value to reflect total investment assets as of August 31, 2018.

(in thousands of dollars)					2017
	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	NAV as Practical Expedient (NAV)	Total fair value
Cash and cash equivalents	\$214,864				\$214,864
US equity	594,477	\$53,365	_	\$757,237	1,405,079
International equity	282,996	19,638	\$19	1,598,400	1,901,053
Fixed income	57,968	655,750	_	219,584	933,302
High-yield credit	_	_	_	334,441	334,441
Absolute return	49,951	50,806	_	1,888,951	1,989,708
Private investments	20,014	358	17,310	2,210,735	2,248,417
Real assets	253,072	16,612	112,719	1,217,986	1,600,389
Other investments	_	34,091	24,966	_	59,057
Interest-rate derivatives	4,000	(3,058)	_	_	942
Subtotal investment assets at fair value	1,477,342	827,562	155,014	8,227,334	10,687,252 ^{(a}
Interest-rate swaps	_	(20,830)	_	_	(20,830
Total	\$1,477,342	\$806,732	\$155,014	\$8,227,334	\$10,666,422

^(a) Investments held at cost totaling \$30,535 thousands should be added to the subtotal investment assets at fair value to reflect total investment assets as of August 31, 2017.

Investments included as NAV as Practical Expedient consist primarily of the University's ownership in investments (principally limited partnership interests in long-only equity and credit, hedge, private equity, real estate, and other similar funds). As a practical expedient, when quoted market prices are not available, the estimated fair values of these investments are generally based on reported partners' capital or NAV provided by the associated external investment managers. In cases where the practical expedient threshold is not met, such as an investment not being in compliance with GAAP, or where a statement of partners' capital is not provided, the investment is reported as Level 3. Since a range of possible values exists for these partnership investments, the estimated values may be materially different from the values that would have been used had a ready market for these partnerships existed. The University exercises diligence in assessing the policies, procedures, and controls of external investment managers; management's assessment includes a valuation review process of the most recent available audited and unaudited financial statements and discussions with the majority of external investment managers' valuations of the securities' fair value if those valuations are not in accordance with GAAP. Management reviewed the valuation policies for all partnerships in which the University is invested and deemed that its policies are appropriate and that the carrying amount of these assets represents a reasonable estimate of fair value. A small number of investments within certain partnerships may have holdings at a carrying value of cost. In the absence of another basis, management has determined this method to be appropriate for these specific investments and representative of an approximation of the fair value.

The following tables summarize changes in the investments and derivatives classified by the University in Level 3 of the fair value hierarchy for the fiscal years ended August 31, 2018 and 2017:

(in thousands of dollars)	2017					2018
	Fair value	Purchases	Sales and	Realized and unrealized gains (losses)	Transfers into and out of Level 3	Fair value
International equity	\$19	\$55	_	(\$8)	_	\$66
Private investments	17,310	5,271	(\$7)	(4,941)		17,633
Real assets	112,719	_	(8,367)	5,199	(\$18,499)	91,052
Other investments	24,966	_	—	833	_	25,799
Total investments	\$155,014	\$5,326	(\$8,374)	\$1,083	(\$18,499)	\$134,550

(in thousands of dollars)	2016					2017
	Fair value	Purchases	Sales and	Realized and unrealized gains (losses)	Transfers into and out of Level 3	Fair value
US equity securities	\$59	_	(\$54)	(\$5)	_	_
International equity	1,329	\$198	(1,304)	(204)	_	\$19
Private investments	14,752	6,726	(575)	(3,593)	_	17,310
Real assets	98,589	12,714	(9,197)	10,613	_	112,719
Other investments	23,488	_	_	1,478	_	24,966
Total investments	\$138,217	\$19,638	(\$11,130)	\$8,289	_	\$155,014

There were no significant transfers or reclassifications between Levels 1 and 2 during fiscal years 2018 and 2017. In fiscal year 2018, there was one transfer out of Level 3, since this underlying fund investment now adheres to US GAAP and uses NAV as a practical expedient. There were no transfers into or out of Level 3 in fiscal year 2017.

As of August 31, 2018 and 2017, investments held at cost included real estate totaling \$19.4 million. Investments held at cost also included property co-ownerships, mortgages, and other investments totaling \$8.3 million and \$11.1 million as of August 31, 2018 and 2017, respectively.

The table below presents funding obligations and redemption terms of investments by asset class. The University is required under certain partnership agreements to advance additional funding up to specified levels over a period of several years. These uncalled commitments have fixed expiration dates and other termination clauses. At August 31, 2018, the University was committed to making future capital contributions in the amount of \$2.3 billion, primarily in the next five years, as detailed in the table. Certain agreements also contain notice periods, lock-ups, and gates that limit the University's ability to initiate redemptions.

(in thousands of	(in thousands of dollars)					
	Fair value	Remaining life	Uncalled commitments	Redemption terms	Redemption restrictions	
US equity	\$1,656,856	No limit	_	Daily to annually, with 1- to 90-day notice periods	Lock-up provisions ranging from none to 3 years	
International equity	1,911,440	No limit	\$26,443	Daily to annually, with 1- to 180-day notice periods	Lock-up provisions ranging from none to 3 years	
Fixed income	903,576	No limit	_	Daily to quarterly, with 1- to 90-day notice periods	No lock-up provisions	
High-yield credit	301,826	No limit to 12 years	152,522	Certain partnerships ineligible for redemption; other funds semiannually to annually, with 90-day notice periods	Certain partnerships not redeemable; other partnerships include side pockets subject to general partner discretion	
Absolute return	2,123,246	No limit	13,206	Daily to greater than annually, with 1- to 120-day notice periods; private partnership ineligible for redemption	Lock-up provisions ranging from none to 5 years; side pockets on many funds; one partnership not redeemable	
Private investments	2,451,664	No limit to 12 years	1,059,468	Partnerships ineligible for redemption; equity securities daily, with 1-day notice period	Private partnerships not redeemable; no lock-up provisions on equity securities	
Real assets	1,783,022	No limit to 14 years	1,013,545	Partnerships ineligible for redemption; commodity and equity funds weekly to quarterly, with 1- to 3-day notice periods	Drawdown partnerships not redeemable; no restriction on commodity and equity funds	

Cash and cash equivalents for investment purposes include bank accounts holding cash and money market funds consisting of short-term US Treasury securities. Cash and cash equivalents are highly liquid and are carried at amortized cost, which approximates fair value.

The University's marketable securities categories include investments in US equities, international equity, and fixed income strategies via separately managed accounts, partnerships, and commingled funds. US equity strategies include large-, mid-, and small-cap public equities. Two investments in this category currently may not be redeemed over the next year.

International equities include developed market (ex–US public equities) and emerging market strategies. Three investments in this category currently may not be redeemed over the next year, while one other may only be partially redeemed over the next year.

Fixed income strategies include US government securities, agency securities, inflation-linked bonds (TIPS), corporate bonds, global bonds, and short-term cash investments.

The high-yield credit portfolio includes investments in distressed debt and other credit instruments with fixed income characteristics but more specific risk tied to the securities and their underlying cash flows.

The absolute return portfolio is weighted toward long-short equity managers, uncorrelated strategies, and diversifying event-driven or hedged tactical credit strategies. Four investments in this portfolio currently may not be redeemed over the next year due to lock-up provisions. As of August 31, 2018, the remaining investments have either full or partial liquidity over the next year, with the exception of those having side pockets.

The private investments portfolio includes investments in global buyout and venture capital funds. The real assets portfolio includes the University's investments in energy, timber, real estate, and public investments in some commodity and equity funds.

Management's estimate of the lives of the funds could vary significantly depending on the investment decisions of the external fund managers, changes in the University's portfolio, and other circumstances. Furthermore, the University's obligation to fund these commitments may be waived by the fund managers for a variety of reasons, including the market environment and/or changes in investment strategy.

Investment Return

The components of total investment return for the fiscal years ended August 31 were as follows:

(in thousands of dollars)	2018	2017
Investment income	\$37,159	\$45,855
Net realized gains	675,390	576,519
Net change in fair values, unrealized	361,209	464,992
Total investment return	\$1,073,758	\$1,087,366

Investment return designated for operations is defined as the investment payout, according to the spending guideline for the Long-Term Balanced Pool and the actual investment income for all other investments. In 2018, a \$100 million adjustment to payout in excess of the spending rule was authorized to support strategic investment and is included in the investment return designated for operations line of the consolidated statement of activities. Gross investment income from specific investments held at cost totaled \$15.9 million and \$15.5 million for the fiscal years ended August 31, 2018 and 2017, respectively. Investment expenses related to specific investments held at cost totaled \$6 million and \$3 million for the fiscal years ended August 31, 2018 and 2017, respectively. All other investment returns are categorized as non-operating. As reflected in the consolidated statement of activities, investment return for the fiscal years ended August 31 was as follows:

(in thousands of dollars)	2018	2017
Changes in unrestricted net assets		
Operating: investment return	\$382,747	\$370,137
Operating: investment return to support strategic investment	100,000	75,000
Nonoperating: investment return, reduced by operating distribution	258,375	293,052
Changes in temporarily restricted net assets		
Operating: investment return	164,454	159,397
Nonoperating: investment return, reduced by operating distribution	168,182	189,780
Total investment return	\$1,073,758	\$1,087,366

Certain expenses paid directly by the University for investment management and custody services totaled \$75 million and \$65.4 million for the fiscal years ended August 31, 2018 and 2017, respectively, and have been netted against investment earnings.

Derivative Financial Instruments

The University has entered into hedging transactions via various interest-rate swaps and swaptions and has maintained those positions since fiscal year 2010. These instruments are held in the fixed income asset class of investments within Level 2.

Credit exposure represents the University's potential loss if all the counterparties fail to perform under the terms of the contracts, and if all collateral, if any, becomes worthless. This exposure is measured by the fair value of the cash collateral held at the counter-parties at the reporting date. The University manages its exposure to credit risk by using highly rated counterparties, establishing risk-control limits, and obtaining collateral where appropriate. As a result, the University has limited credit risk. The University has entered into margin collateral agreements with major investment banks that impose a \$1 million threshold on both parties. As of August 31, 2018 and 2017, the University posted collateral of \$2.5 million and \$4 million, respectively, to one counterparty. To date, the University has not incurred any losses on derivative financial instruments due to counterparty nonperformance.

The University has hired an external manager to use derivative financial instruments to obtain market exposure in equity and fixed income indices on excess cash balances. The University regularly reviews the use of derivative financial instruments by each of the managers of alternative investment funds in which it participates. While these outside managers generally use such instruments for hedging purposes, derivative financial instruments are employed for trading purposes by numerous independent asset managers of the University.

For further discussion of credit-related derivatives, see note 7.

The following tables summarize the derivative financial instruments held by the University as of August 31, 2018 and 2017:

(in thousands of dollars)				2018
				Fiscal year
	Notional amount	Assets	Liabilities	net gain (loss)
Investment-related derivatives				
Interest-rate swaptions	\$200,000	\$2,500	(\$1,742)	_
Total investment-related	200,000	2,500	(1,742)	-
Credit-related derivatives				
Interest-rate swaps	125,002	_	(13,410)	\$7,419
Total credit-related	125,002	_	(13,410)	7,419
Total derivative financial instruments	\$325,002	\$2,500	(\$15,152)	\$7,419

(in thousands of dollars)				2017
				Fiscal year
	Notional amount	Assets	Liabilities	net gain (loss)
Investment-related derivatives				
Interest-rate swaptions	\$200,000	\$4,000	(\$3,058)	(\$145)
Equity futures	60,252	4,443	_	8,179
Total investment-related	260,252	8,443	(3,058)	8,034

(in thousands of dollars)				2017
Credit-related derivatives				
Interest-rate swaps	125,000	_	(20,830)	7,732
Total credit-related	125,000	_	(20,830)	7,732
Total derivative financial instruments	\$385,252	\$8,443	(\$23,888)	\$15,766

5. Land, Buildings, and Equipment

Land, buildings, and equipment for the fiscal years ended August 31 consisted of the following:

(in thousands of dollars)	2018	2017
Land	\$31,036	\$31,036
Construction-in-progress	563,507	688,360
Buildings and leasehold improvements	3,828,036	3,278,609
Equipment	651,033	607,409
Accumulated depreciation	(1,815,577)	(1,671,735)
Total land, buildings, and equipment, <i>net</i>	\$3,258,035	\$2,933,679

Included in construction-in-progress costs are building and leasehold improvement capitalizations. Building costs are funded by bonds, gifts (received or pledged), grants, and unrestricted funds.

Under the University's interest capitalization policy, actual interest expense incurred during the period of construction of an asset for University use is capitalized until that asset is substantially completed and ready for use. The capitalized cost is reflected in the asset's total cost and depreciated over the asset's useful life. Assets may include buildings and major equipment.

Lease Obligations

The University is obligated under numerous operating leases to pay base rent through the lease expiration dates. Operating leases consist primarily of leases for the use of real property and have terms expiring in various years through fiscal year 2031. Real estate lease expenses totaled \$14.1 million and \$13.4 million for the fiscal years ended August 31, 2018 and 2017, respectively. Sublease rental income totaled \$2.9 million for the fiscal years ended August 31, 2018, there were no subleases that are noncancelable for one year or more. The future minimum lease payments under noncancelable operating leases through August 31 of each period are shown below.

(in thousands of dollars)	
2019	\$15,833
2020	15,611
2021	14,122
2022	12,748
2023	10,885
2024 and thereafter	58,025
Total	\$127,224

Rentals under Leases

The University is entitled under numerous operating leases to receive rental payments. Operating leases consist primarily of leases for the use of real property and have terms expiring in various years through fiscal year 2041. The future minimum rental payments under noncancelable operating leases through August 31 of each period are shown below.

(in thousands of dollars)	
2019	\$1,210
2020	491
2021	472
2022	448
2023	460
2024 and thereafter	4,781
Total	\$7,862

6. Deposits Payable and Actuarial Liability of Annuities Payable

Deposits payable and actuarial liability of annuities payable for the fiscal years ended August 31 are summarized on the consolidated statements of financial position as follows:

Total deposits payable and actuarial liability of annuities payable	\$154,743	\$156,179
Other deposits payable	5,799	8,182
Student loan deposits payable	5,537	7,981
Actuarial liability of annuities payable	19,939	20,239
Agency deposits payable	\$123,468	\$119,777
(in thousands of dollars)	2018	2017

7. Bonds, Notes, and Other Debt Payable

Bonds, notes, and other debt payable for the fiscal years ended August 31 are as follows:

(in thousands of dollars)	Interest-rate mode	Fiscal year maturity	Interest rate	2018	2017
Illinois Finance Authority (IFA)–Series 2004	Variable	2034	1.52% ^(a)	\$135,800	\$135,800
IFA–Series 2008	Variable	2046	1.49% ^(a)	125,000	125,000
Taxable–Series 2012	Fixed	2039–2047	4.20%	200,000	200,000
Taxable–Series 2013	Fixed	2015–2044	4.56% ^(b)	568,175	572,945
Taxable–Series 2015	Fixed	2038–2048	3.78% ^(b)	500,000	500,000
IFA–Series 2015	Fixed	2022–2028	4.24% ^(b)	128,545	128,545
Taxable–Series 2017	Fixed	2047–2057	3.74% ^(a)	500,000	-
Commercial paper (\$300,000 available)	Variable	2019	2.19% ^(b)	260,000	145,000

(in thousands of dollars)	Interest-rate mode	Fiscal year maturity	Interest rate	2018	2017
Promissory note	Fixed	2021	1.72% ^(c)	24,000	32,000
Lines of credit (\$750,000 available)	Variable	2019	2.66% ^(b)	115,000	200,000
Bonds, notes, and other debt payable subtotal				2,556,520	2,039,290
Unamortized issuance costs, premiums, and discounts, <i>net</i>				(1,384)	1,312
Total bonds, notes, and other debt payable, <i>net</i>				\$2,555,136	\$2,040,602
 ^(a) Interest rate reset weekly ^(b) Weighted average interest rate at August 31, 2018 ^(c) Imputed rate on non-interest-bearing note 					

Total obligations including bonds, notes, and other debt payable at August 31, 2018, are scheduled to mature through August 31 of each period as noted at right. The schedule has been prepared based on the contractual maturities of the debt outstanding at August 31, 2018. Accordingly, if remarketing of bonds fails in future periods, debt repayments may become more accelerated than presented here. The potential failed remarketings coincide with the interest rate reset dates and amounts noted above.

(in thousands of dollars)			
2019	\$387,935		
2020	13,085		
2021	13,450		
2022	4,790		
2023	6,660		
2024 and thereafter	2,130,600		
Total	\$2,556,520		

Bonds Payable

During the year ended August 31, 2018, the Taxable–Series 2017 Fixed Rate Bonds were issued to acquire, construct, and equip certain educational facilities of the University and to pay certain costs relating to the issuance of the bonds, subject to conditions set forth in a trust indenture between the University and Wells Fargo Bank, NA.

Derivative Financial Instruments

The University has entered into interest-rate swap agreements to hedge variable interest-rate exposure related to certain variable rate debt. The agreements effectively fix the interest rate from 4.12 percent to 4.38 percent. The notional value is \$125 million through expiration on August 31, 2023.

The University recognized a net unrealized gain on the swap investment totaling \$7.4 million and \$7.7 million, respectively, for the fiscal years ended August 31, 2018 and 2017. The fair values of the swap position were in a liability position of \$13.4 million and \$20.8 million as of August 31, 2018 and 2017, respectively, and are included in accounts payable and accrued liabilities on the consolidated statements of financial position. Also see note 4.

8. Endowments

The FASB ASC Not-for-Profit Entities Presentation of Financial Statements Subtopic provides guidance on the net asset classification of donorrestricted endowment funds for not-for-profit organizations subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act (UPMIFA) and improves disclosure about an organization's endowment funds, both donor-restricted and board-designated, regardless of whether the organization is subject to UPMIFA. The University interprets UPMIFA as requiring that the fair value of the original donor-restricted endowment gift be preserved as of the gift date unless there are explicit donor stipulations to the contrary. Therefore, the University classifies as permanently restricted net assets the original value of gifts donated to the permanent endowment, the original value of subsequent gifts, and accumulations to the permanent endowment made in accordance with the applicable donor gift instrument at the time the accumulation was added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until it is appropriated for University expenditure in a manner consistent with UPMIFA's standard of prudence. In accordance with UPMIFA, the University considers the following factors in determining to appropriate or accumulate donor-restricted endowment funds:

The duration and preservation of the endowment fund

The purposes of the institution and of the endowment fund

General economic conditions

Possible effects of inflation or deflation

Expected total return from income and appreciation of investments

Other resources of the institution

The institutional investment policy

The University's endowment consists of about 2,700 individual donor-restricted endowment funds and about 1,000 funds it designates to function as endowments. The net assets associated with endowment funds, including funds designated by the University to function as endowments, are classified and reported based on whether there are donor-imposed restrictions. Institution-designated endowment funds include quasi-endowments established by specific Board of Trustees approval as well as endowments created by management under general guidelines and policies approved by the Board of Trustees.

The following tables present the endowment net asset composition by type of fund at fair value as of August 31, 2018 and 2017:

(in thousands of dollars)				2018
Endowment net asset composition		Temporarily	Permanently	
by type of fund	Unrestricted	restricted	restricted	Total
Donor-restricted endowment funds	(\$45)	\$2,584,982	\$1,572,271	\$4,157,208
Institution-designated endowment funds	4,229,710			4,229,710
Total endowment funds	\$4,229,665	\$2,584,982	\$1,572,271	\$8,386,918

(in thousands of dollars)				2017
Endowment net asset composition		Temporarily	Permanently	
by type of fund	Unrestricted	restricted	restricted	Total
Donor-restricted endowment funds	(\$57)	\$2,422,041	\$1,483,792	\$3,905,776
Institution-designated endowment funds	4,041,798			4,041,798
Total endowment funds	\$4,041,741	\$2,422,041	\$1,483,792	\$7,947,574

Investment and Spending Policies

The University's endowment is primarily invested in the Long-Term Balanced Pool. The Investments Committee of the Board of Trustees annually reviews asset allocation policy for the pool.

The principal objective for the Long-Term Balanced Pool is to preserve purchasing power and to provide a growing stream of income to fund University programs. On average, the pool seeks to achieve an annual total rate of return (i.e., actual income plus appreciation) equal to inflation plus actual spending. This objective of preserving purchasing power emphasizes the need for a long-term perspective in formulating both spending and investment policies.

The Board of Trustees has adopted a guideline for the annual spending rate from the University's Long-Term Balanced Pool. The calculation blends market and spending elements for the total annual spending rate.

The market element is an amount equal to 4.35 percent of the market value of a unit in the pool, averaged for the 12 months ended October 31 of the prior fiscal year. It is weighted at 30 percent in determining the total. The spending element is an amount equal to the current fiscal year's spending amount increased by 1.5 percent plus the actual rate of inflation. It is weighted at 70 percent in determining the total.

If investment income received is not sufficient to support the total-return objective, the balance is provided from realized and unrealized gains. If the income received is in excess of the objective, the balance is reinvested in the Long-Term Balanced Pool on behalf of the unit holders. The University's policy is to reinvest the current income of all other investment pools.

Changes in Endowment Net Assets

The following tables represent changes in endowment net assets for the fiscal years ended August 31:

(in thousands of dollars)				2018
		Temporarily	Permanently	
	Unrestricted	restricted	restricted	Total
Endowment net assets, beginning of year	\$4,041,741	\$2,422,041	\$1,483,792	\$7,947,574
Net investment loss	(3,143)	(3,119)	_	(6,262)
Net appreciation, realized and unrealized	337,549	334,864	-	672,413
Total investment return	334,406	331,745	_	666,151
Contributions	_	3,380	79,265	82,645
Appropriation of endowment assets for expenditure	(167,459)	(165,526)	_	(332,985)
Other changes				
Transfers to create institutional funds	49,811	-	_	49,811
Transfers of institutional funds per donor requirement	_	535	9,339	9,874
Spending of institution-designated endowment fund	(36,152)	_	_	(36,152)
Other reclassifications	7,318	(7,193)	(125)	_
Endowment net assets, end of year	\$4,229,665	\$2,584,982	\$1,572,271	\$8,386,918

(in thousands of dollars)				2017
		Temporarily		
			Permanently	
	Unrestricted	restricted	restricted	Total
Endowment net assets, beginning of year	\$3,831,631	\$2,235,406	\$1,411,130	\$7,478,167
Net investment loss	(6,188)	(6,247)	—	(12,435)
Net appreciation, realized and unrealized	357,024	354,471	_	711,495
Total investment return	350,836	348,224	-	699,060
Contributions	_	1,400	56,575	57,975
Appropriation of endowment assets for expenditure	(164,091)	(159,515)	_	(323,606)
Other changes				
Transfers to create institutional funds	66,740	_	_	66,740
Transfers of institutional funds per donor requirement	_	368	12,305	12,673
Spending of institution-designated endowment fund	(43,435)	_	_	(43,435)
Other reclassifications	60	(3,842)	3,782	_
Endowment net assets, end of year	\$4,041,741	\$2,422,041	\$1,483,792	\$7,947,574

Underwater Endowment Funds

The University monitors endowment funds to identify those for which historical cost was more than fair value. As of August 31, 2018 and 2017, the historical cost of such accounts was approximately \$4.7 million and \$1.9 million, and the market value totaled \$4.7 million and \$1.8 million, respectively. Associated unrealized losses are recorded in the unrestricted net assets classification; subsequent gains increase unrestricted net assets.

9. Retirement Plans

The University maintains two contributory retirement plans for its eligible faculty and staff. The plans offer employees two investment company options, Teachers Insurance and Annuity Association (TIAA) and College Retirement Equities Fund (CREF), and the mutual funds offered by Fidelity Investments. Participating employee and University contributions are immediately vested. The University contributed \$81.5 million and \$77 million to the two plans in 2018 and 2017, respectively. It expects to contribute \$86.5 million to the two plans in 2019.

The University currently sponsors a healthcare plan permitting retirees to continue participation on a "pay-all" basis; it has no liability for participants past age 65. The retiree contribution is based on the average per-capita cost of coverage for the plan's entire group of active employees and retirees rather than the per-capita cost for retirees only. Retirees are also eligible to participate in certain tuition reimbursement plans and may receive a payment for sick days accumulated at retirement. Certain postemployment benefit plans are also sponsored.

The University recognizes an asset or a liability in the consolidated statements of financial position for the plans' overfunded or underfunded status. The asset or liability is the difference between the fair value of plan assets and the related benefit obligation, defined as the projected benefit obligation for post-employment benefit programs and the accumulated postretirement benefit obligation (APBO) for post-retirement

benefit programs, such as a retiree healthcare plan. In the consolidated statement of activities, the University recognizes actuarial gains or losses and prior service costs or credits that arise during the period but are not components of net periodic benefit cost. The University measures plan assets and obligations as of the date of its fiscal year-end and makes specified disclosures for the upcoming fiscal year.

The accrued cost for post-employment benefits was \$9.8 million and \$10.1 million at August 31, 2018 and 2017, respectively, and is included in accounts payable and accrued liabilities on the consolidated statements of financial position.

The University funds the benefit costs as they are incurred. The following table sets forth the postretirement plan's obligations, benefits paid, contributions, net periodic postretirement benefit cost, and assets for the fiscal years ended August 31:

(in thousands of dollars)	2018	2017
Benefit obligations	\$15,924	\$15,691
Benefits paid	1,473	1,003
Employer contributions	816	387
Contributions from participants	656	617
Net periodic postretirement benefit cost	1,299	985
Fair value of plan assets	_	_

The changes in other than periodic benefit cost included in unrestricted net assets on the consolidated statements of financial position totaled net gains of \$1.2 million and \$0.8 million as of August 31, 2018 and 2017, respectively; an increase of \$0.4 million due to net gains during the fiscal year.

The APBO was \$15.9 million and \$15.7 million at August 31, 2018 and 2017, respectively, and is included in accounts payable and accrued liabilities on the consolidated statements of financial position.

The following tables present key actuarial assumptions used in determining APBO as of August 31, 2018 and 2017. For both fiscal years 2018 and 2017, the ultimate healthcare cost trend rate was 5 percent, and the year when the trend rate will reach the ultimate trend rate was 2025.

Additional assumptions used to determine benefit obligations for the fiscal years ended August 31 were as follows:

	2018	2017
Settlement (discount) rate	3.8%	3.3%
Weighted average rate of increase in future compensation levels	2.5%	3%
Healthcare cost trend rate	6.75%	7%

Next, the assumptions used to determine net periodic benefit cost for the fiscal years ended August 31:

	2018	2017
Discount rate	3.3%	3%
Weighted average rate of increase in future compensation levels	3%	3%
Healthcare cost trend rate	7%	6.75%

A one-percentage-point change in assumed healthcare cost trend rates would have had these effects in fiscal year 2018:

(in thousands of dollars)	1% point decrease	1% point increase
(Decrease) increase in total of service and interest cost	(\$73)	\$84
(Decrease) increase in postretirement benefit obligation	(697)	783

Estimated future benefit payments reflecting anticipated service, as appropriate, are expected to be paid as shown below:

(in thousands of dollars)	
2019	\$894
2020	801
2021	885
2022	991
2023	1,043
2024–2028	5,847
Total	\$10,461

The University offers a deferred compensation plan under Internal Revenue Code 457(b) to a select group of management and highly compensated employees. There is no University contribution related to this deferred compensation plan. The University has recorded both an asset and a liability related to the deferred compensation plan that totaled \$89.3 million and \$76.5 million as of August 31, 2018 and 2017, respectively; these are included in investments and deposits payable and actuarial liability of annuities payable on the consolidated statements of financial position.

10. Related Parties

Members of the University's Board of Trustees, senior management, and faculty may on occasion be associated either directly or indirectly with entities doing business with the University. The University bylaws and conflict of interest policies establish guidelines for disclosure and regulation of such activities as circumstances warrant. When such associations exist, measures are taken, in the best interests of the University, to mitigate any actual or perceived conflict. Transactions with related parties may include investment management, common membership in investment partnerships or other investment vehicles, and the purchase of goods or services.

Northwestern Medical Group (NMG) is a not-for-profit, multispecialty physician organization committed to providing clinical care to patients and to supporting the research and academic endeavors of Northwestern's Feinberg School of Medicine (Feinberg). NMG is governed by a board of directors, and its physicians are full-time faculty members or researchers at Feinberg. It is a wholly owned subsidiary of Northwestern Memorial Healthcare Corporation (NMHC), the not-for-profit parent corporation of Northwestern Memorial Hospital (NMH), which is the primary teaching hospital of Feinberg. As such, NMHC and NMG are related parties of the University. Under terms of agreements effective in fiscal year 2014 between the University, NMG, and NMHC, the University receives recurring contributions from NMHC to support the Feinberg research and education programs, basic and applied biomedical research facilities and programs, and research and educational support services.

As of August 31, 2018 and 2017, accounts receivable arising from support and operational activities with NMHC totaled \$19.3 million and \$17 million, respectively, and are included in accounts receivable on the consolidated statements of financial position. For the fiscal years ended August 31, 2018 and 2017, contributions totaling \$109.3 million and \$114.4 million, respectively, have been made from NMHC to the University and are included in private gifts on the consolidated statement of activities. For the fiscal years ended August 31, 2018 and 2017, revenues arising from operational activities with NMHC totaled \$24.4 million and \$23.4 million, respectively, and are included in professional fees on the consolidated statement of activities.

11. Self-Insurance Reserves and Other Contingencies

Reserves for losses under the University's self-insurance program, aggregating \$8.3 million and \$8 million at August 31, 2018 and 2017, respectively, include reserves for probable known losses and for losses incurred but not yet reported. The reserves are presented on a discounted basis. The discount rate was 7.5 percent in fiscal years 2018 and 2017. Self-insurance reserves are based on estimates of historical loss experience,

and while management believes that the reserves are adequate, the ultimate liabilities may be more or less than the amounts provided. These reserves are included in accounts payable and accrued liabilities on the consolidated statements of financial position.

Under an agreement in effect through fiscal year 2013 between the University and NMG, a proportionate share of primary medical professional liability costs that arise out of events prior to November 1, 2004, was borne by NMG. As a part of the clinical integration agreement between NMG, NMHC, and the University, signed September 1, 2013, any remaining liabilities related to the period prior to November 1, 2004, are the obligations of the University and included in the reserves, beginning in fiscal year 2014, for losses noted above.

In August 2009, the University, as originating lender, began participation in a student loan securitization program. It sold student loans to a school trust totaling \$65 million in 2009, \$19.8 million in 2010, and \$22.5 million in 2012; the University issued University-guaranteed notes, which were purchased by a funding trust that procures financing to support the lending program. The programs are managed to break even and generate no servicing assets or liabilities. Guaranteed notes under these programs totaled \$13.2 million and \$20.6 million as of August 31, 2018 and 2017, respectively. These loans are included in notes receivable and deposits payable on the consolidated statements of financial position. Reserves in anticipation of securitized student loan future defaults totaled \$47,000 and \$74,000 at August 31, 2018 and 2017, respectively. Notes receivable on the consolidated statements of financial position are shown net of these reserves as of August 31, 2018 and 2017.

In October 2013, the University purchased a \$61 million portfolio of private education loans from a lending agency; these loans were purchased by the lending agency from the University prior to 2009 and were serviced by the University. As of August 31, 2018 and 2017, respectively, these loans totaled \$18.9 million and \$23.1 million, and are included in notes receivable on the consolidated statements of financial position. The University continues to service the repurchased loans. At August 31, 2018 and 2017, \$68,000 and \$83,000, respectively, were reserved in anticipation of future defaults. Notes receivable on the consolidated statements of financial position are shown net of these reserves as of August 31, 2018 and 2017.

From time to time, various claims and suits generally incidental to the conduct of normal business are pending or may arise against the University. It is the opinion of management of the University, after taking into account insurance coverage, that any losses from the resolution of pending litigation should not have a material effect on the University's financial position or results of operations.

All funds expended in connection with government grants and contracts are subject to audit by government agencies. While any ultimate liability from audits of government grants and contracts by government agencies cannot be determined at present, management believes that it should not have a material effect on the University's consolidated financial position or results of operations.

12. Grants and Contracts

Grants and contracts for the fiscal years ended August 31 are summarized on the consolidated statement of activities as follows:

(in thousands of dollars)	2018	2017
Federal grants	\$484,398	\$461,741
Private grants and contracts	159,565	151,041
State grants	4,045	4,666
Total grants and contracts	\$648,008	\$617,448

13. Functional Classification of Expenses

Expenses by functional categories reflect salaries, wages, benefits, goods, and services used for those specific purposes. The University has allocated functional expenses for maintenance of facilities, as well as for depreciation, accretion for asset retirement obligations, and interest on indebtedness, to other functional categories based on the functional use of space on the University's campuses.

Operating expenses incurred in the fiscal years ended August 31 were as follows:

(in thousands of dollars)					2018
			Interest on indebtedness	All other operating expenses	Total
Instruction	\$29,824	\$22,417	\$10,209	\$742,345	\$804,795
Research	52,358	39,356	17,923	395,198	504,835
Academic support	38,864	29,212	13,305	302,308	383,689

(in thousands of dollars)					2018
Student services	25,153	18,907	8,611	198,438	251,109
Institutional support	13,217	9,934	4,524	336,091	363,766
Auxiliary services	41,117	30,906	14,076	64,890	150,989
Total	\$200,533	\$150,732	\$68,648	\$2,039,270	\$2,459,183

(in thousands of dollars)					2017
			Interest on indebtedness	All other operating expenses	Total
Instruction	\$26,488	\$20,705	\$6,404	\$832,301	\$885,898
Research	47,272	36,952	11,430	398,801	494,455
Academic support	36,419	28,469	8,806	205,578	279,272
Student services	23,262	18,184	5,625	181,574	228,645
Institutional support	10,804	8,445	2,612	276,348	298,209
Auxiliary services	39,295	30,716	9,501	31,305	110,817
Total	\$183,540	\$143,471	\$44,378	\$1,925,907	\$2,297,296

14. Subsequent Events

The University has evaluated subsequent events in accordance with the FASB ASC Subsequent Event Topic through December 19, 2018, the date when the consolidated financial statements were issued. The University did not identify any events to be disclosed.

Supplementary Schedule of Expenditures of Federal Awards

Tessenting of Apriculue Department of Apriculue Responses to all breaksponses Responses to all breaksponses Responses to all breaksponses Responses to all breaksponses Responses Response		\$ 15,899 171,059 38,216	-
Department of Defense National Institute of Standards and Prove the Foundation and Provides in The Light of Magachana and Prove the Standards Advertee of Magachana Advertee of Magachana and Prove the Standa		171,059	
Department of Commerce 208 10.001 DA2.17.62984-169-0210-2-160 Matrice in lensities of Pool and Agriculture Addition policies in free the Fulture (FF) countries 10 10.001 DA2.17.62984-169-0210-2-160 Department of Commerce National Institute of Food and Agriculture Family Centered Foodbane Vibrio valification and Powert Oberly in Early Childhood 17 10.310 2016/2012-2016-2010 Department of Commerce National Institute of Bearsened Foodbane Vibrio valification and Powert Oberly in Early Childhood 11 10.310 2016/2012-2016-2000 Department of Commerce National Institute of Bearsened Foodbane Vibrio valification and Powert Oberly in Early Childhood 11 10.001 NAMERIA 12-2026 Department of Commerce National Institute of Bearsened Foodbane Vibrio valification and Powert Oberly in Early Childhood 11.000 70 70AA98144912 And 6 National Institute of Bearsened Foodbane Vibrio valification and Powert Oberly in Early Childhood 11.000 70AA98177-2285 70AA98177-2285 Nist SURF - Galifiensburg Advanced Materials Center for Excelence: Center for Heinerchical Materials Design (Childbo) 11.000 70AA98177-2285 Nist SURF - Galifiensburg Advanced Materials Center for Excelence: Center for Heinerchical Materials Design (Childbo) 11.620 70AA98177-2285 Nist SURF - Galifiensburg Advanced Watere Bin Inject Center for Excelence: Center for Heinerchic		171,059	_
Department of Defense 179 10.890 PORES32288158/17A-CA-15-008-06 Department of Commerce 10.310 2017-87011-26070 Department of Commerce 10.310 ASUB22/2018-88001-27550 Department of Commerce National Institute of Standards and Technology in Early Childhood 11.809 70NANB114912 And 6 Notice I and Provent Obesity in Early Childhood 11.809 70NANB14912 And 6 11.809 70NANB14912 And 6 Department of Defense Notice I and Provent Obesity in Early Childhood 11.809 70NANB14912 And 6 11.809 70NANB14912 And 6 Department of Defense Notice I and Provent Obesity in Early Childhood 11.809 70NANB14912 And 6 11.809 70NANB14912 And 6 Department of Defense NIST SURF - Gaitmenburg 11.809 70NANB17H028 70NANB17H028 NIST SURF - Gaitmenburg 11.800 70NANB17H028 70NANB17H028 NIST SURF - Gaitmenburg 11.800 12.200 Notit 1-1-1-225 Prot003 Department of Defense Active Narrophotosics in the Flattent with Nivel Hydrid Metasurfaces 153 12.800 PO00412380/W17A-04-10788 Department of Defense Active Narrophotosics in the Flattent with Nivel Hydrid Metasurfaces 153 12.800 PO0043280/W17A-04-10788 Department of Defense Active Narrophotosin the Proces and Octotos			-
National institute of Food and Agriculture NARTX toor effector domains modulate victances of foodborne Whito valificas. The Family Check-ly, a Health. A Family Chectered Health Maintenance Agricult to Improve 10.300 2017-87011-28070 Department of Commerce National Institute of Standards and Technology Advanced Materials Center for Excellence: Center for Hierarchical Materials Design (ChiMaD) 11.009 700ANB14H012 And 6 National Institute of Standards and Technology Advanced Materials Center for Excellence: Center for Hierarchical Materials Design (ChiMaD) 11.009 700ANB14H012 And 6 National Institute of Standards and Technology Advanced Materials Center for Excellence: Center for Hierarchical Materials Design (ChiMaD) 11.009 700ANB14H012 And 6 NIST SURF – Gathersburg 11.620 700ANB14H012 And 6 11.620 700ANB14H012 And 6 NIST SURF – Gathersburg 11.620 700ANB17H088 700ANB17H088 700ANB17H088 NIST SURF – Gathersburg 11.620 700ANB17H088 700ANB17H088 700ANB17H088 Standard Stand Transmith Advine Rise Laser Visionershift Proteins and Catoring Information 199 12.200 Apprint 22/0100000 Oppartment of Defense Fast Light Enformation Rise Standard With Novel Hybrid Materials Design Of Materials Comminated Descentering 199 12.200 MO014-171-3225 P00			_
Food and Agriculture MARTY X toxin effector domains modulate virulence of foodcome Vibrio vulificus The Family Check Up 4 Health A Family Check Up 4 Health Alternation Approach to Improve 17 10.310 ASUB221/2010-88001-27550 Department of Commerce National Institute of Standards and Technology Advanced Materials Cherter for Excelence: Center for Hearthcial Materials Design (ChiMab) 11.000 70MANB 14H012 And 6 Marty Check Up 4 Health Agriculture 11.000 70MANB 14H012 And 6 11.000 70MANB 17H233 Marty Check Up 4 Health Agriculture 11.000 70MANB 17H233 70MANB 17H233 Mist SURF - Gaitheraburg 11.000 70MANB 17H233 70MANB 17H233 Department of Defense Active Materials Cherter for Excelence: Center for Hearthcial Materials Design (ChiMab) 11.000 70MANB 17H233 MIST SURF - Gaitheraburg 11.000 70MANB 17H233 70MANB 17H233 MIST SURF - Gaitheraburg 11.000 70MANB 17H233 70MANB 17H233 Department of Defense Active Material of Sevina with Through Hybrid Medasafraters 12.300 Approx 12/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17H24/17		38 216	
Department of Commerce Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve Natrice and Prevent Obelity in Early Centered Health Maintenance Approach to Improve NIST SURF Centered Health Maintenance Centered Health Maintenance NIST SURF Centered Health Maintenanc		38 216	
Department of Commerce National Institute of Bandbards and Technology Advanced Materials Center for Excelence: Center for Heartchical Materials Design (ChMaD) High-fieldly and reduced for Excelence: Center for Heartchical Materials Design (ChMaD) High-fieldly and reduced for Excelence: Center for Heartchical Materials Design (ChMaD) High-fieldly and reduced for Excelence: Center for Heartchical Materials Design (ChMaD) High-fieldly and reduced for Excelence: Center for Heartchical Materials Design (ChMaD) High-fieldly and reduced for Excelence: Center for Heartchical Materials Design (ChMaD) High-fieldly and reduced for Excelence: Center for Heartchical Materials Design (ChMaD) High-fieldly and reduced for Excelence: Center for Heartchical Materials Design (ChMaD) High-fieldly and reduced for Excelence: Center for Heartchical Materials Design (ChMaD) High-fieldly and reduced for Model Section 11 (EE) 11.620 70NANEI 71-1283 Department of Defense NIST SURF - Gaithersburg NIST SURF - Gaithersburg 11.620 70NANEI 71-72425 P00003 70NANEI 71-72425 P00003 A fast Light E Thinneing Quality of Onhoids Services with Process and Outcome Information Sectiments 153 12.200 N00014-17-12425 P00003 CRDA Financing Quality of Onhoids Services with Process and Outcome Information Sectiments 103 12.80 Pro No. 4440778007 Division Water Teaternet Relation with Novel Hybrid Measurfaces Sectiments 11.80 70NANEI 7440780 233 12.80 North 101-101-102-001330/W121-101-0023 Vision Sectiments 12.80 FAdvis North Control Control Contrelation		00,210	-
Department of Commerce National Initiation of Breinology Advanced Materials Center for Excellence: Center for Herarchical Materials Design (ChiMaD) 11.609 70NANB 14H012 And 6 High-fidelity and reduced order models to investigate the thermal history and residual stress 11.609 70NANB 14H012 And 6 Department of Defense Advanced Materials Center for Excellence: Center for Herarchical Materials Design (ChiMaD) 11.620 70NANB 174283 Department of Defense Advanced Materials Center for Excellence: Center for Herarchical Materials Design (ChiMaD) 11.620 70NANB 174283 Department of Defense Advanced Materials Center for Excellence: Center for Herarchical Materials Design (ChiMaD) 11.620 70NANB 174283 Department of Defense Advanced Materials Center for Decision of Decision Of Externel Materials Design (ChiMaD) 11.620 70NANB 1747085 Department of Defense Advanced Materials Center for Decision of Decision Of Externel Materials Design (ChiMaD) 11.620 70NANB 1747045 Department of Defense Advanced Materials Design (ChiMaD) 11.620 70NANB 1747045 Department of Defense Advanced Materials Design (ChiMaD) 11.620 70NANB 1747045 Department of Defense Advanced Materials Design (ChiMaD) 12.600 12.600 700070771742425 D		7,841	_
Advanced Materials Center for Excellence: Center for Hierarchical Materials Design (ChiMaD) High-fieldly and reduced order models to investigate the thermal history and residual stress 11.609 70NANB14H012 Amd 6 Dip-determined for proved red futuring processes 11.609 70NANB14H012 Amd 6 NIST SURF - Gaithersburg 11.620 70NANB17H283 NIST SURF - Gaithersburg 11.620 70NANB17H088 NIST SURF - Gaithersburg 11.620 70NANB17H088 NIST SURF - Gaithersburg 11.620 70NANB17H088 Scientific Research Active Narroghotonics in the Flatiand with Novel Hybrid Metasurfaces 153 12.300 E chancing Quality of Orbrids Services with Process and Outcome Information 169 12.420 Apm12/1014/07M03/VM161-0788 Scientific Research Active Narroghotonics in the Flatiand with Novel Hybrid Metasurfaces 139 12.RD WEDSVM012380/W012H1015-00039 GDTS Defense and Veterans Brain Injury Center (UVE) contract No. WP17Z-13-C-015 250 12.RD W017YZ-14-C-0015/2380/W012H016-00023 GDTS Defense and Veterans Brain Injury Center (UVE) contract No. WP17Z-13-C-015 250 12.RD W017YZ-14-C-0015/2380/W012H016-00023 GDTS Defense and Veterans Brain Injury Center (UVE) contract No. WP17Z-13-C-015 250 12.RD W017YZ-16-C0012	Department of Agriculture Total	233,015	
National Institute of Standards and Technology Advanced Materials Center for Excellence: Center for Hierarchical Materials Design (ChMaD) High-fidelity and reduced order models to investigate the thermal history and residual stress In 500 70NANB 14H012 Amd 6 High-fidelity and reduced order models to investigate the thermal history and residual stress In 500 70NANB 17H088 Towards Cathering Constraints NIST SURF – Gatheraburg NIST SURF – Gatheraburg NIST SURF – Gatheraburg NIST SURF – Gatheraburg Catheraburg Constraints Catheraburg Catherabur	Department of Agriculture Total	233,013	
Technology Advanced Materials Center for Excellence: Center for Herarchical Materials Design (ChiMaD) 11.69 70NANB 14H012 And 6 Inproved Produced order models to investigate the thermal history and residual stress 11.69 70NANB 17H028 NIST SURF – Gaithersburg 11.69 70NANB 17H028 Department of Defense 11.69 70NANB 17H028 Active Nancohological in the Flatland with Novel Hybrid Metasurfaces 153 12.00 N0014-17.1-2425 P00003 Enhancing Quality of Orhotic Services with Provase and Oxtoom Information 169 12.200 PONA.081799 Drinking Water Treatment Flassburg 73 12.200 PON.0440778007 PON.0440778007 Enhancing Quality of Orhotic Services with Provase and Oxtoom Information 169 12.200 PON.0440778007 Drinking Water Treatment Flassburg Sam Oxtoom Information 153 12.800 WINTC-13-C-0158 OffEr Defense and Veterans Brain Injury Center (POIR) Contract No. WINTZ-13-C-015 250 12.800 WINTZ-13-C-0157/3004730431 GIDITS Defense and Veterans Brain Injury Center (POIR) Contract No. WINTZ-13-C-015 250 12.800 WINTZ-13-C-0015/3004730431 GIDITS Defense and Veterans Brain Injury Center (POIR) Contract No. WINTZ-13-C-015 250 12.800 FA4550-16-10150			
Advanced Materials Center for Excellence: Center for Hierarchical Materials Design (ChMaD) 11.609 70NANB 14H012 And 6 High-fadity and reduced order models to investigate the thermal history and residual stress 11.609 70NANB 17H283 II.600 70NANB 17H283 II.620 70NANB 17H283 III.620 70NANB 17H28 III.			
High-fieldity and reduced order models to investigate the thermal history and residual stress 11.600 70NANB 17H283 Department of Defense 11.620 70NANB 17H283 11.620 70NANB 17H283 Active Nanophotonics in the Flattand with Novel Hybrid Metasurfaces 15.31 12.200 N0014.17.1-2425 P00003 Enhancing Quality of Otholic Services with Process and Outcome Information 153 12.200 N0014.17.1-12425 P00003 Diriking Valer Tradment Residuals as Material for Detection of Extremely Small Vibrations 199 12.200 April 12/91/91/WilVXWH-16-1-0788 Diriking Valer Tradment Residuals as Material for Detection of Extremely Small Vibrations 199 12.200 April 12/91/91/WilVXWH-16-1-0788 Scientific Altonomous Reasoning Agent (SARA) integrating Materials Theory, Experiment and Assistance using Biominery 130 12.R0 WISTXH-16-0.012 Scientific Altonomous Reasoning Agent (SARA) integrating Materials Theory, Experiment and Assistance using Biominery 130 12.R0 WISTXH-14-0.012 ArD Inseptifier for Mating and Amputating Macrosopic Materials 12.800 FA0550-16-1-0136 12.800 FA0550-16-1-0136 MRMC Pain Management 12.800 FA0550-16-1-0136 12.800 FA0550-16-1-0136 12.800 FA0550-16-1-0136 12.800 FA0550-16-1		6,051,965	1,273,213
Department of Defense 11.620 70NANB17H088 Active Nanophotonics in the Flatland with Novel Hybrid Metasurfaces 153 12.00 N00014-17-1-4255 P00003 Enhancing Quality of Ortholic Services with Process and Outcome Information 163 12.400 A00014-17-1-4255 P00003 Comparison of Comparison o		0,001,000	1,270,210
NIST SURF Gaithersburg 11 620 70NANB 18H075-1 Department of Defense Advance 152 70NANB 18H075-1 Department of Defense Advance 153 12.00 N00114-17-1-2425 P00003 Enhancing Quality of Ofthotic Services with Process and Outcome Information 169 12.420 Agmt 12/19/16/W81XWH-16-1-0788 A Fast-Light Enhanced Ring Laser Vibrometer for Detection of Extremely Small Vibrations 89 12.RD PO No. 4440778007 Diriking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated 233 12.RD WDFSPM0012338W012H0160039 Selfments GDIT's Defense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.RD W91YTZ-13-C-0015/3004730431 WHMC Pain Management 139 12.RD W91YTZ-13-C-0015/3004730431 WMI-16-C-0012 WHMC Pain Management 56 12.RD 80776-11044//FA9550-18-1-0136 WMI-10-2-0012 Air Force Office of Scientific Research 12.800 FA9550-16-1-0150 P00002 MED0033/W9110Y-12-C-0039 Add C Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: 12.800 FA9550-16-1-0150 P00002 Abs C Stochastic Multiresolutin Theory for Microstructure Based Predictive Materials Science: <td></td> <td>89,066</td> <td></td>		89,066	
NIST SURF Gaithersburg 11 620 70NANB 18H075-1 Department of Defense Active Nanophotonics in the Flattand with Novel Hybrid Metasurfaces 153 12 300 N00114-17-1-2425 P00003 Enhancing Quality of Orthotic Services with Process and Outcome Information 169 12 420 Agmt 12/19/16/W815WH1-16-1-0788 A Fast-Light Enhanced Ring Laser Vibrometer for Detection of Extremely Small Vibrations 89 12 RD PO No. 4440778007 Diriking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated 233 12 RD W91YTZ-13-C-0015/30047304331 Selfments GDIT's Defense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12 RD W91WTL-1-02007 Selfments GDIT's Defense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12 RD W91WTL-1-2-C0012 Scientific Autonomous Reasoning Agent (SARA) Integrating Materials Theory, Experiment and Computation 56 12 RD W91WTL-1-2-C0039 WHC Prain Management 139 12 RD FA9550-16-10150 P00002 MED0033/W9110Y-12-2C-0039 Add Schechastic Multiresolution Theory for Microstructure Based Predictive Materials Science: Application to Multiphase Polymer Systems. Bornimetic Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications 12 800 FA9550-16-1-1050 P000002 </td <td></td> <td>6,141,031</td> <td>1,273,213</td>		6,141,031	1,273,213
Department of Defense Active Nanophotonics in the Flatland with Novel Hybrid Metasurfaces Enhancing Quality of Ortholic Services with Process and Outcome Information A Fast-Light Enhanced Ring Laser Vibrometer for Defection of Extremely Small Vibrations Drinking Water Treatment Residuals as Material for in-stitu Capping of Metal Contaminated Sediments GDIT's Defense and Veterans Brain Injury Center (DVBIC) contract No. VM1YTZ-13-C-015 (GRAB: Innovative Glove for Rehabilitation and Assistance using Biomimicy Scientific Autonomous Reasoning Agent (SARA) integrating Materials Theory, Experiment and Computation WRMC Pain Management 40 40 40 40 40 40 40 40 40 40 40 40 40		(1,960)	_
Active Nanophotonics in the Field with Novel Hybrid Metasurfaces 153 12.300 N0001-17.1-2425 P00003 Enhancing Quality of Orbitolis Services with Process and Outcome Information 169 12.420 April 12/19/16/W81XVH1-16-1-0788 A Fast-Lipht Enhanced Ring Laser Vibrometer for Detection ofExtremely Small Vibrations 89 12.RD PO No. 4440778007 Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Bolf Ts Defining and Vibrater and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.RD W91YTZ-13-C-0015/300471 GOLT's Defining and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.RD W91YTZ-13-C-0012 Scientific Autonomous Reasoning Agent (SARA) Integrating Materials Theory, Experiment and Computation and Assistance using Biointimicy WRR/C Pain Management 50 KG Computation and Assistance using Biointimicy WRR/C Pain Management 50 KG Computation Applications 50 KG Computation 12.8 KG MICH 200002 ABC Scientific Research 50 KG Computation Theory for Microstructure Based Predictive Materials Science: Application to Multiphase Polymer Systems. Biointenet: Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications Biominet: Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications Biominet: Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications Relevant to the Formation of Liquid Fuels Scientific Calcinophile Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications Relevant to the Formation of Liquid Fuels Superintetic Formation of Liquid Fuels Superintetic For Materials Science: Application to Multiphase Polymer Systems. Biominet: Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications Relevant to the Formation of Liquid Fuels Superintetic Formation Bio-composite and Biominetic Materials		40,731	
Active Nanophrotonics in the Falanda with Novel Hydrid Metasurfaces 153 12.300 N0001-17.1-2425 P00003 Enhancing Quality of Orbotics Services with Process and Outcome Informations 89 12.RD PO No. 4440778007 Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping Drinking Water Treatment Residuals as Materials Theory, Experiment and Computation and Assistance using Bioinmicry WRMC Pain Management 50 (Sarter Resource) A 40 Nanoprinter for Making and Manipulating Macroscopic Materials ABC Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: Application to Multiphase Polymer Systems. Bioinmetic Lipio Manoprinter for Making and Manipulating Macroscopic Materials Colicidal Metal Chalcogenide Quartitices Bio-Sensing and Bio-Functional Applications Bio Street Lipio Manoprinter for Making and Manipulating Macroscopic Materials Science: Application to Multiphase Polymer Systems. Biominetic Lipio Manoprinter for Making and Manipulating Macroscopic Materials Science: Relevant to the Francement Diage Manoprinter Materials Science: Relevant to the France Nature Manipulation Science Science: Relevant to the France Nature Manipulation Science Science: Relevant to the France Nature Nature Nature Science Science: Relevant to the France Nature Nature Nature Science Science: Scientific C		38,771	
Active Nanophrotonics in the Falanda with Novel Hydrid Metasurfaces 153 12.300 N0001-17.1-2425 P00003 Enhancing Quality of Orbotics Services with Process and Outcome Informations 89 12.RD PO No. 4440778007 Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Drinking Water Treatment Residuals as Material for in-situ Capping Drinking Water Treatment Residuals as Materials Theory, Experiment and Computation and Assistance using Bioinmicry WRMC Pain Management 50 (Sarter Resource) A 40 Nanoprinter for Making and Manipulating Macroscopic Materials ABC Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: Application to Multiphase Polymer Systems. Bioinmetic Lipio Manoprinter for Making and Manipulating Macroscopic Materials Colicidal Metal Chalcogenide Quartitices Bio-Sensing and Bio-Functional Applications Bio Street Lipio Manoprinter for Making and Manipulating Macroscopic Materials Science: Application to Multiphase Polymer Systems. Biominetic Lipio Manoprinter for Making and Manipulating Macroscopic Materials Science: Relevant to the Francement Diage Manoprinter Materials Science: Relevant to the France Nature Manipulation Science Science: Relevant to the France Nature Manipulation Science Science: Relevant to the France Nature Nature Nature Science Science: Relevant to the France Nature Nature Nature Science Science: Scientific C	Department of Commerce Total	6,179,802	1,273,213
Enhancing Quality of Orthotic Services with Process and Outcome Information 169 12.420 Aptil 2/19/16/WR1XWH-16-1-0788 A Fast-Light Enhanced Ring Laser Vibrometers for Detection of Externely Small Vibrations 89 12.80 POIN.0.4440778007 Sediments Sediments 233 12.RD UFDSP0001238/W912H018C0039 GDIT's Defense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.RD W81XWH-16-C-0012 Scientific Autonomous Reasoning Agent (SARA) integrating Materials Theory, Experiment 66 12.RD W81XWH-16-C-0012 and Computation 76 12.RD W81XWH-16-C-0012 W81XWH-16-C-0012 WRMC Pain Management 56 12.RD W81XWH-16-C-0012 WRMC Pain Management 56 12.RD W81XWH-16-C-0012 WRMC Pain Management 56 12.RD W81XWH-16-C-0012 Scientific Research 76 12.RD W81XWH-16-C-0012 AdD Nanoprinter for Making and Manipulating Macroscopic Materials 12.80 FA9550-16-1-0150 P00002 AGC Stochastic Multiresolution Through Boindesouter Based Predictive Materials Science: 12.800 FA9550-14-1-0032-P00003 AdD Nanoprinter for Making and Manipulating Macroscopic Materials 12.800 <td></td> <td></td> <td></td>			
A Fast-Light Enhanced Ring Laser Vibremeter for Detection ofExtremely Small Vibrations 89 12.R0 Po. 04.440778007 Dinking Water Treatment Residuais as Material for in-stru Capping of Metal Contaminated 233 12.R0 UFDSP00012338/W012108C0039 CDITs Defense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.R0 W91YTZ-13-C-0015/3004730431 GRAB: Innovative Glove for Rehabilitation and Assistance using Biomimicry 130 12.RD W81XWH-16-C-0012 Scientific Autonomous Reasoning Agent (SARA) integrating Materials Theory, Experiment and Computation WRNC Pain Management 51 2 RD 80776-11044//FA9550-18-1-0136 WRNC Pain Management 51 2 RD 80776-11044//FA9550-18-1-0136 MRC Pain Management 52 2 RD 80776-11044//FA9550-18-1-0136 AGC Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: Application to Multiphase Polymer Systems. 12.800 FA9550-16-1-0150 P00002 Collidia Metal Chalcogenide Quantities Inio-Sensing and Bio-Functional Applications Bornimetic Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications Relevant to the Formation of Liquid Fuels Colloidad Metal Chalcogenide Quantities Through Biomedeule-Encoded Superfatior For Mating and Encluster Stortways for Model Reactions Relevant to the Formation of Liquid Fuels Superfation For Mating and Bior-Functional Applications Relevant to the Formation of Liquid Fuels Combinatorial Screening of Emergening Materials Stortways for Model Reactions Relevant to the Formation of Liquid Fuels Superfatior Formation and Bio-Composite and Biomimicis in Damage Tolerant Functional Bio-Composite and Biomimicis Materials Stortwares and Mechanics in Damage Tolerant Functional Biocomposite and Biomimicis Materials Stortwares and Mechanics in Damage Tolerant Functional Biocomposite and Biomimicis Materials Stortw		118,573 51,203	_
brinking Water Treatment Residuals as Material for in-situ Capping of Metal Contaminated Sediments GDITs Defiense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.RD WB1VTZ-13-C-0015/3004730431 GDITS Defiense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.RD WB1VTZ-13-C-0015/3004730431 GDITS Defiense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.RD WB1VTZ-13-C-0015/3004730431 GDITS Defiense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.RD WB1VTZ-13-C-0015/3004730431 GDITS Defiense and Veterans Brain Injury Center (DVBIC) contract No. W91YTZ-13-C-015 250 250 250 250 250 250 250 250 250 25		49,323	_
GDTS Defense and Veterans Brain lipury Center (DVBIC) contract No. W91YTZ-13-C-015 250 12.RD W91YTZ-13-C-0015/3004730431 GRAB: Innovative Glove for Rehabilitation and Assistance using Biominicry Experiment and Computation Scientific Autonomous Reasoning Agent (SARA) integrating Materials Theory, Experiment and Computation wRMC Pain Management 56 12.RD 80776-11044//FA9550-18-1-0136 WRMC Pain Management 56 12.RD 80776-11044//FA9550-18-1-0136 WRMC Pain Management 12 19 12.RD 80776-11044//FA9550-18-1-0136 AGE Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: 12 800 FA9550-14-1-032-P00002 AGE Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: 12 800 FA9550-14-1-032-P00003 Colloidat Metal Chalcogoride Quantum Dots as Photo-Redox Catalysts for Model Reactions Relevant to the Formation of Liquid Fuels Combinatorial Screening of Emergent Nanophotonic Behavior through Biomelcule-Encoded Superlittice Formation of Liquid Fuels Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant Functional Bio-composite and Biominiet Materials			
IGRAB: Innovative Glove for Relabilitation and Assistance using Biomimicry 30 130 12.00 W12NWH-16-C-0012 Scientific Automous Reasoning Agent (SARA) integrating Materials Theory, Experiment and Computation WRMC Pain Management 56 12.RD 80776-11044//FA9550-18-1-0136 Air Force Office of Scientific Research 56 12.RD Narphote Scientific Research 76950-16-1-0150 P00002 Air Force Office of Scientific Research A D Nanoprinter for Making and Manipulating Macroscopic Materials AGC Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: Application to Multiphase Polymer Systems. 12.800 FA9550-16-1-0150 P00002 Biomimited: Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications Biomimeter Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications Colloidal Metal Chalcogenide Quartum Dots as Photo-Redox Catalysts for Model Reactions Relevant to the Formation of Liquid Fuels Combinational Screening of Emergents Nanophotonic Behavior through Biomolecule-Encoded 12.800 FA9550-17-1-0271 Superlative Formation Cauge Structures and Mechanics in Damage Tolerant Functional Bio-composite and Biomimetic Materials 12.801 FA9550-12-1-0280/P00005		12,030	_
Scientific Autonomous Reasoning Agent (SARA) integrating Materials Theory, Experiment and Computation WRMO Pain Management Air Force Office of Scientific Research A 4D Nanoprinter for Making and Manipulating Macroscopic Materials A 4D Nanoprinter for Making and Manipulating Macroscopic Materials Coloridation to Multiphene Polymer Systems. Relevant to the Formation of Luigidu Folds Combinational Screening of Emergent Nanophotonic Behavior through Biomolecule-Encoded Superlative Formation Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant Functional Bio-composite and Biominetic Materials 20 12.00 5-000700 Amd 6 // USAF FA9550-15-1-0000		71,564 29,141	10,775
WRMC Pain Management 139 12.RD MED0035/W911QY-12-C-0039 Air Force Office of Scientific Research			
Air Force Office of Scientific Research A 4D Nanoprinter for Making and Manipulating Macroscopic Materials ALC Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: Application to Multiphase Polymer Systems Biomimetic Lipid Manoparticles: IBO-Sensing and Bio-Functional Applications Colicidal Metal Chalcogenide Quantum Dots as Photo-Redox Catalysts for Model Reactions Relevant to the Formation of Liquid Fuels Combinatorial Screening of Emergent Nanophotonic Behavior through Biomelecule-Encoded Superfatice Formation Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant Functional Bio-composite and Biomimetic Materials 223 12.800 S-000700 Amd 6 // USAF FA9550-15-1-0009		104 (130,476)	-
Scientific Research A 4D Nanoprinter for Making and Manipulating Macroscopic Materials 12.800 FA9550-16-1-0150 P00002 ABC Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: 12.800 FA9550-16-1-0150 P00002 Application to Multiphase Polymer Systems. 12.800 FA9550-14-1-0032-P00003 FA9550-14-1-0032-P00003 Biomimetic Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications 12.800 FA9550-13-1-0192 Colicidal Metal Chalcogenide Quartim Dots as Phol-Redox Catalysts for Model Reactions 12.800 FA9550-17-1-0271 Relevant to the Formation of Liquid Fuels Combinatorial Screening of Emergening: Multiscale Structures and Mechanics in Damage Tolerant 12.800 FA9550-12-1-0280/P00005 Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant 12.800 Scoportio And 6 // USAF FA9550-15-1-0000		(130,476)	_
ABC Stochastic Multiresolution Theory for Microstructure Based Predictive Materials Science: Application to Multiphase Polymer Systems Biomimetic Lipid Manoparticles: IBO-Sensing and Bio-Functional Applications Colloidal Metal Chalcogenide Quantum Dots as Photo-Redox Catalysts for Model Reactions Relevant to the Formation of Liquid Fuels Combinatorial Screening of Emergent Nanophotonic Behavior through Biomolecule-Encoded Superfatible Formation Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant Functional Bio-composite and Biomimetic Materials			
Application to Multiphase Polymer Systems. 12.800 FA9550-141-10032-P00003 Biomimetic Lipid Nanoparticles: Bio-Sensing and Bio-Functional Applications 12.800 FA9550-131-10192 Colioidal Metal Chalcogenide Quantum Obts as Photo-Redox Catalysts for Model Reactions FA9550-131-10192 FA9550-131-10192 Relevant to the Formation of Liquid Fuels 12.800 FA9550-171-10271 FA9550-171-10271 Combinational Screening of Emergent Nanophotonic Behavior through Biomolecule-Encoded 12.800 FA9550-121-10280/P00005 Superlatice Formation 12.801 FA9550-121-10280/P00005 FA9550-121-10280/P00005 Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant 12.800 S-000700 Amd 6 // USAF FA9550-15-1-0009 Functional Bio-composite and Biomimetic Materialis 223 12.800 S-000700 Amd 6 // USAF FA9550-15-1-0009		1,297,068	304,377
Biominnetic Lipid Nanoparticles: Tilos-Sensing and Bio-Functional Applications 12.00 FA9550-13-1-0192 Colicidad Metal Chalcogonide Quantum Dots as Photo-Redox Catalysts for Model Reactions 12.00 FA9550-13-1-0192 Relevant to the Formation of Liquid Fuels Combinatorial Screening of Emergent Nanophotonic Behavior through Biomolecule-Encoded Superimedian 12.00 FA9550-12-1-0280/P00005 Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant Functional Bio-composite and Biominetic Materials 223 12.00 S-000700 Amd 6 // USAF FA9550-15-1-0009		18.564	
Relevant to the Formation of Liquid Fuels 12.800 FA9550-17-1-0271 Combinatorial Screening of Emergent Nanophotonic Behavior through Biomolecule-Encoded 12.800 FA9550-12-1-0280 Superlattice Formation 12.800 FA9550-12-1-0280 Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant 12.800 FA9550-12-1-0280 Functional Bio-composite and Biomimetic Materials 223 12.800 s-000700 Amd 6 // USAF FA9550-15-1-0009		159,181	_
Combinatorial Screening of Emergent Nanophotonic Behavior through Biomolecule-Encoded 12.800 FA9550-12-1-0280/P00005 Superlattice Formation 12.800 FA9550-12-1-0280/P00005 Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant 12.800 FA9550-15-1-0009 Functional Bio-composite and Biomimetic Materials 223 12.800 S-000700 Amd 6 // USAF FA9550-15-1-0009			
Superlattice Formation 12.800 FA9550-12-1-0280/P00005 Convergent Evolution to Engineering: Multiscale Structures and Mechanics in Damage Tolerant 12.800 S-000700 Amd 6 // USAF FA9550-15-1-0009 Functional Bio-composite and Biomimetic Materials 223 12.800 S-000700 Amd 6 // USAF FA9550-15-1-0009		155,630	_
Functional Bio-composite and Biomimetic Materials 223 12.800 S-000700 Amd 6 // USAF FA9550-15-1-0009		(4,997)	_
		103,054	_
		210,095	_
Electrochemical Imaging and Mechanistic Studies on the Nanometer Scale 12.800 FA9550-14-1-0003-P00006		2,567,656	859,228
Electronic Structure Theory for Photo-Induced Spin-Forbidden Dynamics 12.800 FA9550-15-1-0031/P00002		12,702	_
Electronic Structure Theory for Spin-Forbidden Reaction Dynamics 12.800 FA9550-18-1-0252		19,861	-
Hybrid Plasmonic-MOF Nanoparticle Superlattices 12.800 FA9550-14-1-0274 P00003		(27,391)	-
Investigation of Experimental and Theoretical Challenges for Developing Superluminal Sensors 12.800 FAS550-18-1-0401		5,731	-
Logic-Enabled Spectroscopy of Single Trapped Molecular Ions 12.800 FA8550-13-1-0116 Mergin reactivity and properties: photocontrolled synthesis of m-conjugated polymers 12.800 FA9550-13-1-0159		451 75,794	_
Mingjung reactivity and properties, protocommende systematics of in-compared polyments 2 2.000 PA/9500-16-10-139 Miniaturized Mechanical Tester for the Multiscale Testing of Biomaterials and Metamaterials 12.800 PA/9500-16-10-236		(3,337)	_
Modeling and Predicing Individual Scientific Impact 12.800 FASSO-17-10089 P00001		3,005	_
Molecular lon Quantum Control 12.800 FA9550-17-1-0352		121,158	_
Molecular models to investigate diamagnetic anisotropy: Towards the directed synthesis of rare-earth free permanent magnets 12.800 FA9550-14-1-0358		(9,696)	
10wards the directed synthesis of rare-earth free permanent magnets 12.00 FA9500-14-1-0356 MURI Center for Dynamic Magneto-optics 250 12.800 2300302213/ FA9550-14-1-0040.05		(9,696) 292,262	_
MURI Center to Dynamic magnetic police MURI: Unraveling the Biology, Chemistry and Nanoscience of Natural and Synthetic Melanins 224 12.800 10417018/F/A9550-181-10142		188,060	_
Nanostructured Interfaces and Patterning Tools for Probing Bioinspired Materials and Systems 12.800 FA9550-12.1-0141/P00003		(815)	_
Novel Characterization Methods for Anisotropic and Mixed-Conduction Materials 12.800 FA9550-15-1-0247 P00002		70,164	_

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

luster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thr to subrecipi
	Subagency				· · · · · · · · · · · · · · · · · · ·		subrecipi
partment of Defense (continued)		Novel Materials for Transverse Peltier Refrigeration PECASE: Multi-dimensional Vibrational-Electronic Spectroscopy to Probe Electronic-to-		12.800	FA9550-15-1-0377 P00002	\$ 186,005	
continued)		Vibrational Energy Transfer in Hybrid Nanomaterials		12.800	FA9550-16-1-0379-P00001	206.050	
		Plasmonic Optoelectronic Interactions		12.800	FA2386-13-1-4124 Mod. P00003	(16,500)	
		Polymeric and Molecular Materials for Advanced Organic Electronics		12.800	FA9550-15-1-0044 P00002	235,052	
		Reconfigurable Matter from Programmable Atom Equivalents		12.800	FA9550-17-1-0348 P00001	1,070,757	
		Rotation, Shift and Scale Invariant Ultrafast Automatic Image Recognition Using an					
		Opto-Electronic Correlator		12.800	FA9550-18-1-0359	3,993	
		Soft Chemical Approaches to the Synthesis of Metastable Materials Towards Software Apprentices that Learn in Dynamic Domains		12.800 12.800	FA9550-17-1-0247-P00001 FA9550-16-1-0138 P00002	228,131 305,433	
		Center of Excellence for Advanced Bioprogrammable Nanomaterials (C-ABN)		12.800	FA8650-15-2-5518 P00002 P000011 P000012	1.300.754	:
		Development of a Targeted Intravascular Therapy to Stop Non-Compressible Torso		12.000	FA8030-13-2-3318 F00008 F000011 F000012	1,500,754	
		Hemorrhage	230	12.800	010635-002//FA8650-17-2-6G19	280,932	
		Managing the Mosaic of Microstructure	35	12.800	1150119-294722-P00007//FA9550-12-1-0458	63,096	
						9.117.903	1.1
		High-speed Low-noise Short-wavelength Infrared Type-II Superlattice Heterojunction					
		Phototransistor		12.910	FA8650-18-1-7810	465,393	
		Compact and Integrated IMU for GPS Denied Navigation Using Fast-Light Gyroscopes and		12.010		100,000	
		Accelerometers	64	12.RD	Agmt 3/26/2013 / 01 // FA8651-13-C-0018	85	
		Enterprise APT Detection and Forensics with Provenance Graphs	116	12.RD	PO 5005026677 00001 // FA8650-15-C-7561	268,353	
		Ptychography-based Rapid Imaging of Nano-Structures with Multi-layer Assemblies (PRISMA)	262	12.RD	No. 86101156 Amd 1 // FA8650-17-C-9112	1,807,044	
	Ultrasensitive and Compact Superluminal Ring Laser Accelerometer for Inertial Navigation	64	12.RD	Agreement 3/26/13 / 01//FA8651-13-C-0011	50		
	Army						
		A Novel Approach to Assay DNA Methylation in Prostate Cancer A novel serum and tissue immunoglycomic biomarker panel to distinguish progressive		12.420	W81XWH-13-1-0319	21,321	
		Prostate Cancer		12.420	W81XWH-17-1-0642	134,467	
		Beta-Blockers for the Prevention of Acute Exacerbations of COPD	214	12.420	000507860-008//W81XWH-15-1-0705	170.042	
		Characterization of clustered CTCs to eliminate breast cancer metastasis		12.420	W81XWH-16-1-0021	11,122	
		Cobalt(III) Schiff base complexes as inhibitors of p53 aggregation in cancer		12.420	W81XWH-16-1-0379	34,518	
		Combination of IL13Ra2 CAR T cell therapy with PD-1 immune checkpoint blockade for treatment of glioblastoma		12.420	W81XWH-17-1-0411	125,408	
		Comprehensive Molecular Profiling of African-American Prostate Cancer to Inform on					
		Prognosis and Disease Biology	250	12.420	3003962014//W81XWH-15-1-0661	44,423	
		Connecting Mechanical to Biomechanical Performance of Prosthetic Feet to Design					
		Customized, Passive Devices that Provide Improved Mobility	132	12.420	123775//W81XWH-17-1-0427	17,920	
		Creation and validation of a pre-biopsy nomogram for predicting high-risk prostate cancer in African American men		12.420	W81XWH-17-1-0608	246,635	
		D-Cycloserine for the Treatment of Chronic, Refractory Low Back Pain		12.420	W81XWH-17-1-8426	474,467	
		Development of an Engaging Training Tool to Provide Superior Muscle Computer Interfaces for		12.120		111,101	
		Rehabilitation of Neuromusculoskeletal Injuries	169	12.420	Sub No. 4471 CC81932//W81XWH-15-2-0035	82,377	
		Discovery of Novel Therapeutics for Disordered Sleep in Fragile X Syndrome		12.420	W81XWH1810594	532	
		Effect of a Novel Intervention using Daily Intermittent Hypoxia and High-Intensity Training on					
		Upper Limb Function in Individual with Spinal Cord Injury	169	12.420	SC160072//W81XWH-17-1-0340	25,955	
		Epigenomic Priming as an Immunotherapy Enhancer in Ovarian Cancer Functional Performance Evaluation of the Northwestern University Flexible Sub-Ischial		12.420	W81XWH-17-1-0141	333,569	
		Vacuum (NU-FlexSIV) Socket for Persons with Transfemoral Amputation		12.420	W81XWH-15-1-0708	322,292	1
		Harnessing Druggable Synthetic Lethal Interactions in Triple-Negative Breast Cancer with		12.420	W61XWH-15-1-0708	322,282	
		Elevated MYC Expression		12.420	W81XWH1810053	93,846	
		Hyperexcitability in Sensory Circuits in Fragile X Syndrome		12.420	W81XWH-17-1-0230	408,105	
		Increasing Bone Mass and Bone Strength in Individuals with Chronic Spinal Cord Injury:					
		Maximizing Response to Therapy		12.420	W81XWH-16-1-0763	145,107	
		Inhibiting Prostate Cancer Cell Motility	157	12.420	1007494_NWU Amd 2 // W81XWH-15-1-0527	35,285	
		Investigating Long Noncoding RNAs as Biomarkers and Mediators of Prostate Cancer					
		Progression in African American Men	225	12.420	10358sc//W81XWH-17-1-0302	43,354	
		Investigation of Genetic and Immune Mechanisms of Response to BCG for Non-Muscle Invasive Bladder Cancer: a Translational Study of S1602		12.420	W81XWH1810257	4,623	
		In-vivo functional muscle regeneration utilizing an implantable modular bioreactor	284	12.420	WFUHS441082CF12/W81XWH1420004	4,623	
		Locally applied statins to reduce scarring	284	12.420	WFUHS441012 SR-02//W81XWH-13-2-0054	124,517	
		Longitudinal Observation of Myoelectric Upper Limb Orthosis Use among Veterans with Upper	201	12.120		121,017	
		Limb Impairment		12.420	W81XWH-16-1-0733	135,082	
		Loss of ZDHHC-medicated Scribble palmitoylation disrupts cell polarity and promotes prostate					
		cancer progression		12.420	W81XWH-17-1-0362	179,557	
		Macrophage Responses to Epithelial Dysfunction Promote Lung Fibrosis in Aging		12.420	W81XWH-15-1-0215	359,939	
		Macrophage Responses to Epithelial Dysfunction Promote Lung Fibrosis in Aging		12.420	W81XWH-15-1-0214	178,321	
		Neuromodulation and Neurorehabilitation for Treatment of Functional Deficits after mTBI + PTSD	40	12.420	Pape-0024//W81XWH-15-1-0516	(852)	
		No Longer Smooth: Introducing Striations into Prosthetic Socket Construction to Improve Suspension, Rotation, Fit and Comfort		12.420	W81XWH-16-1-0485	137,867	
		Peer-led Suicide Prevention: Promoting Healthy Family Role Transitions for Military Personnel	261	12.420	416496-G//W81XWH-14-1-0322	175,468	
		Prevention of Bone Loss after Acute SCI by Zoledronic Acid: Durability, Effect on Bone	201	12.420	+ 10+30-0// #0 1/WITE 14* 1-0322	175,466	
		Strength and Use of Biomarkers to Guide Therapy		12.420	W81XWH-14-2-0193	381,980	
		Role of C10orf112 in Prostate Cancer		12.420	W81XWH-17-1-0578	262,405	

30

Supplementary Schedule of Expenditures of Federal Awards

luster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throu to subrecipien
epartment of Defense		SERS Nanosensors for in vivo Glucose Sensing		12.420	W81XWH-16-1-0375	\$ 174.516	
(continued)		SERS Nanosensors for in vivo Glucose Sensing		12.420	W81XWH-16-1-0376	660,499	
		Sleep homeostasis and synaptic plasticity		12.420	W81XWH-16-1-0169	162,177	
		T Cell Receptor Repertoire Analysis as a Biomarker for Predicting Graft Rejection in Transplant					
		Recipients Targeted reinnervation as a means to treat neuromas associated with major limb amoutation		12.420 12.420	W81XWH-17-1-0679 W81XWH-13-2-0100	128,723 262,555	45.4
		Targeted reinnervation as a means to treat neuromas associated with major limb amputation Targeting Balance Confidence as a Strategy to Increase Integration and Improve Outcomes in		12.420	W81XWH-13-2-0100	262,555	45,4
		Users of Lower-limb Prostheses	177	12.420	322801NWU//W81XWH-17-1-0697	42,330	
		Targeting EZH2 in castration-resistant prostate cancer		12.420	W81XWH-17-1-0405	445,514	
		Targeting EZH2 in castration-resistant prostate cancer		12.420	W81XWH-17-1-0406	285,930	
		The Impact of a Gene Expression Profile on Treatment Choice and Outcome Among Minority Men Newly Diagnosed with Prostate Cancer: A Randomized Trial		12.420	W81XWH-15-1-0534	73,719	
		The Role of mDia1 in the Aberrant Innate Immune Signaling in del(5q) Myelodysplastic Syndromes		12.420	W81XWH-15-1-0335	195.106	
		Therapeutic Sleep for Traumatic Brain Injury		12.420	W81XWH-16-1-0166	147.753	
		Ubiquitin pathway activation: A new strategy for treating ALS		12.420	W81XWH-17-1-0086	327,655	
		Why does acute post whiplash injury pain transform into chronic pain? Multi-modal assessment					
		of risk factors and predictors of pain chronification	199	12.420	2018883-NW//W81XWH-15-1-0603	122,101	
		Women's-Specific Footwear with Prosthetic Feet	203	12.420	4182//W81XWH-17-2-0072 / PO 930293	9,672	
						7,986,288	460,2
		1.3.2: Ergodic Control for Optimal Information Acquisition		12.431	W911NF-14-1-0461-P00006	17,114	
		10.2: Adoption of Innovations in Work Networks		12.431	W911NF-14-1-0259-P00004	122,489	
		10.4: Properties Controlling Synchronization in Networks of Dynamical Systems		12.431	W911NF-15-1-0272-P00003	112,491	
		7.4 Reactive Chemical Systems: Assembly and Dynamics of Soft Matter Observed by Liquid		10.101			38.
		Cell TEM 7.4 Reactive Chemical Systems: New Principles for Targeting and Triggering based on		12.431	W911NF-17-1-0326 P00002	158,631	38,
		Molecular Self-Assembly in Topological Defects of Liquid Crystals	274	12 431	776K031 // W911NF-17-1-0575	70.659	
		9.4: Next Generation Nano-electronics Utilizing Piezoelectricity and Piezoresistivity of 2D	2.1	12.101		10,000	
		Materials Beyond Graphene A Comprehensive Study of Surface Defects in traditional Type II InAs_GaSb Superlattices and		12.431	W911NF-15-1-0068\P00001	66,013	
		Ga_free Type II_Research Area 4_3_Electronic Sensing. Ab initio design of noncentrosymmetric metals: crystal engineering in oxide heterostructures.		12.431	W911NF-15-1-0091 P00006	92,304	
		f. Research Area 6: Physics		12.431	W911NF-15-1-0017 P00006	165,339	
		An integrated system for automating ribosome design	100	12.431	W911NF1810181	498,557	
		Autonomous Error Protection in Superconducting Circuits Bridging Dynamic Particle Fracture and High-Strain Rate Comminution of Granular Continua	163	12.431 12.431	SUB0000078 Amd. 5 // W911NF1510421 W911NF-18-1-0035	179,253 79,549	
		Center for Advanced 2D Organic Networks	56	12.431	76091-11011//W911NF-15-1-0447	201,856	
		Collective impact and common goals: Planned vs. emergent networks as tools for leveraging	00	12.101		201,000	
		community outcomes		12.431	W911NF-16-1-0464-P00004	317,233	
		Creating and Manipulating High-Dimensional Photonic Entanglement		12.431	W911NF-12-1-0542/P00008	15	
		Directed Rational Synthesis of Kagome Lattices for the Discovery of Emergent Materials 9.3				00.074	
		Physical Properties of Materials Efficient GHz Surface-Normal Modulators for SWIR ToF Imagers		12.431 12.431	W911NF-18-1-0006 P00001 W911NF-16-1-0458	92,374 106,706	
		Engineering nanoscale protein containers		12.431	W911NF-16-1-0169 P00004	45.640	
		Engineering Synthetic Ribosomes (Topic 9.1)		12.431	W911NF-11-1-0445/P00004	(2,221)	
		Engineering the translation apparatus for the synthesis of electronically active					
		sequence-defined polymers		12.431	W911NF-16-1-0372 P00002	1,279,254	879,
		Exploring Sketching as a Modality for Intelligent Tutoring Systems: Adaptive and Intelligent Training Technologies, Paragraph 4.2.1, page 66		12.431	W911NF-17-2-0054-P00002	176.989	
		Forecasting Emergent Phenomena with Human Computer Collaboration	172	12.431	A12789 001 // W911NF-16-1-0524	13.997	
		Handling Adverse Visual Conditions for Target Tracking and Recognition	172	12.431	W911NF-16-1-0138 P00003	128,613	
		II.A.1.b.i.2: Engineering Nanocellulose Materials for High Ballistic Impact Performance		12.431	W911NF-17-1-0430 P00001	112,664	
		Infinite Coordination Polymer Particles from Polymeric Coordinating Precursors		12.431	W911NF-15-1-0151 P00006	78,053	
		Laser Filamentation Science	227	12.431	6501622/05//W911NF-11-0297	(35,480)	
		Material Synthesis Toward Design Rules for Capture and Sensing of Toxic Chemicals		12.431 12.431	W911NF-18-2-0074 W911NF-15-1-0240 P00004	6,989 76,393	
		Missile Impact with Material Comminution: New Concept – Turbulence Analogy Modeling Neuroscience for Enhancing Memory Operations through Non-Invasive Channels		12.431	W911NF-15-1-0240 P00004	76,393	
		(MNEMONIC)	192	12.431	19-000275 03 // W911NF-16-2-0021	323.253	
		Modeling of concrete failure under blast and fragment loading	73	12.431	PO 12909//W912HZ17C0028	17,649	
		Multisensory Integration by Circadian Clocks – Area 3 Mathematics (Biomathematics) and					
		Area 8 Life Sciences (Neurophysiology)		12.431	W911NF-16-1-0584 P00001	167,700	35,
		New Theoretical and Experimental Methods for Predicting Fundamental Mechanisms of Complex Chemical Processes	253	12.431	C00045065-5//W911NF-14-1-0359	215.685	
		Complex Chemical Processes Physically-based tempered fractional-order operators for efficient multiscale simulations	253	12.431 12.431	C00045065-5//W911NF-14-1-0359 W911NF-15-1-0569 P00001	215,685 80,938	
		Precision Chemical Dynamics and Quantum Control of Ultracold Molecular Ion Reactions	222	12.431	1000 G SA978 Amd 2 // W911NF-14-1-0378	352,430	
		QUANTA: Quantitative Network-based Models of Adaptive Team Behavior	226	12.431	KK1623 03 // W911NF-15-1-0577	125,183	
		Quantum Disc-based Focal Plane Arrays for Low-cost High-performance Uncooled LWIR					
		Imaging		12.431	W911NF-16-1-0410 P00005	540,500	
		Real Time Terahertz Heterodyne Imaging System RFQ for Silver Bullet Program	200	12.431	Agmt 11/21/2017 // W911NF-17-P-0017	27,473	
			148	12.431	PO 8200206547 01 // W911NF-17-C-0024	86,153	
		Sea Urchin Spicules: Assembly of a Fracture-Toughened Material at the Nano- and Mesoscales	145	12.431	F8595-01 02 // W911NF-16-1-0262	60,307	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throug to subrecipients
Department of Defense	Subagency	Selective Laser Melting of Ni-based superalloys with combined precipitation- and oxide-		CFDA	Sponsor award number	expenditures	subrecipient
(continued)		dispersion-strengthening		12.431	W911NF-18-1-0129	\$ 9,073	-
		Socio-Cognitive Networks: Theory & Data Driven Approaches for Understanding the Assembly and Interaction Networks of High Performance Teams		12.431	W911NF-14-1-0686-P00004	13,886	-
		Stabilization of Reactive Chemical Species and Fundamental Studies of Small-Molecule Reactivity in Metal-Organic Frameworks		12.431	W911NF-14-1-0168/P00008	117,946	_
		Stimuli-Responsive Control of Protein-Based Molecular Structure		12.431	W911NF1810200	7,844	_
		Strong Electron-Photon Coupling using Plasmonic Light Compressors Superconducting Single Photon Counter for Quantum Information Processing and		12.431	W911NF-11-1-0390 P00011	127,438	-
		Communications Tool for Direct Deposition and Characterization of Nano-optoelectronic Devices		12.431 12.431	W911NF-17-1-0184 W911NF-17-1-0233 P00001	106,780 245,776	
		TOPIC 1.3.4 Infrared Detectors: Demonstration of Dual-Band SWIR/MWIR Mini-Arrays and FPAs Based on Type-II Superlatices		12.431	W911NF-17-1-0233 P00001 W911NF-13-1-0412/P00002	245,776	
		Towards the Synthesis of Zirconium-based Metal-Organic Frameworks in Water at Room Temperature		12.431	W911NF-13-1-0412/F00002	23,554	
		Ultra-low Energy Receivers based on Electron-Injection Detectors on a CMOS Unified Photonic					
		Integration Platform Wireless, bioresorbable neural stimulators for discovery in neuroscience		12.431 12.431	W911NF1810429 W911NF1810394	349 7.858	
		whereas, bioresorbable neural sumulators for discovery in neuroscience		12.431	W911NF1810394	6.818.123	953.99
		Conversion of Descention Multi-scores Mathematics and Information Chapters	22	12.630	9500012803//Job13765353//W911NF-09-2-0053 Mod. 13	279,046	900,98
		Coevolution of Dynamic Multi-genre Networks and Information Streams OSCM: An Operating System for Cyberphysical Manufacturing	238	12.630	082621-16134 AE887 00 // W31P4Q1420001	279,046 221,881	
		Rapid Process Certification and Verification for High-Value-Added and Low-VolumeProduction	210	12.630	0220160021 // W31P4Q-14-2-0001	745,340	340,31
						1,246,267	340,31
		Syntaurus: An intelligent machine for chemical synthetic planning	92	12.910	W911NF-16-1-0384	284,111	-
		Developing a Clostridium molecular toolkit for bioconversion of food waste Formulation and Validation of Aging Models for CORTUF	197 73	12.RD 12.RD	Agmt 9/13/2017 // W911NF-17-P-0059 PO 12749//W912HZ17C0027	60,000 98,590	
		Industrial Production Methods for Ultra-High-Strength Fibers Based on Double-Walled Carbon					
		Nanotubes Network Sciences Collaborative Technology Alliance	133 22	12.RD 12.RD	Agmt 12/4/15 Amd 1//W912HZ-15-C-0004 PO# LBN9510212-0034 // W911NF-09-2-005	(99,674) 135,867	
		Realization of a High Power MWIR Laser Using Coherent Combination of Emitters	64	12.RD	Agmt 10/10/2017 // W56KGY-17-C-0010	28,852	
		Scaling & Supramolecular Engineering of Metal-Organic Frameworks (MOFs)	152	12.RD	A15A-T014// W911SR-17-C-0007	247,801	
	Defense Advanced Research Projects Agency						
	rigeney	Biochronicity Grand Challenge: Human Time Stamp Development, Validation and Prediction		12.910	D15AP00027	159,287	2,2
		Flexible Asynchronous Space-Time (FAST) Imaging Generation of Mouse-Based Bioelectronic Noses – Phase 2	146	12.910 12.910	HR0011-17-2-0044-P00003 15-AO-00-005162-01//HR0011-16-2-0007	185,503 214,600	
		Montage: Capturing Collective Identity through Multidisciplinary Modeling and Experimentation	283	12.910	446016-19980 02 // D17AC00003	25,588	
		Programmable Multiplexed Droplets and Arrays Containing Reaction Networks Targeted Neuroplasticity Training to Accelerate Complex Skill Learning	274 265	12.910 12.910	798K081//W911NF-18-2-0036 1604551 // N66001-17-2-4011	177,684 253,780	
		Thermoelectric Threads for Thermal Management Fabrics	205	12.910	HR00111710005	90,531	
						1,106,973	2,27
		ACCESS – Agent-based Causal simulator with Cognitive, Environmental, and Social		40.00		100 700	
		System factors Achieving Closed-loop RNA-based PID Control with a Cell-free Testbed	22 251	12.RD 12.RD	PO#4201766990 14811 // HR001118C0022 A005959604 Amd 1 // HR0011-16-C-0134	120,799 92,747	
		Automated Approaches to Cellular Engineering and Biomanufacturing	58	12.RD	D14PC00005/0001	(67,853)	
		Nano Engineered Thermoelectric Systems (NETS) for Lightweight Portable Primary/Secondary Power Sources	283	12.RD	450391-19980//HR0011-16-C-0035 Mod 03	140,961	
		Obtaining Multipath & Non-line-of-sight Information by Sensing Coherence & Intensity with					
		Emerging Novel Techniques The MIT-Broad Foundry: TA-2	189 132	12.RD 12.RD	G001534-7505 // HR0011-16-C-0028 Amd No. 1 5710004200//HR0011-15-C-0084	168,618 42,576	-
		The MIT-Broad Foundry: TA-2 (Phase III)	132	12.RD	HR0011-15-C-0084	28,880	
	Defense Security Cooperation Agency						
	5,	Novel Light Sources Based On Nonlinearity Enhanced By Nano-Antennas	89	12.RD	PO#4440432059 (1) 0620	16,278	
	Defense Threat Reduction						
	Agency	A novel toolbox for rapid, on demand, in vitro glycoprotein synthesis		12.351	HDTRA1-15-1-0052 P00006	985,339	336,46
		Hierarchically engineered porous materials for the protection against chemical threats		12.351	HDTRA1-14-1-0014 P00005 HDTRA11810003	141,124 510.378	45.9
		Highly Stable and Bifunctional Bio-inspired Catalytic MOFs for Destruction of Chemical Threats		12.351		<u>510,378</u> 1.636.841	45,93
	National Reconnaissance					1,030,041	
	Office	DOMinATE (Deployable Optical MembrAne Telescope)		12.RD	NRO000-18-C-0098	144,891	50,18
	Navy						
	Navy						
	Navy	A Bio-inspired Underwater Robot for Station keeping with Omnidirectional Disturbances A Bio-inspired Underwater Robot for Station keeping with Omnidirectional Disturbances		12.300 12.300	N00014-14-1-0594 // N00014-16-1-2132-P00002 N00014-14-1-0594 // N00014-16-1-2132-P00002	(8,799) 89.035	80,38

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thro to subrecipie
partment of Defense	Subagency	Air photoelectron spectroscopy of 2D perovskites for rational design of stable solar cells	ID number	CFDA	Sponsor award number	expenditures	subrecipie
continued)		with >15% efficiency		12.300	N00014-18-1-2102	\$ 221,563	
		An Advanced Atom-Probe Tomograph for Three-Dimensional Studies of Structural Materials					
		with Sub-Nanoscale Spatial Resolution and High Mass Resolving-Power		12.300	N00014-17-1-2870	900,000	
		An Analogical Approach to Autonomy and Social Inference in a Cognitive Architecture		12.300	N00014-16-1-2613-P00002/N00014-13-1-0470	566,463	
		Automated Alignment Engine for Photonics Integration		12.300	N00014-18-1-2089-P00001	152,078	
		Blackbody Thermometry with Quantum-State-Prepared Molecular Ions		12.300	N00014-17-1-2258 P00003	253,511	
		Bulk Nanostructured Materials with Two-Dimensional Building Blocks Cognitive Expertise by Repetition Enhanced Simulation-based (CERES) Training		12.300 12.300	N00014-16-1-2838 P00002 N00014-18-1-2316 P00001	260,634 89.889	
		Consensus-Based Distributed Information Fusion		12.300	N00014-16-1-2316 P00001 N00014-16-1-2106-P00001	93,390	
		Cutset Sampling Topologies for Intelligence, Surveillance, and Reconnaissance		12.300	N00014-17-1-2707 P00002	152,717	58
		Cyberalloys 2020: Naval Materials by Design		12.300	N00014-16-1-2400 P00001	253,422	
		Data Farming from Simulations for Instantaneous Trade-off Analysis using Adaptive					
		Batch-sequential Experiment Design		12.300	N00244-16-2-0002	7,267	
		Design of stable solar cells with >15% efficiency based on 2D perovskites		12.300	N00014-17-1-2231 P00004	184,821	
		Designing Hierarchical Three-dimensional Surfaces byControlling Strain		12.300	N00014-17-1-2482 P00002	130,987	
		Drugs to Stimulate Neurite Regeneration from Damaged Cochlear Neurons		12.300	N00014-15-1-2130//N00014-16-1-2508	342,427	
		Dynamic Allocation of Autonomy for Limited-Bandwidth Human-Robot Teams Based on					
		Measures of Trust in the Human	169	12.300 12.300	Agmt 04/21/17 // N00014-16-1-2247 N00014-16-1-2251 P00005	128,080	1
		Enhancing Intuitive Decision Making Through Implicit Learning Functional Crystals Through Encodable Hard and Soft Matter		12.300	N00014-16-1-2251 P00005 N00014-16-1-3117-P00001//N00014-15-1-0043	226,643	
		Hierarchical Nanoscale Metamaterials		12.300	N00014-16-1-3117-P00001//N00014-15-1-0043 N00014-17-1-3023	649,046 446,889	
		High power, multispectral, phased arrays based on quantum cascade lasers	219	12.300	A18-0471-S001//N00014-17-1-2836-1	188,556	
		High-Strength High-Toughness 10%Ni Naval Steels	219	12.300	N00014-18-1-2594	2.591	
		Instrumentation for Functionalized Two-Dimensional Nanoelectronic Heterostructures		12.300	N00014-16-1-3179	62,333	
		Integrated Optics for Single-Photon Nonlinear Interactions		12.300	N00014-17-1-2409-P00002	117,004	
		Large Scale Optimization Methods for Data Science Applications		12.300	N00014-14-1-0313 P00004	17,843	
		Learning by Reading for Robust Reasoning in Intelligent Agents		12.300	N00014-16-1-2177 P00002	24,049	
		Magneto-Optical Confocal Microscope for Exploring Opto-Electronic Nanomaterial Hybrids and					
		Heterostructures		12.300	N00014-18-1-2131	222,484	
		Mesoscale Integrated Photonic Systems for Structural Health Monitoring		12.300	N00014-16-1-3021-p0003	176,883	
		Mesoscopic quantum science and metrology with levitated mechanical systems	261	12.300	417315//N00014-18-1-2370	16,483	
		Methods for High-Dimensional Nonlinear Optimization		12.300	N00014-18-1-2098 P00001	126,729	
		Multi-Dimensional Control in Laterally-Confined Atomically-Thin Nanostructures Multi-Dimensional Site-Specific and Correlative Studies of High-Strength High-Toughness		12.300	N00014-16-1-3055	186,144	
		Naval Steels		12.300	N00014-15-1-2443-P00002	149.455	
		Multiscale Fabrication via Multiphoton Direct Laser Writing		12.300	N00014-15-1-2443-P00002	44.858	
		Multiscale Modeling of Thermoplastic Elastomers for Enhanced Blast Properties through		12.000	100014-10-1-2001	44,000	
		Microstructural Design		12.300	N00014-14-1-0434 P00002	28,353	
		Nanomanufacturing for Enhancing the Human-Machine Interface: Roll-to-Roll, High Speed					
		Printing of Multifunctional, Distributed Sensor Networks on Flexible Plastic Substrates	251	12.300	A002181204//N00014-11-1-0690 9	70,942	
		Nanomaterials Inspired from the Bacterial Adhesome and Mechanome		12.300	N00014-16-1-3175 P00003	257,853	
		Narrow-Linewidth Tunable Laser Source for Probing Excitons and Polaritons in Layered					
		Hybrid Light-Matter Devices		12.300	N00014-18-1-2135	321,287	
		Operating Microscope System for Translational Research in Regenerative and Transplant					
		Medicine		12.300	N00014-17-1-2319	6,833	
		Optimizing nanoscale precipitates in Al alloys by microalloying with transition metals		12.300	N00014-16-1-2402 P00003	196,077	
		Overcoming Noise and Delay in Mobile Sensor Networks		12.300	N00014-13-1-0331-P00002	(11)	
		Plasmonic-Dielectric Metamaterials for Enhanced Spectroscopy and Controlled Chemistry Properties and Methods for Distributionally Robust Optimization with Decision Dependent		12.300	N00014-17-1-3024	83,654	
		Uncertainty		12.300	N00014-18-1-2097 P00001	19.557	
		Screening For and Preclinical Evaluation of Drugs for Hearing Loss		12.300	N00014-18-1-2097 P00001	4,808	
		Stochastic Optimization for Energy Efficient Outpost Modeling		12.300	N00014-15-1-0046/P00002	5,967	
		Surface and Interface Engineering of van der Waals Nanoelectronic Heterostructures		12.300	N00014-17-1-2993 P00002	165,916	
		The microbiome and responsiveness to stress: Countermeasure strategies for improving					
		resilience to sleep and circadian disruption.	231	12.300	1553361 Mod 4 // N00014-15-1-2809	155,433	
		Theoretical Bounds on Imaging Through Scattering Media		12.300	N00014-15-1-2735 P00002	246,191	1
		Three-dimensional tomographic studies supporting physically based modeling of Li-ion batteries		12.300	N00014-17-1-2688	156,424	
		Towards Flexible Sheet Cameras	50	12.300	1(GG010550) // N00014-16-1-2152 Amd 5	418	
		Towards Intelligent Agents that Learn to Reason and Communicate		12.300	N00014-17-1-2092 P00003	140,902	
		Ultrasensitive Multi-Octave and Multi-dimensional Spectral Sensing by Single Element Detection		40.000	N00044 40 4 0745 200000	170.010	
		and Compressive Sensing		12.300	N00014-16-1-2715 P00002	178,216	
		Understanding Atomic Scale Structure in Four Dimensions to Design and Control Mesoscale Morphologies for Oxidation Resistant Alloys		12.300	N00014-16-1-2280-P00007//N00014-16-1-2280	1,297,163	53
		Morphologies for Oxidation Resistant Alloys		12.300	N00014-16-1-2280-P00007//N00014-16-1-2280		
						10,048,525	81
		Agile Fabrication of Sheet Metal Components with Assured Properties (Agile 1)	11	12.630	0007A-6 Mod 1 // N00014-14-14-2-0002	195,832	
		The Mutual Influence of Sacred Values and Social Responsibilities in Governance and Conflict		.2.000		100,002	
		Management: A Dynamic Interplay between Leaders, Devoted Actor Networks, General					
		Populations, and Time.	144	12.800	Agmnt 12/6/2017 // FA9550-14-1-0030 P00007	63,870	
		Novel Methods for Stochastic Data-Driven Nonconvex Optimization		12.910	N660011824026-P00002	132,747	
		BISC: Bioelectronic Interfacing to Sensory Cortex with massive, fully implanted, flexible, wireless CMOS surface recording and stimulating arrays	50	12.RD	5(GG012664) Amd 3 // N66001-17-C-4002	178.315	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award num	ber	Federal expenditures	Passed-thro to subrecipie
Department of Defense (continued)		Data-driven Discovery of Novel Thermoelectric Materials Improved Infrared Imaging with Variable Resolution Achieved via Post-Processing	167 156	12.RD 12.RD	1267//N66001-15-C-4036 Agmt 10/18/2017 // N00253-17-C-0024	\$	6 (140) 49,930	
		Office of Naval Research Basic Research Challenge- Enhancing Intuitive Decision Making			÷			
		Through Implicit Learning	59	12.RD	P.O. 13-0005311 Release 4 // N00014-13-C-0160		(337,333)	
		Theory-Driven Protocols for Replacing Elemental Composition of Strategic Materials	167	12.RD 12.RD	P.O. 1210//N00014-14-C-0050		3,581	
		Widely Tunable Surface Emitting Quantum Cascade Lasers	150	12.RD	Agmt 3/7/2018 // N68936-17-C-0063	Department of Defense Total	<u>63,011</u> 42,496,564	4.204.3
epartment of Education						Department of Defense Total	42,490,304	4,204,
		Foreign Language and Area Studies Fellowships (FLAS) under Title VI Higher Education Act of 1965	238	84 015			404 400	
		Act of 1965 Proposal for Funding a Comprehensive National Resource Center and Foreign Language and	238	84.015	2015-01858-01 Mod. 3 // P015B140048		104,428	
		Area Studies Fellowships under Title VI Higher Education Act of 1965	238	84.015	076415-15459 03 // P015A140048		107,321	
							211,749	
		Enhancing Middle School Mathematics Achievement through Spatial Skills Instruction	155	84.305	60046917//R305A150365-02		(21,982)	
		Teaching Perceptual and Conceptual Processes in Graph Interpretation	100	84.305	R305A120531-15-7		(1)	
							(21,983)	
	Institute of Education		200		5000 NILL 00//2005204 40040		(2.024)	
	Sciences	Advanced State Specific Design Parameters for Randomized Field Experiments An RCT Institute for Established Researchers	229	84.305 84.305	5898-NU-02//R305D140019 R305B170016		(9,261) 99,499	
		CALDER – State and Local	10	84.305	01023-03230 Mod. 4//R305C120008		2,437	
		Center for Interactive Knowledge Utilization	231	84.305	1551539 Mod 2//R305C140008		486,792	
		Contexts Inside and Outside of School Walls as Predictors of Differential Effectiveness in						
		Preschool Professional Development Enhancing Middle School Mathematics Achievement through Spatial Skills Instruction	230	84.305 84.305	R305A160013 -17 011275-002//R305A170640-17 A1/A2		201,955 96,581	11
		Exploring the Spatial Alignment Hypothesis in STEM Learning Environments	288	84.305	S-00014999 // R305A170165		46,327	
		Further Development of Effect Size Estimators for Single-Case Designs: Extensions to Trend						
		and Diverse Outcome Metrics		84.305	R305D170041 – 17A		191,538	
		Multidisciplinary Program in Educational Sciences Post Doctoral Research Training Fellowship in Education Sciences		84.305 84.305	R305B140042 – 17 Mod 4 R305B100027 – 14		983,579 110,841	
		Proposal to Conduct Annual Workshops on Better Quasi-Experimental Design and Analysis		84.305	R305B140029 – 16		297,309	23
		RAP Club: Improving Mental Health and School Performance in Urban Eighth Graders	122	84.305	2003117335//R305A160082		10,285	
		State Longitudinal Data Systems Public-Use Project	229	84.305	5897-NU//R3050140045-03		180,211	
							2,698,093	35
		NCSER-EIEL Goal 3: An Efficacy trial of J-EMT: Enhanced Milieu Teaching Language Intervention plus Joint Attention, Engagement and Regulation Intervention for Toddlers						
		with Autism	278	84.324	3403-019297 // R324A150094-18 Amd 3		346.669	
		Training-Induced Language and Literacy Improvement in Children with Cochlear Implants	76	84.324	R01834 // R324A160193		331,194	
							677,863	
partment of Energy						Department of Education Total	3,565,722	35
spartment of Energy		A Comprehensive Web Infrastructure for Standardizing, Storing, and Launching Density						
		Functional Calculations of Materials and Chemical Compounds		81.049	Agmt 8/1/16//DE-SC0015106		330,268	
			47				186.486	
		A Scintillating Xenon Bubble Chamber for Dark Matter Detection	47	81.049	DE-SC0012161 0004			
		A Scintillating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity	47	81.049	DE-FG02-05ER46248 0014		115,424	
		A Scintillating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion	47	81.049 81.049	DE-FG02-05ER46248 0014 DE-FG02-99ER14999-0019		115,424 346,832	25
		A Scintillating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argonne-Northwestem Solar Energy Research (ANSER) Center	47	81.049	DE-FG02-05ER46248 0014		115,424	25
		A Scintillating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion	47	81.049 81.049 81.049	DE-FG02-05ER46248 0014 DE-FG02-99ER14999-0019 DE-SC0001059/0008		115,424 346,832 1,477,026	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argome-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Bio-Inspired Energy Science (CBES) Center for Geologic Storage of CO2	238	81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EF46248 0014 DE-FG02-05EF14399-0019 DE-SC0001059/0008 DE-SC0001059/0003 DE-SC0000389 0006 074974-16734// DE-SC0012504		115,424 346,832 1,477,026 158,328 3,047,874 56,204	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argome-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for BioI-Inspired Energy Science (CBES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) COUR: A New System for Dynamic Thermal-Aware Computing		81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05ER46248 0014 DE-FG02-99ER1499-0019 DE-SC001059/0008 DE-SC0014242-0003 DE-SC000989 0006		115,424 346,832 1,477,026 158,328 3,047,874	
		A Scintillating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argonne-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Bio-Inspired Energy Science (CBES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC)	238	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EP46248 0014 DE-FG02-05EP14999-0019 DE-SC0001059/0008 DE-SC0000898 0006 074974-16734/ DE-SC0012504 WU-HT-11-05-MOD-9 Am d 9 // DE-SC0001035		115,424 346,832 1,477,026 158,328 3,047,874 56,204 119,539	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argonne-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Bio-Inspired Energy Science (CBES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) CO2UR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materials Featuring Nanoscale Porosity and Selective Chemical Separation Capabilities	238	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EP46248 0014 DE-FG02-05EP1499-0019 DE-SC0001059/0008 DE-SC0006989 0006 074974-16734/ DE-SC0012504 WU-HT-11-05-MOD-9 And 9 // DE-SC001035 DE-SC0012531/0001 DE-FG02-08ER15967-0008		115,424 346,832 1,477,026 158,328 3,047,874 56,204 119,539 707	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argonne-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Bio-Inspired Energy Science (CBES) Center for Bio-Inspired Energy Science (CBES) Contaoration with Photosynthetic Antenna Research Center (PARC) COOLR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materiabs Featuring Nanoscale Porostly and Selective	238	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EP46248 0014 DE-FG02-05EP1499-0019 DE-SC0001059/0008 DE-SC0000388 0006 074974-16734// DE-SC0012504 WU-HT-11-05-MOD-9 Am1 9 // DE-SC001035 DE-SC0012531/0001		115,424 346,832 1,477,026 158,328 3,047,874 56,204 119,539 707 207,885	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argome-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Bio-Inspired Energy Science (CBES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) COUCR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materials Featuring Nanoscale Porosity and Selective Chemical Separation Capabilities Dark Matter and Track Triggering with the CMS Experiment	238	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EP46248 0014 DE-FG02-05EP1499-0019 DE-SC001424-0003 DE-SC001424-0003 DE-SC001424-0003 DE-SC001424-0003 DE-SC0012531/DE-SC0012504 WU-HT-11-05-MCD-9 Amd 9 // DE-SC0001035 DE-SC00159310001 DE-FG02-08EP15967-0008 DE-SC0015973 0002		115,424 346,832 1,477,026 158,328 3,047,874 56,204 119,539 707 207,885 256,379	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argome-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Biol-Inspired Energy Science (CBES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) COOLR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materials Featuring Nanoscale Porosity and Selective Chemical Separation Capabilities Dark Matter and Track Triggering with the CMS Experiment Design of Next Generation Thermoelectrics Dynamic Visualization and Control of Emergent Phases in Complex Oxide Heterostructures EFRC/UMN: Inorganometaliic Catalysts	238 285	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05ER46248 0014 DE-FG02-05ER1499-0019 DE-SC001059/0008 DE-SC01424-0003 DE-SC012474/DE-SC0012504 WU-HT-11-05-MOD-9 Amd 9 // DE-SC001035 DE-SC0012531/0001 DE-FG02-08ER15967-008 DE-SC0015973 0002 DE-SC0015973 0002 DE-SC0015973 0002 DE-SC0015973 0002 S076-NU-DOE-2375//DE-SC0012375-02 A004527502 // DE-SC0012702 Amd 05		115,424 346,832 1,477,026 158,328 3,047,874 119,539 707 207,885 256,379 713,913	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argonen-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Bio-Inspired Energy Science (CBES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) COOLR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materials Featuring Nanoscale Ponsity and Selective Chemical Separation Capabilities Dark Matter and Track Triggering with the CMS Experiment Design of Next Generation Thermoelectrics Dynamic Visualization and Control of Emergent Phases in Complex Oxide Heterostructures EFRC/UMN: Inorganometallic Catalysts Electrolyte-Mediated Assembly of Like-Charged Colloids	238 285 162	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EF46248 0014 DE-FG02-05EF1499-0019 DE-SC0001059/0008 DE-SC0000890006 074974-16734/ DE-SC0012504 WU-HT-11-05-MOD-9 And 9 // DE-SC001035 DE-SC0012531/0001 DE-FG02-08ER15967-0008 DE-SC0015973 0002 DE-SC0014520-0002 5076-NU-DOE-2375//DE-SC0012375-02 A004327502 // DE-SC0012702 And 05 DE-SC00149033		115,424 346,832 1,477,026 158,328 3,047,874 119,539 707 207,885 256,379 713,913 (1,168) 472,795 229,568	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argome-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) COUR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materials Featuring Nanoscale Porosity and Selective Chemical Separation Capabilities Dark Matter and Track Triggering with the CMS Experiment Design of Next Generation Thermoelectrics Dynamic Visualization and Control of Emergent Phases in Complex Oxide Heterostructures EFRC/UMN: Inorganometallic Catalysts Electrolyte-Mediated Assembly of Like-Charged Colloids Electronice Structure Theories of Singlet Tission and Multiple Exciton Generation	238 285 162	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05ER46248 0014 DE-FG02-05ER14999-0019 DE-SC001059/0008 DE-SC011424-0003 DE-SC011424-0003 DE-SC0012474/DE-SC0012504 WU-HT-11-05-MOD-9 Amd 9 // DE-SC001035 DE-SC0012531/0001 DE-FG02-08ER15967-0008 DE-SC0015973 0002 DE-SC0015973 0002 DE-SC0015973 0002 S076-NU-DOE-2375//DE-SC0012375-02 A004527502 // DE-SC0012702 Amd 05 DE-SC0018093 DE-SC001265 0004		115,424 346,832 1,477,026 158,328 3,047,874 55,204 119,539 707 207,885 256,379 713,913 (1,168) 472,795 229,568 120,406	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argonne-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Bio-Inspired Energy Science (BES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) COOLR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materials Featuring Nanoscale Porosity and Selective Chemical Separation Capabilities Dark Matter and Track Triggering with the CMS Experiment Design of Next Generation Thermoelectrics Dynamic Visualization and Control of Emergent Phases in Complex Oxide Heterostructures EFRC/UMN: Inorganometallic Catalysts Electrolyte-Mediated Assembly of Like-Charged Colloids Electronic Structure Theories of Singlet Fission and Multiple Exclon Generation Electrostitic Driven Self	238 285 162	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EF46248 0014 DE-FG02-05EF1499-0019 DE-SC0001059/0008 DE-SC0001424-0003 DE-SC000989 0006 074974-16734// DE-SC0012504 WU-HT-11-05-MOD-9 Amd 9 // DE-SC001035 DE-SC0012531/0001 DE-FG02-08ER15997-0008 DE-SC0015973 0002 DE-SC0014520-0002 5076-NU-DOE-2375//DE-SC0012375-02 A004527502 // DE-SC0012375-02 A004527502 // DE-SC0012375-02 DE-SC00108093 DE-SC0010265 0004 DE-FG02-08EF46539-0009		115,424 346,832 1,477,026 156,328 3,047,874 19,539 707 207,885 266,379 713,913 (1,168) 472,795 229,568 120,466 237,133	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argonne-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Bio-Inspired Energy Science (CBES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) COOLR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materials Featuring Nanoscale Porosity and Selective Chemical Separation Capabilities Dark Matter and Track Triggering with the CMS Experiment Design of Next Generation Thermoelectrics Dynamic Visualization and Control of Emergent Phases in Complex Oxide Heterostructures EFRC/UMN: Inorganometallic Catalysts Electrolyte-Mediated Assembly of Like-Charged Colloids Electronic Structure Theories of Singlet Fission and Multiple Exciton Generation Electrostic Driven Self-Assembly de Catalysts Electrolic Structure Theories of Singlet Fission and Multiple Exciton Generation Electrostic Driven Self of Jondy for Dioosystems design by integrating computational modeling.	238 285 162	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EF46248 0014 DE-FG02-05EF1499-0019 DE-SC0001059/0008 DE-SC0001424-0003 DE-SC0000989 0006 074974-16734/ DE-SC0012504 WU-HT-11-05-MOD-9 And 9 // DE-SC001035 DE-SC0015231/0001 DE-FG02-08ER15967-0008 DE-SC0014520-0002 5076-NU-DOE-2375/DE-SC0012375-02 A004527502 // DE-SC0012375-02 A004527502 // DE-SC0012375-02 BE-SC00108093 DE-SC0010265 0004 DE-FG02-08EF46539-0009 DE-FG02-08EF46539-0009 DE-FG02-08EF46536 0012		115,424 346,832 1,477,026 156,328 3,047,874 19,532 266,379 707 207,885 266,379 713,913 (1,168) 472,795 229,568 120,406 237,133 101,660	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argonne-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons andPotential Device Applications Center for Bio-Inspired Energy Science (CBES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) COUCR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materials Featuring Nanoscale Porosity and Selective Chemical Separation Capabilities Dark Matter and Track Triggering with the CMS Experiment Design of Next Generation Thermoelectrics Dynamic Visualization and Control of Energent Phases in Complex Oxide Heterostructures EFRC/UMN: Inorganometallic Catalysts Electrolyte-Mediated Assembly Of Like-Charged Colloids Electrone Structure Theroies of Singlet Fission and Multiple Exciton Generation Electrostatic Divide Heterostructures Establishing a Clostridia foundry for biosystems design by integrating computational modeling, systems-level analyses, and cell-free engineenting technologies	238 285 162	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EF46248 0014 DE-FG02-05EF1499-0019 DE-SC0001059/0008 DE-SC0001424-0003 DE-SC000989 0006 074974-16734// DE-SC0012504 WU-HT-11-05-MOD-9 Amd 9 // DE-SC001035 DE-SC0012531/0001 DE-FG02-08ER15997-0008 DE-SC0015973 0002 DE-SC0014520-0002 5076-NU-DOE-2375//DE-SC0012375-02 A004527502 // DE-SC0012375-02 A004527502 // DE-SC0012375-02 DE-SC00108093 DE-SC0010265 0004 DE-FG02-08EF46539-0009		115,424 346,832 1,477,026 156,328 3,047,874 19,539 707 207,885 266,379 713,913 (1,168) 472,795 229,568 120,466 237,133	
		A Scintiliating Xenon Bubble Chamber for Dark Matter Detection Antiferromagnetism and Superconductivity Approaches to Integrated Photochemical Systems for Solar Energy Conversion Argonne-Northwestem Solar Energy Research (ANSER) Center Bose-Einstein Condensation of Magnons and/Potential Device Applications Center for Bio-Inspired Energy Science (CBES) Center for Geologic Storage of CO2 Collaboration with Photosynthetic Antenna Research Center (PARC) COOLR: A New System for Dynamic Thermal-Aware Computing Coordination-Chemistry-Derived Materials Featuring Nanoscale Porosity and Selective Chemical Separation Capabilities Dark Matter and Track Triggering with the CMS Experiment Design of Next Generation Thermoelectrics Dynamic Visualization and Control of Emergent Phases in Complex Oxide Heterostructures EFRC/UMN: Inorganometallic Catalysts Electrolyte-Mediated Assembly of Like-Charged Colloids Electronic Structure Theories of Singlet Fission and Multiple Exciton Generation Electrostic Driven Self-Assembly de Catalysts Electrolic Structure Theories of Singlet Fission and Multiple Exciton Generation Electrostic Driven Self of Jondy for Dioosystems design by integrating computational modeling.	238 285 162	81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049 81.049	DE-FG02-05EF46248 0014 DE-FG02-05EF1499-0019 DE-SC0001059/0008 DE-SC0001424-0003 DE-SC0000989 0006 074974-16734/ DE-SC0012504 WU-HT-11-05-MOD-9 And 9 // DE-SC001035 DE-SC0015231/0001 DE-FG02-08ER15967-0008 DE-SC0014520-0002 5076-NU-DOE-2375/DE-SC0012375-02 A004527502 // DE-SC0012375-02 A004527502 // DE-SC0012375-02 BE-SC00108093 DE-SC0010265 0004 DE-FG02-08EF46539-0009 DE-FG02-08EF46539-0009 DE-FG02-08EF46536 0012		115,424 346,832 1,477,026 156,328 3,047,874 19,532 266,379 707 207,885 266,379 713,913 (1,168) 472,795 229,568 120,406 237,133 101,660	250 962
Supplementary Schedule of Expenditures of Federal Awards

	Cubanana	Desired side	Pass- through	CFDA	Common and a set of	Federal	Passed-throu to
uster title/Federal grantor	Subagency	Project title	ID number		Sponsor award number	expenditures	subrecipier
partment of Energy (continued)		Granular Constraints and Size Effects in Polycrystalline Shape Memory Alloys High Pressure Synthesis of New Magnets, Featuring Diamagnetic Sources of Anisotropy		81.049 81.049	DE-SC0010594 0003 DE-SC0018092	\$ 146,962 113,163	70,4
(continued)		Hybrid Halide Perovskites: Advancing Optoelectronic Materials	226	81.049	KK1508//DE-SC0012541	(47,666)	
		Hybrid Matal Halides: Advancing Optoelectronic Materials	226	81.049	KK1804 // DE-SC0012541	72.732	
		Institute for Environmental Catalysis		81.049	DE-FG02-03ER15457 0015	1,520,353	
		Kinetics and Thermodynamics of Metal and Complex Hydride Nanoparticles		81.049	DE-FG02-07ER46433 Mod. 0009	(6,150)	
		Light-Driven Charge Transfer in Face-to-Face Donor-Spacer-Acceptor Supramolecular					
		Systems		81.049	DE-FG02-96ER14684-0020	42,995	
		Missing links in biological methane and ammonia oxidation		81.049	DE-SC0016284-0002	228,427	
		Nanoengineering of Complex Materials		81.049	DE-FG02-00ER45810/0020	360,366	
		Nanoporous Materials Genome: Methods and Software to Optimize Gas Storage, Separations, and Catalysis	251	81.049	A003127002 Amd 6 // DE-SC0008688	200,032	
		New Methods for Atomic Structure Determination of Nanoscale Materials	201	81.049	DE-FG02-01ER45945 0018	95,949	
		Nonlinear Optimization and Applications		81.049	DE-FG02-87ER25047/0030	117.745	
		PGM-free Engineered Framework Nano-Structure Catalysts	91	81.049	DE-E0008077	283,684	
		Probing Coherent States of Light and Matter in Two-Dimensional Semiconductors		81.049	DE-SC0012130-0004	146,489	
		Properties, Electrochemical Activity, and Stability of Solid Oxide Cell Materials Under Extreme					
		Conditions		81.049	DE-SC0016965	91,323	
		Research in the Energy, Cosmic and Intensity Frontiers and Theoretical Physics at		81.049	DE-SC0015910 0002	803,458	
		Northwestern University Scalable Data-Management, Analysis, and Visualization (SDAV)		81.049	DE-SC0007456	94.373	
		Scalable, In-situ Data Clustering Data Analysis for Extreme Scale Scientific Computing		81.049	DE-SC000/456 DE-SC0014330 0002	94,373 191,754	
		Solid State Solar-Thermal Energy Conversion Center (S3TEC Center)	132	81.049	5710003775 Amd 3 // DE-SC0001299	133,093	
		Strong Field Coherent Dynamics and Control. From Alignment to High Harmonic Generation in	102	01.043	5/10003/13 Allia 5// DE-00001233	100,000	
		Complex Systems		81.049	DE-FG02-04ER15612/0013	(95)	
		Strong Interaction Studies with Medium Energy Probes		81.049	DE-FG02-87ER40344 0039	309,985	
		Surface Plasmon Enhanced Chemistry		81.049	DE-SC0004752-0008	133,110	
		The Evolution of Topologically Complex Structures: Coarsening of Dendritic Mixtures		81.049	DE-FG02-99ER45782-0019	102,896	
		Ultrafast Creation and Manipulation of Emergent Phenomena and Novel Phases in Complex	400			100.404	
		Oxides	162	81.049	5709-NU-DOE-2375 // DE-SC0012375	128,134	
						14,333,999	1,28
		A Novel Lubricant Formulation Scheme for 2% Fuel Efficiency Improvement		81.086	DE-EE0006449-0008	19,871	
		Rapid Freeform Sheet Metal Forming: Technology Development and System Verification	77	81.086	A10-PO14-164103//RQ13-235R07//DE-EE0005764	(63,671)	
						(43,800)	
		C6-C14 Alcohol Production as a Pathway to Hydrocarbon Fuels	65	81.087	619-2 // DE-EE0007728	85.672	
		CHARACTERIZATION AND ACCELERATED LIFE TESTING OF A NEW SOLID OXIDE	60	01.007	619-2 // DE-EE0007728	65,672	
		ELECTROLYSIS CELL		81.087	DE-EE0008079	158.279	
		Transformative Materials for High-Efficiency Thermochemical Production of Solar Fuels		81.087	DE-EE0008089	144.407	
		······································				388.358	
		Computational Design and Performance Prediction of Creep-Resistant Ferritic Superalloys	263	81.089	A15-0315-SOO1-A02//DE-FE0024054	5,774	
		Scalable and Cost Effective Barrier Layer Coating to Improve Performance and Stability of					
		SOFC Cathode	287	81.089	14-749-NU//DE-FE0023407	7,954	
		Transformational SOFC Architecture (TSA)	80	81.089	F720161001s1 // DE-FE0027584	184,880	
						198,608	
		High-Pressure Elastic Properties of Minerals, Glasses and Superhard Materials	34	81.112	4-10469-03 Amd 6 // DE-NA002006 0009	58,876	
		Electrically-Assisted Tubing Processes for Enhancing Manufacturability of Oxide Dispersion	01	011112		00,010	
		Strengthened Structural Materials for Nuclear Reactor Applications		81.121	DE-NE0008409-0001	176,211	
		Solid Acid Fuel Cell Stack for Distributed Generation Applications	181	81.135	C2015.0008 // DE-AR0000495	14,265	
		Advancing Predictive Capability for Brittle Failure Using Dynamic Graphs	128	81.RD	439358 // DE-AC52-06NA25396	3,334	
		Alok Choudhary-Joint NU/Argonne Appointment	209	81.RD	Agmt 9/14/2017	19,605	
		Alok Choudhary-Joint NU/Argonne Appointment (AMASE Project)	209	81.RD	EDSR 1/23/2018	13,080	
		Argonne Joint Appointment – Hupp Argonne Joint Appointment – Kanatzidis	209 209	81.RD 81.RD	Agmt. 10/23/14 Agmt. 08/20/14	(12) 216,191	
		Argonne Joint Appointment – Kanatzidis Argonne Joint Appointment – Low	209	81.RD	Agmt 08/20/14 Agmt 08/31/2017	210,191 85.643	
		Argonne Joint Appointment – Doeppelmeier	209	81.RD	Agmt 06/07/18	39,343	
		Argonne Joint Appointment – Wasielewski	209	81.RD	Agmt 1/16/2018	60,150	
		Bridging neutron total scattering and atom-probe tomography for resolving amorphous and			•		
		nanocrystalline structures	277	81.RD	4000164554//DE-AC05-00OR22725	2,233	
		Center for Electrochemical Energy Science – II	209	81.RD	4F-32002 M0007 // DE-AC02-06CH11357	667,268	
		Center for Emergent Superconductivity (CES)	209	81.RD	3J-30081 // 3J-30081-0046A Rev. 0046E	90,536	
		Concurrent Optimization of Component Capital Cost and Expected O&M	5	81.RD	XEJ-6-62151-01-1 Mod. 3 // DE-AC36-08GO28308	174,376	2
		Cross-linked Polyhydroxyurethanes with Faster Stress Relaxation and Reprocessability	97	81.RD	N000266389 // DE-NA0002839	6,050	
		Development of a New, Lightweight Alloy for Advanced Cylinder Heads in High-Efficiency, Light-Duty Engines	83	81.RD	DE-EE0006082 // PO# TCS67912-001	30.973	
			200				
		Development of Heavy Element Wide Band Gap Semiconductors	209	81.RD 81.RD	BOA 3J-30081 // 3J-30081-0066B 3 J-30081/3 J-30081-0053C & 0053D	77,816	
		Development of Heavy Element Wide Band Gap Semiconductors Dynamics of Active Self-Assembled Materials	209	81.RD	3J-30081/3J-30081-0053C & 0053D	6,733	
		Development of Heavy Element Wide Band Gap Semiconductors	209 209 209 209 209				

Supplementary Schedule of Expenditures of Federal Awards

			Pass- through			Federal	Passed-thro to
Cluster title/Federal grantor	Subagency	Project title	ID number	CFDA	Sponsor award numbe		
partment of Energy (continued)		Fermi Joint Appointment – Eric Dahl Firm-fixed price proposal for the reimbursement of funds to Northwestern University for the	74	81.RD	Agmt 6/27/12 // DE-AC02-07CH11359 Rev 5	\$ 76,480	
(continued)		services of Postdoctoral Research Associate; Wave Ngampruetikorn	74	81 RD	PO No. 636083 // DE-AC02-07CH11359	169,253	
		Friction prediction modeling of Honed and LST treated ring and liner lubricated contact	209	81.RD	3J-30081 // 3J-30081-0064A	(595)	j
		High Luminosity (HL) LHC CMS Detector Upgrade Project – Trigger & DAQ – Track Trigger	74	81.RD	PO NO. 637604 // E9936-&264-o2	14,175	
		High-performance I/O Research, Development, and Deployment for DataLib	209	81.RD	3J-30081 // 3J-30081-0071A	35,145	
		James Dombrowski-Joint NU/Argonne Appointment	209	81.RD	EDSR 5/11/18	4,107	
		James Rondinelli-Joint NU/Argonne Appointment	209	81.RD	Agmt 4/3/2017	(106)	
		Jennifer Dunn – Joint NU/Argonne Appointment	209	81.RD 81 RD	Agmt 7/27/2017	65,253 23,926	
		Jennifer Dunn joint appointment/NAISE-funding for DRINC Joint Appointment Agreement – Petriello	209 209	81.RD 81.RD	Agmt 4/13/18 Agmt. 09/11/18	23,926 128,044	
		Joint Appointment Agreement – Stair	209	81.RD	Agmt 9/13/2017	40.097	
		Joint appointment agreement for Hongxi Xing	209	81.RD	Agmt 8/31/2017	32,769	
		Joint Argonne Appointment – Pyosang Kim	209	81.RD	Agreement 4/17/2018	33,260	
		Joint Center for Energy Storage Research	209	81.RD	3F-31142 Mod. 12 // DE-AC02-06CH11357	143,227	
		Kinetic Modeling of the Catalytic Upgrading of Vapors from Biomass Pyrolysis	5	81.RD	AEV-6-62063-01//DE-AC36-08GO28308	26,216	
		Lei Fang – Joint NU/Argonne appointment Li Ion Battery X-ray Interface Studies	209 209	81.RD 81.RD	58906-MA-105 3J-30081 / 3J-30081-0014A Rev. 0014E	512 22,853	
		Marco Trovato CMS LPC Distinguished Research Award 2017	74	81.RD	No. 634049//DE-AC02-07CH11359	14,570	
		MICCoM Water Electrode Studies	209	81.RD	3J-30081-0054A // Rev No. 0054C	22,611	
		Microstructural Studies of Nb3Sn Coatings for SRF Cavities	74	81.RD	PO No. 631010 Rev 1 // DE-AC0207CH11359	139,722	
		Midwest Integrated Center for Computational Materials	209	81.RD	3J-30081-0056A//3J-30081-0056B	255,990	
		ML/DL and I/O Research, Development, and Deployment for RAPIDS	209	81.RD	3J-30081 // 3J-30081-0069A	18,388	
		Multi-objective Algorithm Optimization of Interfacial Structures	209	81.RD	3J-30081-0055A // 3J-30081-0055A Rev 0055D	41,144	
		Oliver Cossairt-Joint NU/Argonne Appointment	209	81.RD	Agmt. 06/26/18	21,239	`
		Optimizing Superconductor Transport Properties Oxide Dispersion Strengthened (ODS) Alloys	209 209	81.RD 81.RD	3J-30081//3J-30081-0024A Rev 0024D 3J-30081-0070A	(2,694) 12,886	
		Raman Spectroscopy of Catalysis	209	81.RD	3J-30081-0070A 3J-30081-0051A Rev. 00511	42.128	
		Refractory Solar Selective Coatings	209	81.RD	3J-30081//3J-30081-0058A Rev 0058C	7,448	
		Small Worlds Project Development of algorithms and models for 3D Snapshot					
		Holographic Interferometric Microscopy (3D-SIHM) Subproject	209	81.RD	3J-30081 // 3J-30081-0050A Rev. No. 0050E	78,718	
		Structural Characterization in Photocatalysis	209	81.RD	3J-30081 // 3J-30081-0039A Rev. 0039C	63,166	
		Student support for Matthew Kirschner	209	81.RD	3J-30081/3J-30081-0043A Rev. 0043F	55,493	
		Support for Daikang Yan Support for Ming-Feng Tu	209 209	81.RD 81.RD	3J-30081-0062A Rev. 0062E // 3J-30081 3J-30081-0060A-0060B // 3J-30081 Rev 0060C	33,145 31,716	
		Support for Pufan Liu	209	81 RD	3J-30081-0060A-0060B // 3J-30081 Rev 0060C 3J-30081-0063A Revision 0063B	42,216	
		Support for Saugat Kandel	209	81 RD	3J-30081 // 3J-30081-0068A Rev. No. 0068D	56,942	
		Support for Yue Zhang	74	81.RD	PO No. 641287 // DE-AC02-07CH11359	40.000	
		Supported Single-Site Catalysts for Selective Alkane Oxidation	209	81.RD	3J-30081-0057A Rev. 0057B-C//3J-30081	1,800	
		Synchrotron X-ray Studies of Nanostructured Polymer Films, Fibers and Composites Technology Demonstration and Model Assessment of Fit-To-Use Water Availability from	209	81.RD	3J-30081/3J-30081-0013A REV. 0013H	31,245	
		Selective Desalination of Impaired Water for Cooling Tower Operation Testing and Characterization for Pattern Recognition ASIC Development	209 74	81.RD 81.RD	Work Order No. 3J-30081-0067A Rev No. 0067B PO# 640728 // E9935-5264-02	31,702 34,090	
		Travel Support for Prof. Chaitanya Bandi	158	81.RD	351306 Revision 1 // DE-AC05-76RL01830	34,090	
		Understanding Complex Oxide Surfaces in Reactive Environments	209	81.RD	3J-30081//3J-30081-0019H	34,460	
		Understanding Complex Oxide Thin Film Synthesis	209	81.RD	31-30081-0031A 0031H/0031I	38,545	
		Understanding Roles of Ultrafast and Coherent Electronic and Atomic					
		Motions in Photochemical Reactions	209	81.RD	4F-3232 M0003//DE-AC02-06CH11357	29,650	
		US CMS Phase 2 Upgrade R&D – Endcap Calorimeter	74	81.RD	PO No. 622384-1	(306)	
		Wei-Keng Liao-Joint NU/Argonne Appointment Wei-Keng Liao-Joint NU/Argonne Appointment (AMASE Project)	209 209	81.RD 81.RD	Agmt 9/13/2017 Agmt 2/16/2018	145,965 760	
		Youssef Nashed-Joint NU/Argonne Appointment (AMASE Project)	209	81 RD	Agmt 10/12/2017	6,545	
		Yudong Yao-Joint NU/Argonne Appointment	209	81.RD	Agmt 5/22/2018	69,413	
A.d.	vanced Research Projects				3 • • • • •	, .	
	gency-Energy						
		A Novel Hierarchical Frequency-Based Load Control Architecture	101	81.135 81.135	DE-AR0000702	605,620	
		Distributed Electrochemical Production and Conversion of Carbon-neutral Ammonia Micro-scale Ultra-high Efficiency CPV/Diffuse Hybrid Arrays Using Transfer Printing	181 84	81.135 81.135	C2017.0013//DE-AR0000813 17-S32//DE-AR0000882	241,558 83,458	
		Regrowth and Selective Area Growth of GaN for Vertical Power Electronics	289	81.135	GR101471 CON-8000 1218//DE-AR000087	106,911	
		Wide-angle planar microtracking microcell concentrating photovoltaics	162	81.135	5688-NU-EARPA-0626//DE-AR0000626	400,420	
						1,437,967	1:
		Intermediate Temperature Fuel Cell Stack	211	81.RD	PO2603659//Agmt 1215334//DE-AR0000498	(24,627)	
	tional Energy Technology aboratory		211	01.10	Constant and the second s	(24,027)	
		Integrated Computation Materials Engineering (ICME) Development of Carbon Fiber Composites for Lightweight Vehicles	77	81.086	RQ15-016R02 Mod 2//DE-EE0006867	730.124	
Not	tional Nuclear Security	Composites for LightWeight Vehicles	11	01.000	NQ10-010N02 M00 2//DE-EE0000007	730,124	
	Ional Nuclear Security						
~		Actinide Center for Excellence	258	81.112	203186NU // DE-NA0003763	135,944	
		Ternary Heavy Metal Halide Semiconductors for Y-Radiation Detection		81.113	DE-NA0002522	(4,781)	L
						Department of Energy Total 21,183,405	1.43

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
epartment of Health and Human Services							
Human Services	Administration for Children and						
	Families	The Northwestern University Two-Generation Child and Family Outcomes Study of CAP Tulsa's					
		CareerAdvance® Program	52	93.093	Agmt 10/31/2017	\$ 174,439	_
		The Northwestern University Two-Generation Study (NU2Gen) of Parent and Child Human Capital Advancement		93.093	90HG1002-01-01	61,355	33,611
		The Northwestern University Two-Generation Study (NU2Gen) of Parent and Child Human		93.093		247.686	
		Capital Advancement		93.093	90HG1002-02-00	483,480	61,035 94,646
		Expanding the Cycle of Opportunity: Simultaneously Educating Parents and Children in Head				463,460	94,040
		Start		93.600	90YR0073-04-00	(46,550)	_
		Expanding the Cycle of Opportunity: Simultaneously Educating Parents and Children in Head Start		93 600	90YR0073-04-00	66,853	48.631
		Expanding the Cycle of Opportunity: Simultaneously Educating Parents and Children in Head					
		Start		93.600	90YR0073-05-01 Amd 1	257,849	133,117
						278,152	181,748
		Illinois DCFS Implementation of Trauma Affect Regulation: Guide for Education and Therapy (TARGET) for Post Adoption and Guardianship Families	191	93.652	Agmt Signed 10/12/16 // 90CO1122-04	18,624	_
		Evidence-informed Practices in Early Childhood Home Visiting: Prevention, Identification and					
		Treatment of Substance Abuse in Families	134	93.RD	HHSP233201500035I//50525S05679	10,599	_
	Administration for Community Living						
	0	Advanced Rehabilitation Research and Training (ARRT) Program		93.433	90AR5010-02-00	9,120	_
		Advanced Rehabilitation Research and Training (ARRT) Program: Northwestern University Advanced Rehabilitation Research Training Application		93.433	90AR5019-04-00	134,061	_
		Field Initiated Project Programs Motivational Interviewing and Physical Activity Change in Parkinson's Disease	169	93.433	81421//901F0093-01-00	19.043	_
		Improving Electronic Written Communication in Aphasia	169	93.433 93.433	6317//90IFRE0007-01-00	11,391	_
		Interventions for Neurologic Communication Disorders		93.433	90AR5015-02-00	204,365	69,250
		Machines Assisting Recovery from Stroke and Spinal Cord Injury for Reintegration into Society (MARS3)	169	93.433	CC 81765 CL 2910//90RE5010-03-00	4,505	_
		Multi-site Clinical Trial of Hypoxia in Incomplete SCI	169	93.433 93.433	cc81478 6323//90SIMS0001-01-00 90AR5019-03-00	76,420 9,378	_
		Northwestern University Advanced Rehabilitation Research Training Application Northwestern University Policy Research Fellowship		93.433	90ARPO0001-02-00	9,378 31,161	_
		Rehabilitation Science for Basic Scientists and Engineers: An Advanced Training Program Rehabilitation Science for Basic Scientists and Engineers: An Advanced Training Program		93.433 93.433	90AR5031-02-02 90AR5031-03-00	9,630 153,702	_
		Rehabilitation Science for Basic Scientists and Engineers. An Advanced Training Program Rehabilitation Strategies, Techniques, and Interventions	169	93.433	90AR5031-03-00 CC# 81353 3037//90ER5013-01-00	178,881	_
						841,657	69,250
		Developing Optimal Strategies in Exercise and Survival Skills to increase Health and Function	169	93.443	CL3802, CC81039//90RT5027-01-00	47,574	_
	Agency for Healthcare						
	Research and Quality	Health Services Research Training Grant	228	93.225	FP037911//5T32HS000084-20	151,170	_
		Northwestern University-University of Chicago HSR Postdoctoral Training Program	220	93.225	3T32HS000078-20S1	270,153	42,934
						421,323	42,934
		Addressing the Needs of Individuals Early After Stroke: An Adaptation of the 14-Weeks to a					
		Healthier You Program Dental prescribing of antibiotics and opioids: high use in the absence of evidence	237	93.226 93.226	1F32HS024366-01 16659//5R01HS025177-02	6,453 26,314	_
		Develop and Validate Health IT Safety Measures to Capture Violations of the 5 Rights of					
		Medication Safety Development of SCRIPtS: Standardized Consent Redesign and Implementation Protocol for	50	93.226	4(GG012713-02)//1R01HS024538-02	17,492	_
		tPA in Stroke		93.226	5F32HS025330-02 5R18HS023459-03	73,855 136.940	
		EHR Based Medication Complete Communication Strategy to Promote Safe Opioid Use Enhancing Stroke Prehospital and Emergency Evaluation and Delivery (E-SPEED)		93.226 93.226	1R18HS025359-01A1	136,940 31,185	35,925
		Evaluating the Implementation of a Multi-Component Quality Collaborative		93.226	5R01HS024516-03	282,137	6,997
		Examining Non-Visit-Based Antibiotic Use to Improve Safety and Limit Resistance Expansion, Implementation & Evaluation of Electronic Health Record-Integrated		93.226	5R01HS024930-04	562,190	283,893
		Patient-Reported Symptom Screening in a Comprehensive Cancer Center Health related quality of life and seizure medications after hemorrhagic stroke		93.226 93.226	1R18HS026170-01 5K18HS023437-02	7,181 980	
		Health related quality of life and seizure medications after nemormagic stroke Identifying Opportunities to Reduce STI/HIV Disparities among Recent Offenders.	108	93.226	5K18HS023437-02 IN4681903NW//5R01HS023318-02	980 6,053	290
		Improving Outpatient Safety of Older Adults through Electronic Patient Portals		93.226	1R21HS024071-01 REVISED	49,966	
		Improving the Quality of Pediatric Emergency Care Using an Electronic Medical Record In Situ Simulation for Adoption of New Technology to Enhance Safety in Rural EDs		93.226 93.226	5R01HS020270-06 1R18HS024027-03	22,322 146,159	18,377 55,334
		Innovative methods for modeling longitudinal medical costs		93.226	4R01HS020263-05	(34)	
		Innovative methods for modeling longitudinal medical costs		93.226	4R01HS020263-05	6,630	6,630
		Midwest Small Practice Care Transformation Research Alliance		93 226	5R18HS023921-03	3,157,305	1.881.219

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
Department of Health and		Parent Training in Pediatric Primary Care: A Self Directed Tablet Based Approach	237	93.226	Agt4/21/17/15012705sub1/R01HS024273	\$ 9,369	_
Human Services (continued)		Physical Therapy Delivery Models for Long-Term Parkinsons Disease Management Preventing Wrong-Drug and Wrong-Patient Errors with Indication Alerts in CPOE Systems Promoting safe care transitions: Simulation-based mastery learning to improve communication		93.226 93.226	5F32HS025077-02 5R01HS024945-02	67,457 235,713	174,669
		in times of diagnostic uncertainty	204	93.226	080-31050-S27501//R18HS025651	134.305	_
		Redesigning Systems to Improve Quality for Hospitalized Patients		93.226	1R18HS025649-02	200,674	31,190
		Reducing the risk of preventable postpartum lower extremity nerve injuries		93.226	5R03HS025267-02	47,514	3,534
		The Impact of Behavioral Health Treatment among Adolescent Offenders	108	93.226	5R01HS024296-02	12,262	-
		Tools for Optimizing Medication Safety (TOP-MEDS) Using Location-Based Smartphone Alerts within a System of Care Coordination		93.226 93.226	4U19HS021093-05 1R21HS025000-02	99,850 137,030	93,213 20,171
		Using Location-Based Smartphone Alerts within a System of Care Coordination		93.220	182185025000-02	6.152.814	2.849.880
		Measures to National Quality Forum – 2	137	93.RD	Agmt 04/30/17//HHSP233201600230A	33,057	
	Centers for Disease Control and Prevention	The Comprehensive Unit-based Safety Program (CUSP) for Antibiotic Stewardship	122	93.RD	2003757786//HHSP233201500020I	117,855	-
		Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills, and Partnerships Community Counts: Public Health Surveillance for Bleeding Disorders (Region #V-West,	8	93.068	6NU58DP006138-02-02	18,148	_
		HTC #553)	90	93 080	ATHN2015-VW-1-553/ 1 NU27DD001155-03-00	17,515	_
		Rural Cancer Prevention Center 2014-2019	241	93.135	3210000758-18-175//5U48DP005014-04	91,590	_
		Chicago Center for Youth Violence Prevention	228	93.136	FP061138//1U01CE002712-01	234,857	
		Development and Evaluation of Sports Concussion Prevention Strategies	185	93.136	11679SUB//1U01CE002880-01	15,347	
						250,204	
		The roles of TfRs and HSPA5 uptake		93.262	5R01OH010469-04	374,332	153,794
		Prioritizing public health efforts to improve the care and quality of life for people with lupus An Individually Tailored, Family-Centered Intervention for Childhood Obesity: Connecting	142	93.424	1782018//5NU38OT000225-05	13,437	-
		Services in Pediatric Primary Healthcare, the Home, and the Community An Individually Tailored, Family-Centered Intervention for Childhood Obesity: Connecting	17	93.535	18-277//U18P006255	274,013	-
		Services in Pediatric Primary Healthcare, the Home, and the Community.	17	93.535	16-995//1U18DP006255-01	(53,639)	
						220,374	
		Rural Cancer Prevention Center 2014-2019 (SIP-15-007)	241	93.542	3210000447-17-156/3U48DP005014-03S6	1,571	-
		Evaluation Center Extension to Evaluate PrEP Implementation and Data to Care Services Effect of ACA Medicaid Expansion on Diabetes: Diagnosis, Treatment, Patient Compliance,	41	93.940	CONTRACT PO #42045/236320/50105365//U62PS005021	37,159	_
		and Health Outcomes		93.945	5U18DP006120-04	416,320	87,412
		Illinois Perinatal Quality Collaborative (ILPQC)	105	93.946	76380016E//5NU38DP005367-03-00	181,939	144,062
	Centers for Medicare	Intergovernmental Personnel Act Agreement for Theresa Rowe		93.RD	17PA1708457 mod 2	67,583	-
	& Medicaid Services						
		Development and Maintenance of Post-Acute Care Cross-Setting Standardized Patient Assessment Data	168	93.RD	9920170059//HHSM-500-2013-13014I	94,041	_
	Food and Drug Administration						
		A double blind, randomized, vehicle controlled, crossover study with an open-label long-term extension, to evaluate the safety and efficacy of topical naloxone hydrochloride lotion,					
		0.5%, for the relief of pruritus in patients with the mycosis fungoides	70	93.103	No.EL-1007-01-01//R01FD005396	12,477	_
		Increasing the Quality and Efficiency of Clinical Trials	66	93.103	5R18FD005292-02 ADDENDUM	96,574	_
		Increasing the Quality and Efficiency of Clinical trials	66	93.103	203-7585//5R18FD005292-04	23,752	_
		Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic Fibrosis	273	93.103	UWSC8836//2R01FD003704-03A1	14,225	
		Psychometric Evaluation of a New CABP PRO Instrument	102	93.RD	ICON Signed 03/26/18	<u>147,028</u> 630	
		The influence of brand and principal display panel (PDP) for safe consumer use of	102				
	Health Resources and	over-the-counter (OTC) drugs—Advancing the science		93.RD	HHSF223201510126C//0004	149,099	26,956
	Services Administration						
		Hemophilia Treatment Center (HRSA Award) Racial and Ethnic Disparities in Autism Diagnosis and Educational Therapy Utilization:	90	93.110	Agmt 10/31/16//H30MC24052	27,439	-
		Quantifying the Contribution of Modifiable Mediators		93.110	7 R40MC30751-01-00	23,167	
						50,606	
		A joint CCHHS/Northwestern Preventive Medicine Residency with Integrative Health Care Training Program	96	93.117	01353-NoA-NWU03//6D33HP29245-01-01	27,477	_
		Implementation of the Live Donor Champion Program	122	93.134	2003709195//1R39OT31103-01	39,324	-
		Promotoras de Donación: Leveraging Lay Educators to Increase Donor Registration in Older Hispanic Women	201	93.134	1R39OT29878-01-00	38,680	
		Ryan White HIV/AIDS Program Implementation Center for HIV Clinical Quality Improvement	05	00.445	5740 04/2010000000000000000000000000000000000	78,004	
		EVan white HIV/AUUS Program Implementation Center for HIV Clinical Quality Improvement	95	93.145	5740-01//6U28HA30791-02-01	14.767	_
		Affordable Care Act Teaching Health Center (THC) Graduate Medical Education					

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
Department of Health and		Affordable Care Act Teaching Health Center (THC) Graduate Medical Education (GME)			- · · ·		
Human Services (continued)		Payment Program		93.530	6 T91HP215420603	\$ 2,735,022	1,254,995
						2,994,879	1,253,257
		Academic Units for Primary Care Training and Enhancement Use of Social Media to Improve Engagement, Retention, and Health Outcomes along the		93.884	6UH1HP29963-03-01	582,283	91,447
		HIV Care Continuum	99	93.928	AGREEMENT 3/10/16 // 1 H97HA288910100	18,790	_
		Better Health through Education and Transformation of Older Adult care in Illinois Illinois Perinatal Quality Collaborative (ILPQC) Title V	178 105	93.969 93.994	4UQHP28715-02//6U1QHP287150101 86380016F	6,222 121,240	_
		Building Data Infrastructure in the Safety Net to Conduct Patient-Centered Outcomes Research	6	93.RD	001C-06//HHSH25201400001C	3,281	-
	National Institutes of Health	Building Data Infrastructure in the Safety Net to ConductPatient-Centered Outcomes Research	6	93.RD	001C-08//HHSH25201400001C	6	-
	National Institutes of Health	AHA Tobacco Regulatory Science and Addiction Center (A-TRAC)	252	93.077	65105010617-NWU//P50HL120163	(2,844)	_
		American Heart Association Tobacco Regulation and Addiction Center "A-TRACK"	9	93.077 93.077	FX-ATRAC-NWU-04//4P50HL120163-04 FX-ATRAC-NWU-05//5P50HL120163-05	2,334 104.165	_
		American Heart Association Tobacco Regulation and Addiction Center "A-TRACK"	9	93.077	FX-ATRAC-NWU-05//5P50HL120163-05	104,165	
		Association of ALS to gene-environment mediated changes in HDL proteins		93.113	5R01ES022310-05	235.988	
		Carbon Nanotube Structure-Activity Relationships for Predictive Toxicology	222	93.113	0521 G RA276 Amd 5 // 5R01ES022698-05	71,597	_
		Effects of air pollution and gestational diabetes on autism Effects of Flame Retardants on brain function and attentional deficits in school-age	125	93.113	OOS030239NUCS113726//1R56ES028121-0	4,807	_
		children – brain imaging, neurobehavioral, and gut microbiome studies in a longitudinal					
		birth cohort	50	93.113	1(GG013015-01)//1R01ES027845-01A1	8,883	-
		Epigenetic Mechanisms of PM-Mediated CVD Risk Ex Vivo Female Reproductive Tract Integration In a 3D Microphysiologic System	257	93.113 93.113	5104343//4R01ES020836-05 3UH3TR001207-05S1	65,256 82,748	60,019
		Mechanisms of airborne particulate matter induced thrombosis	228	93.113	FP058473/7R01ES015024	10,320	_
		Mechanisms of Cadmium Induced Dysglycemia and Type 2 Diabetes Mellitus Mitioation of asbestos induced alveolar epithelial cell injury		93.113 93.113	1R01ES027011-02 4R01ES020357-05	427,883 4.353	_
		PCOS and androgen-related disease modeling and drug testing in Multi-organ Integrated		53.113	4K01E3020337-03	4,555	_
		Microfluidic Reproductive Platform		93.113	5UG3ES029073-02	1,121,347	148,755
		Protein Adducts as Measures of Exposure Throughout Childhood Development The role of alpha-T-catenin in the pathogenesis of occupational asthma		93.113 93.113	5R21ES026776-02 5F30ES024622-03	211,173 26,743	_
						2,271,098	208,774
		Cortico-striatal plasticity in the transition to chronic pain		93.121	4R01DE022746-05 REVISED	171,518	_
		Enamel matrix 3D organization and maturation stage ion flow Evolution of Chemical, Structural, and Mechanical Properties of the Surface Zone in Caries	78	93.121	NWU025865-2565//5R01DE025865-02	29,082	-
		Lesions: A Multimodal, Correlative Imaging Approach		93.121	1F31DE026952-01A1	23,838	_
		Impacting The Oral HPV Continuum: Prevention, Screening, And Early Detention	122	93.121	2003348761//1R35DE026631-01	6,938	_
		Nanotechnology Strategies for the Growth of Bones and Teeth The role of amorphous intergranular phases in the development of caries lesions		93.121 93.121	5R01DE015920-10 5R01DE025702-03 REVISED	(49) 450,717	(49)
		· · · · · · · · · · · · · · · · · · ·				682,044	(49)
		A randomized, double-blind, placebo-controlled study of 4-hydroxtamoxifen topical gel in					
		women with mammographically dense breasts A randomized, double-blind, placebo-controlled study of 4-hydroxtamoxifen topical gel in	268	93.135	00004892//HHSN261201200034I	38,615	-
		women with mammographically dense breasts -fixed pricing	268	93.135	00004887/HHSN261201200034I	6,744	_
		Effect of Aspirin on Biomakrers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus with Radiofrequency Ablation	268	93.135	Sub#00003350//HHSN261201200034I	509	_
		Effect of Aspirin on Biomakrers of Barrett's Esophagus After Successful Eradication of					
		Barrett's Esophagus with Radiofrequency Ablation	268	93.135	Sub#00003339//HHSN261201200034I	46.018	
		Embedding Pharmacogenotyping in an Integrated Health System for the Underserved	107	93.172	IN4687739NU//5U01HG007762-03	46,018	
		Genomic Medicine at Northwestern: Discovery and Implementation	107	93.172	5U01HG008673-04	930,285	_
		Health Care Provider responses to receiving unsolicited genomic results	44	93.172	GENFD0007484300//1R01HG010004-01A1	7,412	-
		Interactive Multimedia Consent for Blobanking VGER, the Vanderbilt Genome-Electronic Records Project	239 278	93.172 93.172	1001514516//5R01HG008348-03 VUMC66624//2U01HG008672-04S1	111,876 4,103	_
		· , · · · · · · · · · · · · · · · ·				1,091,058	
		A Family-Genetic Study of Language in Autism		93.173	5R01DC010191-08	598,681	135,360
		Ability of older adults to benefit from dynamic pitch for speech recognition in noise		93.173	5F32DC014629-02	2,338	_
		Acoustic and Perceptual Effects of WDRC Amplification Atrophy and resting state connectivity in primary progressive aphasia		93.173 93.173	5R01DC006014-13 5 K23 DC014303-04	268,372 220,755	84,536
		Attophy and resting state connectivity in primary progressive aphasia Attention-depdendent neural oscillations in the human olfactory system		93.173	5R00DC012803-05 REVISED	103,122	_
		Auditory input to cerebellar unipolar brush cells		93.173	1R21DC016759-01A1	40,638	-
		Can Consumers and Audiologists Detect Ear Disease Prior to Hearing Aid Use? Cellular Mechanisms Underlying Corticocollicular Modulation in the Auditory System	260	93.173 93.173	5R33DC013115-05 0033928 (124432-1)//5R56DC031272-02	405,546 (3,488)	241,167
		Central auditory deficits associated with HIV infection and treatment	61	93.173	R924//5R01 DC009972-09	13,258	_
		Characterizing Variability in Hearing Aid Outcomes Among Older Adults		93.173	FDP2R01DC012289-06	454,494	126,467
		Connectome-guided high-definition tDCS for the treatment of tinnitus Core Center for Integrated Research on Human Communication Disorders		93.173 93.173	7R21DC015880-03 5P30DC012035-05 REVISED	74,775 372,331	_
				00.110		572,001	

Supplementary Schedule of Expenditures of Federal Awards

			Pass- through			Federal	Passed-through to
Cluster title/Federal grantor	Subagency	Project title	ID number	CFDA	Sponsor award number	expenditures	subrecipients
epartment of Health and		CRCNS US-French Research Proposal Plastic Neural Circuits in Olfactory Learning		93.173	5R01DC015137-03	\$ 52,728	_
Human Services (continued)		Defining molecular mechanisms in the SLC26 family of proteins		93.173	5R03DC014553-03 REVISED	90,490	-
		Dynamic interaction among proteins in hair cells		93.173	2R56DC011813-06	326,217	
		Effects of hearing experience on audiovisual speech perception in children Elucidating Mechanisms Underlying Odor-Mediated Memory Consolidation During Sleep		93.173	1R56DC015492-01A1	186,659	55,343
		and Wakefulness		93,173	5F31DC015374-03	41.139	_
		fMRI Correlates of Speech and Voice Impairment in Parkinson's Disease		93.173	5F31DC015717-02	38.128	_
		Genetic Determinats of Taste Preferences and Risk of Metabolic Disease		93.173	7R03DC013373-03	53,000	_
		Glomerular domains and olfactory circuitry		93.173	5R03DC014565-03	118,959	_
		Hearing in noise in early childhood: neurophysiological, cognitive, and linguistic mechanisms		93.173	5F31DC016205-02	36,742	-
		Language in Primary Progressive Aphasia		93.173	5R01DC008552-12	846,365	4,201
		Mapping and function of odorant receptors in the human olfactory system		93.173	3R01DC014426-04S1	134,725	_
		Mechanisms Regulating Synaptic Function in the Developing Auditory System		93.173 93.173	5R03DC013841-03 5K08DC013829-05	118,622	_
		Nanotechnological Regeneration of Spiral Ganglion Neurons with Human Stem Cells Neurobiology of Language Recovery in Aphasia: Natural History and Treatment-Induced		93.173	5K06DC013629-05	225,247	_
		Recovery		93,173	5P50DC012283-05 REVISED	1.811.128	959.476
		Neurolinguistic Investigations of Aphasia and Recovery		93.173	5R01DC001948-21 REVISED	451,119	
		Outer and Inner Hair Cell Development		93.173	1R01DC015903-01A1	670,043	_
		Parent-toddler EEG neural synchrony as a window into social communication deficits in autism		93.173	1R21DC017210-01	19,355	-
		Perceptual Coding and Modulation of Odor Objects in the Human Brain		93.173	5R01DC010014-09 REVISED	(1,622)	-
		Perceptual Coding and Modulation of Odor Objects in the Human Brain	259	93.173	573503//7R01DC010014-10	41,928	_
		Physiologically Derived DPOAE Measurement Methods		93.173	1F32DC016773-01	65,053	-
		Principles of olfactory reward processing in the human brain		93.173	5R01DC015426-03	333,822	13,544
		PROMIS-Deaf Profile: Inclusion of Deaf Patients in Disability and Outcomes Research Proteome Biology of Noise Induced Hearing Loss	82	93.173 93.173	0000025075//7R01DC014463-02 5R00DC013805-04 REVISED	48,077 105.322	-
		Proteome Biology of Noise Induced Hearing Loss Regulation of singular expression in Trace Amine-Associated Receptors		93.173 93.173	5F32DC015962-02 REVISED	105,322 53.026	_
		Research and Mentoring on Swallowing Impairment and Respiratory-Swallow Coordination		93.173	5F32DC015902-02 REVISED 5K24DC012801-06 REVISED	160,126	_
		Sensory Interaction in Voice and Voice Disorders	276	93.173	AAC6717//7R01DC014519-04	9,796	_
		Seventh International Brain Computer Interface Meeting	2.0	93.173	1R13DC016830-01	7.917	_
		Spatiotemporal Mechanisms of Olfactory Processing in the Human Brain	259	93.173	573345//7-R01-DC-013243-06	29,982	_
		Studies in Cochlear Hair Cell Transduction		93.173	5R01DC000089-45	(1,902)	_
		Talker-Listener Alignment During Speech Production and Perception		93.173	5R01DC005794-09	(1)	_
		The function of respiratory-linked local field potential oscillations in human olfactory and limbic					
		brain regions		93.173	1R01DC016364-01A1	109,435	-
		The role of parent phenotype in parent-mediated language interventions for autism		93.173	3R01DC014709-03S1	803,872	-
		The Roles of Espins in Hair Cell Stereocilia		93.173	5R01DC004314-17 REVISED	451,089	-
		The When to Worry about Language Study (W2W-L): Joint consideration of developmental		00.470	10100010070 0111	110 500	
		patterning and neural substrates for enhancing early identification of language impairment Trace Amine-Associated Receptors and Olfactory Behavior in Mammals		93.173 93.173	1R01DC016273-01A1 5R01DC013576-05	112,583 621,262	_
		Type-2 inflammation mediates olfactory loss in Chronic Rhinosinusitis: mechanisms and		93.173	5KUIDCUI3576-05	021,202	_
		therapeutic opportunities		93 173	1R01DC016645-01A1	25,762	_
		Understanding the Benefits of Infrared Nerve Stimulators for Neural Interfaces		93.173	4R01DC011855-05	(38,215)	_
		User-centered control of hearing aid signal processing	27	93.173	Agreement 8/14/2017 // 7R44DC013093-03	87,788	_
					J	10.796.588	1.620.094
						10,790,388	1,020,094
		A Mindfulness-Based e-Health Intervention to Improve Medication Adherence among Breast Cancer Survivors		93.213	1R34AT009447-01A1	16,165	
		A robust heterologous expression system of intact fungal secondary metabolite gene clusters		93.213	IK34A1009447-01A1	16,165	_
		for natural product discovery in Aspergillus nidulans	113	93.213	Agreement 6/27/18 //2 R44 AT009158-02	11,633	_
		Brain mechanisms for clinical placebo in chronic pain	115	93.213	4R01AT007987-05	(94,760)	_
		Creating and Optimizing Mindfulness Measures to Enhance and Normalize Clinical				(,)	
		Evaluation (COMMENCE)		93.213	5R01AT009539-02S1	530,583	204,659
		Mass Spectrometric Studies of Thiotemplate Biosynthesis		93.213	5R01AT009143-15 REVISED	325,027	_
		Mechanisms of Probiotic Analgesia		93.213	5R01AT007701-05	585,736	45,418
		Positive Affect Regulation as Adjuvant to Integrative Therapies for Chronic Pain:					
		Development of the LARKSPUR Clinic-Based Intervention		93.213	1R34AT009685-01	77,355	
						1,451,739	250,077
		Multidisciplinary Treatment for Obstructive Sleep Apnea and Insomnia	228	93.233	7R01HL114529-05	359,642	12,380
		SIESTA (Sleep for Inpatients: Educating Staff to Act) Strengthening circadian signals to enhance cardiometabolic function	220	93.233 93.233	5R25HL116372//5R25HL116372-03 5R01HL140580-02	16,041 229,308	_
		Strengthening circadian signals to enhance cardiometabolic function		93.233	5KUTHL140560-02		
						604,991	12,380
		2/2 - Suicide Prevention in Chinese Older Adults		93.242	5R34MH100393-03	30.834	11.581
		2/2 Targeted Sequencing and Functional Evaluation of Mutations in Schizophrenia	149	93.242	EH13-344-S2//5R01MH100915-04 REVISED	153,100	-
		2/3 Community psychosis risk screening: An instrument development study	,	93.242	5R01MH112545-02	140,020	_
		A Family-Genetic Study of Autism and Fragile X Syndrome		93.242	4R01MH091131-05	389,956	78,939
		Acute Estradiol Regulation of Excitatory Synapses in the Hippocampus		93.242	4R01MH095248-05 REVISED	7,077	_
		Age-Related Histone Modification Effect on Antipsychotic Action		93.242	5R01MH109466-03 REVISED	376,020	-
		Artificial Intelligence in a Mobile Intervention fro Depression (AIM)		93.242	5R01MH100482-05	400,320	-
		Behavioral Relevance of Active Dendritic Mechanisms of Integration and Plasticity		93.242	5R01MH101297-05 REVISED	348,789	_
				93 242	1R21MH113262-01REVISED	37 865	_
		Characterizing antidepressant-like effects of a novel peptide HCN channel inhibitor Chloride homeostasis and GABA maturation in fragile X syndrome		93.242	5R21MH104808-02	(132,967)	_

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

uster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thro to subrecipie
partment of Health and	,	Computerized Adaptive Testing of Suicidality in LGBT Young Adults	228	93.242	FP052801-C//5R01MH100155-05S1	\$ 49,995	
Human Services (continued)		Connecting Patients and Therapists Using a Tech-Based Treatment Support System	220	93.242	5K08MH102336-04	145,960	
		Contributions of Parallel Nigrostriatal Dopamine Circuits to Reward Learning and Habit					
		Formation		93.242	4R00MH109569-04	253,709	
		Cortico-Hippocampal Mechanisms of Context Memory		93.242	5R01MH108837-03	512,552	
		Development of Sub 100 nm Resolution X-ray Nanotomography of Centimeter-Sized Tissues		93.242	1R01MH115265-01	90,300	-
		Dimensions of Early Temper Loss and Low Concern: Clinical Utility and Mechanisms		93.242	5U01MH082830-10	655,759	7
		Discovery of novel small molecule antidepressants Discovery of novel small molecule antidepressants	278	93.242 93.242	5R01MH106511-02 REVISED VUMC64676//7R01MH106511-03	78,454 124,596	
		Early Life Adversity, Biological Embedding, and Risk for Developmental Precursors of Mental	270	93.242	VOMC04070/7R01WH100511-05	124,390	
		Disorders	285	93.242	WU-19-11//1R01MH113883-01A1	53,346	
		Evaluation of antidepressant-like effects of hippocampal HCN channel modulation	200	93.242	5R21MH104471-02	(8,506)	
		Exercise and markers of medial temporal health in youth at-risk for psychosis		93.242	5R33MH103231-05	205,144	
		Expanding College Student Mental Health with Stress Management Mobile Technologies		93.242	5K08MH112878-02	101,862	
		Exploring Mellpaladines as New Serotonin Receptor Antagonists		93.242	1R21MH115301-01A1	2,276	
		From Irritability to Impairment: How Neurodevelopment of Executive Function and Parent-Child					
		Neural Synchrony Influence the Transition from Normal to Abnormal	260	93.242	0046528 (126659-1)//5R01MH107540-03	24,426	
		Generating an Earlier Science of When to Worry: A Neurodevelopmental, Transactional					
		Approach to Characterizing Irritability Patterns Beginning in Infancy		93.242	5R01MH107652-03 REVISED	725,433	:
		Health Consequences of Food & Nutrition Insecurity for HIV+ Women & Their Infants		93.242	7K01MH098902-06	87,229	
		Health consequences of water insecurity for HIV-infected mothers & their infants		93.242	5R21MH108444-03 REVISED	187,470	
		High-Risk Psychosis Youth and Caregivers: Emotion in Interaction		93.242	5R21MH115231-02	133,117	
		IGFI and Depression		93.242	4R01MH094835-05	269,773	
		Internet Psychotherapy for Treating Bipolar Disorder in Primary Care	260	93.242 93.242	0046483(126383-1)//1R34MH107541-03	2,421 334 119	
		Interrogating and sculpting synapses and circuits for rapidly acting antidepressant effects	81		1R56MH113923-01		
		LATIN-MH: Latin America Treatment and Innovation Network in Mental Health LifeSense: Transforming Behavioral Assessment of Depression Using Personal Sensing	81	93.242	2016.86612.002//5U19MH098780-05	35,786	
		Technology		93.242	5R01MH111610-02	186,330	
		LiveWell: A Mobile Intervention for Bipolar Disorder		93.242	5R01MH110626-03	724,089	1
		Mechanisms of Stress-Enhanced Aversive Conditioning		93.242	5R01MH078064-12 REVISED	503,823	
		Molecular, anatomic, and functional characterization of midbrain dopamine neuron subtypes		93.242	5R01MH110556-02 REVISED	904 794	
		Multidisciplinary Training Program in Digital Mental Health		93.242	1T32MH115882-01 REVISED	22,379	
		Neural Habituation in Ultra High-Risk Youth		93.242	5R21MH110374-02 REVISED	200,409	
		Neurohypophyseal regulation of midbrain dopamine systems.		93.242	1R01MH117111-01	1.509	
		New Tools to Study Neurosteroid Estrogens		93.242	5R01MH113189-03	729,510	
		Noninvasive Manipulation of Hippocampal-Cortical Brain Networks and Memory		93.242	5R01MH106512-04	599,907	
		Noninvasive modulation of prefrontal contributions to the organization of episodic memories		93.242	5R21MH108863-02 REVISED	168,720	
		Novel Methods for Evaluation and Implementation of Behavioral Intervention Technologies					
		for Depression	50	93.242	1(GG008480)//1R01MH1094696-02	67,846	
		NRSA F30 for Daniel W Fisher in support of: Role of HCN Channels in Major Depressive					
		Disorder Etiology and Treatment		93.242	5F30MH109249-04	20,772	
		Optimized dosing of repetitive transcranial magnetic stimulation for enhancement of					
		hippocampal-cortical networks		93.242	1R01MH111790-03	464,738	
		Perception and central coherence in autism: A family genetic eye-tracking study		93.242	5R03MH107834-02	55,234	
		Plasticity of Auditory Cortical Circuits in Schizophrenia	260	93.242	0038377 (1245412-1)/5R01MH07533-15	111,665	
		Positive affect skills for depression: Optimizing internet and mobile delivery		93.242	5R34MH101265-03	93,573	
		Postsynaptic roles of ankyrin		93.242	5R01MH107182-04 REVISED	461,211	
		Preclinical and Patient Studies of Affective Disorders in Serbia	237	93.242	5R21MH098793-02 2011-06805-05-04-6564//5R01MH90035-	(1,721)	
		Primary Care Internet-Based Depression Prevention for Adolescents Recording Neural Activities onto DNA	169	93.242 93.242	CC 81347 3024//R01MH103910	20,216 (429)	
		Recording Neural Activities onto DNA Regularity in Parenting: a Biopsychosocial Model for Transmission of Depression	109	93.242	5F31MH105092-02 REVISED	(429) 38	
		Risk for Bipolar Disorder: Reward-Related Brain Function & Social Rhythms	201	93.242	360955-NW Amd 5 // 4R01MH077908-9	22,460	
		SchizConnect: Large-Scale Schizophrenia Neuroimaging Data Mediation & Federation	201	93.242	4U01MH097435-04 REVISED	210,608	1
		Simulated Clinician Assessment for Cognitive Behavioral Therapy Skills	186	93.242	5065-NU//R01MH112625	210,008	
		Simultaneous eye tracking and hippocampal iEEG to identify oscillatory signals of memory	100	00.212		20,111	
				93.242	1R21MH115366-01	125,615	
		Small GTPase signaling in spines		93.242	5R01MH071316-14 REVISED	407.888	
		Stepped Telemental Health Care Intervention for Depression		93.242	4R01MH095753-05	306.624	
		Symptom Dimensions of Threat-And Reward-Related Neurocircuitry	222	93.242	0875 G SA507 Amd No. 4 // 5R01MH100177-05	327,372	
		Synaptic and dendritic dysfunction in psychiatric disorders		93.242	5R01MH097216-07	909,128	
		Systematic Functional Interpretation of Regulatory Variants in Schizophrenia	149	93.242	EH15-150-S1//5R01MH106575-03	121,869	
		Tech-Based Depression and Anxiety Treatment for Youth in High Risk Environments		93.242	4K08MH094441-05	541	
		The NewTics Study: A novel approach to pathophysiology and cause of tic disorders	285	93.242	4K08MH094441-05 WU-17-444//1R01MH104030-01A1	129,880	
		The role of glutamate receptors in compulsive and perseverative behavior	200	93.242	4R01MH099114-05	(156,128)	
		The role of glutamate receptors in compulsive and perseverative behavior		93.242	2R01MH099114-06A1	332,613	
		Training Program in Neurobiology of Information Storage		93.242	4T32MH067564-15	177,294	
		Training Program in Neurobiology of Information Storage		93.242	2T32MH067564-16 REVISED	21,938	
		Transformation of the stress response into motor behavior by the external globus pallidus	267	93.242	0012774A//5R01MH112768-02 REVISED	202,773	
		Virtual Reality Job Interview Training to Enhance Supported Employment for Adults with SMI		93.242	1R01MH110524-01	(2,987)	
			250	93.242 93.242	1R01MH110524-01 3004704106//R01MH110524	(2,987) 174,190	
		Virtual Reality Job Interview Training to Enhance Supported Employment for Adults with SMI					

41

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throug to subrecipients
epartment of Health and	oundgeney	Efficacy of Couples-Based HIV Prevention in Vulnerable Young Men		93.273	5R01AA024065-03	\$ 522,490	36,862
Human Services (continued)		Newborn Phosphatidylethanol Screening to Detect Fetal Alcohol Exposure in Uruguay		93.273	5U01AA024005-03 5U01AA023176-03	\$ 522,490 542,559	242,989
numan dervices (continued)		Role of Alcohol Disparities in HIV Risk among Sexual Minority Youth		93.273	5R01AA024409-03 REVISED	359.205	242,303
		······································				1,423,554	279,851
				00.070			
		A Multilevel Network Model of Drug Use and HIV Racial Disparities in Men A New Approach to Integrating Primary and Secondary HIV Prevention in Young Male Couples		93.279 93.279	5K08DA037825-04 1DP2DA042417-01	161,904 411,992	_
		A New Approach to Integrating Hindly and Secondary HV Hereinon in Foling Male Couples A Systems-level Approach to Studying HIV/AIDS Susceptibility and Substance		93.279	4R01DA033773-05	221.137	6,50
		Center for chronic pain and drug abuse		93.279	1P50DA044121-01A1	52,128	
		Center for Prevention Implementation Methodology for Drug Use and HIV (Ce-PIM)		93.279	3P30DA027828-08S1	1,316,120	226,00
		Cognitive-Affective Substrates of Smoking: Targets for Maternal Behavior Change		93.279	3K23DA037913-04	196,966	-
		Different Components of Nicotine-Induced Upregulation of Nicotinic Receptors	228	93.279	FP052975//1R01DA035430-03	45,261	
		Diversity Supplement: Implementation of Evidence-Based Preventative Parenting Programs Drug Abuse, Incarceration, Health Disparities in HIV/AIDS	17	93.279 93.279	15-737//R01DA0033991 5R01DA028763-05	618 (3,199)	
		Efficacy of Internet-based HIV prevention		93.279	4R01DA035145-05	(3,199) 359,876	77,1
		Enhancing Sustainment of State and Other Systems-wide Advances in the Implementation		00.270		000,010	
		of Treatments for Opioid Use Disorders	193	93.279	61867865-128280//7R01DA037222-03 REVISED	4,427	
		Evaluating the Effectiveness of an eHealth EBI for Latino Youth in Primary Care	249	93.279	667381//5R01DA040756-03	21,563	
		fMRI-based biomarkers for multiple components of pain	231	93.279	1554072//4R01DA035484-05	8,474	
		Identifying nicotine, withdrawal mechanisms hidden within habenular complexity		93.279	5R01DA040626-02	325,952	
		KiiDS: Knowing about Intervention Implementation in Detention Sites Measuring Coalition Capacity to Foster Program Sustainment	72 262	93.279 93.279	T811257//5U01DA036233-05 63501087//5R34DA037516-03 REVISED	12,127 54,185	
		Measuring Coalition Capacity to Poster Program Sustainment Methamphetamine and Parkinson's disease: converging mechanisms of pathogenesis	202	93.279	5K99DA039253-02	54,185 66.231	
		Multilevel Influences on HIV and Substance use in a YMSM Cohort		93.279	3U01DA036939-05S1	1,873,559	3.8
		netCanvas: Development, Hardening, and Dissemination of a Software Suite for the Collection				.,,	-,-
		of Complex Network and Contextual Data in HIV and Drug Research		93.279	5R01DA042711-02 REVISED	643,237	53,1
		Neural mechanisms of context-dependent stimulus generalization in humans		93.279	1R03DA040668-01A1	172	
		New Inactivators of GABA Aminotransferase for Addiction and Epilepsy		93.279	5R01DA030604-08	404,213	32,7
		Nicotinic acetylcholine receptor function in the mesolimbic dopamine system Nicotinic receptor gene editing vectors		93.279 93.279	5R01DA035942-05 5R21DA045507-02	341,101 182.097	
		NRSA F32 for Brian Feinstein in Support of: Dyadic influences on HIV risk behavior and		55.215	SK21DA045507-02	102,097	
		substance abuse among young men who have sex with men and their partners		93.279	5F32DA042708-02 REVISED	22,129	
		Photoactivatable ligands for nicotinic optopharmacology		93.279	1R21DA044460-01A1	8,348	
		RCT of an integrative intervention for non-treatment-seeking meth users	225	93.279	8244sc//5R01DA033854-05	4,858	
		Substance Use, Stress, and HIV Influences on Systemic Inflammation Among Young Men					
		Who Have Sex with Men		93.279 93.279	1F32DA046313-01 REVISED 5R34DA044752-02	26,153 178,010	2.6
		System-Level Implementation to Reduce Excess Opioid Prescribing in Surgery UIUC Neuroproteomics and Neurometabolomics Center on Cell to Cell Signaling	238	93.279 93.279	5K34DA044752-02 074103-15022//5P30DA018310-05	202,139	2,6
		Understanding and reducing HIV risk behavior and substance use among self-identified	230	93.279	074103-15022//5P30DA018310-05	202,139	
		bisexual adolescent men		93.279	1K08DA045575-01	79.526	
		Vulnerability to Drug Use & HIV: Advancing Prevention for Rural African Americans	234	93.279	RR376-428/4945376 Amd 6 // 2P30DA027827-06	112,382	
						7,333,686	401,97
		A Formalism for Customizing and Training Intelligent Assistive Devices		93.286	5R01EB019335-03	40,757	3.8
		A Multi-Scale Modeling Construct of Knee Mechanics following ACL Reconstruction	169	93.286	CL 4346 CC 81345 //5U01EB015410-02	80,896	
		Antifouling Peptide Mimetic Polymers		93.286	4R01EB005772-08	253,434	20,3
		Antigen Loaded Particles for Tolerance Induction	250	93.286	Sub#3003585891//5R01EB013198-09 REVISED	462,382	
		Center of Excellence for Mobile Sensor Data-to-Knowledge (MD2K)	248	93.286	5-40604//5U54EB02040-04	203,717	
		Computational methodologies for safety assessment of MRI in patients with deep brain stimulation implants		93.286	7R03EB024705-02	7.859	
		Design-driven engineering of robust mammalian sense-and-respond functions		93.286	1R01EB026510-01	5.230	
		Enhancing Biomedical Engineering Senior Design at Northwestern University		93.286	5R25EB013060-05	5,230	
		High-throughput molecular-specific cell nanocytology for cancer screening		93.286	4R01EB016983-04	216,269	12,6
		Interdisciplinary Graduate Education in Movement and Rehabilitation Sciences		93.286	5T32EB009406-08	200,506	
		In-vivo characterization of pancreatic field carcinogenesis using spatially resolved reflectance					
		measurements via a fiber optic probe		93.286	5F31EB022414-02	33,612	
		Microconnectomics of neocortex: a multiscale computer model	195 122	93.286	1120566-75050/5U01EB017695-04	119,952	
		Neurodegenerative and Neurodevelopmental Subcortical Shape Diffeomorphometry Software Patient-adjustable MRI technology for high-resolution imaging of deep brain stimulation	122	93.286 93.286	2003341343//R01EB020062 4R00EB021320-02	78,800 14,251	
		Preclinical Investigation of a Bioengineered Vascular Graft		93.286	4R00EB021320-02 4R01EB017129-04	14,251 136,260	80,0
		Protein-Releasing Microporous Scaffolds for Cell Replacement Therapy	250	93.286	3003655776//5R01EB009910-09	112.981	00,0
		Rapid Pediatric Cardiovascular MRI without Contrast Agent or Anesthesia	200	93.286	5R21EB024315-02	113,779	5,4
		SCH: Interface Monitoring System to Promote Residual Limb Health		93.286	5R01EB019337-03	416,672	331,8
		Shape Control and Transport Properties of DNA-Copolymer Micelles	122	93.286	2002586569 Amd 2//5R01EB018358-02-REVISED	77,386	
		Steroid-Based Contrast Agents for Magnetic Resonance Imaging of Endocrine Diseases		93.286	5R01EB014806-04	(333)	
		Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer	165	93.286	4102-77270//5R01EB016582-03	128,792	
		Transarterial Immunomodulatory Embolization: A novel approach to cancer therapy Unassisted Blood Pressure Monitoring Using Arterial Tonometry and Photoplethysmography		93.286 93.286	3R21EB022291-02S1 5U01EB020589-02	239,955 135,190	45,6
		Understanding Real-Life Falls in Amputees using Mobile Phone Technology	169	93.286	CC# 81920 CL3719//5R01EB019406-03	(1)	
		encertaining new and interpreted doing movie i none realitionagy	100	00.200		3.078.339	499.75
						3,078,339	433,1
		2017 LGBTQ Health Conference: Bridging Research and Practice A Pragmatic Trial of An Adaptive eHealth HIV Prevention Program for Diverse Adolescent MSM		93.307 93.307	1R13MD011360-01 5U01MD011281-03 REVISED		359.6

Supplementary Schedule of Expenditures of Federal Awards

			Pass- through			Federal	Passed-throu to
Cluster title/Federal grantor	Subagency	Project title	ID number	CFDA	Sponsor award number	expenditures	subrecipien
epartment of Health and Human Services (continued)		African American Cardiovascular pharmacogenetic CONsorTium (ACCOuNT): discovery and translation Effectiveness and Implementation of a Mindfulness Intervention for Depressive Symptoms		93.307	5U54MD010723-03 REVISED	\$ 1,281,788	609,42
		Among Low-income, Racial/Ethnic Minority Adults in a Federally Qualified Health Center		93.307	1R01MD012236-01A1	19,766	
		ELLAS: Environment, Leiomyomas, Latinas and Adiposity Study	250	93.307	3004650350//7R01MD011570-02	33,467	
		Ethics in HIV Prevention Research Involving LGBT Youth	200	93.307	5R01MD009561-04 REVISED	349,931	50,54
		Genomic Analysis of Enhanced Response to Heart Failure Therapy in African Americans	260	93.307	0041119 (124864-3)//1R01MD009118-02	7,961	50,54
		Genomic Analysis of Enhanced Response to Heart Failure Therapy in African Americans	200	53.307	0041119(124004-3)//10010009118-02	7,901	
		(GRAHE)	260	93 307	0041119(124864-6)//R01MD009118-02	7,587	
		Health disparity in pharmacogenomics: African American SNPs and drug metabolism	200	93.307	5R01MD009217-06	440,802	
		Integrating Text Messages into the Mothers and Babies Course to Address Depression in		33.307	510 1ME5032 11-00	440,002	
		Low-Income Women and their Partners		93.307	5R21MD011320-02	200.705	48.4
		Latino vs. Non-Latino Disparities in Advance Care Planning & End-of-Life Care	121	93.307	183120-02//5R01MD007652-05	46.018	1.6
		Reducing Assessment Barriers for Patients with Low Literacy		93.307	3R01MD010440-02S2	494 164	76,0
		The Price of Debt: The Unequal Burden of Financial Debt and Its Impact on Health	245	93.307	S20140000026205// 5R01MD007723-03	17,867	10,0
		Understanding Patterns of Healthy Aging Among Men who have Sex with Men	260	93.307	0047269(126836-2)//5R01MD010680-04	71,719	
		Understanding socioeconomic disparities in perinatal risk: The role of epigenetic and	200	00.001		11,110	
		transcriptional regulation in the placenta		93.307	5R01MD011749-02	151 482	
		Using epigenomic subtyping to understand the racial differences in lymphoma	228	93.307	FP064397//R21MD011439	43.049	
		cong opgenenie eastpring to an electrand the racial an electroce in this proma	220	00.007			-
						5,285,879	1,145,
		A New High-Throughput Technology to Reveal the Dynamic Functional States of RNAs		93.310	7DP2GM110838-02	447,680	203.
		A Phase 2a Multi-Center Study of 18F-FDG PET, Safety, and Tolerablity of AZD0530 in Mild		33.510	101 2010110000-02	447,000	200.
		Alzheimer's Disease	262	93.310	CTAFYN067//4UH3TR000967-02	58.437	
		A systems-level study of signaling networks and differentiation	228	93.310	FP060024 Amd 1 // 1R01EY025957-01A1	115,765	
		Center for 3D Structure and Physics of the Genome	247	93.310	PO No. WA00620170 // OSP2017053 Amd 1 // 5U54DK107	141.087	
		Genetic mapping of visual circuits	241	93.310	3DP2EY027983-01 S1	430,478	
		Identifying Mechanisms Governing T Cell Diversity		93.310	1DP2AI136599-01	343,646	
		National Research Mentoring Network for a Diverse Biomedical Workforce	271	93.310	10045839-07//5U54GM119023-04	31,160	
		National Research Mentoring Network for a Diverse Biomedical Workforce	274	93.310	706K661//5U54GM119023-03	36,819	
		Recording Neural Activities onto DNA	259	93.310	573341//7-R01-MH-103910-06	422,895	
		Regulatory Circuits Controlling Regenerative Growth	200	93.310	1DP2DE024365-01	533.635	
		Sub-micrometer x-ray tomography for neuroanatomy		93.310	5U01MH109100-03	731.631	193
		Sub-micrometer x-ray temography for neuroanatomy		33.510	300 mm 1103 100-03		
						3,293,233	396,
		A National Center for Digital Health Informatics Innovation.	157	93.350	1011902_NWU//U24TR002306	516,815	
		Blood Tests to Screen for Colon and Pancreatic Cancer	228	93.350	FP065282-E//1UL1TR002389-01 REVISED	2,763	
		Improving Patient Reported Outcome Data for Research through Seamless Integration of the					
		PROMIS Toolkit into EHR Workflows		93.350	5U01TR001806-03 REVISED	1,094,401	858
		Northwestern University Clinical and Translational Science Institute (NUCATS)		93.350	5KL2TR001424-04	604,536	
		Northwestern University Clinical and Translational Science Institute (NUCATS)		93.350	5TL1TR001423-04 REVISED	525,252	355
		Northwestern University Clinical and Translational Sciences Institute (NUCATS)		93.350	5UL1TR001422-04	6,071,983	330
		University of Pittsburgh Clinical and Translational Science Institute (CTSI) ACT					
		Administrative Supplement	260	93.350	0055353(130910-17)//5UL1TR001857-03	29,677	
						8.845.427	1.544
		EHR-Based Health Literacy Strategy to Promote Medication Therapy Management		93.361	5R01NR012745-05	(1,099)	
		EHR-based Health Elleracy Strategy to Promote Medication Therapy Management EHR-based Universal Medication Schedule to Improve Adherence to Complex Regimens		93.361	5R01NR012/45-05 5R01NR015444-02	(1,099) 592,882	312
				93.361	4R01NR014182-05	139,827	312
		HippoPCI Hippocampal Predictors of Cognitive Impairment in Breast Cancer Patients Interventions for Symptom Management in Older Patients with HAND	225	93.361	8729sc//5R01NR015223-05	32,845	
			225	93.361	9487sc//5R01NR015223-05	32,045 23 133	
		Life Enhancing Activities for Family Caregivers of People with Dementia More than a Movement Disorder: Applying Palliative Care to Parkinson's Disease	225	93.361	FY17.782.003//1R01NR016037-01A1	23,133 4.913	
		More than a Movement Disorder. Applying Pallative Care to Parkinson's Disease Morning Light Treatment at Home to Improve Glucose Metabolism in People at Increased Risk	231	93.301	FT17.762.003// IRUTNRUT0037-0TAT	4,913	
		for Type 2 Diabetes		93.361	7R21NR016377-02	170.447	53
		Quality of Life in Caregivers of Traumatic Brain Injury: The TBI-CareQOL	250	93.361	3002557849//4R01NR01365805	52 083	53
		Use of simulation to improve ventricular assist device self-management	250	93.361	5R21NR016745-02 REVISED	205,959	
		User-Centered, Web-based Portal to Support Regimen Adherence in Transplant	72	93.361	5R2 INR016745-02 REVISED T539496//R21NR014544	205,959 20,692	
		Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms	50	93.361	1(GG012114-01)//5R01NR015737-03	20,092 21,373	
			00	00.001			
						1,263,055	367
		Annual International Science of Team Science Conference		93.389	5R13TR000046-05	1,247	1
		A population-based approach to single CTC analysis in metastatic breast cancer	204	93.393	080-27000-S27101//1R01CA207468-01A1	45,382	
		Adapting patient navigation to promote cancer screening in Chicago's Chinatown		93.393	5R01CA163830-06	398,015	208
		Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis		93.393	4R01CA164041-05	110,712	1
		Apigenin restores TSP-1 expression in UVB-irradiated keratinocytes	268	93.393	3001001876//7R01CA172669-005	27,932	
		Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers		93.393	5R01CA184211-05	688,453	316
		Communicate and LEarn About youR Variant of Uncertain Significance (CLEAR VUS)		93.393	5R03CA194643-02 REVISED	34,726	ç
		Communicate and Learn About your variant of Uncertain Significance (CLEAR VUS)					
		Comparative Effectiveness of Genomics Assay for Active Surveillance Failure Prediction in					
		Comparative Effectiveness of Genomics Assay for Active Surveillance Failure Prediction in		93,393	5R21CA202552-02 REVISED	66 323	20
		Comparative Effectiveness of Genomics Assay for Active Surveillance Failure Prediction in African American Men: the impact of genetic ancestry and socioeconomic status		93.393 93.393	5R21CA202552-02 REVISED 5R21CA210904-02	66,323 126,381	20
		Comparative Effectiveness of Genomics Assay for Active Surveillance Failure Prediction in					20

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thre to subrecipie
epartment of Health and		Disease Beliefs and Cognition: Effect on Diabetes Management in Older Breast Cancer					
Human Services (continued)		Survivors	100	93.393	0255-3801-4609//1R01CA214491-01A1	\$ 160,325	
		Evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ		93 393	5R01CA218436-02	441.541	208
		Exploring a new therapeutic approach through targeting epigenetic enzymes in ALL		93.393	5R00CA188293-04	441,541 189,954	206.
		Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial	259	93.393	568912//4R01CA165001-05	23,889	
		Feasibility of OncoMed to Improve Self-Management and Adherence to Oral Anticancer					
		Medications		93.393	1R21CA226671-01A1	5,193	
		Functional Dissection of the K27M Histone Mutation In Gliomagenesis		93.393	5R01CA197313-03	339,774	
		Herpesvirus Gene Expression in Transformed Cells		93.393	5R01CA021776-38 REVISED	179,756	14,
		Histone Modification and Transcription Elongation in Human Cancer		93.393	5R50CA211428-03	178,115	
		HPV and the DNA Damage Response In Vivo Model of Epstein-Barr Virus Latency		93.393 93.393	5R01CA142861-07 5R01CA073507-20	355,997 424,870	
		Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH		93.393	5R01CA073507-20 5R01CA172431-05 REVISED	424,870 159,414	30
		Kaposi's Sarcoma-associated Herpesvirus Mimics of Cellular microRNAs		93.393	5R01CA180813-05 REVISED	347.833	50
		Methylomic biomarkers for magnesium deficiency and colon neoplasia prevention	278	93.393	VUMC 57993//5R01CA202936-04	136.319	
		Minimally Intrusive Colorectal Cancer Risk Stratification with Nanocytology: Targeting				,	
		Underscreened Populations	29	93.393	R33CA225323	51,785	
		Mutations of Chromatin and its Modifying Machineries in Malignancies		93.393	5R35CA197569-04	898,694	
		Progesterone Signaling and Blockade in Human Breast Tumorigenesis and Prevention		93.393	5R01CA192124-04	486,721	
		PROMIS AYA/Optimizing Health Related Quality of Life Measurement in Adolescent and					
		Young Adult Oncology: A PROMISing Solution	284	93.393	WFUHS114162//R01CA218398	35,986	
		Prostate Cancer Susceptibility: The ICPCG Study Reducing the Effects of Active Surveillance Stress. Uncertainty and Rumination thru	135	93.393	64853091 NOR-181797-02//5U01CA089600-13	4,606	
		Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination thru Engagement in Mindfulness Education (REASSURE ME)		93.393	5R01CA193331-03 REVISED	518.218	37
		Regulation of Human Papillomavirus Gene Expression		93.393	5R01CA059655-25 REVISED	264.867	37
		Role of NF90 in Prostate Cancer		93.393	1R01CA227918-01A1	2,263	
		Role of the Ndc80 Loop Domain and Cdt1 in Kinetochore Microtubule Attachments		93.393	5R00CA178188-05	89,206	
		ROS and HIFa as molecular targets for chemoprevention in Sirt3 -/- breast cancers		93.393	4R01CA168292-05	260,807	
		SIRT3 is a Mitochondrial Tumor Suppressor in ER/PR Positive Mammary Tumors		93.393	5R01CA152799-05	(11,495)	
		Structural Cell Biology of DNA Repair Machines	221	93.393	7336107 Mod. 1 // 2P01CA092584-16	54,567	
		The National Person-Centered Assessment Resource (PCAR)		93.393	3U2CCA186878-04S1	475,286	18
		Training primary care physicians to perform melanoma opportunistic surveillance		93.393	5R21CA182725-02	13,902	
		Transcriptional Elongation Control in Development and Disease		93.393	3R01CA214035-17S1	752,366	
		Using Text Messaging to Increase HPV Vaccination among Young Sexual Minority Men		93.393	5R21CA208329-02	99,429	3
						8,941,807	1,617
		(PQD5) imaging systemic tissue injuries induced by anticancer drugs		93.394	5R01CA185214-04 REVISED	301,400	
		A comparison of interventions to teach patients skin self-examination		93.394	5R01CA154908-07 REVISED	479,223	24
		Biophotonics to Couple Pancreatic with Upper GI Screening via Ultrathin Endoscopy Catheter-Directed Image-Guided Delivery of Cytostatic and Cytotoxic Combination Therapy to		93.394	5R01CA183101-04 REVISED	438,055	24
		Liver Tumors		93.394	1R01CA218659-01A1	86,262	
		Detection of 5-hmC as a Novel Screening Biomarker for Pancreatic Cancer		93.394	5R21CA187869-02	122,833	
		Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon		93.394	FP064995//U01CA217078		
					FP064995//001CA21/078		
		cancer detection and prognosis	228			97,382	
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma	228 228	93.394	FP066297-02-PR-B//1R01CA223662-01A1	6,389	
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas		93.394 93.394	5R21CA209345-02	6,389 110,651	
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas Molecular Target Variation Across Environments and at Margins of Glioblastoma		93.394 93.394 93.394	5R21CA209345-02 7R01CA176659-06	6,389 110,651 77,622	
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas		93.394 93.394	5R21CA209345-02	6,389 110,651	
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas Molecular Target Variation Across Environments and at Margins of Glioblastoma MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Inversible Electroporation Ablation for Liver Tumors		93.394 93.394 93.394 93.394	5R21CA209345-02 7R01CA176659-06 5R01CA209886-03	6,389 110,651 77,622 410,383	
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas Molecular Target Variation Across Environments and at Margins of Glioblastoma MRI-Guided Dendriti-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer		93.394 93.394 93.394 93.394 93.394 93.394	5R21CA209345-02 7R01CA176659-06 5R01CA209886-03 5R01CA196967-04	6,389 110,651 77,622 410,383 336,243	27
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giloblastomas Molecular Target Variation Across Environments and at Margins of Giloblastoma MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Unversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafehib-Euling Microspheres to Liver Tumors		93.394 93.394 93.394 93.394 93.394 93.394 93.394	5R21(2A209345-02 7R01CA176659-06 5R01(CA196967-03 5R01CA196967-04 5R01CA181658-04 REVISED	6,389 110,651 77,622 410,383 336,243 444,245	2
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma identification of Long Non-coding RNAs as Novel Biomarkners for Heterogeneous Gioblastomas Molecular Target Variation Across Environments and at Margins of Glioblastoma MRI-Guided Dendhin-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Inversible Deckroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Nanoscale/Molecular analysis of Fecal Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening		93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	SR21CA203345.02 7R01CA176659-06 SR01CA209896-03 SR01CA198097-04 SR01CA181658-04 REVISED 4R01CA165309-05 SR01CA15524-04 REVISED SR01CA15524-04 REVISED	6,389 110,651 77,622 410,383 336,243 444,245 532,372 (158) 42,946	
		Epigenomic markers of zirculating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giloblastomas Molecular Target Variation Across Environments and at Margins of Giloblastoma MRI-Guided Drendrilic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Inversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Nanoscale/Molecular analysis of Facal Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Risk-straftication of Prostate Cancer svi Field Carcinogenesis Nanocytology		93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	5R21CA209345-02 7R01CA17659-06 5R01CA196967-04 5R01CA196967-04 SR01CA19509-05 SR01CA19528-04 REVISED SR01CA15528-04 REVISED SR01CA15528-04 REVISED SR01CA15028-04 REVISED SR01CA20004-03	6,389 110,651 77,622 410,383 336,6243 444,245 5532,372 (156) 42,246 632,294	2
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giloblastomas Molecular Target Variation Across Environments and at Margins of Giloblastoma MRI-Guided Dendriti-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Interversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Soration-Elutiong Microspheres to Liver Tumors Nanoscale/Molecular analysis of Fecal Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Buccal Collis: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology Systemic RNA Interference to reactivate pols Stumor suppression	228	93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	5R21(2A209345-02 7R01CA176659-06 5R01(CA209866-03 5R01CA190967-04 5R01CA16559-04 REVISED 4R01CA165309-05 5R01CA165284-04 REVISED 5R01CA155284-04 REVISED 5R01CA20064-03 5R01CA20078-02 REVISED	6,389 110,651 77,622 410,383 336,243 444,245 532,372 (158) 42,246 632,294 434,623	2
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas Molecular Target Variation Across Environments and at Margins of Glioblastoma MRI-Guided Drendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Inversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Nanoscale Analysis of Fecal Condoncytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology Systemic RNA interference to reactivate p53 tumor suppression Targeted MRI contrast agents for differential diagnosis of prostate cancer	228 36	93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	5R21CA209345-02 FR01CA209886-03 5R01CA19589-06 SR01CA1959967-04 5R01CA19509-05 SR01CA155284-04 REVISED 5R01CA155284-04 REVISED 5R01CA155284-04 REVISED SR01CA200783-02 REVISED SR01CA200783-02 REVISED KESS1197/SR01CA211782-02	6,389 110,651 177,622 410,383 336,6243 444,245 552,372 (158) 42,946 632,254 43,623 10,741	
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Gioblastomas Molecular Target Variation Across Environments and at Margins of Gioblastoma NRI-Guided Dendritic-Cell-Based Vaccine ImmunoIterapy for Pancreatic Cancer MRI-Monitored Delvey of Sorafinb-Eluting Microspheres to Liver Tumors Nanoscale/Molecular analysis of Feacl Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Bucci Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Bucci Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology Systemic RNA Interference to readvate pols Stumor suppression Targeted MRI contrast agents for differential diagnosis of prostate cancer Transforming the diagnosis and care of patients with CTCL using TCR sequencing	228	93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	5R21(A209345-02 7R01(CA176658-06 5R01(CA196967-04 5R01(CA196967-04 5R01(CA165594-05 5R01(CA16558-04 REVISED 5R01(CA165284-04 REVISED 5R01(CA155284-04 REVISED 5R01(CA20783-02 REVISED 5R01(CA20783-02 REVISED FR015A20783-02 REVISED RESS11975//JR01(CA21772-02 114835//JR01(CA20737-03	6,389 110,651 77,622 410,383 336,243 444,245 532,372 (156) 4,2,946 632,254 434,623 10,741 73,412	34
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas Molecular Target Variation Across Environments and at Margins of Glioblastoma MRI-Guided Drendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Inversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Nanoscale Analysis of Fecal Condoncytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology Systemic RNA interference to reactivate p53 tumor suppression Targeted MRI contrast agents for differential diagnosis of prostate cancer	228 36	93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	5R21CA209345-02 FR01CA209886-03 5R01CA19589-06 SR01CA1959967-04 5R01CA19509-05 SR01CA155284-04 REVISED 5R01CA155284-04 REVISED 5R01CA155284-04 REVISED SR01CA200783-02 REVISED SR01CA200783-02 REVISED KESS1197/SR01CA211782-02	6,389 110,651 77,622 410,383 336,243 444,245 532,374 42,946 632,294 434,523 10,741 73,412 353,361	34
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giioblastomas Molecular Target Variation Across Environments and at Margins of Giioblastoma MRI-Guided Interversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Optical Nanoscale Analysis of Beacl Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Buacl Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buacl Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology Systemic RNA interference to reactivate p53 tumor suppression Targeted MRI contrast agents for differential diagnosis of prostate cancer Transforming the diagnosis and care of patients with CTCL using TCR sequencing Tumor immune and glycan biomarkers for progressive prostate cancer	228 36	93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	SR21CA209345-02 TR01CA176659-06 SR01CA209886-03 SR01CA1980987-04 AR01CA181589-04 REVISED SR01CA155284-04 REVISED SR01CA155284-04 REVISED SR01CA200783-02 REVISED SR01CA200783-02 REVISED SR01CA200783-02 REVISED RESS1175/KR01CA2178-02 114855/JFKR01CA203731-03 1R01CA212409-01A1	6,389 110,651 77,622 410,383 336,643 444,245 552,372 (158) 42,946 652,294 434,623 10,741 73,412 353,361 4,990,179	34
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Gioblastomas Molecular Target Variation Across Environments and at Margins of Gioblastoma MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Interversible Electroporation Ablation for Liver Tumors Nanoscale/Molecular analysis of Feact Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Bucac Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucac Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology Systemic RNA interference to reactivate platents with CFLC using TCR sequencing Targeted MRI contrast agents for differential idiagnosis of prostate cancer Transforming the diagnosis and care of patients with CFLC using TCR sequencing Tumor immune and glycan biomarkers for progressive prostate cancer	228 36 31	93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	FR21CA209345-02 TR01CA17658-06 SR01CA209886-03 SR01CA19565-04 SR01CA19565-04 RV01CA19568-04 RV01CA195824-04 RV01CA195284-04 RV01CA195284-04 RV01CA195284-04 RV01CA195284-04 RV01CA195284-04 RV01CA195284-04 RV01CA195284-04 RV01CA195284-04 RV01CA200783-02 RV01CA200783-02 1148350/SR01CA217420-02 1148350/SR01CA217409-01A1 11R13CA2248869-01	6,389 110,651 77,622 410,383 336,243 444,243 532,372 (158) 42,346 632,254 434,623 10,741 73,412 353,361 4,990,179 5,000	27 4 34 5 1,20
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma identification of Long Non-coding RNAs as Novel Biomarkers for Hetrogeneous Giloblastomas Molecular Target Variation Across Environments and at Margins of Giloblastoma MRI-Guided Interversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Optical Nanoscale Analysis of Bucal Collis: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carrinogenesis Nanocytology Systemic RNA interference to reactivate p35 tumor suppression Targeted MRI contrast agents for differential diagnosis of prostate cancer Transforming the diagnosis and care of patients with CTCL using TCR sequencing Tumor immune and glycan biomarkers for progressive prostate cancer 2017 Society for Integrative Oncology (SIO) 14th Annual International Conference Alliance for Clinical Trials in Oncology (Allance) Executive Officer	228 36 31 31	93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.395	SR21CA209345-02 TR01CA176659-06 SR01CA209886-03 SR01CA198987-04 SR01CA198590-05 SR01CA195294-04 REVISED SR01CA155284-04 REVISED SR01CA200783-02 REVISED SR01CA200783-02 REVISED SR01CA200733-03 IR01CA212409-0141 IR13CA224869-01 110408/JSU10CA180821-05	6,389 110,651 77,622 410,383 336,243 444,245 532,372 (158) 42,946 632,294 434,523 10,741 73,412 353,361 4,990,179 5,000 184,159	4 34 5
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giloblastomas Molecular Target Variation Across Environments and at Margins of Giloblastoma MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Intervensible Electroporation Ablation for Liver Tumors MRI-Molined Delaritio-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer Section 2014 (Control Cell Cell Cell Cell Cell Cell Cell Ce	228 36 31	93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	5R21CA209345-02 7R01CA17659-06 5R01CA196967-04 5R01CA196967-04 SR01CA195309-05 SR01CA195284-04 REVISED 5R01CA155284-04 REVISED 5R01CA208783-02 REVISED 5R01CA200783-02 REVISED 5R01CA200783-02 REVISED 1R01CA20783-02 REVISED 1R01CA20783-02 REVISED 1R01CA20783-02 REVISED 1R01CA2078-01 1R01CA212409-01A1 1R13CA224869-01 110408/JUICA1080821-05 110408/JUICA1080821-04	6,389 110,651 77,622 410,383 336,243 444,245 452,245 42,246 632,234 434,223 10,741 73,412 353,361 4,990,179 5,000 184,159 148,503	4 34 5 1,20
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkners for Heterogeneous Giloblastomas Micl-Guided Theorshib Electroporation Ablation for Liver Tumors MRI-Guided Inversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Targeted MRI contrast agents for differential diagnosis of prostate cancer Transforming the diagnosis and care of patients with CTCL using TCR sequencing Tumor immune and glycan biomarkers for progressive prostate cancer 2017 Society for Integrative Oncology (SIO) 14th Annual International Conference Aliance for Clinical Trials in Oncology (Aliance) Executive Officer Aliance for Clinical Trials in Oncology (Parations Center An Epigenetic Strategy Or Restoring Carchoptatin Sensitivity in Ovarian Cancer	228 36 31 31 31 31	93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394 93.394	FR21CA209345-02 FR01CA17665-06 FR01CA209886-03 FR01CA19859-06 FR01CA19859-05 FR01CA19859-06 FR01CA19859-04 FR01CA19524-04 FR01CA19524-04 FR01CA15224-04 FR01CA1527-02 1140408/JUICA20073-03 FR01CA15224-05 110408/JUICA160821-05 110408/JUICA160821-05 FR01CA15223-05 FR01CA15232-05 FR01CA15232-05	6,389 110,651 77,622 410,383 336,243 444,245 532,372 (158) 42,946 632,294 434,623 10,741 73,412 353,361 4,990,179 5,000 184,159 148,603 2,622,387	2 34
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giloblastomas Molecular Target Variation Across Environments and at Margins of Giloblastoma MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Molided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Molined Delnity of Sonfrahin-Euling Microspheres to Liver Tumors Nanoscale/Molecular analysis of Fecal Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Targeted MRI contrast agents for differential diagnosis of prostate cancer Transforming the diagnosis and care of patients with CFLC using TCR sequencing Tumor immune and glycan biomarkers for progressive prostate cancer 2017 Society for Integrative Oncology (SIO) 14th Annual International Conference Aliance for Clinical Trials in Oncology Oparisions Center An Epigenetic Strategy for Restoring Carboptian Sensitivity in Ovarian Cancer CDK46 Inhibitor Therapy for Giloblastom Multiforme	228 36 31 31 31 31 85	93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,395 93,395	FR21CA209345-02 FR01CA17658-06 SR01CA198967-04 SR01CA198967-04 SR01CA19509-05 SR01CA19524-04 REVISED SR01CA15284-04 REVISED SR01CA15284-04 REVISED SR01CA15284-04 REVISED SR01CA15284-04 REVISED SR01CA208733-02 REVISED RESS11975/R01CA217452-02 114835//FR01CA203731-03 1R01CA212409-01A1 1R13CA224809-01 110408//5U10CA180821-05 110408//5U10CA180821-04 SR016/1428232-05 EVISED 410676_CFR40751-1U424240006/R01CA10594	6,389 110,651 77,622 410,383 336,243 444,245 (58) 42,246 632,294 434,523 10,741 73,412 353,361 4,990,179 5,000 184,159 148,503 262,387 53,354	4 34 5 1,20
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkners for Heterogeneous Giloblastomas Micl-Guided Denothic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Inversible Deckroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Optical Nanoscale Analysis of Bucal Collis: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carrinogenesis Nanocytology Systemic RNA interference to reactivate politents with CFLC Lusing TCR sequencing Targeted MRI contrast agents for differential diagnosis of prostate cancer Transforming the diagnosis and care of patients with CFLC Lusing TCR sequencing Tumor immune and glycan biomarkers for progressive prostate cancer 2017 Society for Integrative Oncology (SIO) 14th Annual International Conference Aliance for Clinical Trials in Oncology (Aliance) Executive Officer Aliance for Clinical Trials in Oncology (Aliance) Executive Officer Aliance for Clinical Trials in Oncology (Aliance) Executive Officer CDG NCTN Radiation Oncology Review Work Order COS NCTN Radiation Oncology Review Work Order	228 36 31 31 31 31 85 45	93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,395 93,395 93,395	SR21CA209345-02 TR01CA17665-06 SR01CA209886-03 SR01CA198987-04 SR01CA198987-04 SR01CA198284-04 REVISED SR01CA155284-04 REVISED SR01CA155284-04 REVISED SR01CA200783-02 REVISED SR01CA200783-02 REVISED SR01CA200733-02 REVISED IntelSA212409-01 IR13CA224869-01 IR13CA224869-01 IR13CA224869-01 IR13CA224869-01 IR13CA224869-01 IR13CA224869-01 IR13CA224823-05 REVISED SR01CA18223-05 REVISED SR01CA18232-05 REVISED SR01CA18232-05 REVISED 410675_GR40751-NU4424006;R01CA10594 S90008215/01/ICCA180885	6,389 110,651 77,622 410,383 336,243 444,245 532,372 (158) 42,946 632,294 434,623 10,741 73,412 353,361 4,990,179 5,000 184,159 1448,603 262,387 53,554 (544)	4 34 5
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giloblastomas Molecular Target Variation Across Environments and at Margins of Giloblastoma MRI-Guided Dendritic-Cell-Based Vaccine Immunotherapy for Pancreatic Cancer MRI-Guided Intervensible Electroporation Ablation for Liver Tumors Nanoscale/Molecular analysis of Fecal Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Buccal Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology Systemic RNA interference to reactivate positions to prostate cancer Transforming the diagnostis and care of pareitons kin CFLC using TCR Sequencing Tumor immune and glycan biomarkers for progressive prostate cancer 2017 Society for Integrative Oncology (SIO) 14th Annual International Conference Aliance for Clinical Trials in Oncology Oparitions Center An Epigenetic Strategy for Restoring Carboptatin Sensitivity in Ovarian Cancer CDK4/6 Inhibitor Theragy for Giloblastoma Multiforme COG NCTN Radiation Oncology Reviewer Work Order	228 36 31 31 31 31 85 45 45	93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,395 93,395 93,395 93,395	FR21CA209345-02 FR01CA17659-06 SR01CA195867-04 SR01CA195867-04 SR01CA195067-04 SR01CA195067-04 SR01CA195284-04 REVISED SR01CA15284-04 REVISED SR01CA15284-04 REVISED SR01CA195284-04 REVISED SR01CA195284-04 REVISED SR01CA208738-02 REVISED RESS11975/R01CA21782-02 114835//FR01CA203731-03 1R01CA212409-01A1 1R12CA224886-01 1110408//5U10CA180821-05 110408//5U10CA180821-05 110408//5U10CA180821-04 SR01CA182822-05 REVISED SR01CA182822-05 REVISED 10676_CFR0751-NU4242006/R01CA10594 S900080215/JU10CA180886 S900080215/JU10CA180886	6,389 110,651 77,622 410,383 336,243 444,245 452,274 42,946 632,294 434,523 10,741 73,412 353,361 4,990,179 5,000 184,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,159 148,15914,159 148,159 148,159 148,15914,159 148,159 148,15914,159 148,15914,159 148,159	2 34
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giloblastomas Molecular Target Variation Across Environments and at Margins of Giloblastoma MRI-Guided Interversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Optical Nanoscale Analysis of Bucal Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Bucal Coles: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Targeted MRI contrast agents for differential diagnosis of prostate cancer Transforming the diagnosis and care of patients with OTCL using TCR sequencing Tumor immune and glycan biomarkers for progressive prostate cancer 2017 Society for Integrative Oncology (SI(0) 14th Annual International Conference Alliance for Clinical Trials in Oncology (Alliance) Executive Officer Aliance for Clinical Trials in Oncology (Alliance) Executive Officer An Epigenetic Strategy for Giloblastoma Multiforme COG NCTN Radiation Oncology Review Work Order COG NCTN Radiation Oncology Review Work Order Dignity Therapy Vor Elderly Cancer Outpatients: 3 Am Nurse or Chaplain Led Trial	228 36 31 31 31 31 85 45	93 394 93 395 93 395 93 395 93 395 93 395	FR21CA209345-02 FR01CA17659-06 FR01CA20988-03 FR01CA19859-05 FR01CA19859-05 FR01CA19859-04 FR01CA19824-04 REVISED FR01CA19824-04 REVISED FR01CA15284-04 REVISED FR01CA15284-04 REVISED FR01CA15284-04 REVISED FR01CA15284-04 REVISED FR01CA15284-04 REVISED FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1527-05 110408//5U10CA160821-05 110408//5U10CA160821-05 110408//5U10CA160821-05 110408//5U10CA160822-04 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$950080217-05/U10CA180886 \$950080217-05/U10CA180886 \$950080217-05/U10CA180886 \$950080217-05/U10CA180886 <	6,389 110,651 77,622 410,383 336,243 444,245 532,372 (158) 42,946 632,294 434,623 10,741 73,412 353,361 4,990,172 553,361 4,8503 262,387 53,554 (1544) 1,133 21,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,52,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,525 54,525 54,525 54,525 54,525 54,525 54,525 54,5255 54,5255 54,5255 54,5255 54,5255 54,52555 54,525555 54,525555555555	2 34
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giioblastomas Molecular Target Variation Across Environments and at Margins of Giioblastoma MRI-Guided Inversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Microspheres and Analysis of Bucal Collis: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology Systemic RNA interference to reactivate pS1 tumor suppression Targeted MRI contrast agents for differential diagnosis of prostate cancer Transforming the diagnosis and care of patients with CTCL using TCR sequencing Tumor immune and glycan biomarkers for progressive prostate cancer 2017 Society for Integrative Oncology (SIO) 14th Annual International Conference Aliance for Clinical Trials in Oncology (SII) 14th Annual International Conference Aliance for Clinical Trials in Oncology (SII) 14th Annual International Conference CDK4/6 Inhibitor Therapy for Glioblastoma Multiforme COG NCTN Radiation Oncology Reviewer Work Order COG NCTN Radiation Oncology Reviewer Work Order COG NCTN Radiation Oncology Reviewer Work Order Dignity Therapy for Electry Cancer Outpatients: 3 Tarm Nurse or Chaplain Led Trial Discovery of Selective MAPZ4/6 Inhibitors to Target Metastasis	228 36 31 31 31 31 85 45 45	93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,394 93,395 93,395 93,395 93,395	FR21CA209345-02 FR01CA17659-06 FR01CA20986-03 FR01CA19589-06 FR01CA19589-06 FR01CA19589-06 FR01CA19528-04 FR01CA19528-04 FR01CA19528-04 FR01CA19528-04 FR01CA19528-04 FR01CA19528-04 FR01CA19528-04 FR01CA19528-04 FR01CA19528-04 FR01CA20873-02 FR01CA20873-02 114855/FR01CA21782-02 114855/FR01CA21782-03 1170-08/FU10CA19822-04 FR01CA18282-05 110408/FU10CA19822-05 110408/FU10CA18282-05 110408/FU10CA18282-05 110408/FU10CA18282-05 110408/FU10CA18282-05 FR01CA18282-05 FR010-1889-01 <td>6,389 110,651 77,622 410,383 336,6243 444,245 532,372 (158) 42,946 632,294 434,523 10,741 73,412 353,361 4,990,179 5,000 184,159 148,603 262,387 5,3554 (544) 1,133 145,273 196,653</td> <td>34 </td>	6,389 110,651 77,622 410,383 336,6243 444,245 532,372 (158) 42,946 632,294 434,523 10,741 73,412 353,361 4,990,179 5,000 184,159 148,603 262,387 5,3554 (544) 1,133 145,273 196,653	34
		Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Giloblastomas Molecular Target Variation Across Environments and at Margins of Giloblastoma MRI-Guided Interversible Electroporation Ablation for Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors MRI-Monitored Delivery of Sorafenib-Eluting Microspheres to Liver Tumors Optical Nanoscale Analysis of Bucal Colonocytes for Colorectal Cancer Screening Optical Nanoscale Analysis of Bucal Coles: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Optical Nanoscale Analysis of Bucal Cells: Transforming Lung Cancer Screening Targeted MRI contrast agents for differential diagnosis of prostate cancer Transforming the diagnosis and care of patients with OTCL using TCR sequencing Tumor immune and glycan biomarkers for progressive prostate cancer 2017 Society for Integrative Oncology (SI(0) 14th Annual International Conference Alliance for Clinical Trials in Oncology (Alliance) Executive Officer Aliance for Clinical Trials in Oncology (Alliance) Executive Officer An Epigenetic Strategy for Giloblastoma Multiforme COG NCTN Radiation Oncology Review Work Order COG NCTN Radiation Oncology Review Work Order Dignity Therapy Vor Elderly Cancer Outpatients: 3 Am Nurse or Chaplain Led Trial	228 36 31 31 31 31 85 45 45	93 394 93 395 93 395 93 395 93 395 93 395 93 395	FR21CA209345-02 FR01CA17659-06 FR01CA20988-03 FR01CA19859-05 FR01CA19859-05 FR01CA19859-04 FR01CA19824-04 REVISED FR01CA19824-04 REVISED FR01CA15284-04 REVISED FR01CA15284-04 REVISED FR01CA15284-04 REVISED FR01CA15284-04 REVISED FR01CA15284-04 REVISED FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1528-04 FR01CA1527-05 110408//5U10CA160821-05 110408//5U10CA160821-05 110408//5U10CA160821-05 110408//5U10CA160822-04 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$9500080217-05/U10CA180886 \$950080217-05/U10CA180886 \$950080217-05/U10CA180886 \$950080217-05/U10CA180886 \$950080217-05/U10CA180886 <	6,389 110,651 77,622 410,383 336,243 444,245 532,372 (158) 42,946 632,294 434,623 10,741 73,412 353,361 4,990,172 553,361 4,8503 262,387 53,554 (1544) 1,133 21,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,52,523 54,523 54,523 54,523 54,523 54,523 54,523 54,523 54,525 54,525 54,525 54,525 54,525 54,525 54,525 54,5255 54,5255 54,5255 54,5255 54,5255 54,52555 54,525555 54,525555555555	3- - <u></u>

44

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

uster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thr to subrecipi
partment of Health and		ECOG-ACRIN NCORP Research Base: Cancer Care Delivery Research (CCDR)	69	93.395	1UG1CA189828-01-NWU2//UG1CA189828-04	\$ 32,051	
Human Services (continued)		ECOG-ACRIN Nursing Committee	69	93.395	U10CA180820-01-NWU3	4,545	3
		ECOG-ACRIN Operations Center (PI Committee)	69	93.395	U10CA180820-01-NWU2	14,387	
		EMR Adverse Drug Event Detection for Pharmacovigilance	247	93.395	WA00356827/RFA2015095	30,353	
		Exploiting synthetic-lethal interactions to target triple-negative breast cancer		93.395	5R00CA175700-05	110,738	
		Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced					
		Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis	100	93.395	AGMT-4/9/15///5P01CA108671-08	12,763	
		High Density Lipoprotein Nanoparticles for siRNA Delivery		93.395	4R01CA167041-05	9,325	
		Institutional Membership-Alliance for Clinical Trials in Oncology	4	93.395	Fully-executed 11/13/13	29,053	
		Loss of Mitochondrial Sirt3, Decreased MnSOD Activity, and IR Induced Genomic Instability		93.395	5R01CA152601-09 REVISED	344,977	
		MPD Research Consortium	100	93.395	0254-4051-4609//2P01CA108671-10A1	74,001	
		NKG2D superagonist co-stimulation to enhance adaptive immunotherapy of cancer		93.395	7R01CA208246-02	256,472	
		NRG Oncology Foundation, Inc: Member Institution Purchased Service Agreement (PSA)	151	93.395	Agmt Signed 9/5/14	26,776	
		Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma	131	93.395	229149 AZD2014//1R01CA201130-01A1 REVISED	7,167	
		Radiation induced cancer risk reduction as a function of dose protraction: interspecies					
		comparison		93.395	5R01CA221150-02	211,532	
		Randomized Trial of Incentives for Research Participation	259	93.395	567849//5R01CA197332-03	23,887	
		Reducing Cancer Transcriptional Heterogeneity through Regulation of Chromatin Structure		93.395	1R01CA228272-01	20,733	
		Retrospective NCI Phantom-Monte Carlo Dosimetry for Late Effects in Wilms Tumor		93.395	5R01CA219013-02	371,612	2
		S1602 BIQSFP (2): A Randomized Trial to Evaluate the Influence of BCG Strain Differences					
		and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve					
		High-Grade Non-Muscle Invasive Bladder Cancer	157	93.395	9009627-009_Northwestern//3U10CA180	16,382	
		Separating autoimmunity and anti-tumor immunity		93.395	7R01CA191317-04	508,986	
		Small molecule CXCR4 modulators as molecular probes for studying AML		93.395	5R01CA189074-03	446,388	
		Statin Intervention to Slow the Time to Hepatocellular Carcinoma Recurrence in Cirrhotics					
		Awaiting Liver Transplantation	37	93.395	1427448//1R01CA218466-01	44,168	
		Targeting BET Bromodomain in Pancreatic Cancer		93.395	5R01CA186885-04S1	181,116	
		Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma	233	93.395	UFDSP00012107//R01CA187109/16122063	11,134	
		Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells		93.395	1R01CA224275-01A1	4,551	
		Targeting Ovarian Cancer Stem Cells through Selective Inhibition of ALDH1A1	108	93.395	IN4684739NWU/1R21CA198409-02	8,055	
		Tele-based Psychosocial Intervention for Symptom Management & HRQOL in Men Living with					
		Advanced Prostate Cancer		93.395	4R01CA157809-05	72,842	
		The Role of Cidofovir and Structural Analogs as Adjuvant Therapy for Glioblastoma	196	93.395	571003 B.02//5R01CA184283-03	33.518	
		Therapeutic Targeting of Malignant Glioma Stem Cells		93.395	5R35CA197725-05	1,207,457	
		Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients	141	93.395	RC105782NU//5R01CA193706-03	58,934	
						5,769,762	
			050	93.396	3003585711 // 5R01CA173745-06 03	146,963	
		An In vivo Metastasis Sensor Arsenic Trioxide activated pathways in malionant cells	250		40104121102-10		
		Arsenic Trioxide activated pathways in malignant cells	250	93.396	4R01CA121192-10 4R01CA164714-05	159,303	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Glioma	250	93.396 93.396	4R01CA164714-05	159,303 262,146	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Glioma Bayesian Network Models for Cenetics and Metabolomics Studies of Fetal Programming	250	93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01	159,303 262,146 11,977	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Glioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells	250	93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R50CA221848-01	159,303 262,146 11,977 177,135	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Glioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity		93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R50CA221848-01 5R01CA146659-06	159,303 262,146 11,977 177,135 (28,423)	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Glioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia	250	93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R50CA221848-01 5R01CA149669-06 0169-81144/R01CA204231-01	159,303 262,146 11,977 177,135 (28,423) 11,476	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunot Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanyocytic malignancies		93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R50CA221848-01 5R01CA149669-06 0169-81148/R01CA204231-01 5R50CA211534-03	159,303 262,146 11,977 177,135 (28,423) 11,476 138,646	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Glioma Bayesian Network Models for Cenetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R50CA221848-01 5R01CA149669-06 0169-81184/R01CA204231-01 6R50CA211534-03 5R35CA17450-04	159,303 262,146 11,977 177,135 (28,423) 11,476 138,646 8563,366	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanyocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNX translation in human cancers		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R50CA221848-01 5R01CA149669-06 0169-81148/R01CA204231-01 5R50CA211534-03 5R35CA197450-04 4R00CA207656-03	159.303 262.146 11.977 177,135 (28,423) 11,476 138,646 858,366 215,610	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Glioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R03CA211318-01 SR01CA149669-06 0169-81149/R01CA204231-01 SR50CA211534-03 SR3SCA179450-04 4R00CA207865-03 SR00CA175283-04	159,303 262,146 11,977 177,135 (28,423) 11,476 138,646 858,366 215,610 176,509	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanyocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNX translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R50CA221848-01 5R01CA149669-06 0169-81148/R01CA204231-01 5R35CA211534-03 5R35CA211534-03 5R35CA207685-03 5R30CA175293-04 1R01CA217907-01A1	159,303 262,146 11,977 177,135 (28,423) 11,476 38,846 858,366 215,510 176,509 68,751	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Giloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanycocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 5R01CA149669-06 0169-81148//R01CA204231-01 5R35CA17345-04 4R00CA207365-03 5R00CA17529-04 1R01CA217907-01A1 5R50CA211271-03	159,303 262,146 11,977 177,135 (28,429 11,476 138,646 658,366 215,610 176,909 68,751 147,751	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy DISEs – a natural cancer surveillance mechanism – a new road to cancer therapy DISE – guidation of RNX translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R03CA211318-01 1R03CA211318-01 0169-81144/R01CA204231-01 6R50CA211534-03 5R35CA19745-0-04 4R00CA207865-03 5R00CA175293-04 1R01CA217907-01A1 6R50CA211271-03 1 R01 CA214928-01A1	159,303 262,146 11,977 177,135 (28,423) 11,476 136,646 858,366 215,510 176,509 68,751 147,514 17,719	
		Arsenic Trioxide activated pathways in malignant cells B741 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanyocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 SR01CA14968-06 0160-81148//R01CA204231-01 SR35CA197450-04 4R00CA207865-03 SR00CA17529-04 1R01CA217907-01A1 SR55CA211271-03 1 R01 CA214928-01A1 SR00CA16038-0551	159,303 262,146 11,977 177,135 (28,423) 11,476 138,646 858,366 215,610 176,609 68,751 147,719 147,714 17,719 224,436	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel Iherapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy DISEs – a natural cancer surveillance mechanism – a new road to cancer therapy DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNX translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanism specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterom receptor function in endometrial cancer		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R03CA211318-01 1R50CA221848-01 5R01CA149669-06 0169-81148/R01CA204231-01 5R05CA17545-04 4R00CA207865-03 5R00CA175283-04 1R01CA217907-01A1 5R50CA211271-03 1 R01CA214928-01A1 3R00CA160538-0551 4R01CA15511-05	159,303 262,146 11,977 177,135 (28,423) 11,476 138,646 859,366 215,610 176,909 68,751 147,719 224,436 7,4,932	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanycoytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNX translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galphat 1 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterone receptor function in endometrial cancer Integrating Epigenomic and Nuclear Receptor Signating in Castrate Resistant Prostate Cancer		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 5R01CA14968-06 0169-81148/R01CA204231-01 5R35CA11534-03 5R35CA11534-03 5R35CA11534-03 5R35CA11534-03 5R35CA11534-03 5R35CA11534-03 5R35CA11534-03 5R35CA11534-03 5R35CA11534-03 5R00CA17528-04 1R01CA217907-01A1 5R50CA11271-03 1 R01CA217907-01A1 5R50CA11271-03 1 R01CA140583-0551 5R01CA155513-05 5R01CA156270-03	159,303 262,146 11,977 177,135 (28,423) 11,476 858,366 215,610 176,500 68,751 147,814 17,719 224,436 74,532 462,588	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Gloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanism specific to gloma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterone receptor function in endometrial cancer Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer Integration-Induced SLFNs and Tumorigeneesis		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R03CA211318-01 1R50CA221848-01 5R01CA149668-06 0169-81148/R01CA204231-01 5R05CA211534-03 5R35CA197450-04 4R00CA207865-03 5R00CA175283-04 1R01CA217907-01A1 5R50CA211271-03 1 R01 CA214928-01A1 3R00CA160538-0551 4R01CA15513-05 5R01CA191796-05	159,303 262,146 11,977 177,135 (28,423) 11,476 138,846 858,366 215,610 1776,309 68,751 147,814 17,719 224,436 74,932 462,588 (2,073)	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Giloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanyocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterone receptor function in endometrial cancer Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer Integrating Ebiquesting TGF-bi in carcinogenesis		93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396 93,396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 1R05CA2121848-01 SR01CA14968-06 0169-81148/R01CA204231-01 SR35CA197450-04 4R00CA207885-03 SR35CA177528-04 1R01CA217907-01A1 SR45CA1271271-03 1 R01 CA217907-01A1 SR40CA17528-04 1 R01 CA217907-01A1 SR40CA15513-05 SR01CA155513-05 SR01CA167270-03 SR01CA16796-05 7R01CA22948-03	159.303 262.146 11.977 177.135 (28.423) 11.476 858.366 215.610 176.909 68.751 147.614 17.719 224.436 74.532 462.888 (2.073) 101.751	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakarycoyific malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanism specific to gloma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesteron ecceptor function in endometral cancer Interferon-Induced SLFNs and Tumorigenesis Interplay between ER and TGF-b in carcinogenesis Linking Oncogenic Signaling to Tumor Metabolism		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R03CA211318-01 SR01CA149669-06 0169-81149/R01CA204231-01 SR05CA17450-04 4R00CA207865-03 SR00CA175283-04 1R01CA217907-01A1 SR50CA211271-03 1 R01 CA214928-01A1 3R00CA160638-05S1 4R01CA155513-05 SR01CA1615513-05 SR01CA16179-05 SR01CA16179-05 SR01CA219129-03 SR00CA19129-04 SR00CA19129-04	159,303 262,146 11,977 177,135 (26,423) 11,476 138,646 868,866 215,610 176,909 68,751 147,614 17,719 224,436 74,932 462,588 (2,073) 101,751 223,370	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanycoycik malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterone receipor function in endometrial cancer Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer Integrating Eutewent ER and TGF-b in carcinogenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 5R01CA14968-06 0189-81148/R01CA204231-01 5R50CA21184-03 5R50CA211854-03 5R35CA197450-04 4R00CA207865-03 5R50CA21175283-04 1R01CA217307-01A1 5R50CA211271-03 1 R01 CA214928-01A1 3R00CA16088-0551 4R01CA155513-05 5R01CA11976-05 7R01CA20294-03 5R00CA194192-04 4R01CA10777-14	159,303 262,146 11,977 177,135 (28,423) 11,475 38,846 858,366 215,510 176,909 68,751 147,814 17,719 224,435 (20,73) 101,751 233,970 (8,181)	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms peefic to gloma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterone receptor function in endometria cancer Interferon-Induced SLFNs and Tumorigenesis Interplay between ER and TGF-b in carcinogenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mechanisms of Leukemogenesis in Down Syndrome		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA211318-01 1R03CA21134-01 SR01CA149669-06 0169-81148/R01CA204231-01 SR05CA211534-03 SR03CA17450-04 4R00CA207665-03 SR00CA17528-04 1R01CA217907-01A1 SR05CA17271-03 1 R01CA217907-01A1 SR05CA155513-05 SR01CA155513-05 SR01CA15756-05 7R01CA202948-03 SR00CA19492-04 4R01CA101774-14 ZR01CA101774-16	159,303 262,146 11,977 177,135 (26,423) 11,476 138,646 688,866 215,610 176,909 68,751 1417,614 17,719 224,436 74,432 462,688 (2,073) 101,751 233,970 (8,181) 316,031	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galphe13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterone receptor function in endometria (cancer Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer Interferori-Induced SI-RNa and Tumorigenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mechanisms of Leukemogenesis in Down Syndrome Mitchcondrial metabolism and ROS regulate cancer		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 5R01CA149680-06 0169-81148//R01CA204231-01 5R50CA21154-03 5R50CA217950-04 4R00CA2079865-03 5R30CA175283-04 1R01CA217807-01A1 5R50CA211271-03 5R50CA2175283-04 1R01CA217807-01A1 5R50CA2175283-04 1R01CA217807-01A1 5R50CA2121271-03 5R01CA15513-05 5R01CA16270-03 5R01CA16270-03 5R01CA16270-03 5R01CA16270-04 4R01CA01774-14 2R01CA101774-16 5R35CA19753-03	159,303 262,146 11,977 177,135 (28,423) 11,476 858,366 215,610 176,509 68,751 147,614 17,714 147,714 147,714 17,714 224,436 (2,073) 101,751 233,970 (8,181) 316,031 1,140,703	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to gloma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterone receptor function in endometria cancer Interforon-Induced SLTPs and Tumorigenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mitochondrial metabolism and ROS regulate cancer Mitochondrial metabolisms and ROS regulate cancer Mitochondrial metabolism and ROS regulate cancer Mito Pathways and IFM-responses in Malingant Cells		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 SR01CA1138-01 SR01CA1138-01 SR01CA11960-06 0169-81148/R01CA204231-01 Sr83CA179450-04 4R00CA207665-03 SR00CA17529-04 1R01CA217907-01A1 SR5CCA211271-03 1 R01CA217907-01A1 SR00CA175513-05 SR01CA155513-05 SR01CA167270-03 SR01CA167270-03 SR01CA167270-03 SR01CA16778-04 4R01CA10774-14 ZR01CA101774-14 SR01CA15568-05 SR01CA15558-05	159.303 262,146 11.977 177,135 (26.423) 11.476 138.646 688.866 215.610 176.909 68,751 147,714 224.436 74.928 462.688 (2.073) 101.751 233.970 (8.181) 316.031 1,140.703 (606)	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel herapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterone receptor function in endometrial cancer Integrating Egigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer Integrating Egigenomic and TGF-b in carcinogenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mitcchondrial metabolism and ROS regulate cancer Mitchondrial metabolism in Down Syndrome		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 5R01CA149680-06 0169-81148//R01CA204231-01 5R50CA21154-03 5R50CA217950-04 4R00CA2079865-03 5R30CA175283-04 1R01CA217807-01A1 5R50CA211271-03 5R50CA2175283-04 1R01CA217807-01A1 5R50CA2175283-04 1R01CA217807-01A1 5R50CA2121271-03 5R01CA15513-05 5R01CA16270-03 5R01CA16270-03 5R01CA16270-03 5R01CA16270-04 4R01CA01774-14 2R01CA101774-16 5R35CA19753-03	159,303 262,146 11,977 177,135 (28,423) 11,476 858,366 215,610 176,509 68,751 147,614 17,714 147,714 147,714 17,714 224,436 (2,073) 101,751 233,970 (8,181) 316,031 1,140,703	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms – a new statu tumor metastasi Influence of AKT pathway on progesteron receptor function in endometrial cancer Interfaron-induced SLFNs and Tumorgenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Mechanisms of Leukemogenesis in Down Syndrome Mitochondrial metabolism and ROS regulate cancer Mitochondrial metabolism and ROS regulate can	24	93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 5R01CA14968-06 0169-81148//R01CA204231-01 5R05CA197450-04 4R00CA207865-03 5R00CA17529-04 1R01CA217907-01A1 5R50CA17529-04 1R01CA217907-01A1 5R50CA217271-03 1 R01CA217907-01A1 5R00CA155513-05 5R01CA155513-05 5R01CA15527-003 5R01CA1592-04 4R01CA107774-14 2R01CA101774-16 5R30CA197532-03 5R01CA15566-05 4R01CA159811-05	159,303 262,146 11,977 177,135 (26,423) 11,476 138,646 688,366 68,366 68,351 147,814 17,719 2,24,435 74,932 462,588 (2,073) 101,751 2,33,970 (8,181) 3,16,031 1,140,703 (606) 119,245	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesteron receptor function in endometrial cancer Interferon-Induced SLFNE and Tumorigenesis Interplay between ER and TGF-b in carcinogenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Metchanisms of Leukemogenesis in Down Syndrome Metchanisms of Leukemogenesis in Down Syndrome Metchanisms of Leukemogenesis in Buyen Syndrome Metchanism of IF Signaling and ROS regulate cancer Mittochondial metabolism and ROS regulate cancer Mittochondial metabolism in AdROS reg		93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 1R05CA21138-01 SR01CA14968-06 0169-31148//R01CA204231-01 SR50CA21154-03 SR50CA217820-04 4R00CA20788-03 SR00CA175289-04 1R01CA217907-01A1 SR50CA211271-03 1 R01CA217907-01A1 SR50CA211271-03 1 R01CA217907-01A1 SR50CA21030-0551 4R01CA15513-05 SR01CA16028-055 7R01CA202248-03 SR00CA194192-04 4R01CA10777-16 SR3SCA19753-03 SR01CA165566-05 4R01CA10774-16 SR3SC18911-05 2002911519//5U01CA196390-03	159,303 262,146 11,977 177,135 (28,423) 11,476 138,646 858,366 215,510 176,509 68,751 147,814 17,714 17,714 224,436 (2,073) (0,1751 233,970 (8,181) 316,031 (140,703) (119,245 119,245 119,245 18,158	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanycoyfic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms – a new statu tumor metastasi Influence of AKT pathway on progesteron ecceptor function in endometrial cancer Interform-induced SLPNs and Tumorgenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mitochondrial metabolism and RyG regulate cancer Mitochondrial metabolism and RyG regulate cancer Mitochondrial metabolism and RyG regulate cancer Mitochondrial metabolism and RyG regulate cancer Interformo-induced SLPNs and Tumorgenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mitochondrial metabolism and ROS regulate cancer Mitochondrial metabolism and ROS regulate cancer fuection	24 122	93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 SR01CA14968-06 0169-81148//R01CA204231-01 SR05CA197450-04 4R00CA207865-03 SR00CA17529-04 1R01CA217907-01A1 SR05CA172797-01A1 SR00CA17529-04 1R01CA217907-01A1 SR00CA17529-04 1R01CA217907-01A1 SR00CA15513-05 SR01CA15513-05 SR01CA16728-04 4R01CA11774-16 ZR01CA101774-16 SR01CA19752-03 SR01CA15568-05 4R01CA101774-16 SR02CA19752-03 SR01CA15568-05 4R01CA159811-05 SR02CA19762-05 SR01CA159810-05 SR01CA159680-03	159,303 262,146 11,977 177,135 (28,423) 11,476 138,646 688,366 69,215,610 126,509 168,751 147,814 17,719 224,436 (2,073) 101,751 233,970 (8,181) 316,031 1,140,703 (6,081) 316,031 (6,081) 119,245 (5,164)	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel herapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesteron ecceptor function in endometrial cancer Interferon-Induced SLFNs and Tumorigenesis Interplay between ER and TGF-b in carcinogenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mechanisms of Leukemogenesis in Down Syndrome Mechanisms of Leukemogenesis in Down Syndrome Mechanism of Leukemogenesis in Malignant Cells Modulation of Oncogenic Signaling and ROS regulate cancer Mitch of Oncogenic Signaling and ROS regulate cancer Mitch of Oncogenic Approach to Distinguish Lethal from Indolent Prostate Cancer Interferor Men Keuronean Adrivasation	24	93.396 93.396 93.396 93.396 93.395 93.395 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 1R03CA21138-01 SR01CA14968-06 0169-31148//R01CA204231-01 SR50CA21184-03 SR50CA21184-03 SR50CA217828-04 HR01CA20788-03 SR00CA175289-04 IR01CA217907-01A1 SR50CA211271-03 1 R01CA217907-01A1 SR50CA211271-03 SR00CA16038-0551 4R01CA201707-01A1 SR50CA212270-03 SR01CA16028-055 SR01CA16028-055 SR01CA16270-03 SR01CA16270-03 SR01CA16270-03 SR01CA1675566-05 4R01CA101774-16 SR03S0-055 SR01CA162811-05 2020211519//SU01CA196390-03 SR01CA167966-05 94701//5-01CA202177-03	159,303 262,146 11,977 177,135 (28,423) 11,476 136,646 858,366 215,510 176,909 68,751 147,514 17,714 17,714 224,436 (2,073) (10,751) 316,031 1,140,703 (606) 119,245 18,158 (5,164) (5,5797	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanycoyfic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress regonose reguladory networks that enable malignancy Galpha 13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progestrone receptor function in endometrial cancer Interforon-induced SLTNs and Tumorgenesis Linking Decogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mitchondrial metabolism and RGS regulate cancer Mitchondrial me	24 122	93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 SR01CA14968-06 0169-81148//R01CA204231-01 SR3SCA187450-04 4R00CA207865-03 SR3SCA187450-04 4R00CA207865-03 SR40CA175280-04 1R01CA217907-01A1 SR40CCA17528-04 1R01CA217907-01A1 SR40CCA17528-04 1R01CA217907-01A1 SR40CA17528-04 4R01CA20780-03 SR40CA16220-03 SR40CA175513-05 SR40CA161780-05 7R41CA20248-03 SR40CA1978-05 SR40CA1978-05 SR40CA1978-05 SR40CA1978-05 SR40CA1978-05 SR40CA1978-05 SR40CA1978-05 SR40CA1978-05 SR40CA1978-05 SR40CA1978-04 4R01CA101774-16 SR3SCA197532-03 SR401CA155868-05 4R401CA155868-05 4R401CA157896-05 94701/15-U01CA202177-03 4R01CA127515-10	159,303 262,146 11,977 177,135 (28,423) 11,476 138,646 688,366 687,551 147,714 177,714 687,551 224,436 74,932 462,586 (2,073) 101,751 233,970 (8,181) 316,031 1,140,703 (8,181) 316,031 (119,245) 119,245 18,158 (5,164) 65,797 107,747	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukernia Development of novel Iherapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesteron receptor function in endometrial cancer Interforon-Induced SLTPN and Tumorigenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Mechanisms of Leukerngenesis in Down Syndrome Mechanisms of Leukerngenesis in Dawn Syndrome Mitochondrial metabolism and ROS regulate cancer Mith Pathways and IFN-responses in Malignant Cells Modulation of Oncogenic Signaling in Glioblastomas Multidicipinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of European and Arina Ancestry Prostate Cancer Recurrence: models and mechanisms Quantitative analyses of Imor cell extrate machanisms Regulation of Docegenic Signaler path Ancestry Prostate Cancer Recurrence: models and mechanisms Quantitative analyses of Imor cell extratestation Regulation of Docegenic Kinase Pinn 1 in Prostate Cancer	24 122	93.396 93.396 93.396 93.396 93.396 93.395 93.395 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 1R03CA21138-01 SR01CA14968-06 0169-81148/WR01CA204231-01 SR30CA17520-04 SR30CA17520-04 SR00CA17520-04 SR00CA17520-04 SR00CA17520-04 SR00CA17520-04 SR00CA17520-04 SR00CA17520-04 SR00CA19070-01A1 SR00CA19020-051 4R01CA20720-01A1 SR00CA19028-0551 4R01CA10170-01A1 SR01CA1827-0-03 SR01CA1827-0-03 SR01CA1827-0-03 SR01CA1827-0-03 SR01CA1928-0-03 SR01CA1928-0-05 SR02811-05 202911519//SU01CA196390-03 SR01CA127566-05 94701/S-001CA202177-03 4R01CA10720548-04 4R01CA10778-16 SR0264191-05 202911519//SU01CA196390-03 SR01CA1272151-10 SR01CA12484-10 REVISED	159,303 262,146 11,977 177,135 (28,423) 11,476 858,366 215,610 176,909 68,751 147,814 17,719 224,436 (42,888 (2,073) 101,751 233,970 (8,181) 316,031 1,140,703 (608) 1119,245 18,158 (5,164) 65,797 107,747 1779,437	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanycoyfic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress regonose reguladory networks that enable malignancy Galpha 13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progestrone receptor function in endometrial cancer Interforon-induced SLTNs and Tumorgenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mitchondrial metabolism and RGS regulate cancer Mitchondrial metabolism and RGS regulate cancer Role of Oncogenic Signaling in Clioblastomas Mutdicioling Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of European and African Ancestry Prostate Cancer Recurres: models and mechanisms Quantitative analyses of tum	24 122	93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 SR01CA14968-06 0169-81148//R01CA204231-01 SR3SCA187450-04 4R00CA207865-03 SR3SCA187450-04 4R00CA207865-03 SR40CA175280-04 1R01CA217907-01A1 SR40CCA17528-04 1R01CA217907-01A1 SR40CCA17528-04 1R01CA217907-01A1 SR40CA17528-04 4R01CA127207-03 1R01CA217907-01A1 SR40CA162270-03 SR40CA162270-03 SR40CA175513-05 SR40CA161780-05 7R401CA20248-03 SR401CA161780-05 SR401CA161774-16 SR3SCA197532-03 SR401CA161774-16 SR3SCA197532-03 SR401CA155680-05 47001CA155680-05 47001CA155680-05 47001CA155680-05 47001CA22151-10 SR401CA12515-11 SR401CA12515-11 SR401CA12515-11 SR401CA12515-11 SR401CA12515-11 SR401CA1273816-19	159,303 262,146 11,977 177,155 (28,423) 11,476 138,646 688,366 69,215,610 126,509 168,751 147,814 17,719 224,436 (2,073) 101,751 233,970 (8,181) 316,031 316,031 (1,140,703) (606) 119,245 18,158 (5,164) 65,797 107,747 179,437 112,233	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel Iherapies for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to Cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanism specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesteron receptor function in endometrial cancer Interforon-Induced SLTPN and Tumorigenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Mechanisms of Leukemogenesis in Down Syndrome Mechanisms of Leukemogenesis in Down Syndrome Mitochondrial metabolism and ROS regulate cancer Mrk Pathways and IFN-responses in Malignant Cells Modulation of Oncogenic Signaling in Glioblastomas Multidicipinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of European and Africa Ancestry Prostate Cancer Recurrence: models and mechanisms Quantitative analyses of Imor cell startaste Cancer Signal Transduction of Type 1 Interferons in Malignant Cells SirtZ Direct Kras IR Cell Resistance and Tumorigenesis	24 122	93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 SR01CA14966-06 0169-81149/R01CA204231-01 SR50CA211534-03 SR3SCA197450-04 4R00CA207665-03 SR00CA175283-04 1R01CA217907-01A1 SR5CO-172523-04 1R01CA217907-01A1 SR00CA17528-04 3R00CA16083-0551 4R01CA215513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA15178-05 SR01CA155513-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-10 SR01CA15520-03 SR01CA158811-05 2002911519//SU01CA202177-03 4R01CA122151-10 SR01CA12250-05 SR01CA12250-05 SR01CA077816-19 <	159,303 262,146 11,977 177,135 (28,423) 11,1476 138,646 859,366 215,610 176,909 68,751 147,814 17,719 224,436 (42,888 (2,073) 101,751 233,970 (8,181) 316,031 1,140,703 (19,245) 119,245 18,158 (5,164) (5,164) 48,797 107,747 179,437 112,333 431,868	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanycoyfic malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress regonose reguladory networks that enable malignancy Galpha 13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progestrone receptor function in endometrial cancer Interforon-induced SLTNs and Tumorgenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mitchondrial metabolism and RGS regulate cancer Mitchondrial metabolism and RGS regulate cancer Role of Oncogenic Signaling in Clioblastomas Mutdicioling Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of European and African Ancestry Prostate Cancer Recurres: models and mechanisms Quantitative analyses of tum	24 122	93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 SR01CA14968-06 0169-81148//R01CA204231-01 SR3SCA187450-04 4R00CA207865-03 SR3SCA187450-04 4R00CA207865-03 SR40CA175280-04 1R01CA217907-01A1 SR40CCA17528-04 1R01CA217907-01A1 SR40CCA17528-04 1R01CA217907-01A1 SR40CA17528-04 4R01CA127207-03 1R01CA217907-01A1 SR40CA162270-03 SR40CA162270-03 SR40CA175513-05 SR40CA161780-05 7R401CA20248-03 SR401CA161780-05 SR401CA161774-16 SR3SCA197532-03 SR401CA161774-16 SR3SCA197532-03 SR401CA155680-05 47001CA155680-05 47001CA155680-05 47001CA155680-05 47001CA22151-10 SR401CA12515-11 SR401CA12515-11 SR401CA12515-11 SR401CA12515-11 SR401CA12515-11 SR401CA1273816-19	159,303 262,146 11,977 177,155 (28,423) 11,476 138,646 688,366 69,215,610 126,509 168,751 147,814 17,719 224,436 (2,073) 101,751 233,970 (8,181) 316,031 316,031 (1,140,703) (606) 119,245 18,158 (5,164) 65,797 107,747 179,437 112,233	
		Arsenic Trioxide activated pathways in malignant cells B7H1 Mediated Immunosuppression in Ciloma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel Iherapiles for megakaryocytic malignancies DISE – a natural cancer surveillance mechanism – a new road to Cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galpha13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanism specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesteron receptor function in endometrial cancer Interforon-Induced SLTPN and Tumorigenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Interplay between ER and TGF-b in carcinogenesis Mechanisms of Leukemogenesis in Down Syndrome Mechanisms of Leukemogenesis in Down Syndrome Mitochondrial metabolism and ROS regulate cancer Mrk Pathways and IFN-responses in Malignant Cells Modulation of Oncogenic Signaling in Glioblastomas Multidicipinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of European and Africa Ancestry Prostate Cancer Recurrence: models and mechanisms Quantitative analyses of Imor cell startaste Cancer Signal Transduction of Type 1 Interferons in Malignant Cells SirtZ Direct Kras IR Cell Resistance and Tumorigenesis	24 122	93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 SR01CA14966-06 0169-81149/R01CA204231-01 SR50CA211534-03 SR3SCA197450-04 4R00CA207665-03 SR00CA175283-04 1R01CA217907-01A1 SR5CO-172523-04 1R01CA217907-01A1 SR00CA17528-04 3R00CA16083-0551 4R01CA215513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA155513-05 SR01CA15178-05 SR01CA155513-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-05 SR01CA15178-10 SR01CA15520-03 SR01CA158811-05 2002911519//SU01CA202177-03 4R01CA122151-10 SR01CA12250-05 SR01CA12250-05 SR01CA077816-19 <	159,303 262,146 11,977 177,135 (28,423) 11,1476 138,646 859,366 215,610 176,909 68,751 147,814 17,719 224,436 (42,888 (2,073) 101,751 233,970 (8,181) 316,031 1,140,703 (19,245) 119,245 18,158 (5,164) (5,164) 48,797 107,747 179,437 112,333 431,868	
		Arsenic Trioxide activated pathways in malignant cells B7411 Mediated Immunosuppression in Gioma Bayesian Network Models for Genetics and Metabolomics Studies of Fetal Programming Bioinformatic Analysis of Next Generation Sequencing Data from Cancer Cells CD73 and Tumor Immunity Cohesin Mutations in Acute Myelogenous Leukemia Development of novel therapies for megakanycoycik malignancies DISE – a natural cancer surveillance mechanism – a new road to cancer therapy Dissect regulation of RNA translation in human cancers Elucidating the stress response regulatory networks that enable malignancy Galphe13 and pancreatic cancer progression Genomics and bioinformatics analysis to understand castration-resistant prostate cancer Identification and targeting of mechanisms specific to glioma stem cells in glioblastoma Identifying a network of microRNAs and genes that regulate breast tumor metastasi Influence of AKT pathway on progesterione receptor function in endometrial cancer Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer Integrating Epigenomic and Nuclear Receptor Signaling in Castrate Resistant Prostate Cancer Interferon-Induced SI-RNs and Tumorigenesis Linking Oncogenic Signaling to Tumor Metabolism Mechanisms of Leukemogenesis in Down Syndrome Mitchcondrial metabolism and ROS regulate cancer Mitk Pathways and IFN-responses in Malignant Cells Multidicipinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer rinker glicalism and ROS regulate cancer Mitk Pathways and IFN-responses in Malignant Cells Multidicipinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer Rolen of Decogenesis In Down Syndrome Multidicipinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of European and Africas Ancesstry Prostate Cancer Recurrence: models and mechanisms Quantitative analyses of tumor cell extravasation Regulation of Desemosional Catherins In Oral Cancer Role of Oncogenic Kinase Pi	24 122	93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396 93.396	4R01CA164714-05 1R03CA21138-01 1R03CA21138-01 5R01CA14968-06 0169-81148//R01CA204231-01 5R50CA211534-03 5R35CA197450-04 4R00CA207865-03 5R40CA175280-04 1R01CA217907-01A1 5R50CA175280-04 1R01CA217907-01A1 5R50CA217520-04 1R01CA217907-01A1 5R50CA217520-04 1R01CA217907-01A1 5R50CA217520-03 5R01CA15513-05 5R01CA16726-05 7R01CA20248-03 5R01CA16736-05 5R03CA1778-04 4R01CA01774-16 5R35CA19753-03 5R01CA155566-05 4R01CA01774-16 2022911519//SU01CA196390-03 5R01CA15566-05 4R01CA12151-10 2022911519//SU01CA196390-03 5R01CA157686-05 4R01CA122151-10 5R01CA12348-10 5R01CA12348-10 5R01CA123260-05 5R01CA1242506-05 5R01CA1242506-05	159,303 262,146 11,977 177,135 (28,423) 11,476 858,366 215,510 176,909 68,751 147,614 17,719 224,436 (2,073) 101,751 233,970 (8,181) 316,031 1,140,703 (1,181) 316,031 1,140,703 (1,192,455) 119,245 18,158 (5,164) (65,197 107,747 179,437 107,747 172,433 431,868 434,868 44,428	

45

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

luster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thro to subrecipie
epartment of Health and	Subagency			93.396	5R01CA175360-05 REVISED	\$ 505.029	
Partment of Health and Human Services (continued)		The role of deubiquitinating enzyme USP33 in Slit-Robo signaling in lung cancer The role of GPSM3 in tumor-promoting emergency myelopoiesis		93.396 93.396	5R01CA175360-05 REVISED 5R01CA208354-02 REVISED	\$ 505,029 423,613	187.
		The role of ICSBP in the pathogenesis of chronic myeloid leukemia		93 396	5R01CA174205-05 REVISED	271.381	
		The Role of NOV (CCN3) in Prostate Cancer Progression		93.396	5R01CA172384-05 REVISED	82,752	
		Triad1 regulates myelopoiesis and functions as a leukemia suppressor		93.396	5R01CA195642-04 REVISED	470,131	
		WEE1 inhibition and tumor immunity		93.396	1R01CA222963-01A1	17,070	
						8,046,233	187,
		Apigenin restores TSP-1 expression in UVB-irradiated keratinocytes	268	93.397	3001001952//7R01CA172669-05	71,400	
		ECOG/FSTRF PSA for ECOG Clinical Trial Protocols	79	93.397	Agmt 8/13/12 / U01CA021115	28,745	
		Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria		93.397	5U54CA221205-02	558,550	172
		GMaP Region 4: Building Research & Diversity Scholarship through the Cancer Disparities					
		Research Network	111	93.397	Sub# 12305-52//3P30CA006927-50SB	(409)	
		Improving Quality of Life among Hispanic/Latino Breast, Colorectal & Prostate Cancer Survivors: A Randomized Control Trial of Patient Navigators Using the LIVESTRONG					
		Cancer Navigation Services Program	267	93.397	158815/158532//U54CA153511	10,424	
		Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer		93.397	5U54CA199091-03	2,474,908	3
		Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer		93.397	5U54CA193419-04 REVISED	2,046,688	62
		SPORE for Translational Approaches to Brain Cancer		93.397	1P50CA221747-01A1	28,917	
		SPORE in Prostate Cancer		93.397	5P50CA180995-04	3,241,723	1,50
		The Chicago Collaborative to Promote and Advance Cancer Health Equity		93.397	5U54CA203000-04	1,470,082	
		The Robert H. Lurie Comprehensive Cancer Center		93.397	3P30CA060553-22S1	5,916,693	
		The Robert H. Lurie Comprehensive Cancer Center		93.397	3P30CA060553-24S3	402,502	
						16,250,223	2,4
		A Highly Specific, Tissue-Permeable Inhibitor of Gli Transcription Factors		93.398	5F31CA186761-04 REVISED	38,298	
		Alternative Splicing of Amyloid Precursor-Like Protein 2 during the Epithelial-Mesenchymal Transition and Cancer Metastasis		93.398	5F30CA196118-04 REVISED	45,553	
		Behavioral and Psychosocial Research Training in Cancer Prevention and Control		93.398	5T32CA193193-03	500,450	
		Cancer Nanotechnology Training Program		93.398	5T32CA186897-03	243,929	
		Carcinogenesis Training Program		93.398	4T32CA009560-30	(864)	
		Carcinogenesis Training Program		93.398	5T32CA009560-32	360,209	
		Chromatin dysregulation generated by recurrent point mutation in histone methyltransferase,				,	
		MMSET, drives progression of lymphoid malignancies		93.398	5F30CA203292-04 REVISED	31,866	
		Clinical bacterial isolate engineered as an immunotherapy for prostate cancer		93.398	5F30CA203472-03 REVISED	46,177	
		Defining the Role of Pin1 and CDK-mediated Smad3 Phosphorylation in Triple Negative Breast					
		Cancer Migration and Metastasis Designing with Dissemination in Mind: Optimization of a mHealth Physical Activity Intervention	250	93.398	1F31CA206259-02	(5,985)	
		for Breast Cancer Survivors		93.398	5K07CA196840-04	161,093	
		Desmosomal Cadherin Regulation of Pro-inflammatory Cytokine Production in Melanomagenesis		93.398	1F32CA210498-01	(39)	
		Development of a Novel Statewide Learning Collaborative to Increase Lung Cancer Guideline					
		Adherence and Improve Cancer Care Delivery		93.398	5K07CA216330-02	158,277	
		Fellowship for Chelsey Spriggs: The Role of The Fanconi Anemia Pathway in Human Papillomavirus Infection		93.398	5F31CA192801-03	(85)	
		Functional Study of Mammalian Set1A/COMPASS Methyltransferase in Stem Cells and		00.000		(00)	
		Development		93.398	5F31CA228149-02	43,734	
		Investigating catalytic and non-catalytic roles for Trr/COMPASS in regulating enhancer function during Drosophila development		93 398	1F31CA213928-01 REVISED	742	
		Investigating the epigenetics of enhancer function in Cancer		93.398	5F99CA222988-02	38.110	
		Overcoming Temozolomide Resistance using MGMT-targeting Spherical Nucleic Acids		93.398	5F30CA174058-02 5F30CA174058-05 REVISED	38,110	
		Profiling Glycosyltransferase Activities on the Epithelial-Mesenchymal Transition in Breast		33.330	31 300X114030-03 REVISED	3,300	
		Epithelial Cells using peptide arrays and mass spectrometry		93.398	5F30CA196185-03 REVISED	45.705	
		Role of desmoglein 1 in regulating redox and growth factor signaling in head and neck cancer		93.398	5F30CA192788-03	41,109	
		Targeted discovery of anti-proliferative natural products using genomics and metabolomics		93.398	5F32CA221327-02	57,113	
		The Effect Of Cohesin Mutations In Hematologic Malignancies		93.398	5F31CA216976-02	38,124	
		The function of Ubiquitin-Specific Peptidase 22 (USP22) on T regulatory cell function. NRSA					
		for Elena Montauti The role of glioblastoma derived activated leukocyte cell adhesion molecule in peripheral		93.398	1F31CA220801-01A1 REVISED	23,603	
		monocyte PD-L1 induction and immunosuppression		93.398	5F30CA206413-03	44,949	
		The role of the hippocampal-prefrontal network in cancer-related cognitive impairment; a				.,	
		multimodal cross sectional study		93.398	1F31CA210719-02	34,500	
		The role of tumor derived exosomes in bone metastasis of prostate cancer		93.398	1F30CA225133-01 REVISED	20,628	
		The Role of ZEB1 Mutations in Cutaneous T Cell Lymphoma		93.398	5K08CA191019-05 REVISED	141,101	
		Therapeutic and Sustained Cytokine Delivery at the Tumor Site Using Engineered		02.200		10.050	
		Mononuclear Cells		93.398	5F30CA203325-03 REVISED 1F32CA216996-01A1 REVISED	42,959	
		Tissue Factor/Protease-Activated Receptor 2 in IDH1 wild-type and IDH1 mutant gliomas Training Program in Oncogenesis and Developmental Biology		93.398 93.398	1F32CA216996-01A1 REVISED 5T32CA080621-14	26,734 337,957	
		Training Program in Oncogenesis and Developmental Biology Training Program in Signal Transduction and Cancer		93.398 93.398	5132CA080621-14 3T32CA070085-20S1	(5,393)	
		Training Program in Signal Transduction and Cancer		93.398	5T32CA070085-2031	(3,393) 221,848	
		Treating cognitive impairments in cancer patients via systematic light exposure		93.398	5K07CA184145-05	160,123	
						2.895.825	
							·
		30th Annual MR Angiography Meeting		93.837	1R13HL144016-01	10,000	
		4D Flow MRI for characterization of brain arteriovenous malformations		93 837	1F30HL140910-01	265	

(Continued)

Supplementary Schedule of Expenditures of Federal Awards

luster title/Federal grantor	Subagency	Project title	through ID number	CFDA	Sponsor award number	Federal expenditures	to subrecipients
epartment of Health and		4D Flow MRI-based assessment of atrial fibrillation		93.837	5F30HL137279-02	\$ 46.815	
Human Services (continued)		A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple					
		ultra-low-dose treatment for hypertension (QUARTET USA)		93.837	1R61HL139852-01	46,437	-
		A novel implementation and social network strategy for acute pulmonary illnesses		93.837 93.837	5K23HL118139-05 1F32HL140824-01 REVISED	3,598 9,956	-
		A Novel, Patient-Centered Prognostic Tool for Adults with Critical Illness A synthetic heparin derivative that targets collagen to repair damaged vasculature after		93.637	IF32HL140624-01 REVISED	9,950	_
		balloon angioplasty	48	93.837	965-SUB // 3U54HL119810-05S1	41.278	_
		A Systems Science Approach to Understanding Racial/Ethnic Dispartities in Obesity		93.837	5K01HL133531-03	151,211	-
		AAA Geometric Surrogates – Geometric Surrogates for Clinical Management of Abdominal					
		Aortic Aneurysms	266	93.837	1000001715/1R01HL121293-04	13,929	-
		Acute Coronary Syndrome Quality Improvement in Kerala (ACS QUIK)		93.837	5R00HL107749-05	8,176	5,29
		Adolescent Family Stress and Early Cardiovascular Risk: Psychosocial and Behavioral Pathways		93.837	5F32HL134276-03	55,694	
		Aortic Plaques and Stroke: Cardiovascular Therapy of Retrograde Embolization Risk		93.837	5R21HL132357-02	158,458	
		Associations Among Apolipoprotein A1 Structural Variants and High-Density Lipoprotein				,	
		Function		93.837	5K23HL133601-03	144,606	-
		AsthmaNet Clinical Trials	162	93.837	NWUHL098115 // 5U10HL098115	(401,833)	
		AsthmaNet Clinical Trials	162	93.837	NWUHL098115 // 5U10HL098115	337,061	264,07
		Atrial arrhythmias and Ca2+ waves in HF: simulation and experimental studies Atrial fibrillation burden, vascular disease of the brain, and cardiac MRI in MESA	273	93.837 93.837	5R01HL119095-05 UWSC8533//1R01HL127659-01	637,319 123,165	179,23
		BEST-CLI: Trial to Compare Best Endovascular versus Best Surgical Therapy in Patients with	2/3	93.037	0W308333/1R01HE127039-01	123,105	-
		Critical Limb Ischemia (BEST)	143	93.837	Agr. 8/7/14 // U01HL107407	30,197	-
		Beyond PECAM: Mechanisms of Transendothelial Migration		93.837	2R01HL064774-16 REVISED	356,791	-
		Cardiomyocyte Integrin-Matrix Interactions Regulate Cardiac Fibrosis		93.837	5F32HL131301-02	47,506	-
		Cardiomyocyte TGF-beta: a novel therapeutic target for preventing cardiac fibrosis in humans		93.837	1K08HL141659-01	21,370	
		Cardiomyopathy Genomes Project		93.837	5R01HL128075-04	349,842	(1,59
		Cardiovascular Regenerative Medicine CEREBRAL AUTOREGULATION MONITORING TO REDUCE BRAIN INJURY FROM CARDIAC		93.837	5P01HL108795-05	(3,744)	-
		SURGERY		93.837	5R01HL092259-10	276,659	35,39
		Channelopathies and Cardiomyopathies Among Sudden Deaths in the Young		93.837	5U01HL131914-03 REVISED	851,875	71,9
		Characterizing HIV-related Diastolic Dysfunction	66	93.837	223700//U10HL084904	29,140	
		Chicagoland Metropolitan AsthmaNet Consortium		93.837	5U10HL098096-07	120,690	83,7
		Childhood Origins of CHD Disparities: Neural & Immune Pathways		93.837	5R01HL122328-04 REVISED	710,188	54,3
		Chronic Obstructive Pulmonary Disease in Non-Smokers	50 3	93.837 93.837	5(GG011046-01)//1R01HL130506-03	49,832	
		Colony Stimulating Factor-1 in Graft Vascular Disease Community Translation of the South Asian Healthy Lifestyle Intervention (SAHELI)	3	93.837 93.837	310904//5R01HL127700-04 1R01HL132978-02	2,979 709,453	- 148,57
		Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis		93.837	5R34HL122558-03	142,996	140,57
		Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation		93.837	5R01HL117888-05 REVISED	628,835	-
		CXCR4-c-Kit Signaling and BM Progenitor Cell Recruitment in the Ischemic Heart		93.837	5R01HL113541-04	(32,312)	-
		Decrypting Variants of Uncertain Significance in Long-QT Syndrome		93.837	5R01HL122010-04	1,157,710	635,63
		Decrypting Variants of Uncertain Significance in Long-QT Syndrome		93.837	2R01HL122010-05	35,826	
		Defining regulatory regions for cardiomyopathy genes Determinants of Midlife & Longitudinal Change in Cognitive Function: CARDIA Study	125	93.837 93.837	1F30HL142187-01 REVISED 200103-05//5R01HL122658-03	7,628 19.401	
		Determinants of Midne & Longitudinal Change in Cognitive Punction. CARDIA Study Determinants, Trajectories, and Consequences of Abnormal Cardiac Mechanics	125	93.837	5R01HL107577-07	563,215	96,34
		Development of combination immunotherapies for atherosclerotic inflammation		93.837	1DP2HL132390-01	598,215	30,3-
		E2F1 in BM progenitor cell differentiation and cardiovascular repair		93.837	1R01HL131110-01A1 REVISED	(29,851)	
		E2F1 in BM progenitor cell differentiation and cardiovascular repair	214	93.837	000514985-001//7R01HL131110-03	102,599	
		Efferocytosis Directed Inflammation Resolution and Repair in the Hypoxic Heart		93.837	5R01HL122309-05 Revised	351,077	
		Efficacy of Potassium Nitrate In Heart Failure with Preserved Ejection Fraction	259	93.837	569507//5R01HL121510-03	117,046	
		Examination of the Functional Role of Sca1+ Vascular Progenitor Cells following Vascular Injury		93.837	5F32HL129651-02	57.994	
		Exercise in Genetic Cardiovascular Conditions	289	93.837	Yale 2.23.2017//R01HL125918	8,072	
		Exploiting Tie2 Activation for the Treatment of Vascular Diseases	200	93.837	5R01HL124120-04	327,329	
		Favorable Cardiovascular Health and the Compression of Morbidity in Older Age		93.837	5R01HL118289-03	408,773	19,24
		Femoral Plaque Composition, Oxidative Stress, and Coronary Events		93.837	5R01HL109244-04	(1)	
		Fox Transcription factors in lymphatic vessel development		93.837	5R01HL126920-04	385,479	5,27
		Function of the Ubiquitin-Specific Peptidase 22 (USP22) in Acute Myeloid Leukemia Functional Cardiovascular 4D MRI in Congenital Heart Disease		93.837 93.837	5F31HL136107-02 Revised 4R01HL115828-05	30,806	
		Functional Cardiovascular 4D MRI in Congenital Heart Disease Functional Cardiovascular 4D MRI in Congenital Heart Disease		93.837 93.837	4R01HL115828-05 2R01HL115828-06A1	149,253 146.680	75,74
		Genotype-Phenotype Discordance in Long QT Syndrome	36	93.837	RES126034 Amd 2//R01HL124245	93,236	
		HCMR – Novel Predictors of Outcome in Hypertrophic Cardiomyopathy	102	93.837	Study# 2222/0003//1U01HL117006-01A1	10,049	
		Heart Failure Clinical Research Network Coordinating Center – HIV/CHART	66	93.837	203-7618//5U10HL084904-12	78,249	
		Heart Failure Clinical Research Network Coordinating Center - HIV: HFN-HIV Core Lab: The					
		NHLBI Heart Failure Network HIV Study Echocardiography Core Lab	66	93.837	203-8360//5U10HL084904-11 REVISED	17,801	
		Hemodynamic Loading of the Left Ventricle and Aorta in Aortic Valve Disease		93.837	5K25HL119608-05	103,183	
		High Resolution and Functional MRI Assessment of Intracranial Atherosclerotic Plaque Identifying risk factors for subclinical myocardial disease in HIV infection	122	93.837 93.837	5R21HL130969-02 2002507820//5R01HL126552-04	111,629 42,202	12,39
		Identifying risk factors for subclinical myocardial disease in HIV infection Implementation science to improve cardiovascular outcomes among liver transplant recipients	122	93.837 93.837	2002507820//5R01HL126552-04 1K23HL136891-02	42,202 178.286	
		Improve PAD PERformance with METformin. The PERMET Trial		93.837	5R01HL131771-02	779,283	70,48
		Individual response to vitamin D treatment	273	93.837	UWSC9381//5R01HL096875-06	63,549	. 0, 10

Supplementary Schedule of Expenditures of Federal Awards

			Pass- through			Federal	Passed-three to
luster title/Federal grantor	Subagency	Project title	ID number	CFDA	Sponsor award number	expenditures	subrecipi
epartment of Health and Human Services (continued)		INVESTED - : INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)	31	93.837	SUB 5.22.17//5U01HL130163-02	\$ 35.672	
		Joint Effect of Malpractice Risk and Financial Incentives on Cardiac Testing	84	93 837	14-M49-Mod#4//5R01HL113550-05	188,643	
		Low InTensity Exercise intervention for peripheral artery disease: The LITE Trial		93.837	5R01HL122846-04 REVISED	715,616	110
		Lymphatic Conference		93.837	1R13HL136113-01	19,741	
		Mapping electrogram morphology recurrence for atrial fibrillation ablation	88	93.837	1R41HL127907-01A1 NU//1R41HL127907	12,382	
		Maternal-Offspring Metabolics: Family Intervention Trial (MOMFIT)		93.837	3U01HL114344-05S1	274,148	21
		Mechanical circulatory support: Measures of adjustment and quality of life		93.837	5R01HL130502-03 REVISED	611,708	205
		Mechanisms of sulfonylurea receptor mediated cardiomyopathy Mechanistic insights into HIV-mediated heart failure with preserved ejection fraction		93.837 93.837	5R01HL122109-04 REVISED 1R01HL140973-01	385,957 182,787	192
		Mechanistic insights into HIV-mediated heart failure with preserved ejection fraction Mechanistic insights into the deleterious effects of SIRT2 in the heart under stress conditions		93.837	1R01HL1409/3-01 1R01HL138982-01A1	182,787 183,533	
		Mediators of Atherosclerosis in South Asians in America	225	93.837	8696sc//R01HL 093009	206,364	
		Metabolic Pathways Underlying the Contrasting Sodium-BP and DASH/OmniHeart-BP	220	00.007	000000110111200000	200,004	
		Relationships		93.837	5R01HL135486-02 REVISED	433,288	17
		Metabolomics-Measured Urinary Metabolites/Diet & BP, 17 Random Samples		93.837	5R01HL084228-08	(28)	
		Methods to Improve Personalized Cardiovascular Disease Prevention Across the Life Course		93.837	5R01HL136942-02 REVISED	187,378	
		MMP Responsive Nanoparticles for Treating Acute Myocardial Infarction	224	93.837	97966869 // 1R01HL139001-01	109,934	
		Modeling the role of the genome in chemotherapy induced cardiotoxicity using iPSC		93.837	5R00HL121177-04	110,578	
		Modulating senescence in induced pluripotent stem cell-derived endothelial cells for vascular disease modeling and therapy		93.837	5F32HL137292-02	62,542	
		Modulation of Macrophage Function through Alternative Splicing in Cardiometabolic Diseases		93.837	7K08HL135348-02	62,542	
		Modulation of Macrophage Punction anough Alternative Splicing in Cardionetabolic Diseases		93.837	1R01HL144129-01	36.791	
		MRI of Diffuse Left Ventricular Fibrosis in Atrial Fibrillation		93 837	5R01HL116895-05 REVISED	347,072	
		MtDNA variant modifiers of cardiopulmonary responsiveness to physical activity	233	93.837	UFDSP00010117//R01HL121023	10,494	
		Myosin binding protein H-like and its role in cardiomyopathy		93.837	5F32HL131304-03 REVISED	60,090	
		Neonatal Long QT Syndrome and Sudden Infant Death		93.837	5R01HL083374-08	98,948	
		Nonenhanced 3T QISS MR Angiography of the Peripheral Arteries	149	93.837	EH15-107_S2//5R01HL130093-02	56,852	
		Non-Invasive Biosensors To Detect Cardiovascular Changes In Heart Failure	86	93.837	RG884 G2 Amd 1 // R01HL130619	128,916	
		Non-invasive detection of heart transplant rejection with MRI		93.837	5F31HL117618-05 REVISED	25,991	
		Northwestern University Molecular and Translational Cardiovascular Training Program		93.837	5T32HL134633-02 4R01HL116577-04	158,502	
		Novel Vehicles for Targeted Cardiovascular Repair NRSA F32 for Matthew DeBerge in support of: Efferocytosis Regulation by Hypoxia and		93.837	4R01HL116577-04	417,997	2
		Reperfusion After Myocardial Infarction		93.837	5F32HL127958-03	35.690	
		nuMOM2b Hearth Health Study Capitation Funding Memorandum of Understanding (MOU)	174	93.837	0214047//1U10HL119991	37,787	
		Oxidative stress contributes to atrial fibrillation by causing remodeling of the autonomic					
		nervous system		93.837	1R01HL140061-01	297,469	
		PAI-1 and Vascular Senescence		93.837	5R01HL051387-21	340,720	
		PAI-1 and Vascular Senescence		93.837	2R01HL051387-22	19,213	
		Pathophysiological Significance of Atrial Fibrillation Electrogram Patterns		93.837	5R01HL125881-04	356,664	
		Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT					
		(Optimize-SPRINT) Precision Medicine for Dilated Cardiomyopathy in European and African Ancestry	50 155	93.837 93.837	4(GG011659-01)//1R01HL139837-01 60064759//5R01HL128857-03 REVISED	31,899 23,954	
		PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study	31	93.837	116706//2R01HL091069-06	23,954 104,953	
		Pregnancy as a Window for Future Cardiovascular Health	31	93.837	3U10HL119992-03S1	(18.630)	
		Pregnancy as a Window for Future Cardiovascular Health		93.837	3U10HL119992-03S1	(10,000) (25,587)	
		Pregnancy as a Window for Future Cardiovascular Health		93.837	4U10HL119992-04	123.067	
		Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy Outcomes	174	93.837	888-15-16-12//1U10HL119991-01	116,432	
		Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy					
		Outcomes – Heart Health Study	174	93.837	7-312-0214047-52577L//1U10HL119991	13,985	
		Pre-Procedural Evaluation of High-Risk Patients using Next-Generation Radial QISS	149	93.837	EH17-147-S1//1R01HL137920-01A1	13,301	
		PROgenitor Cell Release Plus Exercise to Improve Functional Performance in PAD		93.837	5R01HL107510-05	(925)	
		Progression of Coronary Atherosclerosis in MACS	122	93.837	2002350097/5R01HL25053-04	16,753	
		Projection Imaging of Peripheral Vascular Calcifications Prox1 in Mammalian Lymphangiogenesis	149	93.837 93.837	EH14-410-S2//5R21HL126015-02 Revised 5R01HL073402-15	29,505 (82,036)	
		Prox1 in Mammalian Lymphangiogenesis Prox1 in Mammalian Lymphangiogenesis		93.837	5R01HL073402-15 5R01HL073402-17	(82,036) 527,346	
		Pseudomonas Genomic Signatures Associated With Persistence in Cystic Fibrosis		93.837	5R21HL129930-02	48 421	
		Quantitative MRI for the assessment of subclinical CAD in T2DM		93.837	5K01HL121162-04	165,724	
		Rapid Real-Time Cardiovascular MRI for Detecting Coronary Artery Disease		93.837	5R01HL138578-02	248.874	
		Redox Regulation of Vascular cGMP Signaling in Neonatal Lungs		93.837	5R01HL109478-08	336,343	
		Regulating fibrosis and growth through latent TGFbeta binding proteins		93.837	1R01HL140938-01A1	33,436	
		Regulation of cardiac metabolism and heart failure by tristetraprolin		93.837	5F31HL132552-03	44,267	
		REPRIEVE A5332 and A5333s	131	93.837	Mod. 4/PS#225707//U01HL123336-05	53,189	
		RESEARCH TRAINING IN CVD EPIDEMIOLOGY AND PREVENTION		93.837	5T32HL069771-15 REVISED	263,441	
		Respiratory and Metabolic Adaptation to Hypoxia	24	93.837	5R01HL035440-30	384,008	
		Risk Factors for Ischemic Stroke	31	93.837 93.837	113896//5R01HL08851-07 5R01HL127646-03 REVISED	22,676	
		Role of SNRK in cardiac metabolism and development of heart failure Role of Valve-Mediated Hemodynamics on Bicuspid Aortopathy		93.837 93.837	5R01HL127646-03 REVISED 5R01HL133504-02 REVISED	414,300 407,285	1
		Sarcoglycan in Myopathy and Muscle Membrane Stability		93.837	5R01HL133504-02 REVISED 5R01HL061322-19	407,285 354 378	1
		Social and Cultural Influences on Cardiovascular Risk in South Asians		93.837	5R01HL061322-19 5R01HL120725-04	408 895	2
		Sorafenib In Hepatopulmonary Syndrome	259	93.837	SUB#567266//5UM1HL116886-03 REVISED	(20,184)	2
		Statistical methods for estimating relative intensity physical activity and its association with				(20,104)	
		cardiometabolic disease		93.837	5R01HL131606-02 REVISED	110,644	
		Statistical methods to correct for measurement error in self-reported dietary data from lifestyle					
		intervention trials		93.837	5R01HL127491-03	345.047	

Supplementary Schedule of Expenditures of Federal Awards

uster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-the to subrecip
partment of Health and	Cubagonoy	TAM-Kinases in Transplant		93.837	1R01HL139812-01	\$ 242,707	Junior
Human Services (continued)		Targeting Depression and Nicotine Dependence to Promote Cardiovascular Health		93.837	5F31HL129494-02 REVISED	3 242,707	
. ,		TELmisartan plus EXercise to improve functioning in PAD: The TELEX Trial		93.837	5R01HL126117-04 REVISED	729,791	130
		The Cleveland Clinic Innovation Accelerator	48	93.837	857-548 Amd 1 // U54HL119810-05	8,412	
		The Role of CD99L2 in Leukocyte Transendothelial Migration in vitro and in vivo		93.837	5F31HL131355-03		
		The Role of Gut Microbiota in Neointimal Hyperplasia After Vascular Injury The role of p21-activated Kinase (Pak1) in Atrial Fibrillation.	178	93.837 93.837	5K08HL130601-03 14091801//5R01HL128330-03	729.791 8.412 39.499 170.041 85.154 7.572 10.832 375.289 446,112 492.764 305,697 422.308 26,085,228 5.000 (2.591) 65,247 107,873 69,352 3.138 85,097 44,267 468,359 117,263 422,584 422,584 44,267 468,359 117,263 144,573 19,649 407,744 12,798 9.894 3,717 618,995 44,122 147,429 144,573 12,266 144,573 12,266 144,573 12,278 618,995 644,512 147,449 3,312,213 3,1623 12,266 3,6167 2,377,858 8,185	
		The Role of Plasminogen Activator Inhibitor-1 in the Development and Progression of Obesity	1/0	93.837	1F32HL129695-02		
		The Roles of Endothelial PECAM and the LBRC in Leukocyte Transmigration		93.837	5R01HL046849-27		
		The WHI Strong and Healthy SilenT Atrial febrillation Recording study (WHISH STAR)	193	93.837	61526610-125216//1R01HL136390-01		
		Tissue sodium, inflammation, and blood pressure in MESA	278	93.837	VUMC 59440//5R01HL133860-02	8,412 39,499 170,041 85,154 7,672 422,617 10,832 375,289 442,774 402,774 402,774 402,774 402,774 22,008 26,085,228 26,085,228 26,085,228 26,085,228 26,0352 3,138 85,097 44,267 44,267 44,267 44,267 44,267 44,267 44,267 44,267 44,267 44,267 44,267 44,267 44,267 44,274 3,138 85,097 44,267 44,267 44,267 44,267 44,267 44,274 3,138 85,097 44,274 3,138 85,097 44,267 44,267 44,277 44,267 44,277 44,267 44,277 44,267 44,277 44,267 44,277 44,267 44,277 44,267 44,267 44,277 44,267 44,277 44,267 44,277 44,267 44,277 44,267 44,277 44,267 44,277 44,267 44,277 44,267 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,277 44,	
		Training Grant in Circadian and Sleep Research		93.233	5T32HL007909-20 REVISED		
		Transition from Risk Factors to Heart Failure: Prevalence, Pathogenesis, and Phenomics	284	93.837	WFUHS114489//R01HL127028		
		Vascular Surgery Scientist Training Program		93.837	5T32HL094293-08		
		Vimentin-mediated regulation of the inflammasome in acute lung injury		93.837	5R01HL128194-03 REVISED		
						26,085,228	3,75
		2018 Meeting of the American Association of Sarcoidosis and Other Granulomatous Disorders (AASOG)		93.838	1R13HL142300-01	5,000	
		5 -Hydroxytryptophan Regulation of Endothelial Cell Signals for Lung Inflammation		93.838	4R01HL111624-04		
		A Systems Biology Approach to Mapping Aging in the lung		93.838	5F32HL136111-02		
		Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients		93.838	5K23HL138165-02		
		Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea	259	93.838	570229//1R01HL134015-02		
		Azithromycin and the airway microbiome in asthma	228	93.838 93.838	FP064388-02//1R34HL136991-01A1		
		Chicago Metropolitan Asthma Consortium for severe/exacerbation-prone asthma Chitinase1 as a biomarker and therapeutic target in scleroderma lung disease	228 32	93.838 93.838	FP066077-A//1UG1HL139125-01 00000755//5R01HL115813-04		
		CNB Pathways Integrating Respiratory and Metabolic Control	32	93.838	5R01HL122921-04		
		Differential role of tissue-resident and monocyte-derived alveolar macrophages in the		35.050	510 HE 12232 1-04	400,000	
		development of pulmonary fibrosis		93.838	1R56HL135124-01		
		Glucocorticosteroid Action In Inflammatory Disease		93.838	5R37HL068546-35		
		Glycobiology of Inflammatory Lung Diseases	122	93.838	2002969467//5P01HL107151-07		
		High carbon dioxide impairs lung repair		93.838	5K08HL125940-04		
		Hypercapnia and Suppression of Anti-viral Host Defense		93.838 93.838	1R56HL131745-01 5R01HL131745-02		
		Hypercapnia and Suppression of Anti-viral Host Defense Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control:		93.636	5R01HE131/45-02	407,744	
		determination of neurorespiratory maturation and predictors of co-morbidity risk	14	93.838	901513-NU//5U01HL133704-02	12,798	
		Losartan Effects on Emphysema Progression Trial (LEEP)	12	93.838	5U01HL128954-03		
		LUBAC Mediated Epithelial Signaling During Influenza A Infection		93.838	5F31HL132454-03		
		Lung Function Decline and Disease Risk from Young Adulthood to Middle Age		93.838	5R01HL122477-05		:
		Macrophage Modulation of Lung Fibrosis		93.838	5R01HL134375-02 REVISED		
		Mechanisms of Hydrocortisone Regulation of the Perinatal Pulmonary Vasculature Metabolic Regulation of Pulmonary Vascular Remodeling		93.838 93.838	5K08HL124295-02 5R01HL122062-04		
		miR-17~92 Haploinsufficiency Influences Alveolar and Vascular Endothelial Development	14	93.838	901527-NU//1K08HL140152-01		
		Multi-Level Understanding of Social Contributors to SES Disparities in Asthma	14	93,838	4R01HL108723-05		
		Multi-Level Understanding of Social Contributors to SES Disparities in Asthma		93.838	4R01HL108723-05		
		Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) - CleanUp	260	93.838	9012549(130129-26)//5U01HL128954-03		
		Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) - Insight	260	93.838	9012549 (130129-26)//5U01HL128954-03		
		Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) – Rethinc	260	93.838	9012549(130129-21)//5U01HL128954-03		
		Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) (Insight)	55	93.838	001-Amend1//5U01HL128954-03		
		Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) (RETHINC)	55	93.838	002//5U01HL128954-03	2,895	
		Ohio Consortium Clinical Center for the NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network	48	93.838	989-SUB//5U01HL123009-05	36.167	
		Pathophysiology of Acute Lung Injury	10	93.838	5P01HI 071643-14		
		PETAL Network: VIOLET-Vitamin D to Improve Outcomes by Leveraging Early Treatment	48	93.838	869-SUB//5U01HL123009		
		Pulmonary Complications in a Birth Cohort after a Randomized Trial of Exposure to Antenatal					
		Corticosteroids: the ALPS Follow-Up Study	84	93.838	1-AF-28//2R01HL098354-04	18,368	
		Pulmonary Complications in a Birth Cohort after a Randomized Trial of Exposure to Antenatal				0.494	
		Corticosteroids: the ALPS Follow-Up Study Pulmonary Microvascular Blood Flow and Cor Pulmonale Parvus in Emphysema/COPD	84 50	93.838 93.838	Agmt 6/7/17//R01HL098354 7(GG007619-04)//5R01HL093081-08		
		Pulmonary microvascular blood Flow and cor Fulmonale Farvus in Emphysema/COFD	50	93.838	5(GG010919-03)/5R01HL077612-11	124.574	
		PVDOMICS: Pulmonary Vascular Disease Phenomics Program (U01HL125177)	48	93.838	851-SUB//5U01HL125177-04	10.574	
		Regulation of Inflammation and Acute Lung Injury by the Transcription Factor Miz1		93.838	5R01HL114763-04	38.650	
		Regulatory T cell Uhrf1 and DNA methylation in repair of acute lung injury		93.838	5K08HL128867-04	176,452	
		Role and Regulation of Sodium, Potasium ATPase in Lung		93.838	5R37HL048129-23	266,087	
		Role of the Na K ATPase Beta 1 subunit in alveolar epithelial integrity		93.838	4R01HL113350-04	55,815	
		Self-management behaviors among COPD patients with multi-morbidity	100	93.838	0255-8783-4609//5R01HL126508-03	140,387	
		Self-management behaviors among COPD patients with multi-morbidity	100	93.838	0255-8784-4609//5R01HL126508-04	30,699	
		The deleterious effects of hypercapnia on the lungs		93.838	5R01HL085534-12 REVISED	471,790	
		The Role of Placental Maternal Vascular Underperfusion in Neonatal Pulmonary Hypertension		93.838	1R01HL139798-01	96,966	
		The role of SIRT3 inducers in preventing alveolar epithelial cell death and lung fibrosis		93.838 93.838	5F32HL134222-02 5T32HL076139-14	42,494	
		Training Program In Lung Sciences Wnt/beta-catenin signaling and innate immunity in pulmonary fibrosis		93.838 93.838	5132HL076139-14 1R56HL127245-01A1	492,253 184.807	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
Department of Health and		Wnt-beta-catenin cross interactions in alveolar macrophages and epithelial cells in persistence					
Human Services (continued)		of SSc-ILD		93.838	1R01HL134800-01A1	\$ <u>494,291</u> 9.096.448	673,292
		1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT(C-TRACT TRIAL)	285	93.839	WU-18-261//UG3HL138325	2,170	013,232
		Aberrant megakaryopoiesis in the myeloproliferative neoplasms.	200	93.839	5R01HL112792-06	624,665	47,883
		Defining the Role of IQGAP1 in Leukocyte Transmigration in vitro and in vivo		93.839	5F30HL134202-03	49,645	-
		EHR Anticoagulants Pharmacovigilance Generating Human Cord-Blood-Derived Functional Megakaryocytes and Platelets	247 237	93.839 93.839	WA00406355-RFS2015140//5R01HL125089-02 7800 Amd 2 // R01HL130760-03 / R01HL130760	67,571 110,988	-
		Membrane-Cytoskeletal Remodeling in Platelet Biogenesis	231	93.839	5K08HL114871-03	105,236	_
		Multiscale Modeling of Myelodysplastic Syndromes	282	93.839	FP00000825_SA003//7R01HL128173-02	208,973	_
		Vascular-Targeting Genomic and Genetic Strategies for Acute Chest Syndrome	107	93.839	IN4687826NW//2R01HL111656-06	4,297	
						1,173,545	47,883
		"RISK" The nervous joint: New concepts in the development of osteoarthritis.	178	93.846 93.846	16100402-Sub01//1R61AR073576-01 1R01AR069580-03	45,181 355,991	32,376
		3-D printed hyperelastic bone composites for bone regeneration and spine fusion A Multi-Center Prospective Study of Quality of Life in Adult Scoliosis	285	93.846 93.846	WU-10-154 Amendment 04 //1R01AR055176-02	3.720	32,370
		A Regulatory Checkpoint in the Pathogenesis of Inflammatory Arthritis	205	93.846	5R01AR064349-05 REVISED	251,360	_
		AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments		93.846	1U19AR069526-01 REVISED	668,205	236,38
		Adipokine Modulation of Fibrosis: Novel Scleroderma Pathway		93.846	5R03AR066343-03 REVISED	47,521	-
		Algorithms to Identify Systemic Lupus from Electronic Health Record Data		93.846	1R21AR072263-02	174,094	-
		Association of genetic and autoantibody signatures with SLE clinical course Biomarkers and Pathogenesis of Systemic Sclerosis (NIAMS: CORT)	214 30	93.846 93.846	000504653-SC002//5R01AR064820-03 4500001925/5P50AR060780-05	58,189 (17,793)	
		Breaking down barriers: defining the role of EphA2 in building epidermal tight junctions in	50				_
		atopic dermatitis		93.846	1K01AR072773-01A1	5,566	-
		Cadherin clusters and actin filaments Caspase 8: A Novel Suppressor of Dendritic Cell-Mediated Autoimmunity		93.846 93.846	5R01AR070166-02 5K01AR064313-05	357,128 54.681	-
		Causes and Roles of Hypercitrullination in Preclinical Rheumatoid Arthritis	31	93.846 93.846	117944//5R01AR070171-02	8.267	
		Central Pain Mechanisms, Pain Intensity and Drug Response in Rheumatoid Arthritis	01	93.846	7R01AR064850-06	275,688	86,10
		Contribution of Adipocytes and Adipose Secreted Factors to Fibrosis in Systemic Sclerosis		93.846	1K08AR070285-02	40,910	_
		Core Center for Clinical Research at Northwestern University Desmoplakin Assembly and Function in Epidermis (R37 MERIT Extension		93.846	Require5P30AR072579-02	644,566	-
		Application R37AR043380)		93.846	5R37AR043380-23	509,267	_
		Development of a Novel RA/Atherosclerosis Mouse Model		93.846	5R01AR064546-05	285,344	-
		Epha/Ephrin – A Signaling in Epidermal Differentiation and Disease		93.846	4R01AR062110-05	236,781	-
		EphA/Ephrin-A Signaling in Epidermal Differentiation and Disease		93.846	5R01AR062110-04	(5)	-
		Evolving Adaptive and Effector Mechanisms from Pre-RA Through Established Disease Failed Regeneration in the Muscular Dystrophies: Inflammation, Fibrosis and Fat – Admin Core	232 233	93.846 93.846	FY17.090.001//5UH2AR067681-03 UFDSP0011905//U54AR052646	427,904 6,653	95,10
		Function of Desmodlein 1/Pemphiaus Foliaceus Antigen	200	93.846	4R01AR041836-24	1.302	
		Function of Desmoglein 1/Pemphigus Foliaceus Antigen		93.846	5R01AR041836-26	505,845	-
		Gene expression signatures for treatment response in systemic sclerosis	38	93.846	Agr. 10/06/2015//5R44AR061920-03	12,213	-
		Glycosphingolipids Mediate Diabetic Wound Healing Impairment		93.846	5R01AR068375-03 5R03AR061593-03	439,367	-
		Human Rheumatoid Arthritis in Mice Impaired osteoblast and osteocyte maturation in the pathogenesis of renal osteodystrophy	222	93.846 93.846	5K03AK061593-03 1652GWA093//1R21AR073977-01	(6,781) 2,553	-
		Inflammasome adaptor and effectors in Cryopyrinopathies and crystal arthropathies	222	93.846	5K01AR066739-04 REVISED	105,239	_
		Inflammatory arthritis: mechanistic insights into initiation and progression		93.846	5R01AR070025-02	454,563	-
		Inter-junctional signaling in epithelial junctional complex		93.846	2R56AR044016-20	(805)	-
		Inter-junctional signaling in epithelial junctional complex		93.846	5R01AR044016-22	474,215	-
		Knee OA: Predictors and Outcomes of Physical Inactivity-Activity Transitions Long-term Significance of Pre-radiographic Lesions in Persons at Risk for Knee OA		93.846 93.846	4R01AR054155-09 5R01AR065473-05	275,658 2,086,993	22,33 552,22
		Lupus Intervention Fatigue Trial (LIFT)		93.846	1R01AR071091-01A1	9,968	
		Mapping Modifiers of Cardiomyopathy in Muscular Dystrophy	233	93.846	UFDSP00011909//U54AR052646	288,019	-
		Mechanisms Underlying Heterotopic Ossification		93.846	5R01AR066539-04	373,194	-
		Molecular biomarkers of improvement for patients with systemic sclerosis in an open label trial of mycophenolate mofetil	61	93.846	R284/1R21AR068035-02	57.564	_
		Molecular Pathways of Pain Generation in Osteoarthritis	178	93.846	10012005-Sub01-Amend01//5R01AR060364-07	47.321	_
		NIAMS Multidisciplinary Clinical Research Center in Rheumatology		93.846	5P60AR064464-05	915,145	24,90
		Noninvasive tools for assessing muscle structure and function		93.846	5R01AR071162-03	697,865	246,97
		Northwestern University Skin Disease Reseach Core Center		93.846	5P30AR057216-10	573,302	-
		Novel Role for A20 in Fibrosis Susceptibility OAI Ancillary- Prediction of Incident and progressive OA from imaging biomarkers	216	93.846 93.846	1R21AR074292-01 238323//R01AR066601	19,529 19 156	-
		Osteoarthritis Progression and Sensory Pathway Alterations	178	93.846	12052504-NU//5R01AR064251-05	68,823	_
		Post Graduate Program in Cutaneous Biology		93.846	4T32AR060710-05	34,279	-
		Postdoctoral Rheumatology Training		93.846	4T32AR007611-15	3,149	-
		Postdoctoral Rheumatology Training		93.846	5T32AR007611-17	185,153	-
		Quantifying Underuse and Overuse of Knee Replacement Regulation of the Profibrotic Mechanisms of MACRO+ Myeloid Cells in Scleroderma		93.846 93.846	5R21AR069867-03 REVISED 1R21AR073371-01	177,447 37.882	78,98
		Regulators of Epidermal Gene Expression		93.846	5R00AR065480-04	202,425	
		SBIR Phase II – Radikal Therapeutics	182	93.846	Agmt 03/27/18//2R44AR065886-02A1	4,034	-
		Sedentary Behavior Characteristics, Sedentary Profiles, and Subsequent Functional Loss		93.846	5R21AR068500-02	11,404	7,38
		Selective Inhibition of CYP26A1 in the Skin for the Treatment of Ichthyosis Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lugus Therapy	63	93.846 93.846	NIAMS//1R41AR069416-01A1 5R01AR066634-05	75,113 371.082	63.71
		Simultaneous Targeting of IRE-1a in B Cells and Macrophages for Lupus Therapy Study of Physical Activity Rewards and Telephonic Active Coaching or SPARTAC	31	93.846	115219//5U34AR069187-02	34,287	63,71

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throug to subrecipient
Department of Health and		Synthetic Oleananes: Innovative Treatment of Fibrosis		93.846	5R03AR065800-03	\$ (12,055)	-
Human Services (continued)		The pathogenic mechanism of anti-phosphatidylethanolamine antibodies		93.846	1R21AR071705-01A1	13,348	-
		The Vasculitis of Kawasaki Disease		93.846	5R21AR068041-02	(381)	
		The Vasculitis of Kawasaki Disease		93.846	5R21AR068041-02	26,239	26,09
		Topical Delivery of siRNA Nanoconjugates: Suppressing Epidermal Hyperplasia		93.846	5R01AR060810-04	20	-
		Translation of novel and repurposed drugs to address the acute and late effects of mustard exposure	36	93.846	RES512302//1U01AR071168-01A1 REVISE	13,755	
		Validation of PROMIS Measures in Children with Brain Tumors	30	93.846	5R01CA174452-04 REVISED	43.475	- 1.40
		Validation of PROMIS Measures in Children with Brain Tumors Vasculitis Clinical Research Consortium (VCRC)	259	93.846 93.846	572644//5U54AR057319-15	43,475 2.369	1,40
			200	33.040	372044/3034AR037373-13		
						13,142,855	1,473,98
		10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project		93.847	5U01DK048380-25 REVISED	360,780	
		A Culturally Targeted Transplant Program to Increase Live Donation in Hispanics		93.847	5R01DK104876-03 REVISED	751,281	411,6
		A Multi-Center Group to Study Acute Liver Failure	270	93.847	GMO-161131//5U01DK058369-17	76,649	
		A Novel Approach to Phosphorus Lowering in Patients with Chronic Kidney Disease A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (ornithine ohenvlacetate)	279	93.847	08649005-319676//5U01DK97093-05	21,710	
		A Phase 28 Study to Evaluate the Safety and Tolerability of OCR-002 (omithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury					
		(STOP-ALF) A Multi-Center Group to Study Acute Liver Failure	270	93.847	GMO-170910//5U01DK058369-18	1,159	
		Acute Liver Failure Study Group 13C-Methacetin Breath Test for the Prediction of Outcome in	210	33.047	GMO-170310//5001E/030303-10	1,155	
		Acute Liver Failure	270	93.847	GMO160216//5U01DK058369-18	1.159	
		Altered Microbiome of Chronic Pelvic Pain		93.847	5R01DK103769-03	431.059	155.1
		An Assessment of Liver Disease in HIV-infected and HIV/HBV Co-infected Tanzanians		93.847	5K23DK095707-05 REVISED	73,925	20,9
		Antifibrotic Actions of SARA		93.847	1R01DK105055-02	416,973	82,
		Barrier integrity, microbiome and HIV target cell interactions in the human male genital tract					
		pre and post circumcision		93.847	5R01DK108434-02	271,677	26,
		Basic Science Training Grant in Urology		93.847	5T32DK062716-13	96,464	
		Cholestasis and the Unfolded Protein Response		93.847	5R01DK093807-04	(13,321)	
		Cholestasis and the Unfolded Protein Response		93.847	5R01DK093807-06	399,902	
		Circadian control of nutrient-sensing and fuel utilization in skeletal muscle		93.847	5K01DK105137-03	62,708	
		Circadian Control of Nutrient-Sensing Pathways Through Clock-HIF Interactions in Skeletal					
		Muscle Circadian Genes and Adipose Function: Impact of Chronotype, Obesity and Race	228	93.847 93.847	1R03DK116012-01 FP055658//5R01DK103014-04	38,552 18,930	
		Clinical Islet Transplantation: Data Coordinating Center	228	93.847 93.847	1001443305/5U01DK070431-11	(14,357)	
		Collaborative Islet Transplant Registry (CITR)	239	93.847 93.847	CITR Agmt 4/22/2013	(14,357) (12,611)	
		Community Translation of a Lifestyle Intervention to Improve Health in Diabetes	11	93.847	5R18DK083941-06	(12,011) (1)	
		Control of islet beta specific Pdx-1 and MafA transcription	278	93.847	UNIV59587//5R01DK050203-20	144.771	
		Coordinating Pragmatic Primary care Population management for Obesity (C3PO)	2/0	93.847	1R34DK114773-01A1	7,818	
		Defining bacterial virulence, cAMP and PKA in necrotizing enterocolitis		93.847	5K08DK106450-04	138 515	113.
		Development, cellular plasticity and homeostasis of the exocrine pancreas		93.847	5R01DK106266-05	418,484	
		Diabetes Risk Education and Communication Trial (DiRECT) for Primary Care Patients with					
		Prediabetes		93.847	5R34DK113541-02 REVISED	257,382	40,
		Disordered Tissue Biomechanics as a Driver of Esophageal Disease		93.847	1P01DK117824-01	107,876	
		EDIC Hypoglycemia-Arrhythmia Study	36	93.847	RES512561//2U01DK094157-07 REVISED	20,258	
		EDIC Skeletal Health Study	36	93.847	RES512878//2U01DK094157-07 REVISED	23,191	
		Effect of Barrier Function on HIV Interactions in the Glans after Circumcision		93.847	5R21DK105865-02	151,159	
		Effectiveness of Physiologic Testing in PPI Non-Responders Effects of Biomedical Risk Factors on Neuro-cognition Using MRI: Long term follow-up of the		93.847	5R01DK092217-05	318,554	129,
		Diabetes Control & Complications Trial/Epidemiology of Diabetes Interventions and					
		Complications Study Cohort	36	93.847	3500-07249//1DP3DK114812-01	4.101	
		Epidemiology of Diabetes Interventions and Complications (EDIC)	36	93.847	RES512231/2U01DK094157-07 REVISED	153.521	
		Epidemiology of Diabetes Interventions and Complications (EDIC)	36	93.847	RES511132//4U01DK094157-06S1	(22.305)	
		Expanding live donor kidney transplantation through advocacy training and social media	122	93.847	2003447902//R01DK111966	128,063	
		F32 for Joseph Stephen Uzarski in Support of: Delineating Determinants of Renal					
		Tubulogenesis in an ECM-based Co-culture Model		93.847	5F32DK103499-03 REVISED	11,105	
		FGF23 and Cardiovascular Disease in CKD	66	93.847	2036138//7R01DK081374-11	100,466	
		Functional Retinal Imaging to Monitor Pharmaco-Therapies in Diabetic Retinopathy		93.847	1DP3DK108248-01 REVISED	418,943	
		GATA1 Mutation in Defective Erythropoiesis		93.847	4R01DK101329-05	329,529	
		Genetics and Evolution of Fetal Human Fat Accretion During Development		93.847	5R01DK099820-05	471,344	135
		Genetics and Genomics of Maternal Glycemia During Pregnancy		93.847	5R01DK097534-05	464,602	111
		Genomic Basis for the Circadian Regulation of B-cell Function and Glucose Homeostasis		93.847	1F30DK116481-01	38,883	
		Health and Economic Impacts of Coverage Requirements and Health System-Community		02.047	ED40D/(440744-02	386.804	42
		Coordination for Diabetes Prevention	047	93.847 93.847	5R18DK110741-02	386,804 130,508	13,
		Health literacy intervention to improve diabetes outcomes among rural primary care Home sleep and circadian phase: mediators of racial disparities in diabetes risk	217	93.847 93.847	50961//1R01DK107572-02A2 7R01DK095207-06	130,508	29.
		Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follow Up Study		93.847 93.847	4U01DK094830-05 REVISED	525,914	29.
		Impact of Emerging Health Insurance Designs on Diabetes Complications	93	93.847	AH000527//5R01DK100304-04	9,370	9,
		Impact of phosphate and FGF23 reduction on intermediate end points in CKD	30	93.847	5R01DK102438-05	490.818	287.
		Impact of Pulse Rate on Swallowing Impairment Assessment and Radiation Exposure	138	93.847	MUSC16-102-8A028 // 5R010K098222-05	16,306	207
		Improving Diabetes Risk Assessment and Screening in Minority-Predominant Community	100	33.041	1000010102010201/0101010000222-00	10,300	
		Health Center Patients		93.847	1R21DK112066-01	181.318	30
		Integration of Feeding Time and Glucose Metabolism by the Circadian Gene Network		93.847	5R01DK090625-07	471.765	25
		Interplay of Dietary Lipid and Circadian Dysregulation in Metabolic Syndrome		93.847	5R01DK100814-05	306,116	

Supplementary Schedule of Expenditures of Federal Awards

luster title/Federal grantor	Subagency	Project title	through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thr to subrecipi
epartment of Health and		Kidney Therapeutics: Translating Discoveries into Prevention, Treatment and Cures for			·		
Human Services (continued)		Kidney Diseases Large-scale nutrigenetics and genomics in a tractable metazoan model	247	93.847 93.847	1P30DK114857-01A1 OSP2018042//1R01DK115890-01	\$ 19,932 237,594	
		Lipoteichoic acid mediated immune modulation of chronic pain	247	93.847	5R01DK108127-03	404.335	
		Lysosomes in neonatal enterocytes and their pathologies		93.847	5R01DK111032-03	182,472	
		Mast cells in male pelvic pain and lower urinary tract dysfunction		93.847	5R01DK083609-08	365,646	
		Maternal Obesity and Gestational Diabetes: Impact on Metabolome		93.847	5R01DK095963-03	(1)	
		Maternal Obesity and Gestational Diabetes: Impact on Metabolome		93.847	4R01DK095963-04	214,216	17
		Mechanism of autophagy activation in the prevention of type 2 diabetes Mechanisms of Salmonella Clearance by Neutrophils in the Intestinal Lumen		93.847 93.847	1R01DK113170-01A1 1R03DK116663-01	332,540 12,646	
		Med1 in Liver Metabolism, Regeneration and Cancer		93.847 93.847	5R01DK097249-05	255.445	
		Methylomics of prenatal GDM: Natural history & lifestyle intervention in children Microenvironmental Signaling Cues to Model Glomerular Endothelial Cell and Podocyte	161	93.847	1R01DK0790-50363-S2//5R01DK100790-04	206,667	
		Interactions		93.847	5F31DK108544-02	33,461	
		Molecular and Genetic Mechanisms of Fatty Liver Disease		93.847	1R56DK105824-01A1	888	
		Molecular Mechanisms of Epithelial Contribution to Esophageal Inflammation and Tissue Repair		93.847	1R01DK116988-01	134,651	
		Multifunctional Printed Scaffolds for Enhancing Hepatocyte Viability and Function		93.847	5K01DK099454-05	123,215	
		Nephrolithiasis and Kidney Failure: the Rare Kidney Stone Consortium	135	93.847	NWU-182824/PO#65461505//U54DK083908	35,103	
		Neutrophil interactions with apical ICAM-1 regulate intestinal epithelial homeostasis Nonhuman Primate Model of Bladder Regeneration Using Autologous Bone Marrow Cells		93.847 93.847	5K01DK101675-05 5R01DK109539-02 REVISED	147,641 1.045.313	
		Normanian Primate Model of Bladder Regeneration Using Autologous Bone Marrow Cells Novel Diagnostics and Therapeutic Targets for Calcification in CKD		93.847 93.847	5R01DK109539-02 REVISED	569.777	
		Note Diagnostics and Therapeutic Targets for Calcincation in CKD Nuclear Repressors in Genomic Control of Healthful Obesity		93.847	5R01DK10087-02 5R01DK108987-03 REVISED	321.480	
		NUKIDs: Scientist Training Program in Kidney Disease		93.847	5T32DK108738-03 REVISED	97,515	
		NW University Program in Endo Diabetes and Hormone Action		93.847	5T32DK007169-36	37	
		NW University Program in Endo Diabetes and Hormone Action		93.847	5T32DK007169-39	305,019	
		Omega-3 derived epoxy fatty acids and sEH in pancreatitis-induced carcinogenesis		93.847	5R01DK107767-03 REVISED	575,201	
		Optimization and control of hepatocyte activity via biofunctional modification		93.847	5K08DK101757-05	165,383	
		OPT-IN: Optimizing INtensive Lifestyle Intervention for Weight Loss		93.847	4R01DK097364-05	112,017	
		Pathogenesis of Diabetic Nephropathy		93.847 93.847	4R01DK060635-15	134,137	
		Pathogenesis of Diabetic Nephropathy Pelvic Pain and Depression		93.847 93.847	2R01DK060635-16 5U01DK082342-09	98,367 934.673	
		Pervic Pain and Depression PERL: A multicenter clinical trial of allopurinol to prevent GFR loss in T1D	123	93.847 93.847	100062//2UC4DK101108-02	934,673 224,482	
		PERL: A multicenter clinical trial of allopurinol to prevent GFR loss in T1D	123	93.847 93.847	1987203-6 AMEND 1UC4DK1101108-01 REVISED	224,462 18.916	
		Phenotype of urinary symptoms and relationships with genotype, sleep and obesity	123	93.847	4U01DK097779-06	432,179	
		Pilot Studies Targeting Mineral Metabolism in CKD		93.847	5U01DK099930-07	431,666	
		Predicting Newborn and Childhood Adiposity: An Integrated Omics Approach		93.847	1R01DK117491-01	10,279	
		Pregnancy-Related Risk Factors and Glucose Intolerance in Women during Midlife Prevention of Type-2 Diabetes: The Circadian System as a Novel Target for Long-Term	125	93.847	RNG200279-05//R01DK106201	28,101	
		Maintenance of Weight Loss	228	93.847	FP035726-02-H//5P30DK020595-40	37,827	
		Promoting Utilization of Kidneys by Improving Patient Level Decision Making		93.847	5R21DK108104-02	129,645	
		Promotora Intervention for Metabolic and MentalHealth (PRIME2)		93.847 93.847	5R03DK109243-02 REVISED	82,292 556,682	
		Regulation of FGF23 by DMP1 in Health and in Chronic Kidney Disease (CKD) Regulation of FGF23 in Chronic Kidney Disease (CKD) by iron and inflammation		93.847 93.847	5R01DK101730-03 5R01DK102815-04	556,682 442,834	
		Regulation of FGF23 in Chronic Kidney Disease (CKD) by iron and inflammation Regulation of Ulcerative Colitis by mast cells and histamine		93.847 93.847	5K01DK102815-04 5K08DK097721-04	442,834 187,692	
		Residual Beta Cell Function in Patients with Long-Term Type 1 Diabetes	36	93.847	RES509477//DP3DK104438	605	
		Role of HNF4a in the regulation of FGF23 in health and disease		93.847	1R01DK114158-01A1	188,685	
		SenseWhy: Overeating in Obesity Through the Lens of Passive Sensing Sensorimotor Impairments in Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome:		93.847	1K25DK113242-01A1	84,346	
		Relationship of resting state brain activity to pelvic floor muscle activation	262	93.847	85596622//R01DK110669-02	38,745	
		SMART Weight Loss Management		93.847	5R01DK108678-03 REVISED	875,543	
		T cells in Chronic Pelvic Pain		93.847	3R01DK094898-03S1	(70)	
		T cells in Chronic Pelvic Pain		93.847	4R01DK094898-04	95,475	
		Testing a medication risk communication and surveillance strategy: The EMC2 Trial		93.847 93.847	5R01DK103684-04 1R01DK113011-01A1	533,231 17,383	
		The Circadian System as a Neuronal Regulator of Feeding Time and Body Weight Setpoint The effects of capsinoids on brown adipose tissue recruitment and activation in obesity The genetic identity of the primary citia ion channels of kidney collecting duct cells and their		93.847 93.847	5R01DK113011-01A1 5R01DK112281-03	17,383 229,093	
		regulation by internal calcium		93.847	5R00DK106655-04 REVISED	283.067	
		The mechanics of symptom generation in dysphagia The Role of an RNA Binding Protein, Tristetrapolin, in Hepatic Glucose Metabolism and the		93.847	5R01DK079902-09	273,135	
		Development of Diabetes		93.847	5F30DK109608-02 REVISED	2,015	
		The role of emergency granulopoiesis in the pathogenesis of Fanconi Anemia		93.847	5R01DK098812-04 REVISED	270,053	
		The role of microenvironment in esophageal epithelial homeostasis		93.847	5R00DK094977-05	234,746	
		The Role of PAI-1 and Circadian Disruption in the Pathogenesis of NASH		93.847	4K08DK095992-05	128,891	
		The roles of pleckstrin-2 as a functional node in erythropoiesis		93.847	5R01DK102718-04	362,618	
		Training Grant in Gastrointestinal Physiology and Psychology Transition from Acute to Chronic Pelvic Pain in a Murine Model of Chronic Prostatitis Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies:		93.847 93.847	3T32DK101363-05S1 REVISED 1K01DK114395-01A1	261,799 7,826	
		The TAKE IT Trial		93.847	5R01DK110172-02 REVISED	379,464	
		Transplant Surgery Scientist Training Program		93.847	3T32DK077662-10S2	(2,061)	
		Transplant Surgery Scientist Training Program		93.847	5T32DK077662-12	236,273	
		Tryptase – PAR2 axis involved in urinary voiding dysfunction		93.847	5F32DK104544-03 REVISED	14.676	
		Urinary Knowledge Study (U-KNOW)	129	93 847	206423//5R01DK104842-02	15.994	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
Department of Health and		Vitamin D and type 2 diabetes (D2d study)	206	93.847	5008752-SERV//4U01DK098245-04	\$ 153,470	_
Human Services (continued)		Vitamin D and Type 2 Diabetes (D2d)	205	93.847	5015643-SERV//2U01DK098245-06	26,130	
		(CREST-2) Trial: Carotid Revascularization and Medical Management for Asymptomatic				23,946,938	3,194,938
		Carotid Stenosis Trial	136	93.853	NWU-187276-02//5U01NS080168-03	14,118	_
		A Novel Pharmacological Treatment for Neuropathic Pain	16	93.853	Agmt 3/3/17//1R44NS100173-01 REVISED	31,467	-
		A Primate Model of an Intra-Cortically Controlled FES Prosthesis for Grasp A primate model of an intra-cortically controlled FES prosthesis for grasp		93.853 93.853	5R01NS053603-10 5R01NS053603-12 REVISED	(242) 490,874	_
		A randomized, double-blind, placebo-controlled trial of urate-elevating inosine treatment to		33.035		430,014	_
		slow clinical decline in early Parkinson disease ("Inosine Phase 3")	131	93.853	Agmt 4/24/17//5U01NS090259-03	75,628	-
		A role for beta-arrestins in mGluR-dependent plasticity A wearable myoelectric computer interface to reduce muscle co-activation in acute and		93.853	5R21NS088916-02	(1,677)	-
		chronic stroke		93.853	5R01NS099210-03	294,201	36,111
		AMPK, metabolism and ALS		93.853	5R01NS096746-04 REVISED	267,005	-
		An epigenomic approach to identifying noncoding mutations in epilepsy Assessing Aberrant Motor Learning in Parkinsons Disease	166	93.853 93.853	5R00NS089858-05 41880-A Amd 1//1R21NS083578-01A1	305,454 (87)	_
		AtRial Cardiopathy and Antithrombotic Drugs in prevention After cryptogenicstroke	100	33.035	41000-A Alla 1// 1/2 11/000007/001A1	(67)	_
		(ARCADIA) "study"	230	93.853	010785-133385//1U01NS095869-02	41	-
		Autophagy Regulation of Glioblastoma Tumorigenesis and Responses to Therapy B7-H1 Expressing Macrophages Mediate Immunosupression in Glioma		93.853 93.853	5R01NS095634-04 5R00NS078055-05	439,360 (11,065)	-
		Biomimetic Somatosensory Feedback through Intracorticalmicrostimulation		93.853	5R01NS0/8055-05	903,680	465,17
		BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy		93.853	5R01NS080619-05	205,029	41,28
		Cajal-Retzius cells and neuronal signaling in postnatal cortical networks		93.853	5R01NS064135-09 REVISED	386,832	-
		Cellular and Molecular Role of CXCR4 signaling in Painful Diabetic Neuropathy Cellular dissection of herpes simplex encephalitis with iPS cells	176	93.853 93.853	1R01NS104295-01 5R01NS072381-09	298,939 187,692	-
		Cellular plasticity and equilibrium in GBM progression	170	93.853	5R01NS096376-02 REVISED	418,643	20,00
		Cerebral Small Vessels in Motor and Cognitive Decline		93.853	5R01NS085002-05 REVISED	590,190	_
		Chemokine Signaling in Diabetic Neuropathy		93.853	5K08NS079482-05 REVISED	109,415	-
		Circadian Dysfunction, Encephalopathy, and Cognitive Outcomes after Critical Illness Clinical Coordination Center for STEADY-PD3		93.853 93.853	5K23NS092975-04 5U01NS080818-04	179,364 1,203,779	- 775,39
		Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials		33.035	300 1130000 10-04	1,203,113	115,55
		(NEXT Sites)		93.853	5U10NS077271-07	231,654	-
		Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NEXT Sites)		93.853	1U24NS107213-01	12.380	_
		Clinical Trial Readiness for SCA1 and SCA3	98	93.853	AGMT00000 775//1U01N104326-01	2,765	_
		Coding properties of Vibrissal-Responsive Trigeminal Ganglion Neurons		93.853	5R01NS093585-04 REVISED	245,005	-
		Combined Approach to the Genetic Basis of Epilepsy Concordance of TDP-43 Inclusions with Cortical Atrophy and Clinical Phenotype		93.853 93.853	5R01NS053792-16 REVISED 5R01NS085770-05	387,365 330.858	55,63
		Concordance of TDP-43 inclusions with Cortical Atrophy and Clinical Phenotype Cytohesins, ARF GTP'ases and Neurodegeneration		93.853 93.853	7R21NS093439-03	330,858 83,244	
		Deciphering the Roles of Kainate Receptors in Developing CNS Circuits		93.853	1R01NS105502-01A1	30,390	
		DEFUSE 3: EnDovascular ThErapy Following Imaging EvalUation for ISchemic StrokE 3	230	93.853	010085-110021//1U01NS092076-01A1 R	2,726	-
		Dendritic Organization of Synaptic Input to CA1 Hippocampal Place Cells during Spatial Navigation		93.853	5F31NS098666-02 REVISED	38.518	_
		Designing brain machine interfaces to drive plasticity and enhance recovery after brain injury		93.853	5R01NS094748-03	361,513	94,55
		Determinants of Neurodegenerative Decline in Primary Progressive Aphasia		93.853	4R01NS075075-05	8	-
		Determining How Defective Nucleo-Cytoplasmic Trafficking Leads To Neurodegeneration In C9orf72-Related ALS And FTD		93 853	1R01NS104219-01A1 REVISED	156.849	_
		Developing novel treatment strategies for Spinocerebellar ataxia type 1		93.853	5R21NS099962-02 REVISED	232.994	_
		Development of mouse models for ALS5 and SPG11		93.853	5R21NS096572-02 REVISED	138,072	-
		Development of Novel MR Imaging for Ischemic Stroke Evaluation	228	93.853	FP063797-1//R01NS093908	44,521	
		Differing Neuronal Mechanisms Mediating Locomotion and Spasms After Spinal Cord Injury Dopaminergic and Muscarinic Signaling in the Striatum	215	93.853 93.853	S002//2R01NS047567-13A1 5R01NS034696-22	146,855 463,120	
		Dopaminergic Neurotransmission in a Model of DOPA-responsive Dystonia	72	93.853	T733841//5R01NS088528-04	108,122	
		Effect of Unilateral and Bilateral STN Stimulation on Eye-Hand Coordination		93.853	5R01NS092950-03	270,570	17,1
		Electrical and Mechanical Properties of Motor Units in a Mouse Model of ALS Electrical and Mechanical Properties of Motor Units in a Mouse Model of ALS		93.853 93.853	5R01NS077863-05 5R01NS077863-05	(110) 41,451	41,38
		Electrical and Mechanical Properties of Motor Onits in a Mouse Model of ALS Elp1 function in Familial Dysautonomia		93.853	1R56NS089626-01A1	41,451 (1,178)	41,30
		Elucidating Motor Pathways Involved in Hand Impairment Post Stroke		93.853	5F31NS105486-02	36,938	-
		Epigenetic Regulation of Nerve Injury	274	93.853	761K946//R01NS100510-01A1	26,960	-
		Evaluation of glucocerebrosidase pathway biomarkers in Parkinson Disease FTLD Clinical Research Consortium	100 225	93.853 93.853	0255-1042-4609//U01NS094148 F8568sc//5U54NS092089	65,421 18,514	-
		Functional Development of Motor Networks	225	93.853	5R01NS067299-09	383,312	
		Functional Segregation Within the Whisker-Barrel Neuraxis	285	93.853	WU-16-153-MOD-1//5R01NS091439-02	200,414	
		Functions of filamin in brain development and diseases		93.853	5R01NS087575-03	92,085	
		GABAergic Signaling in the External Globus Pallidus Galectin Modulation of Glutamate Receptors and Neuronal Function		93.853 93.853	5R01NS069777-07 5R01NS080598-05 REVISED	408,232 180,742	41,12
		General Motor Control Mechanisms and Disease Training Program		93.853	5T32NS041234-15 REVISED	(33,454)	-
		General Motor Control Mechanisms and Disease Training Program		93.853	2T32NS041234-16A1 REVISED	47,515	-
		Genetic Modifiers of Childhood Epilepsy		93.853	5R01NS084959-05	387,217	-
		Genetic tools to study CNS development and function Glioblastoma Phenotype Modulation Through miRNA Control of Wnt Signaling		93.853 93.853	5R21NS092034-02 5R01NS093843-04	(42,803) 442 011	- 19,11
							19,11
		HCN channel trafficking in epilepsy		93.853	5R01NS059934-09 REVISED	25,941	-

Supplementary Schedule of Expenditures of Federal Awards

uster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thro to subrecipie
partment of Health and	oubagency	•	254	93.853	17-022-02 // 1R15NS099981-01A1	\$ 9.190	Jubrecipie
partment of Health and Human Services (continued)		Identification of new LAT-1 transporter substrates for drug delivery IDO1 and immunotolerance in glioblastoma.	254	93.853 93.853	17-022-02 // 1R15NS099981-01A1 5R01NS097851-03	\$ 9,190 389,345	
laman oervices (continued)		IL13Ra2 targeted T-cell therapy for glioma		93.853	7R21NS089802-03	(10,104)	
		IL13Ra2 targeted T-cell therapy for glioma		93.853	7R21NS089802-03	63,825	63.
		Immune Modifying Microparticles for Acute Treatment of Spinal Cord Injury		93.853	5F30NS093811-03 REVISED	44,382	
		Immunoregulation and Pathology of Chronic-Relapsing EAE		93.853	4R01NS026543-27	(32,328)	
		Impact of direct dopaminergic neuromodulation of the subthalamic nucleus in health and in					
		experimental Parkinson's disease		93.853	5F31NS100357-02	38,021	
		Induced Pluripotent Stem Cell Core for NINDS Investigators		93.853	4P30NS081774-05	(940)	
		Information Processing in the Thermosensory System of Drosophila Melanogaster Integration of synaptic excitation and inhibition in the deep cerebellar nuclei		93.853 93.853	5F31NS093873-03 5F31NS092329-03 REVISED	30,139 4,678	
		Integration of synaptic excitation and inhibition in the deep cerebenar nuclei Intranasal Stem-Cell Based Therapy of Glioblastoma		93.853	5R01NS087990-05 REVISED	4,078	
		Intrinsic Plasticity and Information Storage in Cerebellar Purkinje Cells	228	93.853	FP038885//R01NS62771	15,405	
		Investigating the role of extremely long-lived mitochondrial proteins in mammalian neurons	220	93.853	1F32NS106812-01A1	9.877	
		Investigation of ALS caused by mutant CHCHD10		93.853	5R01NS099638-03	526,188	1
		Investigation of Histone H3 Post-Translational Modifications in Pediatric Brainstem Glioma		93.853	5K08NS097624-03	164,416	1
		lonic currents and spiking in cerebellar nuclear neurons		93.853	5R37NS039395-17	402,228	
		Ionic Currents and Spiking in Cerebellar Nuclear Neurons		93.853	4R37NS039395-18	106,407	
		Kainate Receptors in Signaling Between Hippocampal Mossy Cells and Granule Cells		93.853	1R21NS090040-01	(7,955)	
		LRP4 signaling in neuromuscular junction formation	36	93.853	RES513371//2R01NS082007-07	2,149	
		LRRK2-mediated molecular and synaptic events in the striatum		93.853	5R01NS097901-03	343,133	
		L-type channels as pharmacological targets for the treatment and prevention of febrile seizures		93.853	5R21NS096424-02 REVISED	114,288	
		Lvsosomal Dvsfunction due to PGRN Mutations		93.853	5F99NS105182-02	30.422	
		Magnetic-vortex microdiscs for glioma therapy		93.853	7R01NS077388-05	60,715	
		Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs	72	93.853	T652681//4U01NS038455-15	112,132	
		Mechanical Signals and Trigeminal Ganglion Neuron Responses During Whisking		93.853	5F31NS090872-03 REVISED	9,494	
		Mechanisms of Distorted Inputs in Chronic Spinal Injury		93.853	5R01NS089313-05 REVISED	128,057	
		Mechanisms of EarlY Recurrence in Intracranial Atherosclerotic Disease (MyRIAD)	249	93.853	SPC-000246//5R01NS084288-05	33,808	
		Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease (MyRIAD)	249	93.853	662706//5R01NS084288-05	15,802	
		Mechanisms Underlying Tau45-230-Induced Neuronal Degeneration		93.853	5R01NS090993-04	355,313	
	Metabolic Control of Immune Suppression in Gliomas		93.853	5R01NS093903-04	578,819		
		MicroRNAs and Perinatal Hypoxia-Ischemia		93.853	5R01NS086945-04	274,902	1
		Minimally Invasive Surgery plus rt-PA for ICH Evacuation Molecular basis of Scapuloperoneal SMA and Charcot-Marie-Tooth disease type 2C	122	93.853 93.853	2001995429//U01NS080824-02 5R01NS078287-04	75,551 (330)	
		Molecular Mechanisms Integrating Circadian Timing and Photic Signaling		93.853	1R01NS106955-01A1	(330) 67,707	
		Molecular Mechanisms integrating circadian rinning and Protic signaling Molecular Mechanisms of CRAC Channel Gating		93.853	5F31NS101830-02 REVISED	43,053	
		Motor Cortical Function During Motor Learning with a Brain-Machine Interface		93.853	5F31NS092356-03 REVISED	58	
		Mouse model studies of TMEM230-linked Parkinson's disease		93.853	5R01NS099623-03	532.280	
		MyCog - Rapid detection of cognitive impairment in everyday clinical settings		93.853	5UG3NS105562-02	477,567	
		Myoelectric Computer Interface to Reduce Muscle Co-Activation after Stroke		93.853	5R21NS084069-02	(1,530)	
		Myoferlin in muscle membrane fusion and repair		93.853	5R01NS047726-12	5,913	
		Myoferlin in muscle membrane fusion and repair		93.853	2R01NS047726-13A1	251,396	
		Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care					
		Clinical Trials Network (SIREN) – Network Clinical Center (Hub) (U24)	137	93.853	MCW Signed 11/09/17//1U24NS100648-0	3,249	
		Neural Stem Cell Carriers for Glioblastoma Immunotherapy Neurogenetic Approaches to Study Directed Behavior in Drosophila		93.853 93.853	5R21NS101150-02 5R01NS086859-05 REVISED	369,902 383,839	
		Neuroimaging Biomarkers in Parkinsonism: Differentiating Subtypes and Tracking Disease		93.653	SRUINSU00039-05 REVISED	363,639	
		Progression	233	93.853	UFDSP00011947//U01NS102038	335,776	
		NeuroNEXT Clinical Trials	131	93.853	Master Agrmnt 2/27/12/ U10NS077271	(5,612)	
		New Directions in Biology and Disease of Skeletal Muscle	101	93.853	1R13NS106917-01 REVISED	(0,012)	
		NN104 / ZZ-3K3A-201: A multi-center, Phase 2 study using a continual reassessment method				,	
		to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human					
		activated protein C (APC), in combination with tissue plasminogen activator (tPA	131	93.853	NN104//U01NS088312	1,500	
		NN105: An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of					
		a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with					
		Huntington's Disease (HD)	131	93.853	4U44NS090616-02	21,883	
		NN106: Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In	131	93.853	1 U01NS093663-01A1	0.774	
		Subjects With Newly Diagnosed Primary Glioblastoma Multiforme NN108: Topiramate as a disease altering therapy for Cryptogenic Sensory Peripheral	131	93.653	1 00 INS093003-0 IAT	3,771	
		Neuropathy (CSPN)	131	93.853	Agmt Signed 02/27/12//U01NS095388	1.081	
		Novel Therapies for Epilepsy Using Biodegradable Immune-Modifying Nanoparticles	131	93.853	5R21NS094999-02	35,014	
		NRSA F31 for Daniel Ohm in Support of: Concordance between cortical atrophy and		00.000		66,611	
		histopathology in PPA with AD pathology		93.853	5F31NS095652-02 REVISED	37,398	
		NRSA F31 for Natalie Mara Frederick in support of: Understanding the role of dystonia gene				21,000	
		Thap1 in the nervous system		93.853	5F31NS095461-02 REVISED	40,156	
		NRSA F31 for Sripadh Balasubramanian Sharma in support of: Micro-RNAs 29b and 21 in					
		Traumatic Brain Injury		93.853	1F31NS105451-01A1 REVISED	16,849	
		NRSA Fellowship for Warren Alexander McGee in support of: TDP-43-regulated microRNAs					
		and TDP-43 Proteinopathy		93.853	5F30NS090893-04 REVISED	38,981	
		NRSA Postdoctoral F32 Misregulation of ER membrane dynamics by alpha-synuclein in					
		Parkinsons disease		93.853	5F32NS101778-02	56,888	
		Pallidostriatal Signaling in Parkinson's Disease		93.853	1F32NS098793-01 REVISED	15.365	

Supplementary Schedule of Expenditures of Federal Awards

ster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thr to subrecipi
artment of Health and		Pilot Project: Communication Bridge: Web-based speech-language therapy for individuals					
luman Services (continued)		with dementia	225	93.853	9788sc/5U54NS092089-03	\$ 24,537	
		POINT: Platelet-Oriented Inhibition in New TIA	71	93.853	Agreement signed 11/9/10 // 1U01NS026835-01A1	29,168	
		Postsynaptic functions of neuronal adhesion molecules: focus on Cntnap2 Probing Somatosensory Representations in the Cuneate Nucleus of Awake Primates	228	93.853 93.853	5R01NS100785-02 FP060211//R01NS095162	566,683 230,903	
		Radiation + Temozolomide Induced Mutation and Malignant Progression of GBM	220	93.853	5R01NS095642-03 REVISED	230,903	
		Radiographic markers of clinical function in Cervical Spondylotic Myelopathy		93.853	5K23NS091430-02 REVISED	179,106	4
		Rational derivation of DA neuron subtypes from iPS cells for improved modelling of Parkinson's disease		93.853	5R01NS096240-03 REVISED	650.009	
		Regulating fibrosis and muscle growth in the muscular dystrophies		93.853	5P01NS072027-06	23.231	
		Regulation of CD4+ T cell-mediated Demyelination Following Oligo Ablation		93.853	1R01NS099334-02	430,234	10
		Regulation of Gliotransmission by Store-Operated Calcium Channels		93.853	5F30NS090817-03 REVISED	38.361	
		Regulation of neural progenitor cell migration by store-operated CRAC channels		93.853	5R01NS094011-04 REVISED	464,068	
		Research Education Program for Trainees in Neurology		93.853	5R25NS070695-09	133,661	
		Reverse Engineering Motor Unit Discharge	273	93.853	UWSC8225*(BPO2840)/5R01NS085331-03	224,015	
		Rhythmicity and Synchrony in the Basal Ganglia		93.853	3P50NS047085-15S1	1,102,837	
		Role of PCDH12 in neural circuit formation during brain development and disease		93.853	5R00NS089943-04	239,257	
		ScanImage: Flexible Software for Laser Scanning Microscopy in Neuroscience	280	93.853	R24NS086549-NU Amd 2	33,120	
		Sensorimotor processing, decision making, and internal states: towards a realistic multiscale					
		circuit model of the larval zebrafish brain	94	93.853	138078-5105175 // 1U19NS10465301 REVISED	38,953	
		Spatiotemporal Integration of Mechanical Information in the Rat Brainstem		93.853	5F31NS092335-03 REVISED	26,389	
		Store-Operated Channels in the Nervous System	470	93.853	5R01NS057499-11 REVISED	470,899	
		Stretch Reflex Contributions to Multijoint Coordination Stroke Trials Network – Regional Coordinating Stroke Centers	170	93.853 93.853	Agmt 1/31/2018 // 5R01NS- 0538139-09 REVISED 5U10NS086608-05	31,273 322 593	
		Subcertical auditory processing in sports-related concussions and contact/collision sports		93.853	1R01NS102500-01A1	322,593	
		SUDEP Translational Research Alliance – SUTRA	36	93.853	RES512393//5U01NS090407-04	102,921	
		Synaptic Circuit Organization of Motor Cortex	30	93.853	5R01NS061963-10	263 898	
		Synaptic Circuit Organization of Motor Cortex		93.853	2R01NS061963-11A1	33.337	
		Synaptic physiology in the zebrafish cerebellum during swimming and learning		93.853	5F31NS095476-03 REVISED	39.525	
		Synaptic Regulation of Innate Freezing by the Fastigial Nucleus of the Cerebellum		93.853	1F32NS106720-01 REVISED	23,315	
		Synaptic Transmission, Plasticity, and Integration in the Subthalamic Nucleus		93.853	5R37NS041280-20	345,965	
		Targeting convergent modulatory systems to regulate striatal synaptogenesis		93.853	5F32NS103243-02	56,768	
		Targeting histone demethylase activity for the treatment of pediatric brainstem glioma Targeting the NMDA receptor-mediated disruption of autonomous subthalamic nucleus activity		93.853	5R01NS093079-04	351,524	
		to ameliorate physiological and motor symptoms in a mouse model of Parkinson's Disease		93.853	5F31NS090845-03 REVISED	10,528	
		The effects of a-synuclein accumulation on proteome composition, stability and aggregation		93.853	1R21NS107768-01	24,645	
		The Human Motor Output Map		93.853	5R01NS098509-03	417,674	
		The Interaction of IDO and TRegs Leads to Immunosuppression in Glioma		93.853	5R00NS082381-05	(1,544)	
		The Loss of Independent Joint Control of the Upper Limb in Spastic Hemiparetic CP		93.853	2R01NS058667-05	45,170	
		The Neural Control of Internal Joint State		93.853	5R01NS086973-05	315,578	
		The role of amyloid precursor protein in HIV-1 replication and associated neurodegeneration		93.853	5R01NS099064-02 REVISED	429,154	
		The role of a-synuclein accumulation in lysosomal hydrolase trafficking and function		93.853	5R01NS092823-04	383,095	
		The role of ATP13A2/PARK9 in secretion of exosomes and alpha synuclein		93.853	5R37NS096241-03	512,864	
		The Role of Glioma Metabolism in Promoting Tumor Immunosuppression		93.853	5F32NS098737-02 REVISED	63,505	
		The Role of Lysosomal Glucocerebrosidase in Synucleinopathies		93.853	5R01NS076054-06	(3,665)	
		The Role of Lysosomal Glucocerebrosidase in Synucleinopathies The Role of Tumor Induced PD-L1 Expression on Mveloid Cells in GBM on Expansion of		93.853	5R01NS076054-08	406,639	
		Regulatory T Cells and Systemic Immunosuppression		93 853	1F32NS101884-01	50,780	
		The role of UCHL1 on the health and stability of upper motor neurons		93.853	5R01NS085161-05	257,044	
		The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial	272	93.853	GC12107-149595//U01NS069498	78,112	
		The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial	272	93.853	GB10253 155953//5U01NS069498-07	4.996	
		Tissue Factor as a Key Determinant of IDH1 Mutant versus IDH1 Wild-type Glioma Thrombosis		00.000		4,000	
		and Malignancy		93.853	5R01NS102669-02	361,795	
		Training in Neurotherapeutics Discovery and Development for Academic Scientists	219	93.853	4R25NS077582-05	763	
		Training in Neurotherapeutics Discovery and Development for Academic Scientists	219	93.853	201602366-02//5R25NS099170-02	28,722	
		Training Program in the Neuroscience of Human Cognition		93.853	5T32NS047987-10	(1,504)	
		TRAINING PROGRAM IN THE NEUROSCIENCE OF HUMAN COGNITION		93.853	5T32NS047987-12	272,382	
		TRPC3 channels as pharmacological targets for the treatment of ataxia		93.853	5R21NS090346-02 REVISED	186,869	
		Understanding the cellular basis of Movement Disorders		93.853	5R01NS082351-05	305,505	
		Validation of the HD-HRQOL (Huntington Disease Health Related Quality of Life)	250	93.853	3002420992//5R01NS077946-04	23,016 30,423,538	2.
		(CTOTC-12/ ARTEMIS) Safety of Donor Alloantigen Reactive Tregs to Facilitate Minimization					2,5
		and/or Discontinuation of Immunosuppression in Adult Liver Transplant Recipients	225	93.855	4U01AI104347-04//9320sc	64,833	
		A Development-Specific Mechanism of Pathogenesis in HSV Encephalitis		93.855	5F30AI116106-03 REVISED	42,862	
		A Master Role of Symmetric Arginine Dimethylation in Lupus Autoantibody Response		93.855	1R21AI131087-01A1	43,912	
		A novel mouse model to monitor inflammasome activation in vivo		93.855	5R21AI120618-02	(7,871)	
		A Phase IV Open-Label Pharmacokinetic Study of Minocycline for Injection Following a					
		Single Infusion in Critically-III Adults (ACUMIN) DMID Protocol Number: 16-0011	66	93.855	225440//5UM1AI104681-05	327	
		A Prospective Trial of Elemental Diet in Adults with Eosinophilic Gastrointestinal Diseases					
		(EGIDs)	46	93.855	135407//U54AI117804	117,973	
		A surface-exposed region of the UL37 protein that is essential for alphaherpesvirus neuroinvasion		93.855	5F32AI116044-03 REVISED	(298)	

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

uster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thro to subrecipie
partment of Health and	outragency	ACTG Data Management Committee Chair	31	93.855	SUB: 110009//5UM1Al068636-12	\$ 20,484	- Subrecipie
Human Services (continued)		ACTG Executive Committee Support	31	93.855	110007//5UM1Al068636-12 REVISED	3 20,484 7,409	
		ACTG LOC Protocol A5320 Vice-Chair	31	93.855	110236 A5320//5UM1AI068636-12	3.657	
		ACTG LOC Protocol Co-Chair for Protocol A5322	31	93.855	110229 A5322//5UM1AI068636-12 REVISED	14,203	
		ACTG Research Group DMC Committee Chair	31	93.855	110009//5UM1AI068636-11	4,820	
		Activate Silent and Cryptic Intact Fungal SM Gene Clusters through FACs for Novel					
		Antibiotics Discovery	113	93.855	Agmt 8/30/16-001 // 2R44AI118086-02	170,612	
		Aging and Fracture Risk Among HIV-infected and HIV-uninfected Men	122	93.855	2001586404//R01Al093520	(15)	
		AIDS Clinical Trial Group Network Protocol Funds AIDS Clinical Trial Group Network Protocol Funds – Cost Reimbursement	31 31	93.855 93.855	Mod 1 //2UM1AI068636-10 111672//5UM1AI068636-12	143,311 220,190	
		AIDS Clinical Trials Group – Protocol A5353 Support	31	93.855 93.855	1116/2//5UM1Al068636-12 110237//5UM1Al068636-12	9 836	
		AIDS Clinical Trials Group – Protocol A5353 Support AIDS Clinical Trials Group – Protocol Chair Support A5322	31	93.855 93.855	110237//5UM1Al068636-12 110237//5UM1Al068636-12	9,836 6,549	
		Allergy Guidelines Assessment Parent Survey	175	93.855	DAIT-SACCC-03-NW//5UM2AI117870-03	43,685	
		Alloantigen Delivery Via ECDI-Fixed Cells for Tolerance to Monkey Islet Grafts	251	93.855	N002854801//1U01AI1102463-01	(12,303)	
		ALPHA-HERPESVIRUS TRANSPORT IN AXONS	201	93.855	5R01AI056346-14	274,833	
		An 'omics' approach towards influenza A replication and pathogenesis	100	93.855	0254-3244-4609//4U19AI106754-05	352,279	
		An Open-Label Population Pharmacokinetic Study of Minocycline for Infection				,	
		Following a Single Infusion in Critically-ill Adult Subjects	66	93.855	203-8439//5UM1AI104681-05	43,728	
		Anti-TSLP (AMG 157) plus antigen-specific immunotherapy for induction of tolerance in					
		individuals with cat allergy CATNIP	23	93.855	FY14ITN011//1UM1AI109565-05	20,013	
		Autoantibody mediated pathogenesis in chronic rhinosinusitis with nasal polyps:					
		mechanisms and consequences		93.855	1R01AI134952-01	55,148	
		Binding Antibody FcMediated Antiviral Functions Across Humans and Non-human Primates	66	93.855	2035489//5P01AI120756-03	7,771	
		Biomarkers for Highly Virulent Pseudomonas aeruginosa Strains		93.855	5R21AI129167-02 REVISED	164,175	
		CARD-only protein regulation of cytosolic Pattern Recognition Receptor signaling		93.855	1R01Al140702-01 5R33Al094584-05	21,087	
		Cervical/Vaginal Mucus and Microbicides Chicago Clinical Trials Unit		93.855 93.855	5R33AIU94584-05 5UM1AI069471-12 REVISED	(791) 1,333,860	5
		Chicago Clinical Thais Onit Chicago WIHS Consortium V (WIHS-V)	96	93.855	50615-324-NWU2-AI034993//5U01AI034993	42.197	:
		Chicago Women's Interagency HIV Study (WIHS V)	96	93.855	50612-324-NWU1-AI034993	42,197	
		Chronic Rhinosinusitis Integrative Studies Program (CRISP)	50	93.855	4U19AI106683-05	1,668,598	1
		Clinical Evaluation of a New Highly Sensitive Multiplex qPCR for Detecting tuberculosis and				.,,	
		Non-tuberculous Mycobacteria		93.855	1R03AI137674-01	25,772	
		Consortium of Eosinophilic Gastrointestinal Disease Researchers: OMEGA	46	93.855	PO 3100545485 135408-CT1-OMEGA//5U54AI117804-04	48,051	
		Control of E1 oligomerization regulates E1 function in papillomavirus DNA replication CTOT-11 Long-term Safety Follow-up: Retrospective, Multicenter Study to Determine Up to 5 Year Clinical Outcomes in Subjects Previously Randomized in the CTOT-11 Study	49	93.855	55890312//1R01Al114897-04	3,648	
		(CTOT-23)	31	93.855	BWH 09/22/16//U01AI063594	3.550	
		Defense-in-depth against mucosal HIV clade C invasion	202	93.855	PO 39802//2P01AI048240-12A1	466,433	
		Defining the Siderophore of Stenotrophomonas maltophilia, an Emerging, Multi-Drug Resistant					
		Pathogen		93.855	1R21AI125968-01A1	156,243	
		Dengue Human Immunology Project Consortium (DHIPC) Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor	100	93.855	0255-8633-4609//5U19AI118610-04	473,966	
		(DPC) for treating multi-drug resistant wound infections	18	93 855	Agmt 04/09/2019//1R41AI136072-01	34.521	
		Development of Immune-Modulated HIV Vaccines	10	93.855	Agint 04/09/2019//1R41A11360/2-01 1K22AI118421-02	34,521 87 857	
		Development of Lipid-based Nanoparticle Vaccines Against Mycobacterium tuberculosis		93.855	1R21AI131035-01	259.543	
		Development of Novel Anti-Biofilm Compounds for Treating Chronic Wounds	2	93.855	ASI//2R44AI092952-02A1	57.251	
		Discovery and validation of avermectin resistance loci in free-living and parasitic nematodes	-	93.855	5R21AI121836-02	93,154	
		Distinct mast cell responses in male and female SJL mice underlie sex dimorphic EAE					
		susceptibility		93.855	5R01AI128292-02	480,168	
		Diverse Functions of p38a MAPK in T Helper Differentiation		93.855	5R03AI125813-02	31,893	
		Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?	202	93.855	15-04442-003//5R01DE023049-06	52,628	
		Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation (deLTa)	225	93.855	10526sc//5U01AI110658-04	83,269	
		Drug at the Right Place & Concentration: Optimizing Combination Vaginal Ring PrEP	3	93.855	31103B // 5U19AI103461-06	89,179	
		Drug at the Right Place and Concentration: Optimizing Sustained PreP Agents	3	93.855	PO659386-31103A // 5U19AI103461-06	30,384	
		Drug at the Right Place and Concentration: Optimizing Sustained PreP Agents	3	93.855	31103A Amd. 7//5U19AI103461-06	74,447	
		Effectiveness, Safety and Value of Integrating Molecular Diagnostics into the Post-Transplant Management of Kidney Transplant Recipients – The Next Frontier of Biomarker Research		93.855	1R34AI118493-01 REVISED	11,090	
		Efficacy of Ustekinumab (Anti-IL_12/23) followed by Abatcept (CTLA4-Ig) for the tretment of		93.600	IR34AII10493-01 REVISED	11,090	
		Psoriasis Vulgaris	23	93.855	FY18ITN093//5UM1AI109565-05	12 046	
		Elucidating a novel regulator of inflammation: the TLR4-Inhibitory Complex (TIC)	25	93.855	1R21AI131179-01A1	102,861	
		EoE Clinical Study 2: Consortium of Eosinophilic Gastrointestinal Disease Researchers	46	93.855	PO 3100545486 135409//5U54AI117804-04	61.137	
		Ethical and Sociocultural Implications of Genetic Testing in Transplantation		93.855	5R03AI126090-02	59,369	
		Fluomics: The Next Generation	100	93.855	0255-A131-4609//1U19AI135972-01	56,507	
		Food Allergy Outcomes Related to White and African American Racial Differences (FORWARD)		93.855	5R01AI130348-02	613,297	3
		Function of Vibrio vulnificus MARTX toxin during early gut infection		93.855	4R01AI098369-05	61,101	
		Group 1 CD1-restricted Autoreactive T cells in Inflammatory Disease		93.855	1R21AI117238-01	4,107	
		Harnessing MUC16-IgG Interactions to Enhance HIV Vaccine Function		93.855	5R01AI125171-03	620,021	1
		High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients	278	93.855	VUMC62776//1U01AI32004-01	47,344	
		HIV and Tuberculosis Transmission and Future Trends in the African Population	273	93.855	UWSC8429 / K01Al095060	(81)	
		HIV Research for Prevention 2016: Vaccine, Microbicide and ARV-based Prevention Science		00.055			
		(HIV R4P)	100	93.855	1R13AI122959-01	1,060,127	
		HOPE in Action: A clinical trial of HIV-to-HIV deceased donor kidney transplantation	122	93.855 93.855	2003649393//1U01Al134591-01 5R01Al127783-02	628	
		Hormones in allergic disease Host-Pathogen Interactions in a Failing Global lineage of MTBC:M.africanum	212	93.855 93.855	5R01AI127783-02 USTTB/NU/1R01AI1110386-02-2016	474,073 31,937	

56

Supplementary Schedule of Expenditures of Federal Awards

ster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thr to subrecipi
artment of Health and		Identification of the Initial Targets of Transmission		93.855	5R01AI094595-05 REVISED	\$ (28.838)	
luman Services (continued)		Identification of the Initial Targets of Transmission		93.855	5R01AI094595-05 REVISED	15,503	1
		Identification of the Initial Targets of Transmission		93.855	5R37AI094595-07	707,383	251
		Identifying Kawasaki Disease-Specific Antibodies and Antigens		93.855	1R21AI140029-01	20,793	
		Immunology and Molecular Pathogenesis Training Program		93.855	3T32AI007476-20S1	(1,571)	
		Immunology and Molecular Pathogenesis Training Program Immunosuppressive Drug Withdrawal from Liver Transplant Recipients on Tacrolimus		93.855	5T32AI007476-22	295,860	
		versus Sirolimus	23	93 855	FY17ITN165//5UM1AI109565-04	8,286	
		IMPAACT Network Leadership and Operations Center (LOC) Grant – CRS 4001 PF	14	93.855	915377-NU//PTCL102002438850/UM1AI068632	55,035	
		Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients	225	93.855	9254sc//5U01AI118594-03	32,550	
		Implementation strategies for a new point-of-care test for early infant diagnosis	122	93.855	2002785688 Amd 3 // R01AI116324	(481)	
		Influenza virus receptors on human airway epithelial cells	184	93.855	5-53557//5R01Al114730-04	143,747	
		Initiators, biomarkers and mechanisms of epithelial dysfunction and immune pathogenesis in					
		chronic rhinosinusitis and aspirin exacerbated respiratory disease (AERD)	100	93.855 93.855	1R01AI137174-01	170,210	
		Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection	183	93.855	60088-12935-NWU//1R01AI127302-02	133,617	
		Integrating Mechanistic Insights from Diverse Models to Prevent CMV Reactivation following Transplantation		93.855	5P01AI112522-04	2,514,266	
		Keeping it LITE: Exploring HIV Risk in Vulnerable Youth with Limited Interaction	96	93.855	50041-324-NWU01//1UG3AI133676-01	2,314,200	
		Lipid Regulation of the Development of Responsiveness to Allergen in Neonates and Infants	50	93.855	1U01AI131337-01	512.044	
		Mechanisms of Gonococcal Pilin Antigenic and Phase Variation		93.855	5R37AI033493-24	176,879	
		Mechanisms of Gonococcal Pilin Antigenic and Phase Variation		93.855	4R37AI033493-25	298,591	
		Mechanisms of MCMV reactivation in immunodeficient transplant recipients		93.855	5R01AI112911-04	315,024	
		Mechanistic Studies of Patatin-like Toxins		93.855	5R01AI053674-13	64,908	
		Modeling concurrent cytomegalovirus infection and transplantation tolerance		93.855	5R01AI114824-02	302,190	
		Molecular mechanism of V. vulnificus MARTX toxin in pathogenesis and food safety		93.855	5R01Al092825-07	608,707	
		Molecular Mechanism of V. Vulnificus MARTX Toxin in Pathogeniesis and Food Safety		93.855 93.855	5R01Al092825-05 REVISED 5R01Al120625-03	(1,093) 617,740	
		Molecular Regulation of Systemic Inflammation Mucosal mechanisms of altered HIV susceptibility in adolescents	249	93.855 93.855	SPC-000886//7R01Al28782-03	617,740	
		Mucosal mechanisms of altered HIV susceptibility in adolescents	249 273	93.855	UWSC9610//5R01Al128782-02	62 088	
		Multicenter AIDS Cohort Study	215	93 855	5U01AI035039-26	4,449,577	:
		Neurotropic herpesvirus envelopment and microtubule-mediated transport	3	93.855	310227//5R01Al125244-02	172,366	
		Next-Generation Phylodynamics-targeted Partner Service Models for Combined HIV Prevention	228	93.855	FP066835-A//1R01AI136056-01	103,492	
		Northwestern University Allergy Immunology Research Program (NUAIR)		93.855	5T32AI083216-09	298,935	
		Northwestern University Infectious Diseases Education and Science (NulDeas)		93.855	5T32AI095207-07 REVISED	107,162	
		Novel long-acting microbicide and contraceptive intrauterine system	67	93.855	S140181-2 Amd. 3 // 5R01Al112009-04	36,362	
		Novel Proteoform Biomarkers of Acute Rejection in Liver Transplant Recipients		93.855	1R21AI135827-01	61,720	
		Optimizing clinical use of Polymyxin B: Teaching an old drug to treat superbugs	250 14	93.855 93.855	3004163905//5R01Al119446	65,680	
		Optimizing the diagnosis of pediatric Clostridium difficile infection Pathogenesis of Jeilongvirus	14 234	93.855 93.855	901507-NU//5K23Al23525-02 RR211-536/S001474/1R01Al128924-01A1	27,729 140,237	
		Pathogenesis of Rebound SIV/HIV Viremia After Antiretroviral Therapy	234	93.855	5P01AI131346-02	1.201.045	:
		Patient-Oriented Research on Hospital-Acquired Pathogens		93.855	4K24AI104831-05	98.981	
		Phenotypic and functional plasticity of mast cells in homeostasis and allergy		93.855	5F30AI129237-02 REVISED	35,559	
		Pig-to-Monkey Islet Xenotransplantation	251	93.855	N004761502//1U01AI120130-04	45,978	
		Post-transcriptional regulation of Crp in Yersinia pestis		93.855	5R21AI111018-02	117,019	
		Poxvirus manipulation of the host cell protein synthesis machinery		93.855	3R01AI127456-02S1	387,145	
		Probing the Functions of KLF2 Downregulation		93.855	5R21AI119137-02	103,591	
		Proteomic Predictors of Chronic Kidney Disease in Liver Transplant Recipients		93.855	5R21AI113916-02	68,706	
		Protocol ITN056ST: Evaluation of Donor Specific Immune Senescence and Exhaustion as				004 504	
		Biomarkers of Operational Tolerance Following Liver Transplantation in Adults	23	93.855 93.855	FY18ITN158//5UM1AI109565-05 5R01AI125366-02	231,524 317,648	
		REDD1 dissociates the therapeutic and adverse effects of glucocorticoids in skin Regulation of Allergic Inflammation by Histamine		93.855	5R01AI125366-02 5R01AI076456-10	259.992	
		Regulation of cytosolic pattern recognition receptor signaling in macrophages		93.855	4R01Al099009-04	253,532	
		Regulation of cytosolic pattern recognition receptor signaling in macrophages		93.855	2R01AI099009-06A1 REVISED	134.730	
		Regulation of food allergy and anaphylaxis by IL 33		93.855	5R01AI105839-05	294,606	
		Regulation of HPV Replication by Sirtuin Deacetylases		93.855	5R21AI133984-02	171,187	
		REPRIEVE A5332 Women's Ancillary Study	31	93.855	5R01AI123001-02//BWH AGMT 11/23/16	40	
		Role of CTCF in HPV replication and viral DNA looping		93.855	5R21AI120492-02	117,768	
		Role of mTOR in inflammatory monocytes in HIV infection		93.855	1F30AI131937-01A1	50,969	
		Role of Thymic Stromal Lymphopoietin in Chronic Rhinosinusitis		93.855 93.855	5R01Al104733-04 1R21Al121742-01	412,428 196,210	
		Roles of Early Life Colonization and Environmental Antigens on Childhood Asthma S. aureus and Regulatory T cells in the Failure of Oral Tolerance		93.855	5K23AI100995-05 REVISED	22,680	
		Structural and Functional Studies of gp42 and HLA Class 2 in EBV Entry		93.855	5R01AI076183-15	362,377	
		Structure and Function of EBV Protein Complexes that Trigger Epithelial Cell Entry		93.855	1R01AI137267-01	119.416	
		Studies of human B cell responses and antibody production during chronic airway inflammation		93.855	1R56Al131239-01A1	300.988	
		Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center		93.855	1U19AI135964-01	888,081	
		Sustained Long Acting Prevention Against HIV Program Operation		93.855	5UM1AI120184-04	2,620,813	1,0
		T regulatory cell responses during viral infection		93.855	1R21AI132848-01A1	38,066	
		Targeting Siglec-8/-F to Treat Eosinophil and Mast Cell Related Disorders		93.855	5R01AI072265-11	172,052	
		Telomere Length and Molecular Mechanisms of Aging among HIV-infected Individuals on ART	31	93.855	1165293//5UM1AI068636-11	14,646	
		The HIV Care Continuum Among Recent Offenders	108	93.855	IN4689683NW//5R01AI114435-02	16,948	
		The Influence of Early Integration Events on HIV Latency and Reactivation Potential		93.855	1K22AI136691-01	14,252	
		The non-canonical role of the CRISPR Cas2 nuclease in infection by Legionella pneumophila		93.855	5R21AI123462-02	141,420	
		The regulation and function of CD1d-restricted T cells		93.855	5R01Al043407-18	310,960	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thro to subrecipie
epartment of Health and		The Role of MHC class Ib in T cell development and infectious disease		93.855	4R01Al040310-19	\$ 66,551	
Human Services (continued)		The role of non-classical MHC class I molecules in immune responses to Mycobacterium					
		tuberculosis infection		93.855	1R01AI141083-01	116,590	
		The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity The roles of Synoviolin in immune tolerance and autoimmunity		93.855 93.855	5R01Al079056-09 5R01Al108634-04	183,462 215.025	
		The Structure and Function of the Influenza Virus Genome		93.855	4R01Al020201-33	215,025 92.107	
		Third Coast Center for AIDS Research		93.855	5P30AI117943-04 REVISED	1,849,999	355
		Tocopherol regulation of the development of responsiveness to allergen early in life		93.855	5R01AI127695-02	488,896	14
		Tolerogenic delivery of donor antigens for cardiac allograft protection	274	93.855	2U01AI102456-06REVISED//773K161	5,724	
		Translational Research Training in Infectious Diseases		93.855	4T32AI095207-05 REVISED	(9,569)	
		Type II Secretion and Legionella pneumophila Infection		93.855	5R01AI043987-19	235,412	
		US Prevalence, Distribution and Determinants of AdulT and childhood Food Allergy (UPDATE-FA)	14	93.855	901526-NU//1R21AI135702-01	57.691	
		Using siglecs and their ligands to treat allergic diseases SALTAD	14	93.855	1U19AI136443-01	243,622	6
		UTI Immune Modulation by LPS Structure		93.855	5F31AI106357-05 REVISED	(38)	
		Virulence Mechanisms of the Emerging Pathogen Stenotrophomonas maltophilia		93.855	5R21AI117082-02	412	
		ZIP Immunology Consensus Substudy	100	93.855	0255-8661-4609//5U19AI118610-03	35,332	
						37,135,915	4,62
		Regulation of Bacterial Aggregation During Host Colonization		93.856	5R21AI117262-02 REVISED	(486)	.,,==
		A Computational Biology Approach to Mapping Nucleosomes in Stem Cells		93.859	5R01GM107177-04 REVISED	(480) 122,033	
		A Quantum Dot Probe for Nanosecond-Timescale Imaging of Fast Biological Processes		93.859	1R21GM127919-01	40.330	
		Activation Mechanisms of Store-Operated Calcium Channels		93.859	5R01GM114210-04 REVISED	342.157	
		Activities of Nucleoprotein Complexes Visualized in Single-Molecule Experiments		93.859	4R01GM105847-04	142,879	
		Algorithms for Glyco-Proteoform Detection		93.859	5R01GM115739-02	363,784	
		Analysis of lamin-chromatin interactions and their regulation of chromosome organization and					
		gene expression	34	93.859 93.859	5-10742-01//R01GM106023 5R01GM111652-04	281,424 300.858	
		Analysis of Novel Virus-Induced RNAs Analyzing the role of chromatin compaction in nuclear mechanics, structure, and function		93.859 93.859	1K99GM123195-01A1	300,858 35,403	
		Analyzing the fole of chromatin compaction in nuclear mechanics, structure, and function Anesthesia-induced learning deficiency and brain hyperoxia	149	93.859	EH16-011-S1 Amd 3//5R01GM112715-03	37,267	
		Assembly and epigenetic inheritance of the human centromere		93.859	5R01GM111907-05	336,431	
		Biological Transition Metals		93.859	2R01GM111097-46A1	26,515	
		Biosynthetic and Biomimetic Investigations into Roseophilin		93.859	5F31GM119368-02 REVISED	21,390	
		Biosynthetic studies on an unusual amino acid monomer deriving the discovery of novel					
		natural products through genome mining		93.859	5F32GM122397-02	51,700	
		Biotechnology Predoctoral Training Program Capturing Transient Protein Structures on Multiple Spatial and Temporal Scales		93.859 93.859	5T32GM008449-25 5R01GM115761-04	371,420 294 633	
		Carbene Catalysis Strategies for Organic Synthesis		93.859	5R01GM073072-13	615.434	ç
		Cellular and Molecular Basis of Disease Training Program		93,859	2T32GM008061-36	750 485	
		Cellular and Molecular Basis of Disease Training Program		93.859	2T32GM008061-36	126,792	
		Center for the Structural Biology of Cellular Host Elements in Egress, Trafficking, and					
		Assembly of HIV (CHEETAH Center)	271	93.859	10044932-10//2P50GM082545-11	257,096	
		Characterization of pmoD		93.859	5F32GM119191-03	57,491	
		Characterization of the antiviral and nuclear regulatory functions of FEZ1 & NEK1 Chemistry of Life Processes Predoctoral Training Program		93.859 93.859	5R01GM101975-05S1 5T32GM105538-05 REVISED	199,524 279,036	
		Chemistry of Life Processes Predoctoral Training Program		93.859	2T32GM105538-06	1.326	
		Coboglobins-Cobalt-Substituted Hemoglobins and Myoglobin		93.859	3R01GM111097-45S1	545.565	
		Control and Function of Ndr/LATS Signaling Systems		93.859	5R01GM084223-09 REVISED	214,419	
		Cryo ptychography combined with x-ray fluorescence analysis of metals in cells		93.859	2R01GM104530-06 REVISED	266,025	
		Cytoskeletal mechanisms of oocyte polarity		93.859	5R01GM124029-02	267,534	
		Defining the molecular and cellular mechanism of epigenetic transcriptional memory		93.859	5R01GM118712-02	287,156	
		Development of dictyBase, an online informatics resource Developmental Dynamics of Ciliated Epithelia		93.859 93.859	5R01GM064426-16 3R01GM089970-09S1	527,877 349,598	
		Direct Determination of the Distribution of Fitness Effects of Spontaneous Mutations in		93.659	3K013W003310-0331	349,390	
		Caenorhabditis Elegans	233	93.859	UFDSP00010414 // R01GM107227-03	82,865	
		Dissecting chromatin and lamin contributions to nuclear structure and function		93.859	5F32GM112422-02	31,649	
		Dissecting functional cooperation among subunits in a catalytic ribonucleoprotein	155	93.859	60045478 Amd 001 // R01GM120582	123,586	
		DNA zip codes and the spatial organization of the yeast genome		93.859	4R01GM080484-09	(47,853)	
		DNA zip codes and the spatial organization of the yeast genome	155	93.859 93.859	5R01GM080484-11 60060542 Amd 001 // R01GM120923	367,187	
		Dynamics and allostery in protein-RNA regulation Eukaryotic Post-Translational Modifications	100	93.859	5R01GM067193-12	37,541 2 940	
		Excitability in Dictyostelium Development		93.859	5K25GM098875-06	65.477	
		Exploration of Novel Silvi Derived d1 Synthon Equivalents		93.859	5F31GM116532-03 REVISED	28,027	
		Genetic Analysis of Beneficial Bacterial Colonization	274	93.859	790K182//R35GM119627	211,625	
		Global Characterization of Protein Palmitoylation in Trypanosomes		93.859	4R01GM102689-04	13,510	
		High Throughput Screening for Small-molecules Facilitating Prion Study		93.859	5R01GM110045-03	152,932	
		Information Processing by Post-Translational Modification	94	93.859	152213.5081815.0003 Amd 3 // 5R01GM105375-04	50,045	
		Integrated Empirical and Translational Research to Diversify the Scientific Workforce Integrative informatics approach to develop safe glucocorticoid therapies		93.859 93.859	5R35GM118184-03 REVISED 5R01GM112945-04	558,032 358,591	
		Integrative informatics approach to develop safe glucocorticold therapies Investigating The Functional Role Of Zinc Fluxes During Sperm Activation		93.859	5F31GM112945-04 5F31GM117971-02 REVISED	358,591 15,500	
		Investigating the molecular mechanism of mitochondrial tethering		93.859	5R01GM120303-02 REVISED	273.157	
				93.859	5F32GM115052-03	38,526	
		Investigation into the Dynamic Zn Proteome during Mammalian Oocyte Maturation					
		Investigation into the Dynamic 2n Proteome during Mammalian Oocyte Maturation Mechanism of Nuclear Signaling and cell-cell adhesion by catenins		93.859	5R01GM076561-09S1	(76,235)	

Supplementary Schedule of Expenditures of Federal Awards

			Pass- through			Federal	Passed-thro to
luster title/Federal grantor	Subagency	Project title	ID number	CFDA	Sponsor award number	expenditures	subrecipie
partment of Health and		Medical Scientist Training Program		93.859	2T32GM008152-31	\$ 1,396,270	
Human Services (continued)		Mentoring for Success: Developing Fundamental Skills for Biomedical Research		93.859	5R25GM079300-12 REVISED	511,949	
		Metalloenzymes and metal homeostasis		93.859	5R35GM118035-03 REVISED	440,738	
		Metalloregulation by MerR and Fur Protein Families		93.859	5R01GM038784-29 REVISED	336,778	
		Microbial Succession and Adaptive Immune Responses in the Premature Infant Microtubule motors and generation of cell polarity		93.859 93.859	5R01GM108494-05 5R01GM052111-20	114,323 438.553	72,
		Microtubule motors and generation of cell polarity Modeling scientific workforce dynamics using social network analysis	94	93.859 93.859	5R01GM052111-20 152451.5080936.0403//5U01GM112623-04	438,553 205,678	
		Molecular Biophysics Training Program at Northwestern University	54	93.859	5T32GM008382-26	203,078 260,151	
		Molecular Mechanisms of Basolateral Targeting in Polarized Epithelial Cells		93.859	5R01GM070736-12	307.976	
		Molecular Regulation of Radial Intercalation		93.859	1R01GM113922-01A1	269,797	
		National Infrastructure for Standardized and Portable EHR Phenotyping Algorithms	121	93.859	17040580//2R01GM105688-06	124,451	
		National Infrastructure for Standardized and Portable EHR Phenotyping Algorithms	121	93.859	16081299-03//R01GM105688-05	23,937	1:
		National Resource for Translational and Developmental Proteomics		93.859	5P41GM108569-04	1,165,696	6
		Neural Crest Ontogeny and the Control of Stem Cell Attributes		93.859	5R01GM116538-04	372,805	
		New Methods and Strategies for the Concise Synthesis of Bioactive Polycyclic Molecules		93.859	1R01GM124089-01A1	44,410	
		Non-coding RNAs and their mechanisms and functions Northwestern University Interdepartmental Neuroscience Postbaccalaureate		93.859	5R35GM118144-03	547,025	
		Research Education Program		93.859	5R25GM121231-02	209,942	
		Pharmacological Inhibitors of Nedd4 ubiquitin ligase as anticancer therapeutics	235	93.859	R-17-0021 // 7R01GM115632	209,942 (59)	
		Prion-mediated protein aggregation/co-aggregation and cellular consequence	200	93.859	1R01GM126318-01A1	14,889	
		Probing Cellular Membrane Processes by Single Particle Orientation and Rotational Tracking	87	93.859	SP00012129-01//1R01GM115763	66.465	
		Regulation and Function of Intermediate Filaments in Cell Mechanics		93.859	5P01GM096971-05	(2,433)	
		Regulation and Function of Intermediate Filaments in Cell Mechanics		93.859	3P01GM096971-05S1	482,253	2
		Regulation of chromosome segregation during oocyte meiosis		93.859	1R01GM124354-01A1	138,548	
		Regulatory Roles of Zinc Fluxes in Metalloprotein Occupancy and Cell Cycle Progression		93.859	5R01GM115848-04	195,246	
		RNA Ligation Pathways in Mammalian Unfolded Protein Response		93.859	5R01GM120307-02	298,608	
		SampleStream: A Radically Simplified Platform for Protein Sample Preparation	114	93.859 93.859	Agmt 2/15/2018 // 1R43GM121130-01A1 5R01GM049725-23	12,140	
		Selective inhibition of nitric oxide synthase for multiple indications Social signals that regulate C. elegans development		93.859	1R01GM049/25-23 1R01GM126125-01A1	594,480 8 374	
		Specific inhibition of transcription factors with Cobalt-Schiff Base Complexes		93.859	5R01GM121518-02	342,957	
		Src kinase phosphoregulation of the human mitotic kinesin, Eq5		93.859	4R01GM107209-04	13.455	
		Structural and biophysical studies of DNA topoisomerases		93.859	2R01GM051350-21A1	177,118	
		Structural and biophysical studies of proteins, nucleic acids, and their complexes		93.859	5R35GM118108-02	405,596	
		Structural mechanism of membrane remodeling during herpesvirus nuclear egress	206	93.859	100169-00001//R01GM111795	22,242	
		Structure and function of desmosomal cadherins	50	93.859	1(GG011995-01)//1R01GM118584-01A1	116,490	
		Structure and Function of Mammalian Copper Transporters		93.859	5R01GM115211-02	338,770	
		Structure and Specificity in Metal Ion Homeostatis		93.859	5R01GM058518-17	(229)	
		Tailoring liposomal spherical nucleic acid nanoparticles for biological and therapeutic potency		93.859	5F31GM119392-02 REVISED	24,711	
		Targets for Design of Drug Combinations that Select against Antibiotic Resistance	222	93.859 93.859	5R01GM113238-04 REVISED 1295 G UA135//5R01GM112938-03 REVISED	238,808 163 474	1
		Team Dynamics, Networks, & Assembly (Team DNA) Team Dynamics, Networks, and Assembly (Team DNA)	222	93.859	1295 G DA135//SR01GM112938-03 REVISED	217,132	
		The Dictyostelium Stock Center	222	93.859	5R01GM087371-09 REVISED	295 469	
		The role of innate immunity in the traumatic brain injury-induced immune suppression syndrome		93.859	5K08GM117341-04	213.635	
		The role of the microtubule regulators Kif4 and EB1 in HIV-1 infection – Project 2	50	93.859	1(GG010108-17)//5P01GM105536-05	537,540	
		Tissue morphogenesis: A study of molecular machines and cell mechanics		93.859	4R01GM098077-04	(134)	
		Tube size control by Src and Yorkie/YAP		93.859	5R01GM108964-04 REVISED	113,412	
		Virus Imaging Core P50 GM082545 CHEETAH	271	93.859	10027535-02//5P50GM082545-10	(13,766)	
		Zinc Regulation of Germline and Embryo Development in Caenorhabditis elegans		93.859	5F31GM112478-03	(4,375)	
						21,640,642	7
		A Cognitive Test Battery for Intellectual Disabilities	219	93 865	201402548-02//1R01HD076189-01A1	5,124	
		A cognitive rest Ballery for Interlectual Disabilities	219	93.865	4R01HD069414-05	143,976	
		Application of Targeted Reinnervation for People with Transradial Amputation	169	93.865	CC#81930 CL4098//5R01HD081525-04	4,791	
		Assessing microenvironment and endothelial cell instruction of testis function	103	93.865	1F31HD089693-02	48.970	
		Bilateral Priming Plus Task Specific Training for Severe Upper Limb Hemiparesis		93.865	5R01HD091492-02	220,083	1
		Career Development in Women's Health (CDWH)		93.865	5K12HD055884-09	(47,851)	
		Center for Reproductive Health After Disease		93.865	5P50HD076188-05 REVISED	665,968	
		Characterizing the Epigenetic GATA Switch in Endometriosis		93.865	5R03HD082558-02	(2,768)	
		Cognitive Architecture of Bilingual Language Processing		93.865	5R01HD059858-05	(91)	
		Cognitive Architecture of Bilingual Language Processing		93.865	2R01HD059858-07	308,039	
		Constraint induced movement therapy for walking in individuals post stroke Cortical Priming to Optimize Gait Rehabilitation Post Stroke	169 237	93.865 93.865	CC# 81388 CL4442//1R01HD082216-03 7201//5R01HD075777-05	4,490 35.409	
		Cortical Printing to Optimize Gait Renabilitation Post Stroke	257	93.605	7201//5R01HD075777-05	35,409	
		with perinatally-acquired HIV: associations with HIV disease severity and cognition		93.865	5F30HD090842-02	23,724	
		Cortisol, Socioeconomic Status, and Genetic Influences on Cognitive Development	264	93.865	UTA16-000087 Amd. 1 // 1R01HD083613-01A1	(4,598)	
		Deubiquitinating Enzymes as Targets for Male Contraception	14	93.865	901501-NU Amd 01//5U01HD084046-04	41.463	
		Development of a Portable Synergy Resistant EMG-driven FES Device for Intuitive		00.000		41,403	
		Control of Grasp and Release During Functional Arm Activities Following Stroke		93.865	1R21HD094073-01	105,299	
		Development of a serum biosignature for ectopic pregnancy	259	93.865	564595//R01HD076279-04	75,126	
		Development of a standardized measure of social-communication abilities for children with				., .	
		neurodevelopmental disorders	225	93.865	10364sc//1R01HD093012-01A1	41,554	
		Effect of a patient-centered decision app on TOLAC: An RCT	225	93.865	8231sc//5R01HD078748-03	187,744	
		Effect of a patient-centered decision app on TOLAC: An RCT Effect of Injury Severity and Location on Spasms Post SCI Effect of Neural Constraints on Movement in Stroke	225	93.865 93.865 93.865	8231sc//SR01HD078748-03 5K01HD084672-03 4R01HD039343-15	187,744 108,882 183.071	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throug to subrecipients
Department of Health and		Endometriosis and Retinoids		93.865	5R37HD038691-19	\$ 690,276	-
Human Services (continued)		Engineering Career Development Center in Movement and Rehabilitation Sciences		93.865	4K12HD073945-05	181,675	179,368
		Genes, Androgens and Intrauterine Environment in PCOS High-performance, low-cost, passive prosthetic knees optimized to replicate physiological		93.865	3P50HD044405-15S1	340,095	146,796
		gait in multiple mobility scenarios	132	93.865	S4526-PO176307//1R03HD092676-01	2,314	_
		Homeostatic to reactive hyaluronan matrices in ovarian reproductive aging	102	93.865	1R01HD093726-01	110,064	_
		How Housing Vouchers Affect Biology & Health	122	93.865	2003262020 // U01HD075957	83,970	-
		Improve dynamic lateral balance of humans with SCI	169	93.865	CL5253//1R01HD083314	4,743	-
		Infant attention in the context of language		93.865	1F32HD095580-01	4,067	
		Influence of rapid sensory feedback on motor learning following stroke Integrative Genomics, Epigenomics and Bioinformatics Analyses of Human Uterine Fibroids		93.865 93.865	1F32HD094552-01 REVISED 1R01HD089552-03	48,092 627,960	99,2
		Integrative Genomics, Epigenomics and Biolinormatics Analyses of Human Oterme Piblious	138	93.865	MUSC14-024//5T15HD074546-07	10,668	55,25
		Intensive Rehabilitation Research Grant Writing Workshops in the United States	138	93.865	MUSC18-033-8D222//2R25HD074546-07	5,289	
		Interdisciplinary Engineering Career Development Center in Movement and Rehabilitation					
		Sciences		93.865	5K12HD073945-07	182,180	110,22
		Intimate Partner Violence in Sexual Minority Female Adolescents and Young Adults Linking language and cognition in infancy: Entry points and developmental change	230	93.865 93.865	010314-003//5R01HD086170-02 5R01HD083310-04 REVISED	473,003 330,417	
		Manipulating cGMP Pathway to Impact Vascular Development in Neonatal BPD and ROP		93.865	5R21HD077336-02	(100)	
		Maternal-Fetal Medicine Units Network The Northwestern Study Center		93.865	5UG1HD040512-19	273,680	49,7
		Meeting Gestational Weight Gain Guidelines: Development of a Group Intervention					
		During Pregnancy for Low-Income Racial/Ethnic Minority Obese Women and Their Providers		93.865	5K23HD076010-04	23,267	
		MFMU Network Capitation Agreement	84	93.865	Agmt 4/25/14//U10HD036801	640,593	216,4
		Molecular Basis of Altered Drug Metabolism During Pregnancy Motor impairment related changes in muscles properties in chronic stroke	237	93.865 93.865	16572//1R01HD089455-01-A1 5R01HD084009-04	208,928 309,217	40,0
		Motor Learning in a Customized Body-Machine Interface for Persons with Paralysis	169	93.865	CC#81750//R01HD072080	99,993	40,0
		Multiethnic Fine-Mapping of Polycystic Ovary Syndrome Susceptibility Loci		93.865	1R01HD085227-01A1	105,118	93,6
		Neuromuscular Mechanisms Underlying Poor Recovery from Whiplash Injuries		93.865	5R01HD079076-05	279,813	
		Oncofertility Consortium Annual Conference		93.865	5R13HD063248-07	15,104	
		OPRC clinical project: Comprehensive evaluation of the safety and utility of pravastatin in prevention of preeclampsia in high-risk pregnant women	269	93.865	17-044//5U54HD047891-12 REVISED	(2,497)	
		OPRC clinical project: Comprehensive evaluation of the safety and utility of pravastatin in	209	93.005	17-044//5054HD047891-12 REVISED	(2,497)	
		prevention of preeclampsia in high-risk pregnant women	269	93.865	18-83997-13//5U54HD047891-13 REVISED	10,194	
		Optimizing Medication Management for Mothers with Depression during Pregnancy (OPTI-MOM)		93.865	5U54HD085601-04	878,496	90,4
		Pathophysiology and Rehabilitation of Neural Dysfunction		93.865	3T32HD007418-25S1	(7,587)	
		Pathophysiology and Rehabilitation of Neural Dysfunction		93.865	2T32HD007418-26	259,646	
		PED Screen: Pediatric Sepsis EHR Registry, Clinical Outcomes, and Predictive Model		93.865	5R01HD087363-02 REVISED	512,375	439,5
		Pediatric HIV/AIDS Cohort Study: Understanding Maternal HIV Disease through Pregnancy and the Postpartum Period and its Role in Child Health Outcomes Sub-study	207	93 865	TUL-HSC-555811-17/18//U01HD052104	35 712	
		Pharmacokinetics of Risperidone Across Pregnancy	207	93.865	5K23HD087529-02	153,777	
		Pharmacologic strategies to use the levonorgestrel implant in HIV-infected women	255	93.865	34-2009-2031-001//5R01HD085887-03	14,819	
		Phonetic echoes of cognitive disruptions in speech production		93.865	5R21HD077140-02	(649)	
		Phonetic echoes of cognitive disruptions in speech production		93.865	5R21HD077140-02	29,006	29,0
		Prevalence and Correlates of School-Based Medicaid-Funded Services for Children with Autism Spectrum Disorder	269	93.865	17-073//5P2CHD065702-08	16.029	
		Autism Spectrum Disorder Preventing the Intergenerational Transmission of Antisocial Behavior: Successful Child	269	93.865	17-073//5P2CHD065702-08	16,029	
		Socialization Strategies in Families with a Parental History of Incarceration		93.865	1R21HD092671-01A1 S1	33,397	
		Probing Mediator 12 function in uterine fibroids		93.865	5R21HD082781-02	(837)	
		Psychosocial Intervention, Maternal Inflammation, and Birth Outcomes: Centering vs Routine					
		Prenatal Care (PIINC)	149	93.865	EH17-256-S2//1R01HD092446-01A1	3,225	
		Regulation of NOD-like receptors in juvenile influenza A virus infection	271 228	93.865 93.865	10034012-CHIC//5K12HD047349-14	57,409	51,0
		Remediating Academic and Non-Academic Skills Deficit among Disadvantaged Youth Research Career Development in Obstetrics and Gynecology	228	93.865	FP053700-3//P01HD076816 5K12HD050121-14	36,727 318,160	
		Rural African American Young Adults' Pathways to Psychosocial and Physical Health	234	93.865	RR376-410/4708620 Amd 3 // 2R01HD03058820A1	99 854	
		Semi-autonomous Robotic Powered Wheelchair Functionality	110	93.865	Agmt 8/24/16 // 1R43HD085317-01	17,266	
		Targeted problem reactivation and incubation during slow-wave sleep		93.865	5R03HD087111-02	53,775	
		The Chicago Longitudinal Study (CLS) Health Screening Examination	251	93.865	A005404701//2R01HD034294-23	165,472	
		UBR7 is a novel chromatin directed E3 ubiquitin ligase		93.865	7R21HD078946-02	(9,498)	
		UBR7 is a novel chromatin directed E3 ubiquitin ligase Understanding Diverging Profiles of Academic and Physical Health Outcomes in African		93.865	7R21HD078946-02	(17,428)	(17,4
		American Youth		93.865	1R01HD093718-01	22.322	
		Uterine Leiomyoma Research Center Program		93.865	5P01HD057877-09	1,058,899	68,0
		, .				10.936.895	1.800.9
							1,000,9
		2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease 7th Intern Conf on AD and Related Disorders in the Middle East		93.866 93.866	1R13AG054189-01 1R13AG055285-01	2,097 35.819	
		7th Intern Cont on AD and Related Disorders in the Middle East A test of the calcium hypothesis of Alzheimers disease		93.866 93.866	1R13AG055285-01 1R21AG060267-01	35,819 164	
		A test of the calcium hypothesis of Alzheimers disease A Universal Medication Schedule to Promote Adherence to Complex Drug Regimens		93.866	5R01AG046352-04	575,670	177,3
		Alterations in BMP Signaling in the Aging Brain		93.866	1R56AG050542-01A1	(10,822)	,
		Alterations of Sleep and Circadian Timing in Aging		93.866	5P01AG011412-19	831,057	
			262	93.866	75689162//U19AG010483-25R	1.205	
		Alzheimer's Disease Cooperative Study – A4	202				
		Alzheimer's Disease Core Center		93.866	3P30AG013854-23S2	1,895,924	
			262				

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throu to subrecipien
epartment of Health and		ARMADA: Advancing Reliable Measurement in Alzheimer's Disease and cognitive Aging.		93.866	3U2CAG057441-02	\$ 1,326,948	381,2
Human Services (continued)		BACE1 as a Therapeutic Target for Alzheimer's Disease		93.866	5R01AG022560-15	126,221	
		Behavioral Economics Applications to Geriatrics Leveraging EHRs (BEAGLE)		93.866	5R21AG057383-02	140,535	
		C. elegans Model for Neurodegenerative Diseases of Aging Cardiovascular and HIV/AIDS Effects on Brain Structure/Function and Cognition	260	93.866 93.866	5R37AG026647-13 0050794(128001-6)//5R01AG034852-06	118,288 109,104	
		Cell aging and vimentin glycation: Effects on the cytoskeleton and cell mechanics	200	93.866	5R21AG049218-02	109,104	
		COCOA to improve walking performance in Peripheral Artery Disease: the COCOA-PAD Study		93.866	5R21AG0549210-02 5R21AG050897-02 REVISED	300 644	42.
		Collaborative Care for the Older Injured Patient: A Trauma Medical Home	107	93.866	IN4688176NW//5R01AG0542493-02	47,033	,
		Communication Bridge: A person-centered Internet-based intervention for individuals with					
		primary progressive aphasia		93.866	1R01AG055425-02	535,235	49
		Comparative Effectiveness of Customary F&S vs Fit and Strong Plus	237	93.866	7950//5R01AG039374-06	8,305	
		Connectomic Imaging in Familial and Sporadic Frontotemporal Degeneration	259	93.866 93.866	571660//5U01AG052943-02 9R01AG056258-06 REVISED	150,737	5
		Determinants of neurodegenerative decline in the aphasic variant of Alzheimer's disease Developing a Longitudinal Resource for Genetic Research in Behavioral and Health Sciences	274	93.866	482K930//1R01AG041868-02	367,794 2.847	5
		Developing a Longitudinal Resource for Genetic Research in Behavioral and Health Sciences	274	93.866	636K694//4R01AG041868-04	(2,375)	
		Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography				(_,)	
		imaging diagnostic for Alzheimer Disease	1	93.866	Agmt 3/5/17//R41AG054337-01	14,043	
		Disordered Proteostasis as a Driver of Disease in the Aging Lung		93.866	5P01AG049665-04	1,974,905	485
		Effects of a Dedicated Nurse Liaison Intervention for Geriatric Patients in the Emergency					
		Department		93.866	1R03AG050945-01A1	99,199	
		Estradiol reduces mitochondrial oxidant stress in SNc DA neurons		93.866	5F32AG058396-02 5R01AG045571-05	51,341	
		Exceptional Cognitive Aging: Neuropsychologic, Anatomic and Pathologic Correlates F31 for Aneesha Nilakantan in Support of: Age-related impairments of recollection precision:		93.866	5RU1AG0455/1-05	496,357	
		Neural mechanisms and modulation via network-targeted brain stimulation		93 866	5F31AG057109-02	37,497	
		F31 for Stephanie Anne Kielb in Support of: Cognitive, Motor, and Emotional Markers of		33.000	313140631183-02	51,451	
		Self-reported Cognitive Concerns		93.866	1F31AG051350-02 REVISED	34.402	
		Functional Properties of the Lateral Entorhinal Cortex in Learning and Aging		93.866	5F31AG055331-02 REVISED	41,493	
		Genetic Epidemiology of Caffeine and Cognitive Decline		93.866	5K01AG053477-03	101,817	
		Hepatocyte growth factor to Improve Functioning in PAD: the HI-PAD Study		93.866	1R21AG056903-01	119,578	1
		High-throughput multi-modal analysis of natural variation in C. elegans healthspan	259	93.866	572177 // 1R21AG053638-01A1	103,951	
		Identification of Heterogeneity within the High-Cost PatientPopulation: A Growth		93.866	15011 0055005 0111	28.692	
		Mixture Modeling Approach Improving Quality & Equity of Emergency Care Decisions (IQED)	262	93.866	1F31AG055235-01A1 1052335943//1R21AG057400-01 REVISED	6,998	
		Integrative Analysis of Longitudinal Studies of Aging	157	93.866	908468 NU//4P01AG043362-05	162,315	
		Integrative Pathways to Health and Illness	274	93.866	618K166///P01AG020166	(843)	
		Integrative Pathways to Health and Illness	274	93.866	834K352//1U19AG051426-01A1	35,726	
		LEAF 2.0: Randomized trial of a technology-based positive emotion intervention for informal					
		caregivers of individuals with Alzheimer's disease		93.866	1R01AG058613-01	529	
		LitCog III: Health Literacy and Cognitive Functionamong Older Adults		93.866	5R01AG030611-11 REVISED	675,067	7
		Living Well With Later Life Multimorbidity: A Biopsychosocial Approach	165	93.866	4102-56030//1R01AG041750-01A1	17,211	
		Long-Term Nicotine Treatment of Mild Cognitive Impairment	262	93.866	81622655//6R01AG047992-02	13,347	
		Long-term Outcomes of Knee OA in the OAI Cohort Molecular and cellular mechanisms of the UNC5C netrin receptor in Alzheimer's disease	225	93.866	10477sc	20,427	
		pathogenesis		93.866	1R01AG057727-01A1	28.659	
		Molecular Neuropathology and Mechanisms of BACE1 Elevation in Alzheimer's Disease		93.866	5R01AG030142-09	327,205	
		MRI of Left Atrial Hemodynamic Disorders in Atrial Fibrillation		93.866	3R21AG055954-02S1	132.557	
		National Alzheimer's Coordinating Center	273	93.866	UWSC7728//5U01AG016976-20	39,513	
		National Health Literacy Mapping to Inform Healthcare Policy	257	93.866	5050165//5R01AG46267-04	18,994	
		NMDA RECEPTOR MODULATORS AS NOOTROPIC THERAPIES IN AGING BRAIN	16	93.866	Agmt 3/3/17//1R43AG051299-01	49,638	
		Noninvasive Stimulation to Improve Hippocampal-Dependent Memory in Older Adults		93.866	5R01AG049002-04	394,067	
		Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA3CT)	255	93.866	36-5360-2141-101//4R01AG037120-04	23,890	
		NRSA F30 Fellowship for Anil Ramesh Wadhwani in support of: Cell autonomous mechanisms of Apolipoprotein E isoform-dependent neurodegeneration		93 866	1F30AG051327-01A1 REVISED	37,458	
		of Apolipoprotein E isoform-dependent neurodegeneration Optimal Older Donor and Recipient Matching to Enhance Liver Transplant Outcomes		93.866	1F30AG051327-01A1 REVISED 1R21AG049385-02	37,458 31,098	
		Personality and Well-being Trajectories in Adulthood		93.866	5R01AG018436-17	529.743	10
		Physical Exercise to Prevent Disability (The Life Study)	233	93.866	UFDSP00010684//U01AG022376	(5.900)	10
		Physiological role of naturally-occuring amyloid beta oligomers	200	93.866	1R21AG060203-01	20,320	
		Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors		93.866	4U01AG043415-05	137,741	
		Preclinical development of a selective attenuator of neuroinflammation for MCI/AD	241	93.866	3200001251-16-257//5U01AG050636-03	364,122	
		PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis		93.866	5R01AG055121-02	164,851	2
		Predoctoral and postdoctoral training program in aging and dementia		93.866	4T32AG020506-15	39,958	
		Predoctoral and postdoctoral training program in aging and dementia	70	93.866	5T32AG020506-17	434,343	
		Preparation for End-of-Life Decision Making in Mild Alzheimer's Disease Quantifying age-related changes in shoulder muscle coordination in healthy adults	72	93.866 93.866	T897810//1R01AG057714-01 Revised 1F31AG057137-01A1 REVISED	16,183 4 429	
		Reducing High-Risk Geriatric Polypharmacy via EHR Nudges	168	93.866	9920180010//R21AG057396	4,429 46,057	
		Regulation of Peripheral Proteostasis	100	93.866	1RF1AG057296-01	40,007	
		Regulation of tau expression in Alzheimer's disease and aging	100	93.866	0255-1551-4609//5R01AG054008-03	130,759	
		RESveratrol To Improve Outcomes in oldeR pEople with PAD (the RESTORE Trial)		93.866	5R21AG047510-02	(5,813)	
		Role of BMP Signaling in the Aging Brain		93.866	1R01AG054429-02	397,760	
		Role of CK2 in NMDAR trafficking during development and in Alzheimer's disease		93.866	5R00AG041225-04 REVISED	126,231	
		Sex Differences in Central Stress Response and Alzheimer's Disease Neuropathology		93.866	1RF1AG057884-01	205,600	
		Sirtuins: novel determinants and therapeutic target in systemic sclerosis		93.866	1R56AG054207-01	288,609	
		Slow Outward Currents and Learning In Aging Hippocampus Sporadic Alzheimer's Disease modeled with diabetes and high cholesterol in rabbit		93.866 93.866	5R37AG008796-27 REVISED 1R56AG050492-01A1	620,490 171,945	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
epartment of Health and		Stellate Ganglion Blockade for the Management of Vasomotor Symptoms		93.866	5R01AG049924-02	\$ 449,634	116,785
Human Services (continued)		Stress and Sexuality Divergent Neuropathy in Alzheimer's Disease		93.866	1R56AG053491-01	274.761	123.380
		Sustaining quality of life of the aged: Heart transplant or mechanical support?		93.866	5R01AG047416-04	629,723	321,198
		Synaptic substrates of age-dependent memory deficits		93.866	2RF1AG017139-15	652,666	195,536
		Testing Tele-Savvy, an On-Line Psychoeducation Program for Informal Alzheimer's Caregivers	72	93.866	T745243//1R01AG054079-01	23,356	_
		The ENRGISE Study	233	93.866	UFDSP00011851//U01AG050499	116,590	_
		Therapeutic Effect of Intranasal Insulin on Cognition, Function, and AD Biomarker	224	93.866	42756369///7RF1AG041845-02	3	-
		Therapeutic Effects of Intranasally-Administered insulin (INI) in Adults with Amnestic Mild					
		Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)	262 222	93.866 93.866	CTAINI067//RF1AG041845	85,439	-
		UCLA Older Americans Independence Center (Administrative Supplement)	222	93.600	1558 G VA507//5P30AG028748-12	24,826	
						18,810,822	2,119,818
		A clinically applicable model of retinal oxygen metabolism		93.867	5R21EY027502-02 REVISED	257,036	_
		Activation of the Angiopoietin-Tie2 Pathway to Treat Ocular Hypertension and Glaucoma		93.867	5R01EY025799-03	744.533	234,160
		Ca2+ channels in retinal photoreceptors	239	93.867	W000941480/1R01EY026817-01A1	75,272	
		Critical Period Plasticity and Binocular Matching in the Visual Cortex		93.867	5R01EY020950-08 REVISED	106.374	_
		Deciding Where to Look Next: Frontal Eye Field's Role during Natural Viewing		93.867	5F31EY025532-03 REVISED	30,186	_
		Diabetic Retinopathy Clinical Research Network Chair Grant		93.867	5U10EY023207-05	392,899	195,057
		Function of Basal Synapses at Mammalian Photoreceptors		93.867	5R01EY012141-20 REVISED	89,031	_
		Homeobox Gene Six3 in Forebrain and Visual System Development		93.867	7R01EY012162-17 REVISED	(29,124)	_
		Investigating nanoscale neuronal damages in early glaucoma towards clinical optical detection		93.867	1R01EY029121-01	47,540	_
		Investigating oxygen metabolism in diabetic retinopathy		93.867	5R01EY026078-03	464,239	242,843
		Light responses and microcircuitry of two novel amacrine cell types in the mouse retina		93.867	5F32EY025930-03	54,340	-
		Long-term Follow-up of Patients Who Participated in the Multicenter Uveitis Steriod Treatment					
		Trial (MUST Trial Follow-up Study)	122	93.867	2003214618//U10EY014660	(466)	-
		Macular Edema Treatment Trials Associated with MUST (META-MUST)	122	93.867	Sub#2002749092//5U10EY024527-04	1,275	-
		Mechanisms of anterior segment development and corneal neovascularization		93.867	2R01EY019484-01A1	14,013	-
		Mechanisms underlying the formation of the cornea and ocular surface epithelium		93.867	1R01EY028304-01A1	93,552	_
		Microvasculature in Colon Field Carcinogenesis: Clinical-Biological Implications	29	93.867	BMC ID 6610//1R01CA224911-01A1	13,434	-
		Multidisciplinary Visual Sciences Training Program		93.867	5T32EY025202-04 REVISED	146,425	-
		Natural dynamics of attention in primate prefrontal cortex		93.867	5F32EY027185-02 REVISED	50,765	_
		Neural Mechanisms of Fixation Choice While Searching Natural Scenes	274	93.867	5R01EY021579-06 676K001//R24EY022883	271,368	_
		Novel Antiangiogenic Peptides for Treatment of Exudative AMD Novel Antiangiogenic Peptides for Treatment of Exudative AMD	274 274	93.867 93.867	676K001//R24EY022883 770K873 // 4R24EY022883-05	(145) 315.743	_
		Novel Antianglogenic Peptides for Treatment of Excidence AMD Novel circuit mapping strategies to reverse engineer the retina	2/4	93.867	1DP2EY026770-01	599,540	_
		Oxygen delivery and metabolism in diabetic retinopathy using visible-light optical coherence		93.007	1DF2E1020770-01	355,540	_
		tomography		93 867	5F30EY026472-03 REVISED	40,060	_
		Role of Host Cell Factors in Herpes Simplex Virus (HSV) Keratitis		93.867	5R01EY023977-03 REVISED	506.118	_
		Signal Processing in the Inner Retina		93.867	5R01EY018204-10 REVISED	86.091	_
		The Mechanical Basis of Primary Open Angle Glaucoma		93.867	5R01EY019696-09	829,576	614,595
		The Retinal Microenvironment in Diabetic Retinopathy		93.867	5R01EY021165-05	(1)	_
		The Role of MicroRNAs in Corneal Epithelial Homeostasis		93.867	5R01EY019463-08	530,598	_
		The Roles of Autophagy in Limbal/Corneal Epithelia.		93.867	1R01EY028560-01	90,808	_
		Understanding Diabetic Eye Disease in the Underserved Using Health Data Exchange		93.867	5R21EY024050-02	(33)	_
		• , • •				5.821.047	1.286.655
						5,821,047	1,200,000
		A New Generation Clinical Decision Support System	260	93.879	0038305 (124684-1)//5R01LM011663-04	136,104	-
		A Novel Graph Processing Architecture to Ascertain & Monitor Care Coordination		93.879	5K01LM011973-03	30,304	_
		Bayesian Generative Methods for Extracting and Modeling Relations in EHR Narratives		93.879	1R21LM012618-02	146,139	_
		Enhancing clinical trials participation though library partnerships		93.879	5G08LM012688-02	76,936	-
		Implementing and Evaluating a Machine Learning Tool for Entity Resolution in Drug Use and					
		Sexual Contact Networks of YMSM		93.879	5R21LM012578-02	138,928	16,564
		Improving Physician Adoption of Pharmacogenomic Clinical Decision Support via Implementation			55041 M040400 00		
		Science Methodologies		93.879	5F31LM012492-02	38,565	-
		Informatics Platform for Mammalian Gene Regulation at Isoform-level		93.879	5R01LM011297-06	334,962	
		Multidimensional Computer Adaptive Testing for Patient Reported Outcomes		93.879	5R01LM011962-04 5T32I M012203-04	359,751	75,996
		Predoctoral Training Program in Biomedical Data Driven Discovery (BD3)		93.879	5132LIVI012203-04	240,107	
						1,501,796	92,560
		Diabetic Retinopathy Clinical Research Network	120	93.988	Agmt 12/13/12 // U10 EY14231	51,843	_
					-		_
		Building Research And Innovation in Nigeria's Science – (BRAINS)	242	93.989	SP0031902-60041063//1D43TW010134-03	115,743	-
		Developing Innovative Interdisciplinary Biomedical Engineering Programs in Africa		93.989	5D43TW009374-05	320,186	98,773
		EHR Anticoagulants Pharmacovigilance	246	93.839	S51110000040313//7R01HL125089	20,790	-
		Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria		93.989	2D43TW009608-06	29,451	-
		Fogarty Global Health Training Fellowship Program	94	93.989	5101817-116559//5D43TW010543-02	22,530	-
		HIV and Mycobacterial Disease in Mali		93.989	5D43TW010350-03	347,020	164,479
		Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria		93.989	2D43TW009608-06	105,035	42,372
		Northwestern and Jos University Research Training Program in HIV and Malignancies		93.989	5D43TW009575-04	309,763	64,103
		Support of Training and Mentoring in Nigeria for Academics (STAMINA)	240	93.989	IJNWU-STAMINA-NU 03//5DW43TW010130-03	122,996	-
		Tobacco Cessation Strategies Among Acute Coronary Syndrome Patients in Kerala, India	278	93.989	VUMC 58837//5R25TW009337-06	529	-
		University of Ibadan MEPI Junior Faculty Research Training Program (UI-MEPI-J)	236	93.989	7/225/29/NU-02//D43TW010140-02	164,258	_

Supplementary Schedule of Expenditures of Federal Awards

			Pass- through			Federal	Passed-thro to
uster title/Federal grantor	Subagency	Project title	ID number	CFDA	Sponsor award number	expenditures	subrecipie
partment of Health and		A real-time, cost-effective, accurate UV measurement and prevention system to reduce skin					
Human Services (continued)		cancer incidence in consumers. Ad5.hAC6 Gene Transfer for CHF	286 279	93.RD 93.RD	AGMT 3/14/18//1R44CA224658-01 08082-NU SUB//CRB-HLBI1-S-10-00076	\$ 57,386 474	
		Addina Cohort Support Contract	2/9	93.RD 93.RD	HHSN275201300013C	690,489	23
		Cancer Prevention Agent Development Program: Early Phase Clinical Research		93.RD	HHSN261201200035I/HHSN26100007	2,545,367	830,
		Center for Structural Genomics of Infectious Diseases		93.RD	HHSN272201200026C	1,039,661	1,037
		Combined Top Down and Bottom Up Proteomics of CompRef Cancer Samples	126	93.RD	13XS108 Mod 06//HHSN261200800001E	3,022	
		Coronary Artery Risk Development in Young Adults (CARDIA) Study – Chicago Field Center		93.RD	HHSN268201800003I	84,968	
		Coronary Artery Risk Development in Young Adults (CARDIA) Study-Chicago Field Ctr EMR Dataset (Eskenazi Health EMR Dataset)	107	93.RD 93.RD	HHSN268201300027C Agr. 4/19/2016 //HHSN27601500744P	552,161 3.897	
		Evaluation of Clinical Samples from DENVax Clinical Trial	21	93.RD	465426/HHSN272201200003//HHSN27200011	16.951	
		Exact neurobiological correlates of key aspects of behavior in real-time	21	93.RD	HHSN271201700289P	23,000	
		Exact neurobiological correlates of key aspects of behavior in real-time		93.RD	HHSN271201800190P	18,553	
		Exact neurobiological correlates of key aspects of behavior in real-time		93.RD	HHSN271201800279P	20,981	
		Folic Acid and Zinc Supplementation Trial (FAZST)	271	93.RD	10026957-03//HHSN27520100007C	4,743	
		IPA Agreement 8/2016	252	93.RD	AGREEMENT 8/18/16	74,055	
		Jackson Heart Study Field Center NHLBI-HV-13-10 Melanoma Early Detection RCT with Smartphones, Cognitive Computing & Family Social Support	252	93.RD 93.RD	66102690414-04NWU/HHSN268201300047C HHSN261201700003C	34,343 12,792	
		Multi-Ethnic Study of Atherosclerosis (MESA) Chicago Field Center Subcontract	201	93.RD 93.RD	UWSC8539//HHSN268201500003I	680,215	
		Multi-Site Study of the Efficacy of Speech Perception Training for Hearing-Aid Users	51	93.RD	CDT-2013-6 Amd 4 // R33DC011174-02	4,617	
		Pediatric Trials Network-CO 25 (SCAMP)	66	93.RD	203-9512//HHSN275201000003I	24,782	
		Phase II Multi-Center, Prospective, Randomized, Double-Blind Study of Nitazoxanide in Acute					
		and Chronic Norovirus in Hematpoietic Stem Cell and Solid Organ Transplant Recipients		93.RD	HHSN272201600016C	418,700	1
		Protocol Implementation	239	93.RD	HHSN2722013-15-0045 Task B	4,292	
		Protocol IRC002 "A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory	100		100000000000000000000000000000000000000	0.550	
		Efficacy Study of Investigational anti-Influenza Immune Plasma for the Treatment of Influenza" Protocol Number: IRC-005 A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety	188	93.RD	HHSN261200800001E/11XS088	2,553	
		of High-Titer versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A	188	93.RD	CRB-SSS-S-15-004659//HHSN2612008000	8,118	
		Role of Valve-Mediated Hemodynamics on Bicuspid Aortopathy	232	93.RD	FY19.954.001//7R01HL133504-03	72,427	
		Structural Genomics Centers for Infectious Diseases		93.RD	HHSN272201700060C	3,267,252	1,9
		Structure and Function of the SS18-SSX-containing mSWI/SNF (BAF) Complex Unveiling New					
		SurvivorConcierge: Extending Cancer Survivorship Care Beyond the Clinic Using a					
		Smartphone-enabled Monitoring, Navigation and Tailored Intervention Program	281	93.RD	HHSN261201500013C	7,776	
		Targeting KRas Switch I with highly specific bacterial endopetidase Top Down Proteomics of KRas Proteoforms	159 126	93.RD 93.RD	17-40-BIAN//HHSN26120080001E 17X183 // HHSN261200800001E	4,321 135,172	
		Top Down Proteomics of KRas Proteoforms	126	93.RD	17X183 // HHSN261200800001E	135,172	
	Office of Minority Health						
		Addressing Lupus Health Disparities Adapting Culturally-Competent Community-Based					
		Education Models Through Local and National Collaborative Partnerships		93.137	1 CPIMP151087-01-00	(9,702)	
		Clinical Trials Awareness Modules for the Lupus Conversations Academic-Community					
		Partnership		93.137	1CPIMP181168-01-00	19,854	
						10,152	
	Office of the Assistant						
	Secretary for Health						
	,	National Lupus Outreach and Clinical Trail Education Program (Lupus program)-LUPUS					
		CONVERSATIONS Project		93.137	1CPIMP171141-01-00	262,666	1
		Re-Entry Community Linkages (RE-LINK)		93.137	5 CPIMP161134-03-00	406,250	
						668,916	1
	Office of the Director.					000,310	·
	National Institutes of Health			93.310	5DP5OD024587-02	380,908	
		Biochemical Basis of Chromatin Folding and Chromosome Condensation					
		Data and Research Support Center Linkage Pilot	278	93.310	VUMC65034/5U2COD023196-02	14,191	
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment	278 100		VUMC65034/5U2COD023196-02 0255-2292-4609//5UG3OD023337-02	14,191 30,124	
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework		93.310 93.310	0255-2292-4609//5UG3OD023337-02	30,124	
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health		93.310			3
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Environmental Contributors to Child Health Originating from the National Fetal Growth Study	100	93.310 93.310 93.310	0255-2292-4609//5UG30D023337-02 1U240D023319-01 REVISED	30,124 2,509,539	3
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Environmental Contributors to Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS)		93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//5UG3OD023316-02	30,124 2,509,539 393,179	
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Environmental Contributors to Child Health Originating from the National Fetal Growth Study	100	93.310 93.310 93.310	0255-2292-4609//5UG30D023337-02 1U240D023319-01 REVISED	30,124 2,509,539	
		Data and Research Support Center Linkage Pilot ECHO Consoltium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Environmental Contributors to Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) Illinois Precision Medicine Consortium (IPMC) Infrastructure: Illinois Precision Medicine Consortium (IPMC) Lifecourse Approach to Developmental Repercussions of Environmental Agents on	100 138	93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//5UG3OD023316-02 1UG3OD023189-01 REVISED 10T2OD026557-01 REVISED	30,124 2,509,539 393,179 4,624,380 571,624	
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PKO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Environmental Contributors to Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) Illinois Precision Medicine Consortium (IPMC) Infrastructure: Illinois Precision Medicine Consortium (IPMC) Lifeocurse Approach to Developmental Repercussions of Environmental Agents on Metabolic and Respiratory health (LA DERAMERS)	100 138 262	93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//5UG3OD023316-02 1UG3OD023189-01 REVISED 10172OD02657-01 REVISED 94743768//UG3OD023287	30,124 2,509,539 393,179 4,624,380 571,624 84,125	
		Data and Research Support Center Linkage Pilot ECHO Consoltium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentaly-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Environmental Contributors to Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) litinois Precision Medicine Consortium (IPMC) Infrastructure: litinois Precision Medicine Consortium (IPMC) Lifecourse Approach to Developmental Repercussions of Environmental Agents on MEtabolic and Respiratory health (LA DREAMERs) Precision Medicine Initiative Cohort Program Coordinating Center (U2C)	100 138	93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//5UG3OD023316-02 1UG3OD024189-01 REVISED 10T2OD026557-01 REVISED 94743768//UG3OD023287 VUMC60724//5U2COD023196-02	30,124 2,509,539 393,179 4,624,380 571,624 84,125 216,305	
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) Illinois Precision Medicine Consortium (IPMC) Infrastructure: Illinois Precision Medicine Consortium (IPMC) Lifecourse Approach to Developmental Repercussions of Environmental Agents on MEtabolic and Respiratory health (LA DREAMERS) Precision Medicine Initiative Cohort Program Coordinating Center (U2C) Self-Organization of the Human Genome	100 138 262	93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//5UG3OD023316-02 1UG3OD023189-01 REVISED 10172OD02657-01 REVISED 94743768//UG3OD023287	30,124 2,509,539 393,179 4,624,380 571,624 84,125	
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Environmental Contributors to Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) linnois Precision Medicine Consortium (IPMC) Infrastructure: Illinois Precision Medicine Consortium (IPMC) Lifecourse Approach to Developmental Repercussions of Environmental Agents on MEtabolic and Respiratory health (LA DREAMERs) Precision Medicine Initiative Contont Program Coordinating Center (U2C) Self-Organization of the Human Genome The role of steady state broadyl neutralizing antibody tissue levels in preventing distal site	100 138 262	93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//5UG3OD023316-02 1UG3OD023189-01 REVISED 10T2OD026557-01 REVISED 94743768//UG3OD023287 VUMC60724//5U2COD023196-02 4DP2OD008717-02	30,124 2,509,539 393,179 4,624,380 571,624 84,125 216,305 (2,797)	
		Data and Research Support Center Linkage Pilot ECHO Consoltium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) Illinois Precision Medicine Consortium (IPMC) Infrastructure: Illinois Precision Medicine Consortium (IPMC) Lifecourse Approach to Developmental Repercussions of Environmental Agents on MEtabolic and Respiratory health (LA DREAMERS) Precision Medicine Initiative Cohort Program Coordinating Center (U2C) Self-Organization of the Human Genome The role of steady state broadly neutralizing antibody tissue levels in preventing distal site SHI/ regication	100 138 262	93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//SUC3OD023316-02 1UG3OD023189-01 REVISED 10172OD026557-01 REVISED 94743768//UG3OD023287 VUMG0724//5U2COD023196-02 4DP2OD009717-02 5K010D024882-02 REVISED	30,124 2,509,539 393,179 4,624,380 571,624 84,125 216,305 (2,797) 185,594	3; 3,4
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Environmental Contributors to Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) linnois Precision Medicine Consortium (IPMC) Infrastructure: Illinois Precision Medicine Consortium (IPMC) Lifecourse Approach to Developmental Repercussions of Environmental Agents on MEtabolic and Respiratory health (LA DREAMERs) Precision Medicine Initiative Contont Program Coordinating Center (U2C) Self-Organization of the Human Genome The role of steady state broadyl neutralizing antibody tissue levels in preventing distal site	100 138 262	93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//5UG3OD023316-02 1UG3OD023189-01 REVISED 10T2OD026557-01 REVISED 94743768//UG3OD023287 VUMC60724//5U2COD023196-02 4DP2OD008717-02	30,124 2,509,539 393,179 4,624,380 671,624 84,125 216,305 (2,797) 185,594 498,313	3,4
		Data and Research Support Center Linkage Pilot ECHO Consoltium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) Illinois Precision Medicine Consortium (IPMC) Infrastructure: Illinois Precision Medicine Consortium (IPMC) Lifecourse Approach to Developmental Repercussions of Environmental Agents on MEtabolic and Respiratory health (LA DREAMERS) Precision Medicine Initiative Cohort Program Coordinating Center (U2C) Self-Organization of the Human Genome The role of steady state broadly neutralizing antibody tissue levels in preventing distal site SHI/ regication	100 138 262	93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//SUC3OD023316-02 1UG3OD023189-01 REVISED 10172OD026557-01 REVISED 94743768//UG3OD023287 VUMG0724//5U2COD023196-02 4DP2OD009717-02 5K010D024882-02 REVISED	30,124 2,509,539 393,179 4,624,380 571,624 84,125 216,305 (2,797) 185,594	
		Data and Research Support Center Linkage Pilot ECHO Consoltium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) Illinois Precision Medicine Consortium (IPMC) Infrastructure: Illinois Precision Medicine Consortium (IPMC) Lifecourse Approach to Developmental Repercussions of Environmental Agents on MEtabolic and Respiratory health (LA DREAMERS) Precision Medicine Initiative Cohort Program Coordinating Center (U2C) Self-Organization of the Human Genome The role of steady state broadly neutralizing antibody tissue levels in preventing distal site SHI/ regication	100 138 262	93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//SUC3OD023316-02 1UG3OD023189-01 REVISED 10172OD026557-01 REVISED 94743768//UG3OD023287 VUMG0724//5U2COD023196-02 4DP2OD009717-02 5K010D024882-02 REVISED	30,124 2,509,539 393,179 4,624,380 671,624 84,125 216,305 (2,797) 185,594 498,313	3,4
		Data and Research Support Center Linkage Pilot ECHO Consortium on Perinatal Programming of Neurodevelopment ECHO PRO Research Resource: A Developmentally-based Measurement Science Framework for Assessing Environmental Exposure and Child Health Environmental Contributors to Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) Illinois Precision Medicine Consortium (IPMC) Lifecourse Approach to Developmental Repercussions of Environmental Agents on MEtabolic and Respiratory health (LA DREAMERs) Precision Medicine Instance Contor Program Coordinating Center (U2C) Self-Organization of the Human Genome The role of steady state broady neutralizing antibody tissue levels in preventing distal site SHIV replication TOP2A effects on transcription in gliomas: implications for personalized therapy	100 138 262 278	93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310 93.310	0255-2292-4609//5UG3OD023337-02 1U24OD023319-01 REVISED MUSC16-087-8C267//5UG3OD023316-02 1UG3OD023189-01 REVISED 10720002657-01 REVISED 94743768//UG3OD023287 VUMC60724//5U2C0D023196-02 4DP2OD008717-02 5K01OD024882-02 REVISED 7DP5OD021356-03	30,124 2,509,539 393,179 4,624,380 671,624 84,125 216,305 (2,797) 185,594 498,313 9,505,485	3,4

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throu to subrecipien
Department of Health and		PAGES (Progressing through the Ages: Global Climate Change, Evolution, and Societal					
Human Services (continued)		Well-being)	238	93.351 93.351	076638-15799 Amd 01 // 1 R25 OD020203	\$ 36,525	
		Science Club Summer Camp: Training Teachers and Youth in Authentic STEM Practice Understanding the mechanism(s) of systemic antibody delivery, distribution, and localization to		93.351	5R25OD020222-02	(97,885)	
		mucosal sites in the in vivo macaque model		93.351	1K01OD026571-01	3,984	
						506,268	
		Science Club Summer Camp: Training Teachers and Youth in Authentic STEM Practice		93.859	8R25GM129223-04	323,738	59,
	Substance Abuse and Mental						
	Health Services	APA/SAMHSA Fellowship for Lisette Rodriguez-Cabezas in Support of: APA/Substance					
		Abuse and Mental Health Services Award	13	93.243	Award Letter 4/5/16 // 5T06SM060562-06	3,537	
		Pilot Evaluation of Crisis Support over Messenger (CSOM)	173	93.243	Agmt 2/7/18	45,875	
						49,412	
					Department of Health and Human Services Total	345,583,946	49,333
Department of Homeland Security		Development of a Real-Time Decision Support System for Proactive Response, including					
Security		Recourse Planning, under Uncertain Active Cascading Emergencies	17	97.061	18-409 // 2017-ST-061-QA001-01	50,086	
		Undergraduate Research Assistant for A Real-Time Decision Support System for Proactive	47	07.004		7 000	
		Response, including Recourse Planning, under Uncertain Active Cascading Emergencies	17	97.061	ASUB00000017//2017-ST-061-QA001-01	7,900	
		.				57,986	
		Chalcogenide semiconductors for g-ray detection from earth abundant elements Novel Compound Semiconductor Radiation Detectors	147	97.077 97.RD	14DNARI00006-05-00 SUB-01//HSHQDC-14-R-B0009	404,363 (34,047)	
					Department of Homeland Security Total		
Department of Housing							
and Urban Development							
		Juvenile Reentry Assistance Program (JRAP)	42	14.897	CONTRACT NO. 11841	19,082	
					Department of Housing and Urban Development Total	19,082	
Department of Justice	National Institute of Justice						
	National Institute of Justice	Firearm Involvement in Delinquent Youth and Collateral Consequences in Young Adulthood:					
	Office of Justice Programs	A Prospective Longitudinal Study		16.560	2016-R2-CX-0039	176,436	
	Once of Justice Programs	Northwestern Juvenile Project: Archiving Data, Part I		16.540	2012-JR-FX-0005	(4,828)	
		Trajectories of Delinquency and the Juvenile Justice Systems Response		16.541	2013-JF-FX-0057	32,015	
		Field-generated Innovations to address elder abuse, neglect and financial exploitation		16.582	2017-VF-GX-K136	134,159	
		Metropolitan Family Services Legal Aid Society Needs Assessment	140	16.582	Agreement 4/19/17//2012-VF-GX-K022	2,818	
						136,977	
		Evaluating a Cognitive Behavioral Approach for Improving Life Outcomes of Underserved					
		Young Women: A Randomized Experiment in Chicago	228	16.726	FP064531 // 2016-JU-FX-0002	29,031	
					Department of Justice Total	369,631	
Department of Labor		Islands of Labor: Reservation Labor Markets and American Indian Well-Being	20	17.RD	NU-2017-001//DOL-OPS-15-C-0060	32,728	
			20	11.110	Department of Labor Total		
Department of State						52,720	
Department of State		U.S. Educational Partnerships	15	19.RD	Agmt 9/26/2017//S-IS400-16-GR-0042	96,146	
					Department of State Total	96,146	
Department of the Interior							
	United States Geological Survey			45 005		7.000	
		Impacts of stormwater-induced road salt runoff on soil and water quality in urban greenspaces	238	15.805	079901-16311-01 // G16AP00051	7,286	
					Department of the Interior Total	7,286	
Department of Transportation	Federal Highway Administration						
	·	2017 Dwight David Eisenhower Transportation Fellowship Program (DDETFP)		20.215	693JJ31845043	4,848	
		The Dwight David Eisenhower Transportation Fellowship Program (DDETFP)		20.215	693JJ31845009	26,345	
						31,193	
		Active Transportation and Demand Management (ATDM) Analytical Methods for Urban Streets Analysis, Modeling, and Simulation (AMS) Testbed Development and Evaluation to Support	127	20.RD	P010177604/DTFH61-12-D-00050	132	
		Dynamic Mobility Applications (DMA) and Active Transportation and Demand Management					
		(ATDM) Programs	26	20.RD	105952SB1M	(1,616)	
		Developing Analysis, Modeling, and Simulation (AMS) Tools for Connected and Automated Vehicle (CAV) Applications	127	20.RD	P010198023 NO.R5 // DTFH6116D00030	52,479	
						., -	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award numb	per	Federal expenditures	Passed-through to subrecipients
Department of Transportation		Development of an Analysis/Modeling/Simulation (AMS) Framework for V2I and CV						
(continued)		Environment	127	20.RD	P010198023 R2 // DTFH6116D00030	\$		_
		Estimation of Travel Time Distributions Along User-Defined Travel Paths	127	20.RD	P010198023 NO. R4 // DTFH6116D00030		110,258	-
		Fundamentals of Travel Time Reliability Guide	127	20.RD	P010198023 R1 // DTFH6116D00030		21,921	_
		Integrated Modeling for Road Condition Prediction (IMRCP) Phase 3	127	20.RD	TO#2 P0#10203492 //D5FH6116D00053		35,457	-
		Role of Calibration in Quantitative Alternatives Analysis	127	20.RD	P010203492 R1 // DTFH6116D00053		69,269	-
		Task Integrated Modeling for Road Condition Prediction – Phase 2	127 127	20.RD	P010178562 Mod 1//DTFH61-12-D-00045		667	-
		Tools for Tactical Decision-Making/Advancing Methods for Predicting Performance	127	20.RD 20.RD	13-014//P010160797 R1//DTFH61-12-D-00020 P010198023 NO. R3 // DTFH6116D00030		1,616 49,990	-
		Tools for Tactical Decision-Making/Advancing Methods for Predicting Performance	127	20.RD			49,990	
Department of Veterans					Dep	partment of Transportation Total	478,884	
Affairs	Edward Hines, Jr. VA Hospital							
		Elisa Gordon VA IPA – Spark Seed Funding		64.018	Agmt 04/25/18		9,980	-
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Elisa J. Gordon		64.018	578/151		13,282	—
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Elisa Jill Gordon: VA Innovators Network Accelerator Program		64.018	IPA Agmt Signed 07/14/17 (578/151)		2,593	_
Department of Veterans		Intergovernmental Personnel Act (IPA) Assignment Agreement for Jennifer Kahn		64.018	IPA Aamt Signed 05/31/2017 (578/151)		5.805	_
Affairs (continued)		Intergovernmental Personnel Act (IPA) Assignment Agreement for Jennier Kann Intergovernmental Personnel Act (IPA) for Geoffrey Brown		64.018	IPA Agmt Signed 05/31/2017 (578/151) IPA Agmt – 578/151		74,814	-
Analis (continued)		IPA Agreement for Kwang-Youn A. Kim: Maneuverability Enhancement Following Spinal		04.018	IFA Agritt = 576/151		/4,014	—
		Cord Injury		64.018	578/151		8,707	_
							115.181	
	Jesse Brown VA Medical Center						113,101	
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Damiano Fantini		64.018	IPA Agmt Signed 08/28/2017		33,913	_
		Intergovernmental Personnel Act (IPA) Assignment Agreement for David Z. Ivancic		64.018	IPA Agmt. Signed 11/09/17		69,588	-
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Elena Livia Sima, FY17		64.018	IPA Agmt. Signed 04/12/2017		61,478	-
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Elspeth Beauchamp		64.018	IPA Agmt. Signed 09/27/2016		74,880	—
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Ewa Kosciuczuk		64.018	Agmt. signed 10/13/2017 (537/151)		30,582	_
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Hao Wang		64.018	IPA Agmt Signed 10/06/2016		(22,114)	-
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Hao Wang		64.018	IPA Agmt. Signed 05/09/18 (537/151)		16,465	-
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Iman Sarami		64.018	IPA Agmt Signed 11/09/17		2,194	-
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Linda India		64.018	IPA Agmt. Signed 11/09/17		8,300	-
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Meng Shang		64.018	IPA Agmt Signed 11/09/2017		40,200	-
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Michael Cavanaugh		64.018	IPA Agmt Signed 01/25/18		24,676 56,586	_
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Michael Dixon		64.018	Agmt Signed 11/07/2017			_
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Monica Chi Intergovernmental Personnel Act (IPA) Assignment Agreement for Salvatore Condello (FY17)		64.018 64.018	IPA Agmt Signed 11/13/2017 IPA Agmt. Signed 09/19/2017 (YR 02)		35,252 87,506	
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Salvatore Condelio (PTTT)		64.018	IPA Agmit. Signed 09/19/2017 (TR 02) IPA Agmit. Signed 11/27/2017		54.411	_
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Saul Soberanes Intergovernmental Personnel Act (IPA) Assignment Agreement for Seok-Jo Kim Intergovernmental Personnel Act (IPA) Assignment Agreement for Shantel Olivares: Molecular		64.018	IPA Agnt: Signed 04/12/2017 IPA Agnt Signed 04/12/2017		50,320	_
		Mechanisms of Nonalcoholic Fatty Liver Disease		64.018	IPA Agmt Signed 11/09/2017		51,929	_
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Vera Shively		64.018	IPA Agmt. Signed 07/06/2016		6,031	_
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Weigi Huang		64.018	IPA Agmt. signed 12/06/17 (537/151)		22,924	_
		Intergovernmental Personnel Act (IPA) Assignment Agreement for Yanni Yu		64.018	Agmt Signed 07/26/18		28,619	_
		IPA for Paul Cheresh		64.018	IPA Agmt Signed 11/13/2017		70,792	-
		VA IPA for Kazumi Ebine		64.018	537/151		69,288	
							873,820	
	VA Salt Lake City Health Care System							
	oyuun	Quality Enhancement Research Inititative (VA SLC Health Care System IPA Agreement for						
		William Thompson)		64.018	IPA Agmt signed 02/10/17		11,682	
					Depa	artment of Veterans Affairs Total	1,000,683	_
Environmental Protection								
Agency								
		The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air): Next Stage	273	66.509	UWSC10113//838300001-0		30,081	_
		Building Energy Efficiency in the U.S. Industrial Sector	101	66.RD	13MGBO0001-101//EP-BPA-12-H-0012		43	
					Environ	nmental Protection Agency Total	30,124	_
lational Aeronautics and Space								
Administration								
		A Novel Approach to the Common Envelope Evolution	187	43.001	TM6-17005X//NAS8-03060		27,034	-
		A simulation pipeline for the study of kilonovae light curves and r-process nucleosynthesis in	050	40.004	400040//000000040//0505		04.00 ·	
		compact binary mergers	256	43.001	180042//80NSSC18K0565		24,681	-
		Biologic and Resource Analog Investigations in Low Light Environments (BRAILLE) Bringing Gravitational Wave Astronomy to Light: Chandra X-ray Localization of LIGO-Virgo	25	43.001	BMSSA-006 // 80NSSC17M0054		21,998	-
		GW Sources	187	43.001	GO7-18033X//NAS8-03060		29.020	_
		Continued Chandra Observations of GW170817 (Proposal 19408644-C)	187	43.001	DD8-19101A//NAS8-03060		6.075	_
		Continued X-Ray Monitoring of GW170817 with Chandra	187	43.001	DD7-18096A // NAS8-03060		5,044	_
		Energetics and Environment of Hydrogen-poor Core-Collapse SNe	187	43.001	heGO5-16064A//NAS8-03060		(105)	_
		Late-time X-rays to map the Zoo of Engine-driven Stellar Explosions	187	43.001	GO7-18057X // NAS8-03060		15,446	_

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throu to subrecipien
ational Aeronautics and Space		Late-time X-rays to map the Zoo of Engine-driven Stellar Explosions	187	43.001	GO8-19044X // NAS8-03060	\$ 10.806	
Administration (continued)		Life Underground	262	43.001	65904754 Amd. 4 // NNA13AA92A	68,289	
		Mapping the Zoo of engine driven explosions with late-time X-rays	187	43.001	GO5-16059A//NAS8-03060	(9,037)	
		Probing Plasma Properties in Supernova Remnants observed by XMM-Newton	162	43.001	5841-NU-NASA-F03G//NNX15AF03G	11,254	
		Probing the Energetics and Environments of Hydrogen-poor Core-Collapse SNe	187	43.001	GO6-17053A//NAS8-03060	38,692	
		Source of energy and pre-explosion progenitor evolution of Super-Luminous SNe Source of Energy and pre-explosion progenitor evolution of Super-luminous Supernovae	187 187	43.001 43.001	GO6-17052A//NAS8-03060 GO7-18046A//NAS8-03060	11,332 9.735	
		Source of Energy and pre-explosion progenitor evolution of Super-luminous Supernovae Source of Energy and pre-explosion progenitor evolution of Super-luminous Supernovae	187	43.001	G07-10046A/INAS6-05060 G08-19047A/INAS8-03060	9,735	
		The Balloon-Borne Large Aperture Telescope for Polarization – BLASTPol	259	43.001	573659 // 80NSSC18K0481	85,333	
		The Late-time X-ray Behavior of Short Gamma-ray Bursts: Implications for Energetics and					
		Rates The Triggering Mechanisms and Accretion Modes of AGN: New Cosmological Simulations to	187	43.001	G08-19025X //NAS8-03060	1,931	
		Interpret Chandra Surveys The unprecedented metamorphosis of SN2014C: from a H-stripped explosion to a strongly	187	43.001	TM7-18007X//NAS8-03060	21,799	
		interacting supernova	187	43.001	GO6-17054A//NAS8-03060	23,190	
						410,541	
		Multiple Undergraduate Research Projects	238	43.008	2015-05200-09(078131-15789)-AB425-03//NNX154AAI05H	105,743	
		Combining Statistical Samples of Resolved-ISM Simulated Galaxies with Realistic Mock	190	43.RD		35.193	
		Observations to Fully Interpret HST and JWST Surveys	190	43.RD 43.RD	HST-AR-14562.001-A//NAS5-26555		
		Fast Light Enhanced Active Gyroscopes, Accelerometers and Fiber-Optic Sensors G.O. Program to Characterize Magnetic Fields in Nearby Interstellar Clouds	64 33	43.RD 43.RD	Agmt 5/30/16 // NNX16CM03C RSA No. 1594471 // NNN12AA01C	100,190 28,000	
		HI and Low Metal lons at the Intersection of Galaxies and the CGM	190	43.RD 43.RD	HST-AR-15045.004-A // NAS5-26555	26,000	
		Identifying Globular Clusters Hosting Large Numbers of Black Holes	190	43.RD	HST-AR-14555.001-A//NAS5-26555	44,198	
		Investigating the Gas within the Planck Galactic Cold Clumps	190	43 RD	HST-AR-14292.001-A	16,094	
		Joint HAWC+/ALMA study of magnetic fields in Ophiuchus	213	43 RD	SOFIA 05-0133 01 // NAS2-97001	53.669	2
		Magnetic Field Structure in Perseus at 0.01 pc Scale	213	43.RD	SOF 05-0081 Santos // NAS2-97001	113,136	
		Metallicity and Azimuthal Angle Diagnostics of Inflows and Outflows: Interpreting HST					
		Measurements of Circum-Galactic Gas Flows	190	43.RD	HST-AR-14293.001-A//NAS5-26555	18,704	
		Modeling the Origins of Sub-subgiant Stars	190	43.RD	HST-AR-13910.001-A//NAS5-26555	13,785	
		Preparation and Characterization of Sn- and Sb-based Zintl Phases as Promising					
		Thermoelectric Materials	33	43.RD	1536068-002//NNN12AA01C	252,824	
		Project AMIGA: Mapping the Circumgalactic Medium of Andromeda	190	43.RD	HST-GO-14268.022-A	16,196	
		Sofia Wide-Field Far-IR Polarimetry and Fine-Structure-Line Imaging with the HAWC+ Upgrade Toward the Next Breakthrough: Detecting the Electromagnetic Counterparts to Gravitational	33	43.RD	Subk No. 1478794 Mod 14 // NNN12AA01C	84,690	
		Waves	190	43.RD	HST-HF2-51390.001-A // NAS5-26555	107,302	
		Tracing Galactic Outflows to the Source: Spatially ResolvedFeedback in M83 with COS	190	43.RD	HST-GO-14681.011-A//NAS5-26555	466	
		Underlying Hosts or Highly-Kicked? Determining the Nature of Host-less Short Gamma-ray Bursts with HST	190	43.RD	HST-GO-14685.007-A // NAS5-26555	32,170	
N	IASA Ames Research Center	Duista with hor	150	45.110	101-00-1400.001-47 1400-2000	52,110	
N.	AGA Alles Research Genter	Effects of Spaceflight on Gastrointestinal Microbiota in Mice: Mechanisms and Impact on					
		Multi-System Physiology		43.007	NNX15AL05G 000010	547,814	121
		HAWC+ Observations of two Galactic center Molecular clouds: G0.13-0.13 and G359.44-0.10	213	43.RD	SOFIA 05-0037 // NAS2-97001	7,000	
	IASA George C. Marshall Space						
	Flight Center	The Columnar to Equiaxed Transitionand Dendrite Fragmentation		43.003	NNX17AD48G 000002	90.963	
		Microstructure Evolution in Freeze-Cast Materials		43.003	80NSSC18K0196-P00001	16.862	
		MICIOSI UCIUTE EVOLUIOTI III FIEEZe-Casi Materiais		43.007	801335 1000 130-F 0000 1	10,802	
	IASA Goddard Space Flight Center						
		Continued NuSTAR monitoring of the unprecedented metamorphosis of SN2014C		43.001	NNX17AI13G	43,993	
		Correcting and Coating Thin Walled X-ray Optics via a Combination of Controlled Film		42.004	NNX4745400 000004	114.781	
		Deposition and Magnetic Smart Materials Deciphering Kepler's Planetary Systems		43.001 43.001	NNX17AE10G-000001 NNX14AD21G 000005	114,781 96,252	
		Detailed mapping of extreme mass loss with coordinated NuSTAR-XMM observations		43.001	NNX14AD21G 000005 NNX17AC09G	20,000	
		Detailed mapping of extreme mass loss with coordinated NdSTAR-XMM observations Detailed mapping of extreme mass loss with coordinated NuSTAR-XMM observations		43.001	NNX17AC000002	36,522	
		Detailed Mapping of Extreme Mass-Loss From Evolved Massive Stars With Swift		43.001	80NSSC18K0575	35,436	
		Dynamical Modeling of Dense Star Clusters with a Parallel Monte Carlo Code		43.001	NNX14AP92G/000005	129.754	
		Energy and Environment of Hydrogen-poor Core-Collapse SNe		43.001	NNX16AT58G	31,489	
		Energy and Geometry of Jet-driven Explosions in the Local Universe		43.001	80NSSC17K0052	32,834	
		Energy source and pre-explosion progenitor evolution of SuperLuminous Supernovae		43.001	NNX17AD89G	23,756	
		Explosion mechanisms and energy sources powering super-luminous supernovae		43.001	NNX16AT51G	8,869	
		Explosion mechanisms and energy sources powering super-luminous supernovae		43.001	NNX16AT81G	5,434	
		Late-time X-ray Behavior of Short Gamma-Ray Bursts: Implications for Energetics and Rates		43.001	80NSSC18K0189	4,550	
		Lipid Biomarkers of the Deep Subsurface Biosphere		43.001	NNX15AM08G 000002	63,253	
		Low Frequency Gravitational Wave Astrophysics		43.001	NNX13AM10G/000003	6,985	
		Probing the Mass-Loss History of Massive Stars with Swift		43.001	NNX17AD82G	33,075	
		Supernova Remnant Observations and Dark Matter Searches with Micro-X		43.001	80NSSC18K1445	129,211	29
		Supernova Remnant Observations with Micro-X	259	43.001 43.001	NNX16AL94G-000001 560958 Amd 6 // NNX13E50G	505,443 22.047	2
		The Balloon-borne Large Aperture Submillimeter Telescope – BLAST	209				
		The Physical Nature of Circum-Galactic Gas The Strontium Isotope Composition of Neoproterozoic Carbonates: Implications for the Carbon		43.001	NNX15AB22G-000002	110,291	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
National Aeronautics and Space		The unprecedented metamorphosis of SN2014C: from a H-stripped explosion to a		40.004	100//21.0020		
Administration (continued)		strongly interacting SN		43.001	NNX17AG80G	\$ <u>31,063</u> 1,612,684	29,085
		Convective Effects on Solid/Liquid Interface Dynamics in the Freeze-Casting Process		43.008	NNX16AI78A	73,336	45.606
		Further Development of Aperture: A Precise Extremely large Reflective Telescope Using Re-configurable Elements		43.009	NX16AL31G-000001	242,513	133,458
		Compact Robust Integrated PPM Laser Transceiver Chip Set with High Sensitivity, Efficiency, and Re-Configurability		43.012	NNX16AE02G 000003	240,069	42,968
		Efficient and Scalable Fabrication of Solid Oxide Fuel Cells via 3D-Printing		43.012	80NSSC17K0192-P00001	60,002 300,071	42,968
	NASA Lyndon B. Johnson Space						
	Center	A US-Russian Collaborative Proposal for Data Collection in HERA: The Relationship between Composition, Interpersonal Relations, and Team Effectiveness in Space Crews	62	43.002	501237SG138 Amd 2 // NNX16AQ48G	76.469	_
		CREWS: Crew Recommender for Effective Work in Space		43.003	NNX15AM32G 000008	307.322	134.997
		HERO Twin Astronaut Study Consortium (TASC) Project: Metagenomic Sequencing of the Bacteriome in GI Tract of Twin Astronauts		43.003	NNX14AH26G-000005	36,498	-
		SCALE: Shared Cognitive Architectures for Long-term Exploration Team Task Switching in Astronaut Crews on the International Space Station: Integrating Multiteam Membership, Multiteam Systems, multi-tasking, & Multiteimensional Networks to Monitor &		43.003	80NSSC18K0221	334,232	_
		Enable Functional Work Shifts in Astronaut Crews		43.003	80NSSC18K0276	320,839	
						998,891	134,997
		NRI: Collaborative Research:Integrating Physics Models and Control Methodologies for Enhanced Legged Locomotion on Yielding Terrain		43.007	NNX15AR24G 000007	144,072	
					National Aeronautics and Space Administration Total	5,555,113	529,678
National Foundation of the Arts and Humanities							
the Arts and Fidmanities	Institute of Museum and Library						
	Services	Engaging Engineering Experts: Facilitating Family STEM Learning in Museums and Libraries					
		Through Narrative Storytelling and Object-Based Inquiry Activities Getting to know their data doubles: An inquiry into student perceptions of privacy issues	129	45.312	517350-NWU//MG-77-16-0118-16	24,821	-
		associated with academic library participation in learning analytics	107	45.312	IN-4370124-NU // LG-96-18-0044-18	3,329	
						28,150	
	National Endowment for the Humanities						
		Metal Soap Protrusions on Georgia O'Keeffe's Paintings: Establishing a New Quantitative Imaging Paradigm for Linking Scientific Research and Preservation		45.149	PR-258900-18	55,769	
		Tools for Listening to Texts-in-Performance		45.149	HAA-258709-18	14,948	
					National Foundation of the Arts and Humanities Total	98,867	
lational Science Foundation		3D Braided Composite Structures - Experimental Characterization and Modeling of					
		Fracturing Behavior		47.041	CMMI-1435950	17,519	_
		3D Near Field e-Writing with Submicron Resolution Advancing Dynamic Relief Response: Integration of New Data Streams and Routing Models		47.041 47.041	CMMI-1404489 CMMI-1265786	43,431 2,180	_
		An Optimal Design of Experiments Approach for Reliable Risk Assessment with Error-prone					_
		Electronic Medical Records CAREER: Engineering Non-Growth Metabolism for High-Yield Biochemical Production		47.041 47.041	CMMI-1436574 CBET-1452549-003	95,497 130,008	_
		CAREER: Functional Imaging to Prevent Blindness		47.041	CBET-1055379	130,000	=
		CAREER: Mechanics of Geomaterials Exposed to Multi-Physical Perturbations: Innovating Science, Training and Education through Fundamental Principles		47.041	CMMI-1351534-005	125,643	_
		CAREER: Prediction of multiscale emergent dynamics in decentralized cell populations		47.041	CBET-1653315	75,449	_
		CAREER: Rational design of a biomimetic nanomaterial library to probe mechanisms behind virus-induced immunopathology		47 041	CBET-1453576	130.442	_
		CAREER: Tuning passive prosthetic leg dynamics to create low-cost, robust devices that can	400			,	0.000
		replicate physiological gait in multiple activities of daily living CBET-EPSRC A Game-Changing Approach for Tunable Membrane Development: Novel	132	47.041	5710004259//CBET-1653758	30,690	9,028
		Covalent Organic Framework Active Layers Supported by Solvent Resistant Materials CDI-Type I: Discovery of Novel Biochemical Pathways	238	47.041 47.041	087147-16468 // CBET-1706219 CBET-0835800	80,317 (338)	_
		Collaborative Research: Analysis and Solution Methods for Function Robust Optimization Models		47.041	CMMI-1361942	53,992	_
		Collaborative Research: Concurrent Design of Quasi-Random Nanostructured Material Systems (NMS) and Nanofabrication Processes using Spectral Density Function Collaborative Research: EAGER: Explore the Theoretical Framework of Engineering		47.041	CMMI-1662435	6,905	_
		Knowledge Transfer in Cybermanufacturing Systems		47.041	CMMI-1833195	29,857	-
		Collaborative Research: Electrorotational fluid instabilities		47.041	CBET-1704996	82,360	_

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throug to subrecipients
ational Science Foundation		Collaborative Research: Elucidation and Evaluation of Strategies to Mitigate Secondary					
(continued)		Reactions in Cellulose Pyrolysis for Enhanced Production of Hydrolysable Anhydrosugars		47.041	CBET-1435228	\$ 27,351	_
		Collaborative Research: Engineering Polymer Nanodielectric Systems using a					
		Descriptor-based Design Methodology		47.041	CMMI-1334929	(1,400)	-
		Collaborative Research: Ergodic Trajectories in Discrete Mechanics		47.041	CMMI-1334609	(201)	-
		Collaborative Research: Formation and Stability of Eutectic Nanostructures in Laser-Irradiated Particle Suspensions		47.041	CMMI-1663196	6.755	
		Collaborative Research: GOALI: Modeling and optimizing patient-flow dynamics in hospitals		47.041	CWIMI-1003190	0,755	-
		and hospital networks		47.041	CMMI-1763100	853	_
		Collaborative Research: Integrated Measurement and Predictive Modeling of Adsorbate					
		Coverage and Compositional Effects on Catalytic Activity		47.041	CBET-1264963	(3)	-
		Collaborative Research: Model-Based Multidisciplinary Dynamic Decisions in Design		47.041	CMMI-1537641	93,412	-
		Collaborative Research: Quantitative Analysis of Liposome Deformation at Nanoscale Using Resistive Pulse Sensing in Solid State Nanopores		47.041	CMMI-1740011	77,923	
		Collaborative Research: Workshop on Acquiring and Sharing Data within the CMMI Research		47.041	CMIMI-1740011	11,823	-
		Community		47.041	CMMI-1654469	10.419	-
		Computational Discovery and Analysis of Catalytic Routes to Bio-based Renewable Chemicals	119	47.041	Agmt 3/10/2017 // 400-72-04-33-15F1 Amd 2	36,057	-
		Control of Hybrid Locomotion with Impacts		47.041	CMMI-1436297	100,403	-
		CPS: Synergy: An Integrated Simulation and Process Control Platform for Distributed					
		Manufacturing Process Chains		47.041	CMMI-1646592-002	57,669	
		Curved Waterjet-Guided Laser Micro-Manufacturing		47.041	CMMI-1234491	(298)	
		Cutting and Shuffling: A New Dynamical Systems Paradigm for Mixing		47.041	CMMI-1435065	69,154	
		Data-driven multiscale damage and failure prediction Design and exploration of high-temperature steels for electric power generation applications		47.041 47.041	CMMI-1762035 CMMI-1462850	988 76,329	
		Diffraction-grating coupled surface emitting Terahertz quantum cascade laser source for high		47.041	CMMI-1402050	76,329	
		power, room temperature continuous wave operation		47 041	ECCS-1607838	117,082	
		EAGER: MOCVD Growth of beta-(Al, In, Ga)2O3 for Transistor Applications		47.041	ECCS-1748339	90,013	
		EAGER: Optical Coherence Elastography (OCE): A novel tool for rapid, non-destructive,				,	
		spatially resolved quantification of mesoscale biofilm mechanical properties		47.041	CBET-1701105	43,765	
		EFRI 2-DARE: Scalable Growth and Fabrication of Anti-Ambipolar Heterojunction Devices		47.041	EFRI-1433510	393,653	136,7
		EFRI CEE: Macrogenomic engineering via modulation of chromatin nanoenvironment		47.041	EFMA-1830961	711	
		EFRI-BioFlex: Miniature, Low-cost Fiber-optics Technology for Measurement of Tissue					
		Structure at Sub-diffractional Length Scales: A Platform for Cancer Screening		47.041	EFRI/EFMA-1240416-004	265,709	
		Electric Field Guided Micro Additive Manufacturing Process Electromechanical Properties and Deformation of Biomembranes		47.041 47.041	CMMI-1463411 CMMI-1748049	54,844 87,652	
		Engineering a recombinant methane monooxygenase to convert methane to methanol for the		47.041	CMIMI-1740049	87,032	
		production of fuels and chemicals	164	47.041	PNU-001//1534743	73,557	
		Engineering a secretion-based, high-titer protein production process in bacteria	101	47.041	CBET-1706125	79.428	
		Engineering Research Center for Innovative and Strategic Transformation of Alkane				., .	
		Resources – CISTAR	165	47.041	4101-83478 // 1647722-EEC	218,316	
		Exploiting Network Structure in Routing Problems: Applications to School Bus Routing		47.041	CMMI-1727744	168,800	
		Exploring local confinement of ultrafast light to enable nondestructive acoustic metrology					
		at the nanoscale		47.041	ECCS-1611356	112,631	
		Feedback-based radiofrequency ablation system for user-defined three-dimensional ablation geometries	109	47.041	Agmt 8/9/2016//IIP-1622842	(86)	
		Fractal Mechanics of Stretchable Piezoelectrics for Mechanical Energy Harvesting	109	47.041	CMMI-1400169	106,787	
		Friction in Full View		47.041	CMMI-1400103	64 158	
		Functionalities Emerging in Adaptive Brain Networks through Selective Synchronization of		-11.011		01,100	
		Neurons by Targeted Feedback		47.041	CMMI-1435358	51,316	
		GOALI/Collaborative Research: Reliable Prediction of Endurance Life of Ultra-High-Strength					
		Aerospace Rolling-Element Bearings		47.041	CMMI-1434834	54,408	
		GOALI: Computer Simulation Analytics		47.041	CMMI-1537060	87,476	
		GOALI: Models and Methods for Marathon Course Design using Multi-Objective Approaches		47.041	CMMI-1405231	23,493	
		GOALI: Strength Loss in Clays During Earthquake and Other Cyclic Loading		47.041	CMMI-1434876	94,875	
		Green Simulation: A Methodology for Reusing the Output of Past Computer Simulation Experiments		47.041	CMMI-1634982	36.211	
		Experiments Hot Extrusion of High-Strength Aluminum Alloys with Rotary Porthole Dies		47.041	CMMI-1634982 CMMI-1743691	36,211 49,918	
		I-Corps: Clinical Workforce Schedule Optimization Technology		47.041	IIP-1764312	37 815	
		IDR: Engineering Electroactive-Polymer-Based Phononic Crystals as a Sustainable Energy		47.041	11-1704312	57,015	
		Source		47.041	CMMI-1130948	(610)	
		Investigating the impact of tumor heterogeneity on sustained low dosage immunotherapy					
		via a peritumoral immunotheranostic hydrogel		47.041	CBET-1806007	10,969	
		iSee: A Smart Device based Depression Behavior Monitoring and Analytics Service for					
		College Students	141	47.041	RC106479NU//1632051	5,455	
		Magnetic microrollers as a platform for active transport	145	47.041	F0276-01 // CBET-1706562	9,662	
		Magnetically Controlled- Laser Induced Plasma Micro-Machining (MC-LIPMM)		47.041	CMMI-1563244	25,553	
		Managing Downstream Patient Flow Processes Using Improved Coordination and Staffing Market Expectations, Long Term Risk, and Stochastic Spectral Theory		47.041 47.041	CMMI-1335585 CMMI-1536503	19,939	
		Market Expectations, Long Term Risk, and Stochastic Spectral Theory Molecular Organization and Transport in Synthetic and Biological Nanopores		47.041	CMMI-1536503 CBET-1403058	59,267 74 412	
		Monolithic Nanofabrication: A Bottom-up Approach for Manufacturing Nanotextured Surfaces		47.041	CMMI-1462633 001	26,395	
				···· ··· ···		20,393	
		Multidimensional Network Analysis for Analyzing and Predicting Complex Customer-Product					
		Multidimensional Network Analysis for Analyzing and Predicting Complex Customer-Product Relations in Engineering Design		47.041	CMMI-1436658	97,829	
		Multidimensional Network Analysis for Analyzing and Predicting Complex Customer-Product Relations in Engineering Design Neuroprotective Engineering Based on Innate Responses to Stroke		47.041 47.041	CMMI-1436658 CBET-1403036	97,829 93,277	

68

Supplementary Schedule of Expenditures of Federal Awards

luster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throu to subrecipien
ational Science Foundation		Northwestern University Planning Grant: I/UCRC for Industry/University metal deFOrmation					
(continued)		Center for US (iuFOCUS) NRI: Task-Based Assistance for Software-Enabled Biomedical Devices		47.041 47.041	IIP-1624823 CBET-1637764	\$ (475) 62,351	
		On-demand Generation of Diamond-like-carbon Layers for Efficient Lubrication of		47.041	GBE1-103/704	02,351	
		Mechanical Systems		47.041	CMMI-1662606	46,961	
		PFI: AIR-TT SAFE (Situational Awareness for Events): A Data Visualization System		47.041	IIP-1640736	69,649	
		PFI:AIR – TT: BaTiO3 Photonic Crystal Electro-optic Devices for 50 GHz Applications		47.041	IIP-1500222 001	12,709	
		PFI:BIC – Smart CROwdsourced Urban Delivery (CROUD) System PFI:BIC: A Smart, "Always-on" Health Monitoring System		47.041 47.041	IIP-1534138 IIP-1534120-002	311,338 430,391	111,1 314,4
		PFI.BIC. A Smart, Always-on Health Monitoring System PFI-AIR: Technology Translation – Highly Sensitive Eye-safe Flash LiDARs based on		47.041	IIP-1534120-002	430,391	314,4
		Nanoinjection Detectors		47.041	IIP-1500314 001	(48)	
		Process Modeling and Enhancements of Laser-Induced Plasma Micro-Machining (LIP-MM)		47.041	CMMI-1335014	63,670	
		Processing of Advanced Foam Scaffolds for Iron-Air Battery Applications		47.041	CMMI-1562941	104,404	
		RAPID: Addressing Geographic Disparities in the National Organ Transplant Network RAPID: Adaptive management of geotechnical construction in urban areas		47.041 47.041	CMMI-1743886 CMMI-1603060	59,606 10,730	
		RAPID: Adaptive management or geotechnical construction in urban areas Robust Multi-Criteria Optimization With Application to Radiation Therapy		47.041 47.041	CMMI-1603060 CMMI-1463489	10,730	
		SampleStream: A Sample Preparation Platform for Biologics	114	47.041	Agmt 8/15/2017 // IIP-1721594	59,043	
		Service Systems with Outbound Work and Blending		47.041	CMMI-1436518	39,486	
		SNM: Collaborative Research: 3D Nanomaunfacturing by Imprint and Strain Engineering					
		via a peritumoral immunotheranostic hydrogel	122	47.041	2003142248 Amd 2 // 1635443	238,942	
		SNM: Customized Inkjet Printing of Graphene-Based Real-time Water Sensors	275	47.041	1727846//183405339/AAC5754	105,265	
		SNM: Robust Scalable Nanomanufacturing of Photonic Structures Soil Slip Versus Flow Failure in Rain-infiltrated Slopes: Using Principles of Geomechanical		47.041	EEC-1530734	383,236	10
		Stability to Enhance Spatially Distributed Models for Shallow Landslides		47.041	CMMI-1324834	(44)	
		Spectroscopic photon localization microscopy for super-resolution molecular imaging		47.041	CBET-1706642 001	190,896	
		Stability and Optimality Properties of Sequential Action Control for Nonlinear and Hybrid					
		Systems		47.041	CMMI-1662233	34,618	
		Strong and Multifunctional Geopolymer Composites: A Multi-Scale Study		47.041	CMMI-1829101	34,237	
		SusChEM: Integrated Materials and Process Systems Development for Sustainable Carbon Capture		47.041	CBET-1604890	130.537	
		SusChEM: Using theory-driven design to tailor novel nanocomposite oxides for solar		47.041	CBE1-1004890	130,337	
		fuel production		47.041	CBET-1438721	176,242	
		Terahertz source frequency comb based on difference frequency generation from a					
		mid-IR quantum cascade laser		47.041	ECCS-1505409	132,147	
		Two-compartment microfluidic bioreactor with functionalized PEG hydrogels to promote			0057 4005000	(222)	
		platelet production in culture Unlocking Efficiencies in Earthmoving for Future Infrastructure: Modeling Plowing and Cutting		47.041	CBET-1265029	(880)	
		Processes in Soils		47.041	CMMI-1742849	93.870	
		UNS: Controlling mixing and segregation of granular media using unsteady flows		47.041	CBET-1511450	51,974	
						8,071,079	982
		3he in Confinement		47.049	DMR-1602542	134,960	
		A Sheaf-Theoretic Approach to M5-Brane Geometry		47.049	DMS-1708503	75,375	
		Accretion and Star Formation Induced by the Galactic Center Supermassive Black Hole Sgr A*		47.049	AST-1517246 002	125,901	
		Advanced Algorithms for Colloids with Induced Many-Body Interactions			DMR-1610796-001		
				47.049		132,376	
		Algorithms for Nonlinear Nonconvex Optimization under Uncertainty		47.049	DMS-1522747	49,005	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA		47.049 47.049	DMS-1522747 CHE-1709888	49,005 98,865	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups		47.049	DMS-1522747	49,005	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA		47.049 47.049	DMS-1522747 CHE-1709888	49,005 98,865	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds		47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-1799888 DMS-1352173-004 DMR-1207539/ Amd 003 DMS 1502632 003	49,005 98,865 64,736 (29) 437,294	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakeloy geometry, Shimura varieties, and L-functions of motives		47.049 47.049 47.049 47.049	DMS-1522747 CHE-1709888 DMS-1352173-004 DMR-1207539/ Amd 003	49,005 98,865 64,736 (29)	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in NI-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry. Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in		47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-1709888 DMS-1522173-004 DMR-1207539/ Amd 003 DMS 1502632 003 DMS-1702019	49,005 98,865 64,736 (29) 437,294 48,930	
		Allosterically Regulated Supramolecular Capsules and Receptors Åssembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples		47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-1799888 DMS-1352173-004 DMR-1207539/ Amd 003 DMS 1502632 003	49,005 98,865 64,736 (29) 437,294	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe		47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-1709888 DMS-1322173-004 DMR-1207539/ Amd 003 DMS-1702019 DMS-1702019 DMS-1043080	49,005 98,865 64,736 (29) 437,294 48,930 68	
		Allosterically Regulated Supramolecular Capsules and Receptors Åssembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples		47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-1709888 DMS-1522173-004 DMR-1207539/ Amd 003 DMS 1502632 003 DMS-1702019	49,005 98,865 64,736 (29) 437,294 48,930	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercur; Speciation and Processes at the Cell Surface		47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-170888 DMS-1352173-004 DMS-1352173-004 DMS-1502632 003 DMS-1702019 DMS-1043080 DMR-1610367 002 DMR-1610367 002 DMR-160399-002 CHE-1306504	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331)	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Ni-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomics Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Dense Star Clusters		47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-1709888 DMS-1352173-004 DMS-1502539 / Amd 003 DMS-1602632 003 DMS-1702019 DMS-1043080 DMS-1043080 DMS-1610367 002 DMR-1508399-002 CHE-1308504 AST-1716762	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,644	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Ai-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptaker Mercury: Speciation and Processes at the Cell Surface Black Holes in Dense Star Clusters CAREEF: Complexity Objected Systems		47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-170888 DMS-1352173-004 DMS-1352173-004 DMS-1502632 003 DMS-1702019 DMS-1043080 DMR-1610367 002 DMR-1610367 002 DMR-160399-002 CHE-1306504	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331)	
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Ni-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry. Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Dense Star Clusters CAREER: Complexity of Disordered Systems CAREER: Ligand Engineering of Sinucture and Electronic Function in Complex Metal		47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-170888 DMS-1352173-004 DMR-1207539/ Amd 003 DMS-1502632 003 DMS-1702019 DMS-1043080 DMR-1610387 002 DMR-1508399-002 CHE-1308504 AST-1716762 DMS-1653552	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,644 104,291	1
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Saparation in NI-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry. Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bicengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Dense Star Clusters CAREER: Ligand Engineering of Structure and Electronic Function in Complex Metal Oxyfluorides		47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-170888 DMS-1352173-004 DMR-1207539/ Amd 003 DMS-1702019 DMS-1702019 DMS-1043080 DMR-1610367 002 DMR-1610367 002 DMR-1610369-002 CHE-1308504 AST-1716762 DMS-165552	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,644 104,291 156,062	14
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Ni-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry. Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Dense Star Clusters CAREER: Complexity of Disordered Systems CAREER: Ligand Engineering of Sinucture and Electronic Function in Complex Metal		47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-170888 DMS-1352173-004 DMR-1207539/ Amd 003 DMS-1502832 003 DMS-1702019 DMS-1043080 DMR-1610367 002 DMR-1610367 002 DMR-1610369-002 CHE-1306504 AST-11716762 DMR-1454688 004 AST-1352369	49,005 98,865 64,736 (29) 437,294 48,530 68 166,043 90,701 (3,331) 46,644 104,291 156,062 61,887	14
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-IA-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry. Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistics Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Denes Star Clusters CAREER: Complexity of Disordered Systems CAREER: Ligand Engineering of Sinucture and Electronic Function in Complex Metal Oxyfluorides CAREER: Planet Formations in the Age of Kepler CAREER: Planet Formations in the Age of Kepler CAREER: Planet Formations in the Age of Capter Super Adres Supported by Bulky, Redox-Active Benzoquinonold Bridging Ligands		47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-170888 DMS-1352173-004 DMR-1207539/ Amd 003 DMS-1702019 DMS-1702019 DMS-1043080 DMR-1610367 002 DMR-1610367 002 DMR-1610369-002 CHE-1308504 AST-1716762 DMS-165552	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,644 104,291 156,062	14
		All disterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Denes Star Clusters CAREER: Complexity of Disordered Systems CAREER: Complexity of Disordered Systems CAREER: Planet Formations in the Age of Kepler CAREER: Planet Formations in the Age of Kepler CAREER: Synthesis and Studies of One-Dimensional Magnets Supported by Bulky, Redox-Active Benzoquinonid Bridging Ligands CAREER: Synthesis and Disclared recordinc-spin based qubits enabled by new empirically		47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049 47.049	DMS-1522747 CHE-170888 DMS-1352173-004 DMS-1207539/ Amd 003 DMS-1702019 DMS-1702019 DMS-1043080 DMR-1610367 002 CHE-130809-002 CHE-130804 AST-1716762 DMR-1454688 004 AST-1352369 DMR-1351959 004	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,844 104,291 156,062 61,887 96,184	12
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-IA-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry. Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Dense Studies of Clusters CAREER: Complexity of Disordered Systems CAREER: Ligand Engineering of Situcture and Electronic Function in Complex Metal Oxyfluorides CAREER: Planet Formations in the Age of Kepler CAREER: Planet Formations in the Age of Kepler CAREER: Synthesis and Studies of One-Dimensional Magnets Supported by Bulky, Redox-Active Benzoulnonold Bridging Ligands CAREER: Synthesis of molecular electronic-spin based qubits enabled by new empirically derived design principles		47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049	DNS-1522747 CHE-170888 DNS-1352173-004 DMR-1207539/ Amd 003 DNS 1502632 003 DNS-1702019 DNS-1043080 DMR-1610367 002 DMR-1610367 002 DMR-1610367 002 CHE-1306504 AST-1716762 DMS-1633552 DMR-1454688 004 AST-1351559 004 CHE-1455017	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,644 104,291 156,062 61,887 96,184 115,971	12
		All disterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Dense Star Clusters CAREER: Complexity of Disordered Systems CAREER: Ligand Engineering of Structure and Electronic Function in Complex Metal Oxyluurides CAREER: Planet Formations in the Age of Kepler CAREER: Synthesis and Studies of One-Dimensional Magnets Supported by Bulky, Redox.Active Berzoquinonoid Bridging Ligands CAREER: Synthesis and Studies of One-Dimensional Magnets subported by new empirically derived design principles CAREER: The Physics Of Stellar Feedback and Star Formation Regulation in Galaxies		47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049	DMS-1522747 CHE-170888 DMS-1352173-004 DMS-1207539/AmJ 003 DMS-1702019 DMS-1043080 DMS-1611387 002 DMR-1611387 002 CHE-1308504 AST-1716762 DMR-1454688 004 AST-1552269 DMR-1351959 004 CHE-1455017 AST-1652622	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,844 104,291 156,062 61,887 96,184 115,971 54,706	14
		Allosterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry. Shimure varieties, and L-functions of motives ATD: A Nixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenmics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Specialation and Processes at the Cell Surface Black Holes in Dense Staration and Processes at the Cell Surface Black Holes in Dense Staration and Processes at the Cell Surface Black Holes in Dense Staration and Processes at the Cell Surface Black Holes in Dense Staration and Processes at the Cell Surface Black Holes in Dense Staration and Processes at the Cell Surface Black Holes in Dense Staration and Processes at the Cell Surface Black Holes in Dense Staration and Processes at the Cell Surface Black Holes in Dense Starations in the Age of Kepler CAREER: Complexity of Disordered Systems CAREER: Planet Formations in the Age of Kepler CAREER: Planet Formations in the Age of Kepler CAREER: Synthesis and Studies of One-Dimensional Magnets Supported by Bulky, Redox Active Benzourionol Briding Ligands CAREER: Synthesis of molecular electronic-sin based qubits enabled by new empirically derived design principles CAREER: The Physics of Stellar Feedback and Star Formation Regulation in Galaxies CAREER: Theories for Magnetic Properties of Lambanide and Actinice Complexes	274	47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049	DMS-1922747 CHE-170888 DMS-1352173-004 DMR-1207539/ Amd 003 DMS 1502832 003 DMS-1702019 DMS-1043080 DMR-1610367 002 DMR-1610367 002 DMR-1610367 002 DMR-1610367 002 DMR-1610367 002 DMR-1610367 002 DMR-145688 004 AST-1716762 DMR-145688 004 AST-1352369 DMR-1351959 004 CHE-1455017 AST-1652822 CHE-1351598	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,644 104,291 156,062 61,887 96,184 115,971 54,706 134,751	14
		All disterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-Al-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Arakelov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Dense Star Clusters CAREER: Complexity of Disordered Systems CAREER: Ligand Engineering of Structure and Electronic Function in Complex Metal Oxyluurides CAREER: Planet Formations in the Age of Kepler CAREER: Synthesis and Studies of One-Dimensional Magnets Supported by Bulky, Redox.Active Berzoquinonoid Bridging Ligands CAREER: Synthesis and Studies of One-Dimensional Magnets subported by new empirically derived design principles CAREER: The Physics Of Stellar Feedback and Star Formation Regulation in Galaxies	274	47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049	DMS-1522747 CHE-170888 DMS-1352173-004 DMS-1207539/AmJ 003 DMS-1702019 DMS-1043080 DMS-1611387 002 DMR-1611387 002 CHE-1308504 AST-1716762 DMR-1454688 004 AST-1552269 DMR-1351959 004 CHE-1455017 AST-1652622	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,844 104,291 156,062 61,887 96,184 115,971 54,706	14
		All disterically Regulated Supramolecular Capsules and Receptors Assembled via the WLA Amenable and recurrent actions of finitely generated groups An Atom-Probe Tomography and Lattice Kinetic Monte Carlo Study of Phase Separation in Ni-A-Based Alloys from the Atomic Scale Up to Link with Continuum Theories Analysis on Manifolds Araketov geometry, Shimura varieties, and L-functions of motives ATD: A Mixture Modeling Framework for Statistical Identification of Multiple Genomes in Metagenomics Samples Atomistic Studies of Concentrated Multicomponent Nickel-Based Alloys Utilizing Atom-Probe Tomography and Vacancy-Mediated Lattice Kinetic Monte Carlo Simulations Bioengineering Single Crystal Growth Biouptake of Mercury: Speciation and Processes at the Cell Surface Black Holes in Dense Star Clusters CAREER: Complexity of Disordered Systems CAREER: Ligand Engineering of Structure and Electronic Function in Complex Metal Oxyfluorides CAREER: Synthesis and Studies of One-Dimensional Magnets Supported by Bulky, Redox. Active Benzoquinonoli Bridging Ligands CAREER: Synthesis of Molecular electronic-spin based qubits enabled by new empirically derived design principles CAREER: The Physics of Stellar Feedback and Star Formation Regulation in Galaxies CAREER: The Physics of Stellar Freedback and Star Formation Regulation in Galaxies CAREER: The Physics of Stellar Freedback and Star Formation Regulation in Galaxies CAREER: The Physics of Stellar Forperties of Lanthanide and Actinide Complexes CCI Phase II: Center for Sustanable Nanotechnology	274	47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049 47,049	DMS-1922747 CHE-170888 DMS-1352173-004 DMR-1207539/Amd 003 DMS-1702019 DMS-1043080 DMS-1613087 002 DMR-1508399-002 CHE-1308504 AST-1716762 DMR-163504 AST-1352369 DMR-1454688 004 AST-1352369 DMR-1454688 104 AST-1352369 DMR-14545017 AST-1635222 CHE-1351598 CHE-1351598	49,005 98,865 64,736 (29) 437,294 48,930 68 166,043 90,701 (3,331) 46,644 104,291 156,062 61,887 96,184 115,971 54,706 134,751 187,119	14

Supplementary Schedule of Expenditures of Federal Awards

uster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-thro to subrecipie
tional Science Foundation		Charge Transfer as a Probe of the Permeability of Organic Adlayers on Colloidal					
(continued)		Semiconductor Quantum Dots		47.049	CHE-1400596	\$ 2,319	
		Coherent and Incoherent Control in Material Systems		47.049	CHE-1465201	7,847	
		Cohomological and singularity invariants via Hodge modules and derived equivalences		47.049 47.049	DMS-1405516-002 DMS-1620022	11,815 119,650	
		Collaborative Research: Algorithms for Large-Scale Stochastic and Nonlinear Optimization Collaborative Research: Axion Resonant InterAction DetectioN Experiment (ARIADNE)		47.049	PHY-1826505	6,403	
		Collaborative Research: Axion Resonant InterAction Detection Experiment (ARIADNE) – a		47.049	FH1-1620505	0,403	
		continuation proposal		47.049	PHY-1806671	27,950	
		Collaborative Research: CDS&E: FIRE: Physically-Predictive Cosmological Simulations of				,	
		Galaxy Formation with Resolved Feedback		47.049	AST-1412836	24,463	
		Collaborative Research: Controlled Disorder and Topological Defects in Magnetically					
		Frustrated Thin Film Metamaterials		47.049	DMR-1507058	25,200	
		Collaborative Research: Designer Glass Ceramics		47.049	DMR-1600837	73,212	
		Collaborative Research: Enhancing Access to Radio Spectrum for Real-time Monitoring and Control		47 049	AST-1547328	86 419	
		Collaborative Research: Factorization Homology and the Cobordism Hypothesis		47.049	DMS-1508040-002	66.182	
		Collaborative Research: Factorization Homology, Deformation Theory, and Duality		47.049	DMS-1812057	51 781	
		Collaborative Research: Fluctuating Hydrodynamics of Suspensions of Rigid Bodies		47.049	DMS-1418672	6,104	
		Collaborative Research: High-Throughput Quantification of Solid State Electrochemistry for					
		Next Generation Energy Technologies		47.049	DMR-1505103 004	159,929	
		Collaborative Research: Integrated Computational and Experimental Studies of Solid Oxide					
		Fuel Cell Electrode Structural Evolution and Electrochemical Characteristics		47.049	DMR-1506925-002	103,422	
		Collaborative Research: Investigating Structural Dynamic Coherences of Transition Metal					
		Complexes in Photochemical Processes		47.049	CHE-1363007 DMR-1310292	(15)	
		Collaborative Research: NanoMine: Data Driven Discovery for Nanocomposites Collaborative Research: Predictive theory, synthesis and characterization of a new type of		47.049	DMR-1310292	(4,542)	
		transparent conductor without doping		47.049	DMR-1806912	6,018	
		Collaborative Research: Size Effects on Magneto-Mechanics of Ni-Mn-Ga Fibers		47.049	:DMR-1207282	(158)	
		Collaborative Research: Size-Effect Driven Nanoparticle Ferromagnetism		47.049	DMR-1508323 002	54.572	
		Collaborative Research: The SuperCDMS SNOLAB Experiment		47.049	PHY-1809730	8,485	
		Collaborative Research: Tolerance-Enforced Simulation of Stochastic Processes		47.049	DMS-1720433	4,875	
		Collaborative Research:CDS&E: Mining Physically Predictive Cosmological Simulations		47.049	AST-1715216	52,537	
		Collaborative Research:Ultrafast Excited State Electron and Nuclear Coherences in Transition					
		Metal Dimer Complexes and Their Roles in Photochemistry		47.049	CHE-1665021	62,462	
		Collective dynamics of particles at fluid interfaces		47.049	DMS-1716114	90,535	
		Complex algebraic dynamics and geometry		47.049	DMS-1600718-001	160,759	
		Conference: Manifolds and Groups: Towers of Covers; September 7th - September 12th, 2015, Ventotene. Italy		47.049	DMS-1522981-001	13.600	
		Dark Matter and Neutrino Physics with Cryogenic Detectors		47.049	PHY-1550658-002	2,405	
		Deposition, Equilibrium Structure and Mechanical Response of Polyelectrolyte Complexes		47.049	DMR-1710491	143,574	
		Design and Synthesis of Non-equilibrium Systems		47.049	CHE-1308107	(112,596)	
		Deterministic and Stochastic Models of Water Limited Ecosystems: Implications of Pattern				(,)	
		Formation, Bifurcations, Model Reduction, and Data	228	47.049	FP063753 // DMS-1639761 Amd 1	65,437	
		DMREF/Collaborative Research: Computationally Driven Targeting of Advanced Thermoelectric					
		Materials		47.049	DMR-1333335 002	38,152	
		DMREF: Collaborative Research: Accelerating Thermoelectric Materials Discovery via Dopability					
		Predictions		47.049	DMR-1729487-001	68,670	
		DMREF: Collaborative Research: Structure Genome of Metal-Insulator Transitions		47.049	DMR-1729303	64,410	
		DMREF: Collaborative Research: Synthesis, Characterization, and Modeling of Complex		17 0 10	DMR-1729016	141 295	
		Amorphous Semiconductors for Future Device Applications DMREF: Collaborative Research: Tackling disorder and ensemble broadening in materials		47.049	DWR-1729016	141,295	
		made of semiconductor nanostructures		47.049	DMR-1629383	39,935	
		DMREF: Simulation-Driven Design of Highly Efficient MOF/Nanoparticle Hybrid Catalyst Materials		47.049	DMR-1334928	(519)	
		DMREF: Simulation-Driven Design of Highly Efficient MOF/Nanoparticle Hybrid Catalyst Materials		47.049	DMR-1334928	6,979	
		Donor-Acceptor Energy Transfer in the Presence of Photonic and Plasmonic Structures		47.049	CHE-1760537	24,607	
		Doping in Non-Planar Heterostructures		47.049	DMR-1308654 Amd 002	(337)	
		Dynamical aspects of Ramsey theory		47.049	DMS-1700147	40,374	
		Dynamics with a Combinatorial Bent		47.049	DMS-1800544	52,177	
		Dynamics with a combinatorial flavor		47.049	DMS-1500670	24,007	
		EAGER: Bulk Nanostructured Metals from Twinned Nanowires		47.049	DMR-1747776	45,722	
		Elliptic and parabolic PDEs on manifolds		47.049	DMS-1709544	71,595	
		EMSW21-RTG: Applied Mathematics Training Program for Interdisciplinary Research in		17 0 10	DNO 000057 (2005	(4.050)	
		Science & Engineering Geometric Analysis on complex manifolds		47.049 47.049	DMS-0636574/005 DMS-1610278-002	(4,853) 74,230	
		Geometric Analysis on complex manifolds Global Harmonic Analysis		47.049 47.049	DMS-1610278-002 DMS-1506591-001	74,230 87,315	
		Gravitational-Wave Astrophysics: Getting Ready for the Advanced LIGO Era		47.049	PHY-1307020/002	6,512	
		Gravitational-Wave Inference from Binary Compact Objects		47.049	PHY-1607709 0002	156,687	
		GROW: strengthening the mathematical workforce		47.049	DMS-1619748	29,809	
		High-precision QCD Meets High-performance Computing		47.049	PHY-1520916-002	60,900	
		High-Pressure Synthesis of Missing Pnictide Superconductors		47.049	DMR-1801632	34,823	
		High-throughput Computational Discovery of New Nanoporous Materials for Energy Storage		47.049	DMR-1308799	(246)	
		High-throughput Computational Discovery of New Nanoporous Materials for Energy Storage Hodge theory and birational geometry Homotopy theory of foliations and diffeomorphism groups		47.049 47.049 47.049	DMR-1308799 DMS-1700819 DMS-1810644	(246) 87,661 14,615	
Supplementary Schedule of Expenditures of Federal Awards

			Pass- through			Federal	Passed-through to
uster title/Federal grantor	Subagency	Project title	ID number	CFDA	Sponsor award number	expenditures	subrecipient
tional Science Foundation		Interfacial ordering in aqueous solutions: X-ray scattering studies		47.049	DMR-1612876 DMR-1408901-003	\$ 128,129	-
(continued)		Investigation of High Strain-Rate Deformation and Failure of FCC and BCC Nanostructures IRES: Nanomaterials undergraduate Research in Germany (NanoRING)		47.049 47.049	DMR-1408901-003 IIA-1460031	71,775 37.052	-
		Joint US-Africa Materials Advanced Studies Institute		47.049	DMR-1539724	27.769	
		JUAMI (Joint Undertaking for Africa Materials Institute)		47.049	DMR-1756245	12,520	-
		Kahler manifolds with curvature lower bound		47.049	DMS-1709894	49,122	
		Knots, Sheaves, and Mirrors		47.049	DMS-1406024	85,791	
		Linear Partial Differential Equations on Singular Spaces Manipulating Multi-Spin Dynamics in Systems Targeting Organic Spintronics		47.049 47.049	DMS-1600023 CHE-1266201	64,479 (1,045)	
		Mathematical Modeling of Biomembranes		47.049	DMS-1312935	(1,045) 654	
		Measuring gravity at the micron scale with laser-cooled trapped microspheres: a continuation		47.049	PHY-1806686	39.247	
		Microlocal Sheaves, Symplectic Geometry and Applications in Representation Theory		47.049	DMS-1710481	16,303	
		Midwest Dynamical Systems Seminar		47.049	DMS-1600654	11,714	
		Midwest Probability Colloquium 2017-2019		47.049 47.049	DMS-1744209-001 DMS-1413786	16,099	
		Midwest Topology Seminar Midwest Topology Seminar		47.049	DMS-1413786 DMS-1747457	3,917 8,761	
		Moduli of Galois representations and applications		47.049	DMS-1802037	11,916	
		Moduli Spaces of complex dynamical systems		47.049	DMS-1517080	209	
		Molecular Ion Entanglement Detection by Single-Molecule Fluorescence		47.049	PHY-1404455-002	29,048	
		Molecular Plasmonics: Single Molecule and Ultrafast Surface-Enhanced Raman Spectroscopy		47.049	CHE-1506683	109,502	
		MRSEC: Center for Multifunctional Materials	162	47.049 47.049	DMR-1720139	993,792	30,
		MRSEC: Center for Nanoscale Science Nanoscale Curvature Effects on the Properties of Anisotropic Nanomaterials	162	47.049 47.049	5204-NU-NSF-0620-1// DMR-1420620 CHE-1507790	80,103 144,887	
		New Lewis Bases for Chemical Catalysis		47.049	CHE-1665141	122.985	
		New Stereoselective Fragment Coupling Reactions for Organic Synthesis		47.049	CHE-1361173	151,848	
		Nonequilibrium States of Topological Quantum Fluids and Unconventional Superconductors		47.049	DMR-1508730-003	68,677	
		Nonlinear Optical Surface Studies of Iron and its Oxides		47.049	CHE-1464916	81,514	
		Nonlinear PDEs and complex geometry Northwestern University Quantitative Biology Center (NUQuB)		47.049 47.049	DMS-1406164 DMS-1764421	11,404 99.863	
		Nucleic Acid Nanostructures and their Cellular Transport Mechanisms		47.049	DMR-1822422	99,863 82,683	55
		OP: Coherence and Energy Transfer Processes in Lattice Plasmon Lasers		47.049	DMR-1608258	150.381	
		Organo-f-Element Chemistry: Integrated Synthetic, Mechanistic, and Catalytic and Thermochemical					
		Studies		47.049	CHE-1464488	227,000	
		Oxide Surfaces, From Bulk to Nanoparticles	250	47.049	DMR-1507101 001	97,852	
		Predictive Computational Modeling of Two-Dimensional Materials: Defects and Morphologies Properties and Applications of the Microlocal Category	250	47.049 47.049	3003700315 // DMR-1509033 Amd 2 DMS-1612437	78,559 47,759	
		Quantum Information and Quantum Computation for Chemistry: Challenges and Opportunities		47.049	CHE-1655187	47,755	
		Quantum Interference and Coherence Effects on Charge Transport in Organic Semiconductors		47.049	DMR-1710104	100,641	
		REU Site: Preparing a Diverse Workforce through Interdisciplinary Astrophysics Research		47.049	AST-1359462-003	29,270	
		REU Site: Preparing a Diverse Workforce through Interdisciplinary Astrophysics Research		47.049	AST-1757792	68,167	
		RTG: Interdisciplinary Training in Quantitative Biological Modeling		47.049 47.049	DMS-1547394	352,866	
		Shape and Dimensional Precision in Polymeric Nanostructures Singularities and Smoothness in Geometric Partial Differential Equations		47.049	DMR-1508731/003 DMS-1809011	214,588 43,031	
		Size Effect on the Evolution of Kirkendall Pores in Ti-Coated Ni Wires		47.049	DMR-1611308	43,031 82,569	
		Solid State Chemistry of Complex Chalcogenides		47.049	DMR-1708254	202,432	
		Solid-State Oxides and Oxide-Flourides		47.049	DMR-1307698	(665)	
		Solid-State Oxides and Oxide-Fluorides		47.049	DMR-1608218	162,929	
		Solution-Processed Monodisperse Nanoelectronic Heterostructures		47.049 47.049	DMR-1505849 AST-1343381	80,527 248.890	95
		Spectrum Sharing in the Shadow of Uncertainty: Risk, Incentives and Investment Spin Dynamics of Photogenerated Multi-Spin Systems		47.049	AS 1-1343381 CHE-1565925	248,890 166,868	95
		Statics and Dynamics of Spatially and Dimensionally Constrained Oxides		47.049	DMR-1507810-001	99.862	
		Structures and excited state dynamics of self-assembled photonic structures.		47.049	CHE-1465045	180,464	
		SuperCDMS SNOLAB: Calibration, Commissioning, and Beyond		47.049	PHY-1708153	112,500	
		Supernova Progenitors, Stellar Remnants, and their Binary Companions		47.049	AST-1517753	138,396	
		Surfaces of Secondary Organic Aerosol Particles		47.049	CHE-1607640	164,950	
		SusChEM: Visible Light-Driven Reduction of Carbon Dioxide using Heavy Metal-Free Colloidal Quantum Dots as Sensitizers		47.049	CHE-1664184	116,157	
		Synthesis and Properties of Complex Crystalline and Glassy Metal Chalcogenides		47.049	DMR-1410169	(39,000)	
		The Center for Chemistry at the Space-Time Limit (CaSTL)	220	47.049	2014-3122 Amd No 4//CHE-1414466	425,031	
		The Massive Black Hole at the Center of the Galaxy and Its Immediate Environment		47.049	AST-1109753/002	(587)	
		The Midwest Probability Colloquium		47.049	DMS-1449300	2,388	
		The Science and Fundamental Understanding of the Radio Frequency Surface Resistance of		47.040	DUV 4724222	oc	
		Nitrogen Doped SRF cavities Total Tomography of III-V Non-Planar Heterostructures		47.049 47.049	PHY-1734332 DMR-1611341	68,780 148,687	
		Toughness and Friction of Model Polyelectrolyte Gels		47.049	DMR-1611341 DMR-1410968	(2,355)	
		Toward physically-predictive modeling of massive black hole growth and feedback in galaxy				(2,000)	
		formation		47.049	AST-1517491 002	157,711	
		Unveiling the Obscured Formation of Stars and Galaxies: Large-Scale Legacy Surveys with a					
		New Three Color High Resolution Imaging Polarimeter on a 50-m Telescope Voltage-dependent interfacial structure and properties of room temperature ionic liquids: operando	244	47.049	17-009589 D Amd. 1 // AST-1636621	74,808	

Supplementary Schedule of Expenditures of Federal Awards

Juster title/Federal grantor	Subagency	Project title Workshop on Multidisciplinary Complex Systems Research Workshops: Homotopy Harnessing Higher Structures Australia cretaceous climate and tectonics: oceanic anoxic events and cooling within the L cretaceous greenhouse at SHL CAREER: South Greenland's Holocene Climate History Reconstructed Using Three Paleolimnological Approaches CO2 evasion from the Greenland ice sheet Colaborative Research: Assessing the Impact of Small, Canadian Arctic River Flows (SCARFs) to the Freshwater Budget of the Canadian Archipelago	ID number	CFDA 47.049 47.049 47.050	Sponsor award number DMS-1647351 DMS-1833295	expenditures \$ 2,703 6,619 13,106,665	<u>subrecipien</u>
(continued)		Australia cretaceous climate and tectonics: oceanic anoxic events and cooling within the 1. cretaceous greenhouse at SHL CAREER, South Greenland's Holocene Climate History Reconstructed Using Three Paleolimnological Approaches CO2 evasion from the Greenland ice sheet Collaborative Research: Assessing the Impact of Small, Canadian Arctic River Flows (SCARFs) to the Freshwater Budget of the Canadian Archipelago	50		DMS -1833295		
		I. cretaceous greenhouse at SHL CAREER: South Greenland's Holocone Climate History Reconstructed Using Three Paleolimnological Approaches CO2 evasion from the Greenland ice sheet Collaborative Research: Assessing the Impact of Small, Canadian Arctic River Flows (SCARFs) to the Freshwate Budget of the Canadian Archipelago	50	47 050			246.6
		CAREER: South Greenland's Holocene Climate History Reconstructed Using Three Paleolimnological Approaches CO2 evasion from the Greenland ice sheet Collaborative Research: Assessing the Impact of Small, Canadian Arctic River Flows (SCARFs) to the Freshwater Budget of the Canadian Archipelago	50	47 050			
		Approaches CO2 evasion from the Greenland ice sheet Collaborative Research: Assessing the Impact of Small, Canadian Arctic River Flows (SCARFs) to the Freshwater Budget of the Canadian Archipelago			71(GG009393) // OCE-1450528-2	10,789	
		Collaborative Research: Assessing the Impact of Small, Canadian Arctic River Flows (SCARFs) to the Freshwater Budget of the Canadian Archipelago		47.050	PLR-1454734	174,085	
				47.050	PLR-1304686/002	13,713	
		Collaborative Research: NSF/EAR-BSF: Coupled Sand and Clay Motion, Bed Morphodynamics,		47.050	PLR-1304675	98	
		and Porewater Exchange		47.050	EAR-1734300	90,669	
		Collaborative Research: Evolution of the Midcontinent Rift as a Rift/Lip Hybrid Critical Zone Observatory Network for Intensively Managed Landscapes	238	47.050 47.050	EAR-1550108 072212-14695	65,623 60,783	
		EAGER: FEW: Life cycle comparison of water, energy, nutrient, and carbon requirements of urban	230				
		and conventional food production strategies EarthCube IA: Collaborative Proposal: Advancing biogeoscience community standards and		47.050	EAR-1541891	27,138	
		cyberinfrastructure via Critical Zone domain engagement in synthesis science ELT Collaborative Research: Perturbation of the Marine Food Web and Extinction During the Oceanic		47.050	ICER-1540938	(2,331)	
		Anoxic Event at the Cenomanian/Turonian Boundary Hazards SEES Type 2: From Sensors to Tweeters: A Sustainable Sociotechnical Approach		47.050	EAR-1338312-005	48,477	
		for Detecting, Mitigating, and Building Resilience to Hazards	260	47.050	0036115 (011529-3) // OCE-1331463	34,922	
		Hydration State of the Transition Zone and Lowermost Mantle		47.050	EAR-1452344-002	146,075	
		INSPIRE Track 1: Earthcasting fluvial systems: Physical, ecological, and biogeochemical dynamics The Ca and Sr (radiogenic and stable) isotope geochemistry of weathering in Iceland		47.050 47.050	EAR-1344280 EAR-1613359	154,823 111,083	
						935,947	
		A Low-Cost Integrated Agent-based Modeling and Physical Computing Platform AF: Small: Collaborative Research: Boolean function analysis meets stochastic design		47.070 47.070	IIS-1438813 CCF-1814706	3,080 36,515	
		AF: Small: Non-revelation Mechanism Design		47.070	CCF-1618502	103.415	
		AitF: Collaborative Research: Algorithms for Probabilistic Inference in the Real World		47.070	CCF-1637585	15,350	
		AitF:Mechanism Design and Machine Learning for Peer Grading BD Spokes: SPOKE: MIDWEST: Collaborative: Advanced Computational Neuroscience Network		47.070	CCF-1733860	112,241	
		(ACNN)	107	47.070	BL-4831218-NWUC//IIS-1636893	2,622	
		BD Spokes: SPOKE: MIDWEST: Collaborative: Integrative Materials Design (IMaD): Leverage, Innovate. & Disseminate		47.070	IIS-1636909	11,403	
		BIGDATA: EAGER: Catalyzing Research in Multimodal Learning Analytics		47.070	IIS-1832234	134,011	
		CAP: Collaborative Research: Building a Network to Advance Collaborative Research on Young Children's Learning through Public Media Assets		47.070	IIS-1239599	12,289	
		CAP: Collaborative Research: Building Capacity for Political and Cultural Perspectives to Strengthen					
		the Learning Sciences CAREER: Advancing Online Social Support for Older Adults with Disabilities		47.070 47.070	IIS-1555805 IIS-1551574/002	7,245 85,770	
		CAREER: Beyond Worst-Case Analysis: New Approaches in Approximation Algorithms and Machine					
		Learning		47.070 47.070	CCF-1652491 001 IIS-1453192	37,015	
		CAREER: Coherent Computational Imaging: Micro Measurements in a Macro World CAREER: Energy-Efficient and Energy-Proportional Silicon-Photonic Manycore Architectures		47.070	IIS-1453192 CCF-1453853 002	63,431 85,642	
		CAREER: Robot Learning from Motor-Impaired Instructors and Task Partners	169	47.070	81454 Letter 7/12/16 //IIS-1552706	78,867	
		CAREER: SOISTICe: Software Synthesis with Timing Contracts for Cyber-Physical Systems		47.070	CCF-1834701	12,539	
		CAREER: Understanding and addressing geographic inequalities in location-aware technologies		47.070	IIS-1707296 002	32,830	
		CAREER: Web Information Extraction: Scaling and Integration CC*DNI CI Engineer: Integrating Campus Cyberinfrastructure and Research Computing at		47.070	IIS-1351029 005	93,172	
		Northwestern University		47.070	ACI-1541457	41,049	
		CHS: Large: Collaborative Research: TextureShop: Tools for the Composition and Display of Virtual Texture		47.070	IIS-1518602 003	269,416	
		CHS: Medium: Collaborative Research: Understanding online creative collaboration over multidimensional networks		47.070	IIS-1514427	78 712	
		mutitolimensional networks CHS: Small: Assessing the Role of Platform Algorithms in Shaping News Attention		47.070	IIS-1514427 IIS-1717330	138,538	
		CHS: Small: Collaborative Research: Pathways to Community Success: Advancing a					
		Comparative Science of Online Collaborative Organization		47.070	IIS-1617468	60,826	
		CHS: Small: Collaborative Research: RUI: Human-centered Semantic Relatedness CHS: Small: Collaborative Research: The Presentation of Self in Networked Life		47.070 47.070	IIS-1707319 IIS-1617387 001	82,248 68.597	
		CHS: Small: Collaborative Research: The Presentation of Self in Networked Life CHS: Small: Coordination of Opportunistic Actions to Produce Globally Effective Behaviors for		47.070	115-1617387 001	68,597	
		Physical Crowdsourcing		47.070	IIS-1618096	59,101	
		CHS:Small: Robust Interactive Audio Source Separation		47.070	IIS-1420971	113,422	
		CI-EN: Collaborative: Run Your Research with Redex		47.070	CNS-1405756 001	12,524	
		CIF:Small: Many-user Information Theory: A New Paradigm CIF21 DIBBs: PD: Ontology-enabled Polymer Nanocomposite Open Community Data Resource	172	47.070 47.070	CCF-1423040 A12761 Amd 01 // ACI-1640840	112,386 14.388	
		Collaborative Research: Chameleon: A Large-Scale, Reconfigurable Experimental Environment for	172			,	
		Cloud Research Collaborative Research: Designing Digital Rails to Foster Scientific Curiosity around Museum		47.070	CNS-1419138	164,105	
		Collections		47.070	IIS-1550051	(179)	
		Collaborative Research: Personalized Benchmarks for HPC Applications Collaborative Research: Responses of the Rodent Vibrissal-Trigeminal System to Air Currents		47.070 47.070	ACI-1535112 IIS-1208118	3,002 (1,401)	

Supplementary Schedule of Expenditures of Federal Awards

luster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throug to subrecipients
	Subagency		ID number	CFDA	Sponsor award number	expenditures	subrecipients
tional Science Foundation (continued)		Collaborative Research: SI2-SSI: Scalable Infrastructure for Enabling Multiscale and Multiphysics Applications in Fluid Dynamics, Solid Mechanics, and Fluid-Structure Interaction		47.070	ACI-1450374	\$ 100,689	-
		Collaborative Research: SI2-SSI: Software Framework for Electronic Structure of Molecules and Solids		47.070	ACI-1550481	147,412	-
		Computer Science for All: Researcher Practitioner Partnerships Workshops (CS for All: RPP), Chicago and Los Angeles		47.070	CNS-1821362	175,878	_
		CPS: Breakthrough: Collaborative Research: A Framework for Extensibility-Driven Design of Cyber-Physical Systems		47.070	CCF-1834324	14,773	_
		CPS: Synergy: Collaborative Research: Learning Control Sharing Strategies for Assistive	100				
		Cyber-Physical Systems CPS: Synergy: Collaborative Research: Mutually Stabilized Correction in Physical Demonstration	169	47.070 47.070	CC# 81394 CL 4811 // 1544741 CNS-1329891	58,106 167,874	-
		CRII: CHS: Automatically Praising Learning Process to Promote the Growth Mindset in Computer					-
		Science		47.070	IIS-1755628	33,774	
		CRII: CHS: Early Detection of Collective Misconceptions with Network-aware Machine Learning Tools CRII: CHS: Remote Paper Prototype Testing for Mobile Applications		47.070 47.070	IIS-1755873 IIS-1464315	36,725 75,085	
		DIP: Collaborative Research: CRAFT: An Online Learning Platform for Scaffolding the Crowd					
		Feedback Loop for Design Innovation Education		47.070	IIS-1530837	68,504	
		DIP: Digital Studios for Social Innovation Networks		47.070	IIS-1530833	180,356	
		DIP: Modeling in Levels EAGER: Developing Partnership Structures to Collaboratively Grow Urban STEM Hubs		47.070 47.070	IIS-1441552 IIS-1824536	195,302 109,101	
		EAGER: Developing Partnership Structures to Collaboratively Grow Orban STEM Hobs EAGER: PUF-Locked Circuit Obfuscation for Counterfeit and Piracy Prevention		47.070	CNS-1651695 001	43 625	
		EXP: Advancing Early STEM Learning through Haptic Feedback Displays		47.070	IIS-1522921	43,025	
		EXP: Agile Research Studios: Scaling Cognitive Apprenticeship to Advance Undergraduate and				,	
		Graduate Research Training in STEM EXP: Collaborative Research: Engaging Interdisciplinary Students in Innovation Education Through		47.070	IIS-1623635	59,634	
		Crowd-Based Technology EXP: Readily Available Learning Experiences: Turning the Entire Web into Scaffolded Examples to		47.070	IIS-1217225	(13,363)	
		Bridge Conceptual Knowledge Gaps for Novice Web Developers		47.070	IIS-1735977	50,097	
		Future Technology to Preserve College Student Health and Foster Wellbeing (StudentHealth)		47.070	IIS-1545751	2.005	
		GENI Multi-Service Exchange (SDX)	22	47.070	Agmt 9/28/16 Mod 3 // CNS-1536090	63.075	
		GENI Spiral 4: Prototype GENI Multi-Services Network Exchange (GMNE)	22	47.070	BBN Ref ID 14303 PO #9500012297//CNS-1346688	(3.886)	
		GPU-Enabled General Relativistic Simulations of Misaligned Black Hole Accretion Systems		47.070	OAC-1811605	8,459	
		HCC: Medium: Collaborative Research: Force Feedback for Fingertips HCC-SMALL: A Joint Action Approach to Understanding and Supporting Interpersonal Attention In		47.070	IIS-1302422	(650)	
		Virtual Organizations		47.070	IIS-1217143/005	(7,964)	
		ICES: SMALL: Mechanism Design With Information-Sensitive Agents		47.070	CCF-1216006	(484)	
		III: Small: Collaborative Research: Algorithms for Query by Example of Audio Databases		47.070	IIS-1617497	56,049	
		III: Small: Collaborative Research: Automatically Generating Contextually-Relevant Visualizations					
		Relatedness	106	47.070	IIS-1702440	27,930	
		III: Small: Quantifying Multifaceted Perception Dynamics in Online Social Networks INSPIRE: Glitch Zoo: Teaming Citizen Science with Machine Learning to Deepen LIGO's View of the	106	47.070	SA17-0018-S001//1618244	35,360	
		Cosmos IRNC: RXP: StarLight SDX – A Software Defined Networking Exchange for Global Science Research		47.070	IIS-1547880-002	240,387	158,5
		and Education		47.070	ACI-1450871	382,003	85,0
		NeTS: SMALL: Broadband Service Reliability: Characterization And Improvement NeTS: Small: Collaborative Research: Leveraging Personalized Internet Services to Combat Online		47.070	CNS-1619317	94,549	
		Trollina		47.070	CNS-1615837	34,514	
		NeTS: Small: Endpoint User Profile Control		47.070	CNS-1319086	(72)	
		NeTS: Small: Mashup Content Harvesting for an Open Internet		47.070	CNS-1526052	154,720	
		NRI: Autonomous Synthesis of Haptic Languages		47.070	IIS-1426961	280,745	
		NRI: Electrosense imaging for underwater telepresence and manipulation NSCI SI2-SSE: The N-jettiness software framework for precision perturbative QCD calculations in		47.070	IIS-1427419-005	180,896	27,
		particle and nuclear physics		47.070	OAC-1740142	33,986	
		NSFSaTC-BSF: CORE: Small: The Utilitarian Implications of Privacy Protections		47.070	CNS-1718670	80,822	
		RI: Small: Collaborative Research: Information-driven Autonomous Exploration in Uncertain		47.070	10 4747054	549	
		Underwater Environments RI: Small: Contextual Mining and Learning for Video Scene Understanding		47.070 47.070	IIS-1717951 IIS-1217302/001	548 27.654	
		RI: Small: Modeling and Learning Visual Similarities under Adverse Visual Conditions		47.070	IIS-1217302/001 IIS-1619078	58,582	
		RI:Small:Dynamic In-Hand Robotic Manipulation		47.070	IIS-1527921	196,846	
		SaTC: STARSS: ICM: Invariant Carrying Machine for Hardware Assurance		47.070	CNS-1441695	100,781	
		SCH:INT:Collaborative Research:High-throughput Phenotyping on Electronic Health Records using Multi-Tensor Factorization		47.070	IIS-1417819	111,915	
		SHF: Small: Collaborative Research: ALETHEIA: A Framework for Automatic Detection/Correction of Corruptions in Extreme Scale Scientific Executions		47.070	CCF-1619253	31.390	
		SHF: Small: Collaborative Research: Designing a Programming Language for Patient-Oriented Prescriptions		47.070	CCF-1526109	149,977	
		SHF: Small: Greybox Computing: An Associative Computing Methodology with Instruction Directed					
		Power and Clock Management		47.070	CCF-1618065-001	119,718	
		SHF: Small:Thermal Monitoring in 3D Integrated Circuits with Bimetallic Thin Film Thermocouples		47.070	CCF-1422489/001	82,129	
		SHF:Medium:Collaborative Research: Scalable Algorithms for Spatio-temporal Data Analysis		47.070	CCF-1409601	165,662	
				47.070 47.070	CCF-1409601	165,662 28,073	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
National Science Foundation	oundgonoy	TWC SBE: Medium: Collaborative: Incentive Compatible Wireless Security		47.070	CNS-1314620	\$ 67,485	
(continued)		TWC: Medium: Collaborative: Neuroscience Meets Computer Security: Designing Systems Secure Against Coercion Attacks		47.070	CNS-1228357	4,017	_
		TWC: TTP Option: Medium: Collaborative: Identifying and mitigating trust violations in the smartphone					
		ecosystem WiFiUS: Collaborative Research: Ultra-low latency and High Reliability for Wireless IoT		47.070 47.070	CNS-1408790 CNS-1701921	132,404 20,871	_
		Workshop: Doctoral Consortium for HCOMP 2017		47.070	IIS-1748375	8,234	_
		XPS: EXPL: CCA: Merging Parallel Run-times and Operating Systems		47.070	CCF-1533560 001	102,906	-
		XPS: FULL: FP: Design and Synthesis of New Energy-efficient Self-healing Computing Electronics with Real-time Configurability		47.070	CCF-1533656	195,811	_
		• •				7,079,113	270,804
		Biophysical Studies of Metalloenzymes		47.074	MCB-1515981 001	334.623	_
	CAREER: Uncovering Quantitative Design Principles of RNA Regulators for Synthetic Biology		47.074	MCB-1650040 002	115,577	82,486	
	CEIN: Predictive Toxicology Assessment and Safe Implementation of Nanotechnology in the Environment	222	47.074 47.074	0521 G RA112-005 Amd. 4// DBI-126 MCB-1745753	87,700 34,330	-	
	Collaborative Research: EAGER: Customized cell biosensors for interrogating cancer cell physiology Collaborative Research: A New Twist on Muscle Contraction		47.074	IOS-1456623	34,330 125,323		
	Collaborative Research: Bilateral BBSRC-NSF/BIO: Synthetic Biology for Lignin Utilization		47.074	MCB-1614953	105,333	-	
		Collaborative Research: Glycoengineering Without Borders: Bacterial Cell-Free Glycoprotein Synthesis Collaborative Research: IDBR: Type A: The Nanosizer: A New Tool For the Photochemical Fabrication		47.074	MCB-1413563	113,906	-
	of Bioactive Nanoarrays		47.074	DBI-1353682	(8,900)	-	
	Collaborative Research: Repurposing the translation apparatus for mirror image polypeptide synthesis		47.074	MCB-1716766	19,812	-	
		Collaborative Research: Uncovering the Role of Sirtuins in Linking Food Availability and Stress Tolerance Through Multi-Scale Signaling Networks in Mussels		47.074	IOS-1557495	32.552	_
		CRCNS: Functional imaging and computational models of place field integration in pyramidal cell dendrites		47.074	IOS-1516235-001	266.741	_
		Dissecting the anatomy of regulatory divergence		47.074	IOS-1708518	106,231	-
		EAGER: Toward engineering a synthetic enhancer in Caenorhabditis elegans		47.074	MCB-1748307	43,113	-
		IDBR: Development of Higher Eigenmode Ultrasound Bioprobe for Sub-Cellular Biological Imaging IDBR: Type A: Directly Integratable Photoacoustic Microscopy with Established Optical Microscopy for		47.074	DBI-1256188	52,988	-
		Comprehensive Sub-cellular Biological Imaging		47.074	DBI-1353952/002	17,164	-
		Regulation of Nuclear Receptor Function during Drosophila Development Reticulospinal Execution of Innate Decision-Making	243	47.074 47.074	27790-Z4573001//IOS-145714 IOS-1456830	46,401 275.058	-
		REU Site: Synthetic Biology (SynBREU)		47.074	DBI-1757973	61,204	
		Synthetic Biology of Yeast	218	47.074	00009607 // 1330914	102,166	-
		The Response of Primary Mesenchyme Cells to VEGF		47.074	IOS-1456837	228,444	-
		The Vibrissotactile Natural Scene Understanding the Mechanism of Import for Bacterial Transporters		47.074 47.074	IOS-1558068 MCB-1121872	133,891 9.111	-
				47.074		2,302,768	82,48
		Biological links between rhythm and reading		47.075	BCS-1430400	79.483	_
		CAREER: Comparative Statics and Dynamic Models		47.075	SES-1151410/003	42,649	-
		CAREER: Crime Victimization Patterns in American Cities		47.075	SES-1840443	68,479	-
		CAREER: Leadership for Virtual Organizational Effectiveness CAREER: Social Networks, Labor Markets and Agricultural Technology Adoption in Developing Countries		47.075 47.075	SES-1738297 SES-1254380-005	13,330 45,222	8.30
		Collaborative Research: Dynamic Mechanisms without Transfers		47.075	SES-1254380-005 SES-1530608	45,222 78,102	8,30
		Collaborative Research: Econometric Methods for Models with Clustered Data and Covariate-Adaptive		11.010		10,102	
		Randomization		47.075	SES-1530534	41,281	-
		Collaborative Research: Equilibria in Health Exchanges: Adverse Selection, Reclassification Risk, and Dynamic Contracting		47.075	SES-1260949	24,819	22,395
		Collaborative Research: Media Characters: The Unhidden Persuaders in Food Marketing to Children		47.075	BCS-1251345	8,477	22,390
		Collaborative Research: Mind Mapping Consumers and Activists' Response to NGO-Corporate Partnerships		47.075	SES-1359610 001	40,278	_
		Collaborative Research: NCS-FO: Sleep's role in determining the fate of individual memories		47.075	BCS-1533512	235,890	-
		Collaborative Research: SBE Alliance: Great Lakes Alliance for the Social and Behavioral Sciences (GLASS) Collaborative Research: State Variation in Mass Incarceration Reforms.		47.075 47.075	SES-0750621/003 SES-1655382	(324) 49,078	_
		Collaborative Research: Time-Sharing Experiments for the Social Sciences (TESS): Proposal for		41.015	020-1000002	43,070	
		Renewed Support, 2016-2019		47.075	SES-1628057	455,266	260,215
		CompCog: Reading as a rational process of visual information gathering	407	47.075	BCS-1734217	115,865	-
		Connectome mapping algorithms with application to community services for big data neuroscience Consequences and Context of Stunting in the Bolivian Amazon	107	47.075 47.075	BL-4831222-NU//BCS-1734853 SUB0000853//BCS-1519120	13,389 7,770	_
		Consequences and context of ordinary in the bolinary finazon Constructions of Traditional Medicine during Decolonization and the Global Cold War	234	47.075	SES-1456984	11,112	_
		Coordination and Information Design		47.075	SES-1730483	93,464	-
		Dissertation Grant: Social Science's Use of Controlled Field Experiments		47.075	SES-1556343	8,282	-
		DNA Examiners: Judgment and Influence Doctoral Dissertation Improvement Award: The Effect of War On The Transformation of Social Hierarchies		47.075 47.075	SES-1356899 BCS-1546972	4,919 651	_
		Doctoral Dissertation Improvement Award: The Role of Heritage in Community Organization		47.075	BCS-1546972 BCS-1630141	12.717	_
		Doctoral Dissertation Improvement: Conceptualizing the Adaptive Significance of Brown Adipose Tissue in Cold Climates				,	
				47.075	BCS-1455804	566	-
		Doctoral Dissertation Research in DRMS: Where Does Innovation Come From? Exploring the Dynamic					
		Doctoral Dissertation Research in DRMS: Where Does Innovation Come From? Exploring the Dynamic Processes of Organizing and Managing Social Entrepreneurship and Innovation		47.075	SES-1730079	24,748	-
		Doctoral Dissertation Research in DRMS: Where Does Innovation Come From? Exploring the Dynamic Processes of Organizing and Managing Social Entrepreneurship and Innovation Doctoral Dissertation Research in DRMS: Who's at Stake? Nonhuman Agency Concepts and Cultural				, .	-
		Doctoral Dissertation Research in DRMS: Where Does Innovation Come From? Exploring the Dynamic Processes of Organizing and Managing Social Entrepreneurship and Innovation		47.075 47.075 47.075	SES-1730079 SES-1427035 BCS-1728173	24,748 (75) 4,323	-
		Doctoral Dissertation Research in DRMS: Where Does Innovation Come From? Exploring the Dynamic Processes of Organizing and Managing Social Entrepreneurship and Innovation Doctoral Dissertation Research in DRMS: Who's at Stake? Nonhuman Agency Concepts and Cultural Resource Conflict Among Indigenous and Mainstream Actors in Panama		47.075	SES-1427035	(75)	-

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subs	Decise data	Pass- through	CFDA	Cr	Federal	Passed-throu to
	Subagency	Project title	ID number	CFDA	Sponsor award number	expenditures	subrecipien
ational Science Foundation (continued)		Doctoral Dissertation Research: Cultural and Social Dimensions of Anti-Mullerian Hormone Screening Technologies		47.075	BCS-1823543	\$ 1,286	
(continued)		Doctoral Dissertation Research: Exclusion and the Social Construction of Citizenship		47.075	BCS-1424025	8,280	
		Doctoral Dissertation Research: Intergenerational impacts of culture change-The role of traditional foods				-,	
		in shaping the cardiometabolic health of Alaska Native people		47.075	BCS-1613340	3,562	
		Doctoral Dissertation Research: Organizational Emergence in the Era of Racial Risk: The Black Guerilla		17.075	SES-1703056		
		Family and the Aryan Brotherhood in California Doctoral Dissertation Research: Population Shifts and Suburban Governance		47.075 47.075	SES-1703056 BCS-1528569	8,114 227	
		Doctoral Dissertation Research: Population Shifts and Suburban Governance		47.075	SES-1637182	9.007	
		Doctoral Dissertation Research: Standardizing Persecution in US Asylum Adjudications		47.075	SES-1702602	4,374	
		Doctoral Dissertation Research: The Intergenerational Consequences of Incarceration		47.075	SES-1628126	5,586	
		Doctoral Dissertation Research: The Online Processing of NP-Ellipsis and the Mechanisms of Antecedent					
		Retrieval		47.075	BCS – 1749580	1,225	
		Doctoral Dissertation Research: The Regeneration of Human Settlements amidst Ruins after Episodes of Societal Collapse		47.075	BCS-1806248	4.561	
		Early environments, epigenetics, and inflammation during pregnancy		47.075	BCS-1440564	22.812	22,
		Econometric Tools for Analysis of Derivatives Data		47.075	SES-1530748	96,635	,
		Fiduciary Duty, Financial Regulation, and the Market for Retirement Products		47.075	SES-1824463	1,477	
		INSPIRE: Gradient Symbolic Computation	122	47.075	2001990798 // BCS-1344269-001	3,090	
		Investigating the Origin and Development of Analogical Processing		47.075	BCS-1423917	15,376	
		Manipulating and classifying memory processing during sleep	141	47.075	BCS-1461088 002 RC107136NU//1654929	66,085 8,595	47
		Motor exploration and motor learning during child development NCRN-SN: Census Bureau Data Programs as Statistical Decision Problems	141	47.075 47.075	SES-1129475	8,595	
		NCS-FO: Collaborative Research: Understanding the neural basis for sensorimotor control loops		47.075	3E3-1129475	10,370	
		using whisker-based robotic hardware platforms		47.075	BCS-1734981	137,294	
		NSF Intergovernmental Personnel Act (IPA) Assignment – Fay Lomax Cook		47.075	SMA(SBE)-1451416-006	311,532	
		NSF/SBE-BSF:Integration of kinesthetic and tactile information in perception, action, and learning	169	47.075	81464/CL5296//1632259	119,047	
		Spatial Intelligence Learning Center	201	47.075	330161-18110-7343-Amd 5//SMA-1041707	206,419	
		Surviving the Terminal Classic Maya Collapse: Settlement and Household Archaeology at Aventura, Belize		47.075	BCS-1732129	47,698	
		The Development of Relational Processing in Infancy The Effect of School Finance Reforms on the Distribution of Spending, Academic Achievement and		47.075	BCS-1729720	150,899	
		Adult Outcomes		47.075	SES-1324778	(6,226)	
		The International Cognitive Ability Resource		47.075	SMA-1419324	15,735	
		WORKSHOP: Enhancing robustness and generalizability in the social and behavioral sciences		47.075	BCS-1647219	(7,607)	
						2,736,521	360,
		A Whole-School Model for Integrating Computational Thinking in High School Science and Mathematics		47.076	DRL-1640201 003	565,679	40.
		An investigation of the impact of culture and experience on reasoning about complex ecological		47.070	BRE-1040201 003	303,013	40,
		phenomena among students from diverse backgrounds		47.076	DRL-1713368	135,196	
		CAREER: Blocks, Stickers, and Puzzles: Rethinking Computational Literacy Experiences in Informal					
		Environments		47.076	DRL-1451762 003	162,616	
		Collaborative Proposal: Learning Linkages: Integrating Data Streams of Multiple Modalities and Timescales		47.076	DRL-1418020	2,724	
		Collaborative Research to Understand the Role of Culture, Identity, Epistemology and Bi-Cultural Efficacy in American Indian Educational and Professional Success in STEM		47.076	DRL-1251516	20,521	
		Collaborative Research: Adapting and Implementing a Geospatial High School Course in Career and		47.070	DRL-1251516	20,521	
		Technical Education Clusters in Urban Settings		47.076	DRL-1759360	71.821	
		Collaborative Research: Advancing Early STEM Learning Opportunities Through Tinkering and Reflection		47.076	DRL-1515788-002	200,308	
		Collaborative Research: AGEP Transformation Alliance: CIRTL AGEP - Improved Academic Climate for					
		STEM Dissertators and Postdocs to Increase Interest in Faculty Careers		47.076	HRD-1647146	15,060	
		Collaborative Research: Cognitive and Neural Indicators of School-based Improvements in Spatial Problem Solving.		47.076	DRL-1420599	154.261	
		Solving. Collaborative Research: Engaging Introductory Astronomy Students in Authentic Research through Citizen		47.076	DRL-1420599	154,201	
				47.076	DUE-1525725	52 406	20.
				47.076	DRL-1614745	243,371	36
		Science Collaborative Research: Group-Based Cloud Computing for STEM Education Project					
		Science Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across		47.076			
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions		47.076	DUE-1504952	63,434	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mechanisms of Visuospatial Thinking in STEM			DUE-1504952 DRL-1661264 002		
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums,		47.076 47.076	DRL-1661264 002	63,434 208,908	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mechanisms of Visuospatial Thinking in STEM Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music		47.076		63,434	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: USE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative research: Neural and Cognitive strengthening of conceptual knowledge and reasoning in		47.076 47.076 47.076	DRL-1661264 002 DRL-1612619	63,434 208,908 85,798	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mechanisms of Visuospatial Thinking in STEM Collaborative Research: Winding Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative research: Neural and cognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education		47.076 47.076 47.076 47.076	DRL-1661264 002 DRL-1612619 DRL-1661089	63,434 208,908 85,798 63,428	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: USE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative research: Neural and Cognitive strengthening of conceptual knowledge and reasoning in		47.076 47.076 47.076	DRL-1661264 002 DRL-1612619	63,434 208,908 85,798	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: USE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mechanisms of Visuospatial Thinking in STEM Collaborative Research: Mining Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative research: Neural and cognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: Using Educational DVDs to Enhance Young Children's STEM Education Doctoral Dissertation Research: A Geospatial Analysis of Alpine Glacial Variability EAGER: MAKER: A Calutaral Framework for Equity in Maker Practices		47.076 47.076 47.076 47.076 47.076	DRL-1661264 002 DRL-1612619 DRL-1661089 DRL-1252121	63,434 208,908 85,798 63,428 199,326	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative research: Neural and cognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: Using Educational DVDs to Enhance Young Children's STEM Education Doctoral Dissertation Research: A Geospatial Analysis of Apine Glacial Variability EAGER: MAKER: The Design and Engineering of Scientific Instrumentation as a Pathway for Introducing		47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076	DRL-1661264 002 DRL-1612619 DRL-1661089 DRL-1252121 DCS-1812764 DRL-1723750	63,434 208,908 85,798 63,428 199,326 4,080 87,023	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: USE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative Research: Neural and cognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: A Geospatial Analysis of Alpine Glacial Variability Collaborative Research: A Geospatial Analysis of Alpine Glacial Variability EAGER: MAKER: A Cultural Framework for Equity in Maker Practices EAGER: MAKER: The Design and Engineering of Scientific Instrumentation as a Pathway for Introducing Making into High School Science Classrooms		47.076 47.076 47.076 47.076 47.076 47.076	DRL-1661264 002 DRL-1612619 DRL-1661089 DRL-1252121 DRL-1252121 BCS-1812764	63,434 206,908 85,798 63,428 199,326 4,080	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative Research: Neural and cognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: Using Educational DVDs to Enhance Young Children's STEM Education Doctoral Dissertation Research: A Geospatial Analysis of Alpine Glacial Variability EAGER: MAKER: A Cultural Framework for Equity in Maker Practices EAGER: MAKER: A Cultural Framework for Equity in Maker Practices EAGER: MAKER: A Cultural Framework for Equity in Maker Practices EAGER: MAKER: The Design and Engineering of Scientific Instrumentation as a Pathway for Introducing Making into High School Science Classrooms		47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076	DRL-1661264 002 DRL-1612619 DRL-1661089 DRL-1252121 BCS-1612764 DRL-1723750 DRL-1623550-01	63,434 208,908 85,798 63,428 199,326 4,080 87,023 118,061	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: USE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative Research: Nuring Learning Experiences for Computer Programming Across Museums, Classroom-based spatial education Collaborative Research: Neural and cognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: A Geospatial Analysis of Alpine Glacial Variability EAGER: MAKER: A Cultural Framework for Equity in Maker Practices EAGER: MAKER: The Design and Engineering of Scientific Instrumentation as a Pathway for Introducing Making into High School Science Classrooms FUSE Studios: A New, Interest-Driven Model for Engaging Youth In STEM and Career Development Through Challenges and Partnership with Industry		47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076	DRL-1661264 002 DRL-1612619 DRL-1661089 DRL-1252121 BGS-1812764 DRL-1723750 DRL-1623550-01 DRL-1433724/001	63,434 208,908 85,798 63,428 199,326 4,080 87,023 118,061 201,476	
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative Research: Neural and coognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: Neural and coognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: A Geospatial Analysis of Aprine Glacial Variability EAGER: MAKER: A Claural Framework for Equity in Maker Practices EAGER: MAKER: Claural Framework for Equity in Maker Practices FAGER: MAKER: Chaural Framework for Equity in Maker Practices FUSE Studies: A New, Interest-Driven Model for Engaging Youth In STEM and Career Development Through Challenges and Partnership with Industry FUSE Studies: A New, Interest-Driven Model for Engaging Youth In STEM and Career Development		47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076	DRL-1661264 002 DRL-16612619 DRL-1661089 DRL-1252121 BCS-1612764 DRL-1723750 DRL-1623550-01 DRL-1433724/001 DRL-1433724/001 DRL-1433724/001	63,434 208,908 85,798 63,428 199,326 4,080 87,023 118,061 201,476 26,576	4
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: USE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Machanism of Visuospatial Thinking in STEM Collaborative Research: Machanisms of Visuospatial Thinking in STEM Collaborative Research: Neural and cognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: Neural and cognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: A Geospatial Analysis of Alpine Glacial Variability EAGER: MAKER: A Cultural Framework for Equity in Maker Practices EAGER: MAKER: The Design and Engineering of Scientific Instrumentation as a Pathway for Introducing Making into High School Science Classrooms FUSE Studios: A New, Interest-Driven Model for Engaging Youth In STEM and Career Development Through Challenges and Partnership with Industry FUSE Studios: A Alternative Infrastructure for STEM Learning and Interest Development Graduate Research: (GRFP)		47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076	DRL-1661264 002 DRL-1612619 DRL-1661089 DRL-1252121 DRCS-1612764 DRL-1723750 DRL-1623550-01 DRL-1433724/001 DRL-1348800 DGE - 142165	63,434 208,908 85,798 63,428 199,326 4,080 87,023 118,061 201,476 26,576 345,001	4
		Collaborative Research: Group-Based Cloud Computing for STEM Education Project Collaborative Research: IUSE: EHR – Enhancing and Expanding Experiential Learning Modules across Disciplines and Institutions Collaborative Research: Mixing Learning Experiences for Computer Programming Across Museums, Classrooms, and the Home Using Computational Music Collaborative Research: Neural and coognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: Neural and coognitive strengthening of conceptual knowledge and reasoning in classroom-based spatial education Collaborative Research: A Geospatial Analysis of Aprine Glacial Variability EAGER: MAKER: A Claural Framework for Equity in Maker Practices EAGER: MAKER: Claural Framework for Equity in Maker Practices FAGER: MAKER: Chaural Framework for Equity in Maker Practices FUSE Studies: A New, Interest-Driven Model for Engaging Youth In STEM and Career Development Through Challenges and Partnership with Industry FUSE Studies: A New, Interest-Driven Model for Engaging Youth In STEM and Career Development		47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076 47.076	DRL-1661264 002 DRL-16612619 DRL-1661089 DRL-1252121 BCS-1612764 DRL-1723750 DRL-1623550-01 DRL-1433724/001 DRL-1433724/001 DRL-1433724/001	63,434 208,908 85,798 63,428 199,326 4,080 87,023 118,061 201,476 26,576	

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
National Science Foundation (continued)		INSPIRE Track 1: Primary School Organizations as Open Systems: Strategic External Relationship Development to Promote Student Engagement in STEM Topics		47.076	DRL-1344266/003	\$ 11,843	6,728
		Learning Ethnographies of New Engineers: A New Approach to Understanding the Transition from School to Work Learning Labs: Using Videos, Exemplary STEM Instruction and Online Teacher Collaboration to Enhance		47.076	DRL-1252372	114,514	51,961
		Elementary Math and Science Practice and Classroom Discourse Methods to Protect Privacy in State Longitudinal Data Systems Research Files	198 229	47.076 47.076	2015-02//1417757 5968-NU 02 // DGE-1437953	65,438 129,400	=
		MOOC-Supported Learning Communities for Future STEM Faculty: Multiple Paths to Advance Evidence-based Teaching Across the Nation NRT-DESE: Training in Data-Driven Discovery – From the Earth and the Universe to the Successful	141	47.076	RC103138NW//DUE-1347605	14,121	-
		Careers of the Future Careers of the Future Preparing Future Faculty to Improve STEM Education: Broadening the National Impact of the CIRTL Network SPrEab: Broadening implementation of an innovative STEAM Bearing environment: Scaling up FUSE Studios	274	47.076 47.076	DGE-1450006-003 795K406//1726625	336,930 4,274	_
		through two models of partnership engagement with industry and schools Supporting Scientific Practices in Elementary and Middle School Classrooms Using hyperlocal and networked strategies to support computer science education for middle grade		47.076 47.076	DRL-1657438 DRL-1020316 Amd 005	527,081 77,517	36,188 68,699
		students in Chicago		47.076	DRL-1824551	320,066	
						8,960,841	264,827
		IRES: US-Dutch Research Collaboration in Cultural Heritage Science PIRE: Computationally-Based Imaging of Structure in Materials (CuBISM)		47.079 47.079	IIA-1460143 OISE-1743748	99,338 429,940	_
				41.013		529,278	
		Collaborative Research: Three-dimensional Microstructural and Chemical Mapping of Solid Oxide Fuel Cell Electrodes: Processing, Structure, Stability, and Electrochemistry		47.082	DMR-0907639	(785)	
		Rheo-X-Ray Investigation of Structure Development in Polymer Melts Under Uniaxial Extension Flow		47.082	DMR-0907659 DMR-0907068	(785) (3,610)	
						(4,395)	
		PIRE: Integrated Computational Materials Engineering for Active Materials and Interfaces in Chemical Fuel Production	238	47.083	2015-02361-02 // 1545907 01	85,755	_
		GHz Time-of-Flight Depth Sensing for Robotic Bin Picking	194	47.RD	Amgt. 08/31/17//1647888 National Science Foundation To	37,233 tal 43.840.805	2.256.132
Nuclear Regulatory Commission	United States Nuclear Regulatory Commission	Service Lifetime Extension of Nuclear Power Plants: Prediction of Concrete Aging and Deterioration Through Accelerated Tests, Nondestructive Evaluation, and Stochastic Multiscale Computations Service Lifetime Extension of Nuclear Power Plants: Prediction of Concrete Aging and Deterioration		77.009	NRC-HQ-60-14-G-0003 M0007	(23,763)	_
		Through Accelerated Tests, Nondestructive Evaluation, and Stochastic Multiscale Computations		77.009	NRC-HQ-60-14-G-0003 M0007	118,615	95,282
					Nuclear Regulatory Commission To	94,852 tal 94.852	95,282
Scholarship Foundations					Nuclear Regulatory Commission 10	tai <u>94,852</u>	95,282
	Vietnam Education Foundation	Vietnam Education Foundation Fellowship		85.802	Agmt 2/19/13	1,317	_
		Vietnam Education Foundation Fellowship – Hoang Thai Nguyen		85.802	Letter 10/14/14	(8)	
						1,309	
Social Security Administration					Scholarship Foundations To	tal <u>1,309</u>	
		Regulating Markets for Retirement Products: Evidence from Chile	28	96.007	5002110-S4 // 5 RRC08098402-08-00	41,113	
					Social Security Administration To	tal <u>41,113</u>	
.S. Agency for International Development							
		Comparing HIV Mucosal Targets in US and Kenyan Populations Next-generation products for prevention of HIV infection in women (Project NIX HIV) Testing the Effectiveness of Tailored Non-Formal Education Interventions Promoting Critical Thinking	115 67	98.001 98.001	7503// AID-OAA-A-16-00032 NXS-17-001 // AID-OAA-A-17-00014	254,854 371,602	_
		and Emotional Literacy in the Middle East	250	98.001	3003719520 // AID-OAA-A-15-00075 02	116,367	
						742,823	
		An osmotic pump vaginal insert for sustained delivery of anti-retrovirals An osmotic pump vaginal insert for sustained delivery of anti-retrovirals	54 54	98.RD 98.RD	MAPS2-15-056//AID-OAA-A-14-00010 MAPS2-15-056//AID-OAA-A-14-00010	(16,976) 66,973	63,197
		Preclinical Development of Longer Acting Topical Antiretroviral Delivery Systems	54	98.RD	MAPS2-14-029 //AID-OAA-A-14-00010	39,388	
					U.S. Agency for International Development To		63,197
					Research and Development Cluster To	tal 472,169,587	59,544,217

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
Student Financial Assistance Cluster Department of Education	r.						
Department of Education		Federal SEOG 2017-2018		84.007	P007A171246	\$ 2,186,241	_
		Federal Work-Study 2016-2017 Federal Work-Study 2017-2018		84.033 84.033	P033A161246 P033A171246	365,783 3,062,324	-
		Federal Work-Study 2018-2019		84.033	P033A171246 P033A181246	88,602	_
		Federal Work-Study Administrative Cost Allowance FY18		84.033		80,000 3.596,709	
		Federal Perkins Loans – New Loans Issued during FY18		84.038		404,620	
		Federal Perkins Loans – Outstanding as of 9/1/17		84.038		30,778,672	_
		· · · · · · · · · · · · · · · · · · ·				31,183,292	
		Federal Pell Grant 2016-2017		84.063	P063P161371	(1,838)	_
		Federal Pell Grant 2017-2018		84.063	P063P171371	6,447,368	
		5.1.1.5.1.1			2000//12/07/	6,445,530	
		Federal Direct Loan Program 2016-2017 Federal Direct Loan Program 2017-2018		84.268 84.268	P268K171371 P268K181371	(49,938) 179,848,063	_
		Federal Direct Loan Program 2018-2019		84.268	P268K191371	6,095,443	
		Federal TEACH Grant 2017-2018		84.379	P379T181371	185,893,568	
		Federal TEACH Grant 2017-2018		84.379	P3/911813/1 Department of Education Tot		
					Department of Education for	229,308,134	
		Health Professionals Student and Primary Care - Outstanding as of 9/1/17		93.342		189,863	
					Department of Health and Human Services Tot		
Other Programs					Student Financial Assistance Cluster Tot	229,497,997	
Corporation for National and Community Service	Corporation for National and Community Service	Jumpstart Northwestern	124	94.006	920200	(2)	_
		Jumpstart Northwestern	124	94.006	Agmt 9/20/2017 // 920200	63,524 63,522	
Department of Commerce					Corporation for National and Community Service Tot	63,522	
Separation of commerce	National Institute of Standards						
	and Technology	Development of Roadmap and Consortium for Innovation in Sheet Metal Forming		11.609	70NANB14H056	51,012	1,423
	United States Patent and	Enhancing Teaching of Standards and Standards Development In U.S. Universities	60	11.U01	Subcontract Agmt 1/4/16	192	-
	Trademark Office						
		Research Conference on Innovation Economics 2016		11.U02	USPTO MOA No. 16147009-0000-001	63,042	
					Department of Commerce Tot	114,246	1,423
Department of Defense	Air Force Office of Scientific Research						
		(SECAF 2030 S&T) Air Force 2030 Science and Technology Organizational and Process Study at Northwestern University		12.800	FA9550-18-1-0302	223,949	_
	Army	,					
	Navy	24th International Workshop on Oxide Electronics		12.431	W911NF-17-1-0307	7,500	_
		24th International Workshop on Oxide Electronics		12.300	N00014-17-1-2456	6,000	
Dependenced of Education					Department of Defense Tot	237,449	
Department of Education		Online Curriculum Consortium for Accelerating Middle School (OCCAMS)	154	84.206	Award 02/02/2017 // S206A150004	(3,967)	_
		Advancing and Scaling Science Education's New Terrain (ASSENT): Developing Systemic Leadership in Connecticut	53	84.366	Agmt 5/2/16// 648-100 12060-21592-2	(16,623)	_
					Department of Education Tot		

Supplementary Schedule of Expenditures of Federal Awards

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-throu to subrecipien
Department of Health and	- Cubugeney			U. DA			Cabreelpier
Human Services							
		Illinois Perinatal Quality Collaborative Partnership (ILPQC) – Federal Flow-through	104	93.667	FCSWU04929//G17011LSOSR	\$ 24,270	
	Centers for Disease Control and Prevention						
	Flevenuon	Promoting Adolescent Health Through School-Based HIV-STD Prevention and School-Based Surveillance	43	93.079	15-0303-PRC2//5U87PS004162-03	23,864	12,3
		Hepatitis C Community Alliance for Testing and Treatment in Chicago (HepCCATT)	228	93.270	FP058209-B//5NU51PS004607	72,354	
		Meeting the Needs of Early Childhood Systems to Integrate Evidence-Based Parenting Programs Assuring Comprehensive Prevention and Treatment for Families Affected by HIV to Eliminate Perinatal	19	93.424	33-18-8812//6NU38OT000140-05-02	43,530	10,5
		HIV Transmission in the United States	255	93.939	34-5311-3017-001//NU65PS923665	20,895	
Department of Health and		Evaluation Center Extension to Evaluate PrEP Implementation and Data to Care Services Strengthening the Infrastructure of the Evaluation Center	41 41	93.940 93.940	CONTRACT PO #42045/236320/50105365//U62PS005021 CDPH032017//NU62PS003644-05-05	147,639 29,492	5,3
Human Services (continued)		Strengthening the intrastructure of the Evaluation Center	41	93.940	CDPH032017//N062PS003644-05-05		
						177,131	5,2
		Illinois Perinatal Quality Collaborative Working Together for Healthier Moms and Babies in Illinois		93.946	1NU58DP006360-02-00	183,500	63,0
		The HIV Outpatient Study (HOPS) Activity to Abstract Data from Persons Receiving Ambulatory Care for HIV Infection in the United States (the "Prime Agreement")	39	93.U03	Agr. 11/19/2015 // 200-2015-63931	185,361	
	Centers for Medicare & Medicaid	Hiv intection in the onited states (the Prime Agreement)	39	93.003	Agi. 11/19/2015 // 200-2015-65931	105,301	
	Services						
		Great Lakes Practice Transformation Network MACRA-Provider Resource Network (M-PRN)	108 7	93.638 93.U04	5345/L1CMS331444-02-00 SC-17-009//HHSM-500-2017- 00004	4,304,727 367,304	3,084, 35.
	Substance Abuse and Mental		,	35.004	00-17-008/1110W-00-2017-00004	307,304	55,
	Health Services	Center for Child Trauma Assessment and Service Planning		93.243	5U79SM061254-04	64,652	
		Center for Child Trauma Assessment. Services and Interventions		93.243	5U79SM080018-03	658.349	78,
		Lake County BHTCC	57	93.243	LC# 15058//H79SM061684	(1,149)	
						721,852	78,
					Department of Health and Human Services Tota	6,124,788	3,289,
	Department of Homeland Security	DHS Center of Excellence for Accelerating Operational Efficiency (CAOE) – Preaward Planning Meeting	17	97.077	Agmt 11/2/2017	11,738	
				07.077	Department of Homeland Security Tota		
Dependence of Insting					Department of Homeland Security For		
Department of Justice	Bureau of Justice Assistance						
		Center on Wrongful Convictions of Youth		16.746	2016-FA-BX-0001	136,761	
	Office on Violence Against Women						
		Northwestern University Proposal for OVW 2014 Grant to Reduce Sexual Assault, Domestic Violence,					
		Dating Violence, and Stalking on Campus		16.525	2014-WA-AX-0006	47,922	
					Department of Justice Tota	184,683	
Department of Labor							
	Occupational Safety and Health Administration						
		Northwestern university machine hazards and machine guarding training for students and young					
		workers ages 16-24		17.502	SH-31214-17-60-F-17	139,038	
					Department of Labor Tota	139,038	
Department of State							
		Young African Leaders Initiative Young African Leaders Initiative	118 118	19.009 19.009	FY17-YALI-BE-NWU-04//SECAGD16CA1146 FY18-YALI-BE-NWU-05	3,204 121,953	
			110	10.000		125,157	
					Agmt Signed 5/8/14		
		Establishment of a Center of Journalism Excellence Fulbright Pre-Departure Orientation 2017-2018	117 112	19.501 19.U05	FSC1801 NWU 4.23.18//S-ECAGD-18-CA-1024	50,227 124,462	
		Establishment of a Center of Journalism Excellence Fulbright Pre-Departure Orientation 2017-2018			FSC1801 NWU 4.23.18//S-ECAGD-18-CA-1024	124,462	
Department of Veterano					FSC1801 NWU 4.23.18//S-ECAGD-18-CA-1024 Department of State Tota	124,462	
Department of Veterans Affairs					FSC1801 NWU 4.23.18//S-ECAGD-18-CA-1024	124,462	
Department of Veterans Affairs	VHA Office of Informatics and				FSC1801 NWU 4.23.18//S-ECAGD-18-CA-1024	124,462	
	VHA Office of Informatics and Analytics	Fulbright Pre-Departure Orientation 2017-2018		19.U05	FSC1801 NWU 4.23.18//S-ECAGD-18-CA-1024 Department of State Tota	124,462 I 299,846	
					FSC1801 NWU 4 23.18//S-ECAGD-18-CA-1024 Department of State Tota	124,462 1 299,846 3,369	
Affairs		Fulbright Pre-Departure Orientation 2017-2018		19.U05	FSC1801 NWU 4.23.18//S-ECAGD-18-CA-1024 Department of State Tota	124,462 1 299,846 3,369	
Affairs National Aeronautics and		Fulbright Pre-Departure Orientation 2017-2018		19.U05	FSC1801 NWU 4 23.18//S-ECAGD-18-CA-1024 Department of State Tota	124,462 1 299,846 3,369	
Affairs		Fulbright Pre-Departure Orientation 2017-2018 Intergovernmental Personnel Agreement (IPA) Assignment Agreement for Madhusudhana C. Reddy Meteoritic Nanodiamond Analysis by Atom-Probe Tomography	285	19.U05 64.018 43.001	FSC1801 NWU 4.23.18//S-ECAGD-18-CA-1024 Department of State Tota Agmt 05/13/2016 Department of Veterans Affairs Tota WU-14-06-MOD-2//NNX13AF53G	124,462 299,846 3,369 4 3,369 (3,009)	
Affairs National Aeronautics and		Fulbright Pre-Departure Orientation 2017-2018 Intergovernmental Personnel Agreement (IPA) Assignment Agreement for Madhusudhana C. Reddy	112	19.U05 64.018	FSC1801 NWU 4 23.18//S-ECAGD-18-CA-1024 Department of State Tota Agmt 05/13/2016 Department of Veterans Affairs Tota	124,462 1 299,846 3,369 1 3,369 (3,009) 33,881	
Affairs National Aeronautics and		Fulbright Pre-Departure Orientation 2017-2018 Intergovernmental Personnel Agreement (IPA) Assignment Agreement for Madhusudhana C. Reddy Meteoritic Nanodiamond Analysis by Atom-Probe Tomography	285	19.U05 64.018 43.001	FSC1801 NWU 4.23.18//S-ECAGD-18-CA-1024 Department of State Tota Agmt 05/13/2016 Department of Veterans Affairs Tota WU-14-06-MOD-2//NNX13AF53G	124,462 299,846 3,369 4 3,369 (3,009)	

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

Cluster title/Federal grantor	Subagency	Project title	Pass- through ID number	CFDA	Sponsor award number	Federal expenditures	Passed-through to subrecipients
National Foundation of the							
Arts and Humanities		Avalon Media System: Integrating audiovisual collections with research, digital preservation, and a sustainable developer community Beyond the Repository: Integrating Local Preservation Systems with National Distribution Services		45.312 45.312	LG-70-17-0042-17 LG-72-16-0135-16	\$ 345,101 	133,450
						373,658	133,450
		Digging Deeper, Reaching Further: Libraries Empowering Users to Mine the HathiTrust Digital Library Resources	238	45.313	077281-15575//RE-00-15-0112-15	5,929	-
National Foundation of the Arts and Humanities (continued)	National Endowment for the Arts	National Endowment for the Arts Research Labs William Blake and the Age of Aquarius	278	45.024 45.024	UNIV59613 // DCA 2017-05 17-4400-7128	67,745 20,000	53,912
						87,745	53,912
	National Endowment for the						
	Humanities	The American Indian Center of Chicago and Urban Native American Histories The Digital Berkeley Folk Music Festival Collection		45.149 45.149	PY-258677-18 PW-253873-17	7,507 111,987	
						119,494	_
		Caravans of Gold, Fragments in Time: Art, Culture, and Trans-Saharan Exchange		45.164	GE-250133-16	11,842	
					National Foundation of the Arts and Humanities Total	598,668	187,362
U.S. Agency for International Development							
		Partners in Hope Agreement May 2017 Promoting Rule of Law in Georgia	160 68	98.001 98.001	AID-OAA-A-15-00070 AID-114-A-15-00004	2,811 37,904	_
		· · · · · · · · · · · · · · · · · · ·				40,715	_
		Juventud sin Prisión	171	98.U06	1/19/16//AID-523-A-15-00010	38,659	
					U.S. Agency for International Development Total	79,374	
					Other Programs Total	7,867,003	3,478,196
Maternal, Infant, and Early Childhood Department of Health and Human Services							
		Mothers and Babies Infrastructure Mothers and Babies Training and Technical Assistance	104 104	93.870 93.870	FCSWS04131 FCSXS04131	35,076 7,106	-
		Notifers and Bables fraining and reclinical Assistance	104	93.870	FC3X304131	42,182	
	Health Resources and Services						
	Administration	Florida Statewide Mothers and Babies Training 2018-19	75	93.870	#15-23//1X10MC31134-01	4,842	_
		Statewide Mothers and Babies Course Training	75	93.505	D89MC2826//Agreement #15-23-FY1617 Department of Health and Human Services Total	38,095	
					Maternal, Infant, and Early Childhood Programs Total	85,119	
CCDF							
Department of Health and Human Services	Administration for Children and						
	Families	Improving Caregiver Quality through Observation and Individualized Instructional Feedback		93.575	90YE0159-02-00	8,071	_
					Department of Health and Human Services Total	8,071	
					CCDF Total	8,071	
Medicaid Medical Assistance Program Department of Health and Human Services	Centers for Medicare & Medicaid Services						
		Illinois Medicaid EHR Incentive Program Education and Outreach Program	103	93.778	2018-37-002	426,149	103,145
					Department of Health and Human Services Total	426,149	103,145
					Medicaid Medical Assistance Program Total Grand Total	426,149 \$ 710,053,926	103,145 63,125,558
					Grand Total	φ /10,000,920	03,123,300

See accompanying notes to supplementary schedule of expenditures of federal awards.

Supplementary Schedule of Expenditures of Federal Awards

Legend for Pass-Through Award Prime Recipients

ID	Sponsor full name
1	Acumen Pharmaceuticals, Inc.
2	Agile Sciences, Inc.
3	Albert Einstein College of Medicine, Inc.
4	Alliance for Clinical Trials in Oncology
5	Alliance for Sustainable Energy, LLC, National Renewable Energy Laboratory
6	Alliance of Chicago Community Health Services
7	Altarum Institute
8	American College of Rheumatology
9	American Heart Association
10	American Institutes for Research
11	American Lightweight Materials Manufacturing Innovation Institute
12	American Lung Association
13	American Psychiatric Association
14	Ann & Robert H. Lurie Children's Hospital
15	An-Najah National University

- 16 Aptinyx Inc.
- 17 Arizona State University
- 18 Arrevus, Inc.
- 19 Association of University Centers on Disabilities
- 20 Avar Consulting, Inc.
- 21 Battelle Memorial Institute
- 22 BBN Technologies
- 23 Benaroya Research Institute at Virginia
- 24 BloodCenter of Wisconsin, Inc.
- 25 Blue Marble Space
- 26 Booz, Allen & Hamilton Inc.
- 27 Bose Corporation
- 28 Boston College
- 29 Boston Medical Center
- 30 Boston University
- 31 Brigham and Women's Hospital
- 32 Brown University
- 33 California Institute of Technology, Jet Propulsion Laboratory
- 34 Carnegie Institution of Washington
- 35 Carnegie Mellon University
- 36 Case Western Reserve University
- 37 Cedars-Sinai Medical Center
- 38 Celdara Medical, LLC
- 39 Cerner Corporation
- 40 Chicago Association for Research and Education in Science
- 41 Chicago Department of Public Health
- 42 Chicago Housing Authority

Supplementary Schedule of Expenditures of Federal Awards

Legend for Pass-Through Award Prime Recipients

Year ended August 31, 2018

Sponsor full name
Chicago Public Schools
Children's Hospital Boston
Children's Hospital of Philadelphia
Cincinnati Children's Hospital Medical Center
Citrine Informatics
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cold Spring Harbor Laboratory
Columbia University
Communication Disorders Technology, Inc.
Community Action Project of Tulsa County, Inc.
Connecticut Science Center
CONRAD Program
COPD Foundation
Cornell University
County of Lake
Covitect Inc.
D&S Consultants, Inc.
Dakota Consulting, Inc.
Dartmouth College
DePaul University
DermaXon LLC
Digital Optics Technologies, Inc. Dow Chemical Company
Duke University
Eastern Virginia Medical School
East-West Management Institute Inc.
ECOG-ACRIN Medical Research Foundation, Inc.
Elorac, Inc.
EMMES Corporation
Emory University
Engineering and Software System Solutions, Inc.
Fermi Research Alliance, LLC, Fermi National Acceloratory Laboratory
Florida Association of Healthy Start Coalitions, Inc.
Florida State University
Ford Motor Company
Forsyth Institute
Frontier Science and Technology Research Foundation
FuelCell Energy, Inc.
Fundação Faculdade de Medicina
Gallaudet University
General Motors Corporation
George Washington University

Supplementary Schedule of Expenditures of Federal Awards

Legend for Pass-Through Award Prime Recipients

ID	Sponsor full name
85	Georgetown University
86	Georgia Institute of Technology
87	Georgia State University
88	Gold T-Tech, Inc.
89	Government of Israel Ministry of Defense Mission to the USA
90	Great Lakes Hemophilia Foundation
91	Greenway Energy LLC
92	Grzybowski Scientific Inventions, Ltd.
93	Harvard Pilgrim Health Care, Inc.
94	Harvard University
95	Health Research, Incorporated
96	Hektoen Institute for Medical Research
97	Honeywell Federal Manufacturing & Technologies, LLC
98	Houston Methodist Research Institute
99	Howard Brown Health Center
100	Icahn School of Medicine at Mount Sinai
101	ICF International, Inc.
102	ICON Clinical Research, LLC
103	Illinois Department of Healthcare and Family Services
104	Illinois Department of Human Services
105	Illinois Department of Public Health
106	Illinois Institute of Technology
107	Indiana University
108	Indiana University Purdue University Indianapolis
109	Innoblative Designs, Inc.
110	Innovative Design Labs, Inc.
111	Institute for Cancer Research
112	Institute of International Education, Inc.
113	Intact Genomics, Inc.
114	Integrated Protein Technologies, Inc.
115	International AIDS Vaccine Initiative
116	International Business Machines Corporation
117	International Center for Journalists
118	International Research & Exchanges Board
119	Iowa State University
120	Jaeb Center for Health Research
121	Joan and Sanford I. Weill Medical College
122	Johns Hopkins University
123	Joslin Diabetes Center, Inc.
124	Jumpstart for Young Children, Inc.
125	Kaiser Foundation Research Institute
126	Leidos Biomedical Research, Inc.

Supplementary Schedule of Expenditures of Federal Awards

Legend for Pass-Through Award Prime Recipients

ID	Sponsor full name
127	Leidos, Inc.
128	Los Alamos National Security, LLC, Los Alamos National Laboratory
129	Loyola University Chicago
130	Lynntech, Inc.
131	Massachusetts General Hospital
132	Massachusetts Institute of Technology
133	Materials and Electrochemical Research Corporation
134	Mathematica Policy Research, Inc.
135	Mayo Clinic
136	Mayo Clinic Jacksonville
137	Medical College of Wisconsin
138	Medical University of South Carolina
139	MedPro Technologies, LLC.
140	Metropolitan Family Services
141	Michigan State University
142	National Association of Chronic Disease Directors (NACDD)
143	New England Research Institute, Inc.
144	New School
145	New York University
146	New York University School of Medicine
147	Nious Technologies Incorporated
148	Northrop Grumman Corporation
149	NorthShore University HealthSystem Research Institute
150	Nour, LLC
151	NRG Oncology Foundation, Inc.
152	NuMat Technologies, Inc.
153	Office of Naval Research
154	Ohio Department of Education
155	Ohio State University
156	Opto-Knowledge Systems, Inc.
157	Oregon Health & Science University
158	Pacific Northwest National Laboratory
159	Pancreatic Cancer Action Network, Inc.
160	Partners in Hope
161	Pennington Biomedical Research Center
162	Pennsylvania State University
163	Princeton University
164	Protabit LLC
165	Purdue University
166	Queens College, CUNY
167	QuesTek Innovations LLC
168	RAND Corporation

Supplementary Schedule of Expenditures of Federal Awards

Legend for Pass-Through Award Prime Recipients

ID	Sponsor full name
169	Rehabilitation Institute of Chicago
170	Rehabilitation Institute Research Corporation
171	Reinserta un Mexicano, A.C.
172	Rensselaer Polytechnic Institute
173	Research Foundation for Mental Hygiene, Inc.
174	Research Triangle Institute
175	Rho Federal Systems Division, Inc.
176	Rockefeller University
177	Rosalind Franklin University of Medicine and Science
178	Rush University Medical Center
179	Rutgers University, the State University of New Jersey
180	RxGen, Inc.
181	SAFCell, Inc.
182	Salzman Group, Inc.
183	Sanford Burnham Prebys Medical Discovery Institute
184	Scripps Research Institute
185	Seattle Children's Hospital
186	SIMmersion LLC
187	Smithsonian Astrophysical Observatory
188	Social & Scientific Systems, Inc.
189	Southern Methodist University
190	Space Telescope Science Institute
191	Spaulding for Children (MI)
192	SRI International
193	Stanford University
194	StarSight, Inc.
195	State University of New York Health Science Center at Brooklyn
196	Swedish Medical Center
197	Synvitrobio, Inc.
198	Teaching Channel
199	Technion - Israel Institute of Technology
200	Technology Assessment and Transfer, Inc.
201	
202	Texas Biomedical Research Institute
203	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
204	Thomas Jefferson University
205	Tufts Medical Center, Inc.
206	Tufts University
207	
208	U.S. Civilian Research & Development Foundation

- 209 UChicago Argonne, LLC, Argonne National Laboratory
- 210 UI Labs

Supplementary Schedule of Expenditures of Federal Awards

Legend for Pass-Through Award Prime Recipients

Year ended August 31, 2018

Sponsor full name		

252 University of Mississippi Medical Center

Supplementary Schedule of Expenditures of Federal Awards

Legend for Pass-Through Award Prime Recipients

Year ended August 31, 2018

ID Sponsor full name 253 University of Missouri-Columbia 254 University of Nebraska at Kearney 255 University of Nebraska Medical Center 256 University of New Hampshire 257 University of North Carolina at Chapel Hill 258 University of Notre Dame 259 University of Pennsylvania 260 University of Pittsburgh 261 University of Rochester 262 University of Southern California 263 University of Tennessee 264 University of Texas at Austin 265 University of Texas at Dallas 266 University of Texas at San Antonio 267 University of Texas Health Science Center 268 University of Texas M. D. Anderson C 269 University of Texas Medical Branch at Galveston 270 University of Texas Southwestern Med University of Utah 271 272 University of Virginia 273 University of Washington 274 University of Wisconsin-Madison 275 University of Wisconsin-Milwaukee 276 University of Wisconsin-Whitewater 277 UT-Battelle, LLC, Oak Ridge National Laboratory 278 Vanderbilt University 279 Veterans Medical Research Foundation of San Diego 280 Vidrio Technologies, LLC 281 Vignet Inc. 282 Virginia Commonwealth University 283 Virginia Polytechnic Institute and State University 284 Wake Forest University Health Sciences 285 Washington University in St. Louis 286 Wearifi. Inc. 287 West Virginia University 288 WestEd 289 Yale University

Notes to Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

(1) Organization and Scope of Operations

Northwestern University (the University) is a not-for-profit corporation organized under the laws of the State of Illinois, whose charter establishes a Board of Trustees to oversee the implementation of its mission to carry out research and education. All federal expenditures of the University are included in the scope of the U.S. Office of Management and Budget Circular OMB Single Audit Report. The U.S. Department of Health and Human Services has been designated as the University's cognizant agency for the single audit.

(2) Summary of Significant Accounting Policies

Basis of Accounting – The accompanying supplementary schedule of expenditures of federal awards (the Schedule) summarizes the expenditures of the University and its subsidiaries under programs of the federal government for the year ended August 31, 2018. The Schedule is prepared on the accrual basis of accounting. Since the Schedule presents only a selected portion of the operations of the University, it is not intended to, and does not, present the consolidated financial position or changes in net assets of the University.

For purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between the University and agencies and departments of the federal government and all subawards to the University by nonfederal organizations pursuant to federal grants, contracts, and similar agreements. Complete CFDA numbers and pass-through numbers are provided on the Schedule when available.

Indirect Costs – The University has negotiated indirect cost rates with the U.S. Department of Health and Human Services. The University does not use the de minimis F&A rate described in 2 CFR 200.414 of the Uniform Guidance.

Expenditure and Revenue Recognition – The Schedule presents the expenditures of individual programs on the accrual basis of accounting. All program outlays, including accrued expenditures and capital outlays, are reported as expenditures. Related revenues (which are not presented herein) are recognized up to award amounts for financial statement and program reporting. Award reporting periods do not necessarily coincide with the fiscal reporting period of the University. Negative amounts presented in the Schedule represent adjustments, in the normal course of business, to expenditures reported in prior years.

Pass-Through Awards – The University receives certain federal awards from pass-through awards of the State of Illinois and other nonfederal organizations. The total amount of expenditures for such pass-through awards is included in the Schedule.

Subrecipients – The University passes through certain funds to subrecipient organizations. The total amount of such subrecipient expenditures is included in the Schedule for each federal award, where applicable.

De Minimis F&A – The University applies the 10% de minimis F&A rate to modified total direct costs (MTDC) to subawards if the subrecipient does not receive an approved negotiated F&A rate as described in 2 CFR 200.414 of the Uniform Guidance.

Notes to Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2018

(3) Federal Student Loan Programs

Loans made by the University to eligible students under federal student loan programs and federally guaranteed loans originating with the University and issued to its students during the year ended August 31, 2018, are summarized as follows:

Federal Perkins Loan Program (CFDA 84.038)	\$	404,620
Federal Direct Loan Programs (CFDA 84.268)		179,848,063
HPSL Primary Care Loans (CFDA 93.342)	_	
Total Federal Student Loan Programs	\$_	180,252,683

The Perkins and Health Professions Student Loan (HPSL) programs are administered directly by the University and balances and transactions relating to these programs are included in the University's consolidated financial statements. The balances of loans outstanding under the Perkins (CFDA 84.038) and HPSL (CFDA 93.342) programs were \$24,280,878 and \$188,251, respectively, at August 31, 2018. The University incurred \$80,000 and \$0 in administrative expenses under the Federal Work Study and Perkins programs, respectively, for the year ended August 31, 2018.



KPMG LLP Aon Center Suite 5500 200 E. Randolph Street Chicago, IL 60601-6436

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

The Board of Trustees Northwestern University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Northwestern University (the University), which comprise the consolidated statement of financial position as of August 31, 2018, the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 19, 2018.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's consolidated financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of consolidated financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



Chicago, Illinois December 19, 2018



KPMG LLP Aon Center Suite 5500 200 E. Randolph Street Chicago, IL 60601-6436

Independent Auditors' Report on Compliance for Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

The Board of Trustees Northwestern University:

Report on Compliance for Major Federal Program

We have audited Northwestern University's (the University's) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on the University's major federal program for the year ended August 31, 2018. The University's major federal program is identified in the summary of auditors' results Section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for the University's major federal program based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance)*. Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the University's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the University's major federal program. However, our audit does not provide a legal determination of the University's compliance.

Opinion on Major Federal Program

In our opinion, Northwestern University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended August 31, 2018.

Other Matters

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as items 2018-001 and 2018-002. Our opinion on the University's major federal program is not modified with respect to these matters.



The University's responses to the noncompliance findings identified in our audit are described in the accompanying schedule of findings and questioned costs. The University's responses were not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the responses.

Report on Internal Control Over Compliance

Management of the University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies in internal control over compliance that we consider to be material weaknesses. However, we identified certain deficiencies in internal control over compliance, as described in the accompanying schedule of findings and questioned costs as items 2018-001 and 2018-002, that we consider to be significant deficiencies.

The University's responses to the internal control over compliance findings identified in our audit are described in the accompanying schedule of findings and questioned costs. The University's responses were not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the responses.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



Report on Supplementary Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the consolidated financial statements of the University as of and for the year ended August 31, 2018, and have issued our report thereon dated December 19, 2018, which contained an unmodified opinion on those financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.



Chicago, Illinois May 30, 2019

Schedule of Findings and Questioned Costs Year ended August 31, 2018

(1) Summary of Auditors' Results

- (a) Type of report issued on whether the consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles: Unmodified
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial statements:
 - Material weaknesses: No
 - Significant deficiencies: None reported
- (c) Noncompliance material to the consolidated financial statements: No
- (d) Internal control deficiencies over major program disclosed by the audit:
 - Material weaknesses: No
 - Significant deficiencies: Yes
- (e) Type of report issued on compliance for major program: Unmodified
- (f) Audit findings that are required to be reported in accordance with 2 CFR 200.516(a): Yes
- (g) Major program:
 - Research and Development Cluster Various CFDA numbers
- (h) Dollar threshold used to distinguish between Type A and Type B programs: \$3,000,000
- (i) Auditee qualified as a low-risk auditee: Yes
- (2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with *Government Auditing Standards*

None

Schedule of Findings and Questioned Costs

Year ended August 31, 2018

(3) Findings and Questioned Costs Relating to Federal Awards:

Finding 2018-001	Inadequate Process for Updating Property Management Records
Federal Agency:	Corporation for National and Community Service (CNCS) U.S. Agency for International Development (USAID) U.S. Department of Agriculture (USDA) U.S. Department of Commerce (USDOC) U.S. Department of Defense (USDOD) U.S. Department of Education (USDE) U.S. Department of Education (USDE) U.S. Department of Health and Human Services (USDHHS) U.S. Department of Health and Human Services (USDHHS) U.S. Department of Homeland Security (USDHS) U.S. Department of Housing and Urban Development (USHUD) U.S. Department of Interior (USDOI) U.S. Department of Justice (USDOJ) U.S. Department of Justice (USDOJ) U.S. Department of State (USDOS) U.S. Department of State (USDOS) U.S. Department of Veterans Affairs (USDVA) U.S. Department of Veterans Affairs (USDVA) U.S. Social Security Administration (USSA) National Aeronautics and Space Administration (NASA) National Endowment for the Humanities (NEH) National Science Foundation (NSF) Nuclear Regulatory Commission (NRC) Scholarship Foundations All Pass-Through Entities
Program Name:	Research and Development Cluster
CFDA # and Program Expenditures:	Various (\$472,169,587)
Federal Award Numbers:	Various – See schedule of award numbers
Federal Award Year:	Various – See schedule of award numbers
Questioned Costs:	None

Condition Found

The University did not consistently follow property management regulations relative to equipment purchased with federal funding from the Research and Development (R&D) Cluster program.

Schedule of Findings and Questioned Costs

Year ended August 31, 2018

The University conducts research and development activities in multiple locations on its Chicago and Evanston campuses. Equipment items purchased with federal funds are utilized at both of these locations. The University identifies all equipment in its property management records with individually assigned asset numbers and each individual asset record includes the specific location of the asset, the federal award general ledger account number which funded the purchase of the asset, and other required information. An asset tag with the assigned asset number is affixed to each asset in accordance with University policy.

During our physical observation of 40 pieces of equipment purchased with R&D Cluster funds, we noted 6 items included on the R&D Cluster inventory list (with a cost value of \$641,848 and a net book value of \$225,122) that could not be located for observation. It was determined that these items had been disposed of previously; however, the property records had not been updated to reflect the disposals.

While the University has documented policies and procedures which have been communicated and are available to University staff and the University's control procedures include performing a biennial inventory, monitoring procedures to verify equipment records are accurate are not operating at a sufficient level of precision to identify all disposals that have not been reported by decentralized units in a timely and complete manner.

As of August 31, 2018, the cost value of equipment purchased with R&D Cluster funds was \$187,740,626 (with a net book value of \$41,330,066).

Criteria

According to 2 CFR 200.313(c), equipment must be used in the program which acquired it or, when appropriate, other federal programs. 2 CFR 200.313(d) requires a non-Federal entity to establish a control system to safeguard equipment and to ensure equipment is adequately maintained. 2 CFR 200.313(e) also requires the nonfederal entity to request disposition instructions from the Federal awarding agency, if required by the terms and conditions of the Federal award, when equipment is no longer needed.

In addition, 2 CFR 200.303 requires nonfederal entities to, among other things, establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. Effective internal controls should include establishing procedures to ensure equipment inventory records are accurate and updated for disposals in a timely and complete manner.

Cause

In discussing these conditions with University officials, they stated the property records were not updated for the disposals tested due to the departments not communicating the updates in a timely manner.

Possible Asserted Effect

Failure to maintain accurate property results in noncompliance with federal requirements and may result in federal approvals not being obtained when required and federal programs not receiving the appropriate share of proceeds from disposals of equipment purchased with federal funds.

Repeat Finding

A similar finding was not reported in the prior year audit.

Schedule of Findings and Questioned Costs Year ended August 31, 2018

Statistical Sampling

The sample was not intended to be, and was not, a statistically valid sample.

Recommendation

We recommend the University implement procedures to ensure property records are updated in a timely manner to reflect equipment disposals.

Views of University Officials

Management agrees. Exceptions noted during external audit interim fieldwork were corrected for fiscal year end close. Additional efforts to identify and record potential missing disposals for the fiscal year 2018 re-inventory process were also implemented (as described below in steps 1-4).

In fiscal year 2019, Accounting Services shall reiterate proper procedures to department Unit Representatives regarding the disposition of equipment, including timely submission of disposal requests.

In addition, Accounting Services shall continue the following steps introduced in summer 2018 designed to enhance controls around completeness and accuracy of disposals:

- 1. Department representatives submit individual asset disposal requests through NU Financials.
- 2. Department representatives submit biennial re-inventory sheets to Accounting Services.
- 3. Accounting Services compares disposals per the biennial re-inventory sheets to requests per NU Financials for completeness and accuracy.
- 4. Accounting Services then follows up on discrepancies with department representatives as necessary.

Note: Previously, Accounting Services made the disposal entries based on the biennial re-inventory sheets alone.

Further in fiscal year 2019, Accounting Services shall perform its own audit of the re-inventories prepared by the department Unit Representatives. This entails judgmentally selecting assets from the re-inventory sheets, and verifying the existence of assets and accuracy of the information (e.g., location, custodian, etc.) through observation. Accounting Services will judgmentally gear its sample towards higher risk items, including higher dollar values and older assets. In addition, Accounting Services' audit sample size shall increase to address risks highlighted from this control activity observation.

These procedures will be fully in place before August 31, 2019.

Schedule of Findings and Questioned Costs

Year ended August 31, 2018

Finding 2018-002	Untimely Completion of Subrecipient Single Audit Desk Reviews
Federal Agency: Program Name:	Corporation for National and Community Service (CNCS) U.S. Agency for International Development (USAID) U.S. Department of Agriculture (USDA) U.S. Department of Commerce (USDOC) U.S. Department of Defense (USDOD) U.S. Department of Education (USDE) U.S. Department of Energy (USDOE) U.S. Department of Henergy (USDOE) U.S. Department of Homeland Security (USDHS) U.S. Department of Homeland Security (USDHS) U.S. Department of Homeland Security (USDHS) U.S. Department of Housing and Urban Development (USHUD) U.S. Department of Interior (USDOI) U.S. Department of Justice (USDOJ) U.S. Department of Labor (USDOL) U.S. Department of State (USDOS) U.S. Department of State (USDOS) U.S. Department of Veterans Affairs (USDVA) U.S. Department of Veterans Affairs (USDVA) U.S. Social Security Administration (USSSA) National Aeronautics and Space Administration (NASA) National Endowment for the Humanities (NEH) National Science Foundation (NSF) Nuclear Regulatory Commission (NRC) Scholarship Foundations All Pass-Through Entities Research and Development Cluster
CFDA # and Program Expenditures:	Various (\$472,169,587)
Federal Award Numbers:	Various – See schedule of award numbers
Federal Award Year:	Various – See schedule of award numbers
Questioned Costs:	None

Condition Found

The University does not have adequate controls in place to ensure single audit desk reviews are completed on a timely basis for subrecipients of the Research and Development (R&D) Cluster program.

The University requires subrecipients who expend more than \$750,000 in federal awards during the subrecipient's fiscal year to submit a single audit report. University staff in Accounting Services for Research and Sponsored Programs (ASRSP) are responsible for reviewing these reports, determining whether required audits are completed, and issuing management decisions on findings reported for the awards passed through by the University within required time frames.

Schedule of Findings and Questioned Costs

Year ended August 31, 2018

During our testing of single audit reports for 40 subrecipients (with aggregate expenditures of \$34,503,656), we noted that single audit desk reviews for 10 of those subrecipients (with total expenditures of \$8,346,825) were not performed on a timely basis. Specifically, the single audit report reviews were not completed within six months after the report was accepted by the Federal Audit Clearinghouse. Delays in reviewing these reports ranged from 7 to 164 days.

While none of the reports that were reviewed late contained findings requiring the University to issue a management decision, the timing of the University's review procedures would not permit compliance with the requirement to issue management decisions within six months.

Amounts passed through to subrecipients of the R&D Cluster program during the year ended August 31, 2018 were \$59,544,217. Total R&D Cluster program expenditures for the year ended August 31, 2018 were \$472,169,587.

Criteria

According to 2 CFR 200.331(d)(3) and 2 CFR 200.521 require that a pass-through entity is required to issue a management decision on audit findings within six months after receipt of the subrecipient's audit report and ensure that the subrecipient takes timely and appropriate corrective action on all audit findings.

Additionally, 2 CFR 200.303 requires non-Federal entities receiving Federal awards establish and maintain internal control designed to reasonably ensure compliance with Federal laws, regulations, and program compliance requirements. Effective internal controls should include procedures to monitor whether (1) federal awards passed through to subrecipients have been properly included in the subrecipient's single audits, (2) subrecipients expending \$750,000 or more in Federal awards during the subrecipient's fiscal year have met the audit requirements of Uniform Guidance, including that the audits are completed within nine months after the end of the subrecipient's fiscal year end, (3) the subrecipient audit reports are reviewed in a timely manner, and (4) management decisions on reported findings are issued within six months after acceptance of the subrecipient's audit reports by the Federal Audit Clearinghouse.

Cause

In discussing these conditions with University officials, they stated the Standard Operating Procedures should better reflect the prioritization needed to complete the reviews in a timely and compliant manner.

Possible Asserted Effect

Failure to review subrecipient single audit reports in a timely manner could result in the University not issuing management decisions within required timeframes.

Repeat Finding

A similar finding was not reported in the prior year audit.

Statistical Sampling

The sample was not intended to be, and was not, a statistically valid sample.

Schedule of Findings and Questioned Costs Year ended August 31, 2018

Recommendation

We recommend the University review its current procedures to determine the necessary changes needed to ensure single audit reports are reviewed on a timely basis and any management decisions are issued within required timeframes.

Views of University Officials

Management agrees. Although these desk reviews were not completed within the required timeframe, none of the reviews required the issuance of management decisions to mitigate compliance risks. The University has implemented necessary steps to ensure that the desk reviews, and issuance of management decisions, if necessary, will be made within six months of the audit report acceptance date from the Federal Audit Clearinghouse (FAC).

Schedule of Findings and Questioned Costs

Table of Award Numbers Year ended August 31, 2018

Year ended August 31,

Name of Federal Program or Cluster (CFDA #)

Research and Development Cluster (Various):

Award Number 920200 0000025075//7R01DC014463-02 0000025075//7R01DC014463-02 0000755//5R01HL115813-04 00004897/HHSN261201200034I 00004892//HHSN261201200034I 00009667/ 1330914 000054653-SC002//5R01AR064820-03 000507860-008//W81XWH-15-1-0705 000514985-001//7R01HL131110-03 0007A-6 Mod 1 // N00014-14-14-2-0002 0012774A//5R01MH112768-02 REVISED 0012774A//5R01MH112766-02 REVISED 001-Amend1/5U01H1.129854-03 001C-08//HISH25201400001C 001C-08//HISH25201400001C 002/5U01H128954-03 003928 (124432-1)/5R56DC031272-02 0039151 5(011529-3) // OCE-1331463 003805 (124684-1)/5R01LM011663-04 0038377 (1245412-1)/5R01MH07533-15 0041119 (124864-3)//1R01MD009118-02 0041119(124864-6)//R01MD009118-02 0041119(124864-6)/Ro1MD009118-02 0046483(126383-1)//1R34MH107541-03 0046528(126659-1)//5R01MH107540-03 00677269(12836-2)//5R01MH107540-03 0050794(12001-6)/5R01M6034852-06 0055353(130910-17)//5UL1TR01857-03 010085-110021//1U01NS092076-01A1 R 01023-03230 Mod. 4//R305C120008 010314-003//5R01HD086170-02 010535-07(2.8456)-17-2-6C19 010635-002//FA8650-17-2-6G19 010785-133385//1U01NS095869-02 011275-002//R305A170640-17 A1/A2 01353-NoA-NWU03//6D33HP29245-01-01 01353-NoA-NWU03/kD33HP29245-01 0169-81148/R01CA204231-01 0214047//1U10HL119991 0220160021 // W31P4Q-14-2-0001 0254-3244-4609//U1N30H3106754-05 0254-4051-4609//U1N3091148 0255-1024-4609//U0N3091148 0255-1514-609//K01AC054008-03 0252-0024-609//EUN20020327.05 0255-2292-4609//5UG3OD023337-02 0255-3801-4609//1R01CA214491-01A1 0255-8633-4609//5U19AI118610-04 0225-863-4609//SU194/118610-04 0255-861-4609//SU194/118610-03 0255-8783-4609//SU194/118610-03 0255-8783-4609//SU191126508-03 0255-8784-4609//SU11126508-04 0255-4784-4704/DB1-126 0521 G RA12-005 Amd. 4// DB1-126 0521 G RA12-1005 Amd. 4// DB1-126 0521 G RA12-005 Amd. 4// DB1-126 05744-51-5145 03 // P015A10045 074403-1549 3 Amd 01 // 1 R25 OD20203 079601-1631-01 // G16AP00051 080-27000-527101//R01CA207468-01A1 080-3105-527501//R18HS025651 08062-NU SUB//CRB-HLB1-5-10-00076 08262-0139767/SUD10K97093-05 0255-8661-4609//5U19AI118610-03 08649005-319676//5U01DK97093-05 087147-16468 // CBET-1706219 0875 G SA507 Amd No. 4 // 5R01MH100177-05 1 CPIMP151087-01-00 1 R01 CA214928-0141 1 U01NS093663-01A1 1 (GG008480)//1R01MH1094696-02 1(GG010108-17)//5P01GM105536-05 1(GG010550) // N00014-16-1-2152 Amd 5 1(GG010550) // N00014-16-1-2152 Amd 5 1(GG011995-01)//R01080118584-01A1 1(GG012114-01)//R011NR015737-03 1(GG013015-01)//R011NE015737-03 1(GG013015-01)//R011NE-14-1-0378 10000 G SA978 Amd 2 // W911NE-14-1-0378 1000001715//R011HL121293-04 1000062/2UC4DK101108-02 10012005-5001-Amend01//SR01AR060364-07 100143305/SU01DK070431-11 10905-1476/EDAU/CO00140 oc 1001443305/SU01DK070431-11 1001514516//5R01HG008348-03 100169-00001//R01GM11795 10026957-03//HISN27520100007C 10027535-02//5P50GM082545-10 10034012-CHIC//K12HD047349-14 10044932-10//2P50GM082545-11 10045839-07//5U54GM119023-04 10045839-07//5U54GM119023-04 1007494_WVU Amd 2 / W81XWH-15-1-0527 1011902_NWU/U24TR002306 10356sc//W81XWH-17-1-0302 10364sc//R01HD093012-01A1 104170196//FA9550-18-1-0142 10477sc 1052335943//1R21AG057400-01 REVISED 105235943/1/R21A0057400-01 REVISED 105258c//SU01AI110658-04 105952581/ 110007//SUM1AI068636-12 REVISED 110029/A5222//SUM1AI068636-12 REVISED 110228 A5322//SUM1AI06636-12 REVISED 110237//EMIA I069526-12 110237//5UM1Al068636-12 110237//5UM1Al068636-12 110408//5U10CA180821-04 110408//5U10CA180821-05

111672//5UM1Al068636-12 111672//SUM1Al068636-12 1120566-75050/5U01EB017695-04 113896//SR01HL08851-07 114835//SR01HL08851-07 1150119-294722-P00007//FA9550-12-1-0458 115219//SUAAR060187-05 1162293//SUM1Al068636-11 415276//PD04U H004060_05 116706//2R01HL091069-06 11679SUB//1U01CE002880-0 117944//5R01AR070171-02 12052504-NU//5R01AR064251-05 12052504-NU//SR01AR064251-05 123775/W91X0H-17-1-0427 12577/W916001-15-C-4036 1295 G IA11-1//SR010GM112938-03 REVISED 13-014//P010160797 R1//DTFH61-12-D-00020 13-047/IJC4A1117804 138078-5105175 // 1019NS10465301 REVISED 13MGB00001-101//E-PBA-12-H-0012 13MGB00001-101//E-PBA-12-H-0012 13MGB00001-101//E-PBA-12-H-0012 13MGB000012 14091801//5R01HL128330-03 1427448//1R01CA218466-01 1427448//1R01CA218466-01 14-749-NU/0E-FE002307 14DNAR100006-05-00 14-MA9-Mod#4//5R01HL113550-05 15-04442-003/5R01DE023049-06 152213.5081815.0003 Amd 3 // SR01GM105375-04 152451.5080930.6043//SU01GM112623-04 153608-002//ININ12AA01C 1551539 Mod 2//R305C140008 1553381 Mod 4 // N00014-15-1-2809 1554077//IPID1D026446 6 1554072//4R01DA035484-05 1558 G VA507//5P30AG028748-12 1558 G VA507//5P30AG028748-12 15-737//R01DA0033991 15815/156532//U54CA153511 15-AO-00-05162-01/HR0011-16-20007 1604551 // N66001-17-2-4011 16081299-03//R01GM105688-05 16100402-Sub01//1R61AR073576-01 16520X A093//R21AR073377-01 16522V/1R01HD089455-01-A1 16552V/1R01HD089455-01-A1 16550/2/H014D09457-02 16659//5R01HS025177-02 16-995//1U18DP006255-01 17-009589 D Amd, 1 // AST-163662 17-009589 D Amd. 1/ AST-1636621 17-022-02/ 11615N039981-01A1 17042580//2R01GM105688-06 17-044//5U54HD047891-12 REVISED 17-073//PZCHD065702-08 1727846//183405339/AAC5754 1728-048//NH1HSN26120080001E 1782018//SNU38OT000225-05 17PA1708457 mod 2 17-S32//DE-AR0000882 17X183 // HHSN261200800001E 180042//80NSSC18K0565 180042//80NSSC18K0565 182170/18P006255 183120-02//SR01MD007562-05 18-409 // 01757-061-QA001-01 18-83997-13//SUG4HD047891-13 REVISED 19-000275 03 // W911NF-18-2-0021 1987203-6 AMEND 1UC4DK1101108-01 REVISED 1-AF-28//2R01HL098354-04 1CPIMP171141-01-00 1CPIMP181168-01-00 1DP2AI136599-01 1DP2DA042417-01 1DP2DE024365-01 1DP2EY026770-01 1DP2HL132390-01 1DP2HL132390-01 1DP3DK108248-01 REVISED 1F30AG051327-01A1 REVISED 1F30Al131937-01A1 1F30CA225133-01 REVISED 1F30DK116481-01 1F30DK116481-01 1F30HL140910-01 1E30HI 142187-01 REVISED 1r30HL142187-01 REVISED 1F31AQ051350-02 REVISED 1F31AQ055235-01A1 1F31AQ057137-01A1 REVISED 1F31CA206259-02 1F31CA210719-02 1F31CA210719-02 1F31CA213928-01 REVISED 1F31CA220801-01A1 REVISED 1E31DE026952-01A1 1F31DE026952-01A1 1F31HD089693-02 1F31NS105451-01A1 REVISED 1F32CA210498-01 1F32CA216996-01A1 REVISED 1F32DA046313-01 REVISED 1F32DC016773-01 1F32GM122349-02 1F32E094122349-02 1F32E0094552-01 REVISED 1F32E10095580-01 1F32E1L129695-02 1F32E1L140824-01 REVISED 1F32E024366-01 1F32E024366-01 1F32E024366-01 1F32NS101884-01 1F32NS106720-01 REVISED 1E32NS106812-01A1 1K01AR072773-01A

1K01DK114395-01A1 K010D026571-0 1K01OD026571-01 1K08AR070285-02 1K08DA045575-01 1K08HL141659-01 1K22AI118421-02 1K22AI136691-01 1K23HL136891-02 1K25DK113242-01A1 1K99GM123195-01A1 10T20D026557-01 REVISED 1P01DK117824-01 1P30DK114857-01A1 1P30DK114857-01A1 1P50CA221747-01A1 1P50DA044121-01A1 1R01AG054429-02 1R01AG055425-02 1R01AG057727-01A1 1R01AG058613-01 1R01Al134952-01 1R01Al137174-01 1R01Al137267-01 1R01AI140702-01 1R01AI141083-01 1R01Al141083-01 1R01AR069580-03 1R01AR071091-01A1 1R01AR072721-01A1 1R01CA212409-01A1 1R01CA217907-01A1 1R01CA218659-01A 1R01CA222963-01A 1R01CA224275-01A 1R01CA227918-01A 1R01CA228272-01 1R01CA232347-01 1R01CA232347-01 1R01DC015630-01A1 1R01DC015630-01A1 1R01DC016364-01A1 1R01DC016645-01A1 1R01DK100505-053-S2//SR01DK100790-04 1R01DK105055-02 1R01DK113011-01A 1R01DK113170-01A 1R01DK114158-01A 1R01DK114158-01A1 1R01DK116988-01 1R01DK117491-01 1R01EB026510-01 1R01ES027011-02 1R01EY028304-01A1 1R01EY028304-01A1 1R01EY029121-01 1R01EY029121-01 1R01GM113922-01A1 1R01GM124089-01A1 1R01GM124354-01A1 1R01GM126125-01A1 1R01GM126318-01A1 1R01GM126318-01A1 1R01HD085227-01A1 1R01HD089552-03 1R01HD093718-01 1R01HD093726-01 1R01HL131110-01A1 REVISED 1R01HL132978-02 1R01HI 134800-01A1 1R01HL138982-01A1 1R01HL138982-01A1 1R01HL139798-01 1R01HL139812-01 1R01HL140061-01 1R01HL140938-01A1 1R01HL140973-01 1R01HI 144129-01 1R01MD012236-01A1 1R01MD012236-01 1R01MH110524-01 1R01MH111790-03 1R01MH115265-01 1R01MH117111-01 1R01NS099334-02 1R01NS102500-01A1 1R01NS104219-01A1 REVISED 1R01NS104219-01A1 1R01NS104295-01 1R01NS105502-01A1 1R01NS106955-01A1 1R03AG050945-01A1 1R03Al137674-01 1R03CA211318-01 1R03DA040668-01A1 1R03DA040668-01 1R03DK116012-01 1R03DK116663-01 1R13AG054189-01 1R13AG055285-01 1R13Al122959-01 1R13CA224869-01 1R13DC016830-01 1R13bL016830-01 1R13HL136113-01 1R13HL142300-01 1R13HL144016-01 1R13MD011360-01 1R13NS106917-01 REVISED 1R18HS024027-03 1R18HS025359-01A1 1R18HS025649-02 1R18HS026170-01

1R21AG056903-0 1R21AG056903-01 1R21AG060203-01 1R21AG060267-01 1R21AI17238-01 1R21AI121742-01 1R21AI125968-01A1 1R21AI131035-01 1R21AI131087-01A1 1R21AI131179-01A1 1R21AI132848-01A1 1R21AI135827-01 1R21AI140029-01 1R21AI140029-01 1R21AR071705-01A1 1R21AR072263-02 1R21AR073371-01 1R21AR074292-01 1R21CA226671-01A1 1R21DA044460-01A1 1R21DC016759-01A1 1R21DC017210-01 1R21DK112066-01 1R21GM127919-01 1R21HD092671-01A1 S1 1R21HD092671-01A1 S1 1R21HD094073-01 1R21HS024071-01 REVISED 1R21HS025000-02 1R21LM012618-02 1R21LM012618-02 1R21MH115301-01A1 1R21MH115366-01 1R21NS090040-07 1R21NS107768-0 1R21OD025330-0 1R210D025330-01 1R34A1018493-01 REVISED 1R34AT009685-01 1R34DK114773-01A1 1R390T28978-01-00 1R41HL127907-01A1 NU//1R41HL127907 1R41HL127907-01A1 NU//1R41HL127907 1R50CA221848-01 1R56AG050492-01A1 1R56AG050542-01A1 1R56AG053491-01 1R56AG054207-01 1R56AG054207-01 1R56AI131239-01A1 1R56DC015492-01A1 1R56DK105824-01A1 1R56HL127245-01A1 1R56HL131745-01 1R56HL135124-01 0E56NU42022 01 1R56MH113923-01 1R56NS089626-01A1 1R61HL139852-01 1RF1AG057296-01 1RF1AG057884-01 1S100D023681-01A1 1T32MH115882-01 REVISED 1U01AI131337-01 1U19AI135964-01 1U19AI136443-01 1U19AR069526-01 REVISED 1019AR069526-01 REVISED 1024N5107213-01 1024OD023319-01 REVISED 10G1CA189828-01-NWU1//UG1CA189828-04 10G1CA189828-01-NWU2//UG1CA189828-04 10G0C023188-01 REVISED 200103-05//5R01HL122658-03 2001586404//R01Al093520 2001586404//R01AI033520 2001990789 / IBCS-1344269-001 2001995429//J01NS080824-02 2002350097/5R01HL25053-04 20025607820//R01HL126552-04 200258698 Amd 2//R01E18358-02-REVISED 2002785888 Amd 2// R01AI116324 2002911519//5U01CA196390-03 2002911513/JSU01CA196390-03 2002969467/JSP01HL107151-07 2003117335//R305A160082 2003142248 Amd 2 // 1635443 2003214618//U10EY014660 2003262020 // U01HD075957 200334134/R01EB020062 200334173/R01EB020062 2003447902//R01DK111966 2003649393//1U01AI134591-01 2003649333/1001Af134591-01 2003709195/1R39OT31103-01 2003757786//HHSP233201500020I 2011-06805-05-04-6564//5R01MH90035-2012-JR-FX-0005 2013-JF-FX-0057 201402548-02//1R01HD076189-01A1 201402548-02//1R011HD076189-01A1 2014-3122 Amd No 4//CHE-1414466 2015-01858-01 Mod. 3 // P015B140048 2015-02//1417757 2015-0220-00(78131-15789)-B8425-03//NNX154AA02 2015-6520-00(78131-15789)-B8425-03//NNX154AA02 2016-68612-002//EU19MH08780-05 2016-0366-07/B6728/E000470 00 201602366-02//5R25NS099170-02 2016-R2-CX-0039 2017-67011-26070 2017-VF-GX-K136

1R21AG049385-02

Schedule of Findings and Questioned Costs

Table of Award Numbers Year ended August 31, 2018

Name of Federal Program or Cluster (CFDA #)

Research and Development Cluster (Various):

Award Number 2018883-NW//W81XWH-15-1-0603 2018883-NW//W81XWH-15-1 203186NU // DE-NA0003763 2035489//5P01Al120756-03 2036138//7R01DK081374-11 203-7585//5R18FD005292-04 203-7618//5U10HI 084904-12 203-8360//5U10HL084904-11 REVISED 203-8439//5UM1AI104681-05 203-8439//SUM1AI104681-05 203-9512/HN8N275201000031 206423//5R01DK104842-02 223700//U10HL084904 225440//SUM1AI104681-05 229149 AZD2014//1R01CA201130-01A1 REVISED 23003023213 // FA9550-14-1-0040 05 238323//R01AR066601 27790-74573001//IOS-145714 27790-24573001///OS-145714 2D43TW 009608-06 2D43TW 009608-06 2R01Al099009-06A1 REVISED 2R01CA101774-16 2R01DK060635-16 2R01EY019484-01A1 2R01EY019484-01A1 2R01GM051350-21A1 2R01GM104530-06 REVISED 2R01GM111097-46A1 2R01HD059858-07 2R01HL051387-22 2R01HL051387-22 2R01HL064774-16 REVISED 2R01HI 115828-06A1 2R01HI 122010-05 2R01HE122010-05 2R01MH099114-06A1 2R01NS047726-13A1 2R01NS058667-05 2R01NS061963-11A1 2R56AR044016-20 2R56DC011813-06 2RF1AG017139-15 2T32GM008061-36 2T32GM008061-36 2T32GM008061-36 2T32GM008152-31 2T32GM105538-06 2T32HD007418-26 2T32MH067564-16 REVISED 2T32NS041234-16A1 REVISED 2T32NS041234-16A1 REVISED 2U01A10246-06REVISED//738161 3001001876//7R01CA172669-005 3001001952//7R01CA172669-05 300242092//5R01NS077946-04 3002557849//4R01NR01365805 3003585711 // 5R01CA173745-06 03 3003655776//5R01EB009910-09 3003655776//SR01EB009910-09 3003700315 // DMR-1509033 Amd 2 3003719520 // AID-OAA-A-15-00075 02 3003962014//W81XWH-15-1-0661 3004163905//SR01AI119446 3004650350//7R01MD011570-02 3004704106//R01MH110524 310270//SP014115244.02 310227//5R01Al125244-02 310904//5R01HL127700-04 310904//5R01HL127700-04 31103A Mm. //5U19A1103461-06 31103B // 5U19A1103461-06 31-30081-0031A 0031H/00311 3200001251-16-257//5U01AG050636-03 3210000447-17-156/3U48DP005014-03S6 3210000758-18-175//5U48DP005014-04 3210000758-18-17/5/5U48DP005014-04 322801NW/W1W81XW1-17-16697 330161-18110-7343-Amd 5//SIMA-1041707 3403-019297 // R324A150094-18 Amd 3 42-009-2031-001/5R011408587-03 3500-07249//1DP3DK114812-01 351308 Revision 1 // DE-ACO5-76RL01830 360955-NW Amd 5 // 4R01MH077908-9 06 2200 044 100///DR4 0007270 04 36-5360-2141-101//4R01AG037120-04 36-5360-2141-101/JR01AG037120-04 30P2EY027983-01 S1 3F-31142 Mod. 12 // DE-AC02-06CH11357 3J-30081 / 3J-30081-0014A Rev. 0014E 3J-30081 // 3J-30081-0039A Rev. 0039C 3J-30081 // 3J-30081-0039A Rev. 0050E 3J-30081 // 3J-30081-0064 Rev. No. 0050E 3J-30081 // 3J-30081-00618 3.J-30081 // 3.J-30081-0064A 3J-30081 // JJ-30081-0064A 3J-30081 // JJ-30081-0068A Rev. No. 0068D 3J-30081 // JJ-30081-0069A 3J-30081 // JJ-30081-0071A JJ-30081 //JJ-30081-0019H 3J-30081 //JJ-30081-0024A Rev 0024D 3J-30081 //JJ-30081-0058A Rev 0058C 2J-20081 //JJ-20081-0058A Rev 0058C 3J-30081//3J-30081-0058A Rev 0058C 3J-30081/3J-30081-0013A REV. 0013H 3J-30081/3J-30081-003A Rev. 0043F 3J-30081+0253.0081-0055C & 0053D 3J-30081+0055A 0081-0055A & 0055D 3J-30081+0055A // 3J-30081+0055A Rev 0055D 3J-30081-0056A//3J-30081-0056B 3J-30081-0057A Rev. 0057B-C//3J-30081 3J-30081-0057A Rev. 0057B-C//3J-30081 3J-30081-0060A-0066D ¥ 3J-30081 Rev 0060C 3J-30081-0062A Rev. 0062E // 3J-30081 3J-30081-0063A Revision 0063B 3J-30081-0070A 3K23DA037913-04

3P01GM096971-05S1 3P01GM096971-055 3P30AG013854-23S2 3P30CA060553-22S1 3P30CA060553-24S3 3P30DA027828-08S1 3P50HD044405-15S1 3P50NS047085-15S1 3R00CA160638-05S1 3R00CA160638-05S1 3R01Al127456-02S1 3R01CA206456-03S1 3R01CA214035-17S1 3R01DC014426-04S1 3R01DC0144709-03S1 3R01DK094898-03S1 3R01GM089970-09S1 3R01GM111007-45S1 3R01GM111097-45S1 3R01MD010440-02S2 3R21AG055954-02S1 3R21EB022291-02S1 3T32Al007476-20S1 3T32CA070085-20S1 3T32DK077662-10S2 3T32DK101363-0551 PEV/ISED 3132DK101363-05S1 3T32HD007418-25S1 3T32HS000078-20S1 3U01DA036939-05S1 3U01HL114344-05S1 3U10HL119992-03S1 3U10HI 119992-03S1 3U2CAG057441-02 3U2CAAG057441-02 3U2CCA186878-0451 3UH3TR001207-0551 4(GG011659-01)//1R01HL139837-01 4(GG012713-02)//1R01HS024538-02 4000164554//DE-AC05-000R22725 4101-83478 // 1647722-EEC 4101-83478 // 1647722-EEC 4102-56030//1R01AG041750-01A 4102-77270//5R01EB016582-03 4102-77270/5R01EB01582-03 4-10469-03 Amd 6 // DE-NA002006 0009 410676_GR40751-NU4424006/R01CA10594 416496-G/W81XWH-14-1-0322 417315//N00014-18-1-2370 4182//W81XWH-17-2-0072 / PO 930293 4182/W81XW1-17-20072 / PO 930293 41880-A md (11/R21NS03578-01A1 42756369///7RF1AG041845-02 439358 // DE-AC52-06NA25396 446016-19980 02 // D17AC00003 450001925/5P50AR060780-05 450391-19980//HR0011-16-C-0035 Mod 03 465426/HHSN272201200003I/HHSN27200011 482K930//1R01AG041868-02 482K930/1R01A6041868-02 4DP2OD003717-02 4F-32002 M0007 // DE-AC02-06CH11357 4F-3323 M0003//DE-AC02-06CH11357 4K08DK05992-05 4K08MH094441-05 4K08DK05926-05 4K12HD073945-05 4K24AI104831-05 4P30NS081774-05 4R00CA207865-03 4R00EB021320-02 4R00H109569-04 4R01Al020201-33 4R01Al040310-19 4R01Al098369-05 4R01AI099009-04 4R01AR041836-24 4R01AR041836-24 4R01AR054155-09 4R01AR062110-05 4R01AT007987-05 4R01CA101774-14 4R01CA121192-10 4R01CA122151-10 4R01CA155513-05 4R01CA155513-05 4R01CA157809-05 4R01CA159811-05 4R01CA164041-05 4R01CA164714-05 4R01CA165309-05 4R01CA167041-05 4R01CA168292-05 4R01CA160292-05 4R01DA033773-05 4R01DA035145-05 4R01DC011855-05 4R01DE022746-05 REVISED 4R01DK060635-15 4R01DK094898-04 4R01DK095963-04 4R01DK097364-05 4R01DK097364-05 4R01DK101329-05 4R01EB005772-08 4R01EB016983-04 4R01EB017129-04 4R01ES020357-05 4R01GM080484-09 4R01GM098077-04 4R01GM102689-04 4R01GM102689-04 4R01GM105847-04 4R01GM107209-04 4R01HD039343-15

4R01HD069414-05 4R01HD069414-05 4R01HL108723-05 4R01HL108723-05 4R01HL110624-04 4R01HL113350-04 4R01HI 115828-05 4R01HL116577-04 4R01HS020263-05 4R01HS020263-05 4R01HS020253-05 4R01MH091131-05 4R01MH094835-05 4R01MH095248-05 REVISED 4R01MH095753-05 4R01MH099114-05 4R01NR014182-05 4R01NS026543-27 4R01NS075075-05 4R01N307507582-05 4R25NS077582-05 4R37Al033493-25 4R37NS039395-18 4T32AG020506-15 4T32AI095207-05 REVISED 4T324R007611-15 4T32AR007611-15 4T32AR060710-05 4T32CA009560-30 4T32MH067564-15 4U01AG043415-05 4U01AI104347-04//9320sc 4U01DK094830-05 REVISED 4U01DK094830-05 REVISED 4U01DK097779-06 4U01MH097435-04 REVISED 4U10HL119992-04 4U19AI106683-05 4U19HS021093-05 4U14NE000016 02 4U44NS090616-02 4UQHP28715-02//6U1QHP287150101 5 CPIMP161134-03-00 5 K23 DC014303-04 5 K23 DC014303-04 5(GG010919-03)//5R01HL077612-11 5(GG011046-01)//1R01HL130506-03 5(GG012664) Amd 3 // N66001-17-C-4002 5002110-S4 // 5 RRC08098402-08-00 50041-324-NWU01//1UG3Al133676-01 50041-324-NW U01/1/UG3Al133676-01 5008752-SERV//JU01DK089245-04 501237SG138 Amd 2 // NNX16A048G 5015643-SERV//ZU01DK08245-06 5050165//SR01AG46267-04 50612-324-NWU1-A034993 50615-324-NWU1-A034993//5U01Al034993 5065 // W044 Mark 2007 5065-NU//R01MH112625 5076-NU-DOE-2375//DE-SC0012375-02 5076-NU-DOE-2375/DE-SC0012375-0 50961//R0D1K107572-02A2 5101817-116559//5D43TW010543-02 510343//4R01ES020836-05 5-10742-01//R01GM106023 517350-NWU//MG-77-16-0118-16 5204-NU-NSF-0620-1//DMR-1420620 537/151 5-40604//5U54EB02040-04 5-40604//5U54EB02040-04 5-53557//5R01Al114730-04 55890312//1R01Al114897-04 55R01CA202963-03 560958 Amd 6 // NNX13E50G 564595//R01HD076279-04 567849//5R01CA197332-03 5688-NU-EARPA-0626//DE-AR0000626 5688-NU-EARPA-0626//DE-AR00006/ 568912//R01CA165001-05 569507//5R01HL121510-03 570229/1R01HL134015-02 5709-NU-DOE-2375 // DE-SC0012375 5710003775 Amd 3 // DE-SC001239 5710004200//RR011-15-C-084 5710004259//CBET-1653758 571003 B 02//5R01CA184283-03 571003 B.02//5R01CA184283-0 571660//5U01AG052943-02 572177 // 1R21AG053638-01A1 572644//5U54AR057319-15 573341//7-R01-MH-103910-06 573345//7-R01-DC-013243-06 573503//7R01DC010014-10 573659 // 80NSSC18K0481 5740-01//6U28HA30791-02-01 5740-01//6028HA30791-02-01 578/151 578/151 5841-NU-NASA-F03G//NNX15AF03G 58906-MA-105 5897-NU//R3050140045-03 5897-NU//R3050140045-03 5898-NU/02//R305D140019 5968-NU 02 // DGE-1437953 5043TW009374-05 5043TW009375-04 5043TW010350-03 50P50D024587-02 5F30A1116106-03 REVISED 5F30A1116106-03 REVISED 5F30AI129237-02 REVISED 5E30CA174058-05 REVISED 5F30CA192788-03 5F30CA192788-03 5F30CA196118-04 REVISED 5F30CA196185-03 REVISED 5F30CA203292-04 REVISED

5E30CA203325-03 REVISED 5F30CA203325-03 REVISED 5F30CA203472-03 REVISED 5F30CA206413-03 5F30DK109608-02 REVISED 5F30ES024622-03 5F30EV026472-03 REVISED 5F30HD090842-02 5F30HI 134202-03 5F30HL134202-03 5F30HL137279-02 5F30MH109249-04 5F30NS090817-03 REVISED 5F30NS090893-04 REVISED 5F30NS093811-03 REVISED 5E31AG055331-02 REVISED 5E31AG057109-02 5F31AG057109-02 5F31A1106357-05 REVISED 5F31CA186761-04 REVISED 5F31CA192801-03 5F31CA216976-02 5F31CA228149-02 5F31DC015374-03 5E31DC015717-02 5F31DC015717-02 5F31DC016205-02 5F31DK102371-02 5F31DK108544-02 5F31EB022414-02 5F31EY025532-03 REVISED 5F31GM112478-03 5F31GM116532-03 REVISED 5F31GM116532-03 REVISED 5F31GM11971-02 REVISED 5F31GM119368-02 REVISED 5F31GM119302-02 REVISED 5F31HL17618-05 REVISED 5F31HL122494-02 REVISED 5F31HL131355-03 5F31HL132454-02 5F31HL132454-03 5F31HI 132552-03 5F31HL134331-02 5F31HL134331-02 5F31HL136107-02 Revised 5F31LM012492-02 5F31MH105092-02 REVISED 5F31NS090845-03 REVISED 5F31NS090872-03 REVISED 5F31NS092329-03 REVISED 5F31NS092329-03 REVISED 5F31NS092335-03 REVISED 5F31NS092356-03 REVISED 5F31NS095873-03 5F31NS095461-02 REVISED 5F31NS095476-03 REVISED 5F31NS095652-02 REVISED 5F31NS098666-02 REVISED 5F31NS100357-02 5F31NS100357-02 5F31NS101830-02 REVISED 5F31NS105486-02 5F32AG058396-02 5F32AI116044-03 REVISED 5F32CA221327-02 5F32DA042708-02 REVISED 5F32DC014629-02 5F32DC014629-02 5F32DC015962-02 REVISED 5F32DK103499-03 REVISED 5F32DK104544-03 REVISED 5F32EY025930-03 5F32EY027185-02 REVISED 5F32GM112422-02 5E32GM115052-03 5F32GM119191-03 5F32GM119191-03 5F32GM122397-02 5F32HL127958-03 5F32HL129651-02 5F32HL131301-02 5F32HL131304-03 REVISED 5F32HI 134222-02 5E32HI 134276-03 5F32HL134276-03 5F32HL136111-02 5F32HL137292-02 5F32HS025077-02 5F32HS025330-02 5F32NS098737-02 REVISED 5F32NS101778-02 5F32NS103243-02 5F92N3103243-02 5F99CA222988-02 5F99NS105182-02 5G08LM012688-02 5K01AG053477-03 5K01AR064313-05 5K01AR066739-04 REVISED 5K01DK099454-05 5K01DK101675-04 5K01DK101675-05 5K01DK105137-03 5K01HD084672-03 5K01HL121162-04 5K01HL133531-03 5K01LM011973-03 5K01OD024882-02 REVISED 5K07CA184145-05 5K07CA196840-04 5K07CA196840-04 5K07CA216330-02 5K08CA191019-05 REVISED 5K08DA037825-04

Schedule of Findings and Questioned Costs

Table of Award Numbers Year ended August 31, 2018

Name of Federal Program or Cluster (CFDA #)

Research and Development Cluster (Various):

Award Number

5K08DC013829-05 5K08DC013829-03 5K08DK097721-04 5K08DK101757-05 5K08DK106450-04 5K08GM117341-04 5K08HI 114871-03 5K08HL124295-02 5K08HI 125940-04 5K08HL125940-04 5K08HL126867-04 5K08HL130601-03 5K08MH102336-04 5K08MH112878-02 5K08NS079482-05 REVISED 5K08NS097624-03 5K12HD050121-14 5K12HD055884-00 5K12HD055884-09 5K12HD073945-07 5K12HS023011-05 5K18HS023437-02 5K23AI100995-05 REVISED 5K23DK095707-05 REVISED 5K23DK095707-05 REVISED 5K23HD087529-02 5K23HD087529-02 5K23HL118139-05 5K23HL138165-02 5K23HL138165-02 5K23NS091430-02 REVISED 5K23NS091430-02 REVISED 5K23NS092975-04 5K24DC012801-06 REVISED 5K25GM098875-06 5K25GM098875-06 5K25HL119608-05 5K99DA039253-02 5KL2TR001424-04 5P01AG011412-19 5P01AG049665-04 5P01AI112522-04 5P01AI131346-02 5P01GM096971-05 5P01GM096971-05 5P01HD057877-09 5P01HL071643-14 5P01HL108795-05 5P01NS072027-06 5P30AI117943-04 REVISED 5P30AR057216-10 5P30DC012035-05 REVISED 5P30DC012035-05 REVISED 5P41GM108569-04 5P50CA180995-04 5P50DC012283-05 REVISED 5P50HD076188-05 REVISED 5P60AR064464-05 5R00AG041225-04 REVISED 5R00AR065480-04 5R00CA175293-04 5R00CA175700-05 5R00CA178188-05 5R00CA188293-04 5R00CA194192-04 5R00DC012803-05 REVISED 5R00DC013805-04 REVISED 5R00DK094977-05 5R00DK106655-04 REVISED 5R00HL107749-05 5R00HL121177-04 5R00NS078055-05 5R00NS082381-05 5R00NS089858-05 5R00NS089943-04 5R01AA024065-03 5R01AA024409-03 REVISED 5R01AG018436-17 5R01AG022560-15 5R01AG030142-09 5R01AG030611-11 REVISED 5R01AG045571-05 5R014G046352-04 5R01AG046352-04 5R01AG047416-04 5R01AG049002-04 5R01AG049924-02 5R01AG055121-02 5R01Al043407-18 5R01AI043987-19 5R01Al043967-19 5R01Al053674-13 5R01Al056346-14 5R01Al057460-14 5R01Al072265-11 5R01Al076183-15 5R01Al076456-10 5R01AI079056-09 5R01Al092825-05 REVISED 5R01Al092825-05 REVISED 5R01Al092825-07 5R01Al094595-05 REVISED 5R01Al094595-05 REVISED 5R01Al104733-04 5R01AI105839-05 5R01AI108634-04 5R01AI112911-04 5R01AI114824-03 5R01Al114824-02 5R01Al118257-03 5R01Al120625-03 5R01Al123001-02//BWH AGMT 11/23/16 5R01AI125171-03 5R01Al125171-03 5R01Al125366-02 5R01Al127695-02 5R01Al127783-02 5R01Al128292-02 5R01AI130348-02 5R01AR041836-26 5R01AR044016-22 5R01AR060810-04 5R01AR060810-04 5R01AR064349-05 REVISED 5R01AR064349-05 REVISED 5R01AR064546-05 5R01AR065473-05 5R01AR066539-04 5R01AR066634-05 5P014P068375-03 5R01AR068375-03 5R01AR070025-02 5R01AR070166-02 5R01AR071162-03 5R01AT007701-05 5R01AT009143-15 REVISED 5R01AT009143-15 REVISED 5R01AT009539-02S1 5R01CA021776-38 REVISED 5R01CA0259655-25 REVISED 5R01CA073507-20 5R01CA077816-19 5R01CA123484-10 REVISED 5R01CA123484-10 REVISED 5R01CA142861-07 5R01CA149669-06 5R01CA152601-09 REVISED 5R01CA152601-09 REVISED 5R01CA152799-05 5R01CA154908-07 REVISED 5R01CA155284-04 REVISED 5R01CA155284-04 REVISED 5R01CA155584-04 REVISED 5R01CA154566-05 5R01CA161796-05 5R01CA163830-06 5R01CA163830-06 5R01CA167966-05 5R01CA172384-05 REVISED 5R01CA172431-05 REVISED 5R01CA174205-05 REVISED 5R01CA174452-04 REVISED 5R01CA175360-05 REVISED 5R01CA180813-05 REVISED 5R01CA181658-04 REVISED 5R01CA181658-04 REVISED 5R01CA182506-05 5R01CA182832-05 REVISED 5R01CA183101-04 REVISED 5R01CA183214-04 REVISED 5R01CA186885-04S1 5R01CA186885-0451 5R01CA188015-03 REVISED 5R01CA188015-03 REVISED 5R01CA189074-03 5R01CA192124-04 5R01CA193331-03 REVISED 5R01CA195642-04 REVISED 5R01CA196270-03 5R01CA196967-04 5R01CA197313-03 5R01CA197313-03 5R01CA200064-03 5R01CA208354-02 REVISED 5R01CA208783-02 REVISED 5R01CA209886-03 5R01CA214025-02 REVISED 5R01CA218436-02 5R01CA219013-02 5R01CA219013-02 5R01CA221150-02 5R01DA028763-05 5R01DA030604-08 5R01DA035942-05 5R01DA040626-02 5R01DA040261-02 5R01DA042711-02 REVISED 5R01DC000089-45 5R01DC000089-45 5R01DC001948-21 REVISED 5R01DC004314-17 REVISED 5R01DC005794-09 5R01DC006014-13 5R01DC000852-12 5R01DC010014-09 REVISED 5R01DC010014-09 REVISED 5R01DC010191-08 5R01DC013576-05 5R01DC015376-05 5R01DC015137-03 5R01DC015426-03 5R01DE015920-10 5R01DE025702-03 REVISED 5R01DK079902-09 5R01DK083609-08 5R01DK090625-07 5R01DK090625-07 5R01DK092217-05 5R01DK093807-04 5R01DK093807-06 5R01DK095963-03 5R01DK097249-05 5R01DK097249-05 5R01DK097534-05 5R01DK098812-04 REVISED 5R01DK099820-05 5R01DK100814-05 5R01DK100814-05 5R01DK101730-03 5R01DK102438-05 5R01DK102718-04

5R01DK102815-04 5R01DK102815-04 5R01DK103684-04 5R01DK103769-03 5R01DK104785-03 REVISED 5R01DK104876-03 REVISED 5R01DK106266-05 5R01DK107767-03 REVISED 5R01DK108127-03 5R01DK108127-03 5R01DK108434-02 5R01DK108678-03 REVISED 5R01DK108887-03 REVISED 5R01DK109539-02 REVISED 5R01DK110087-02 5R01DK110172-02 REVISED 5R01DK111032-03 5P01DK112281-03 5R01DK112281-03 5R01EB014806-04 5R01EB019335-03 5R01EB019337-03 5R01ES022310-05 5R01EY012141-20 REVISED 5R01EY018204-10 REVISED 5R01EY018204-10 REVISED 5R01EY019696-09 5R01EY019696-09 5R01EY020950-08 REVISED 5R01EY021579-06 5R01EY021579-06 5R01EY023977-03 REVISED 5D04EY023977-03 REVISED 5R01EY025799-03 5R01EY026078-03 5R01EV026078-03 5R01GM038784-29 REVISED 5R01GM049725-23 5R01GM052111-20 5R01GM058518-17 5R01GM064426-16 5R01GM064426-16 5R01GM067193-12 5R01GM070736-12 5R01GM073072-13 5R01GM073072-13 5R01GM076561-09S1 5R01GM080484-11 5R01GM084223-09 REVISED 5R01GM087371-09 REVISED 5R01GM101975-05S1 5R01GM107177-04 REVISED 5R01GM107177-04 REVISED 5R01GM108494-05 5R01GM108964-04 REVISED 5R01GM110045-03 5R01GM111652-04 5R01GM111907-05 5R01GM112945-04 5R01GM113238-04 REVISED 5R01GM114210-04 REVISED 5R01GM115211-02 5R01GM115211-02 5R01GM115739-02 5R01GM115761-04 5R01GM115848-04 5R01GM116538-04 5R01GM118712-02 5R01GM120303-02 REVISED 5R01GM120307-02 5R01GM121518-02 5R01GM124029-02 5R01HD059858-05 5R01HD079076-05 5R01HD083310-04 REVISED 5R01HD084009-04 5R01HD084009-04 5R01HD087363-02 REVISED 5R01HD091492-02 5R01HL035440-30 5R01HL035440-30 5R01HL051387-21 5R01HL051387-21 5R01HL061322-19 5R01HI 073402-15 5R01HI 073402-17 5R01HL083374-08 5R01HL083374-08 5R01HL084228-08 5R01HL085534-12 REVISED 5R01HL092259-10 5R01HL107510-05 5R01HL107577-0 5R01HI 109244-04 5R01HL109244-04 5R01HL109478-08 5R01HL112792-06 5R01HL113541-04 5R01HL114763-04 5R01HL116895-05 REVISED 5R01HL117888-05 REVISED 5R01HL118289-03 5R01HL119095-05 5R01HL119095-05 5R01HL120725-04 5R01HL122010-04 5R01HL122062-04 5R01HL122109-04 REVISED 5R01HL122309-05 Revised 5R01HL122328-04 REVISED 5R01HL122328-04 REVISED 5R01HL122477-05 5R01HL122846-04 REVISED 5R01HL122921-04 5R01HL122921-04 5R01HL125881-04

5R01HL126117-04 REVISED 5R01HL126117-04 REVISED 5R01HL126920-04 5R01HL127491-03 5R01HL127646-03 REVISED 5R01HL128075-04 5R01HL128194-03 REVISED 5R01HL130502-03 REVISED 5R01HI 131606-02 REVISED 5R01HL131606-02 REVISED 5R01HL131745-02 5R01HL131771-02 5R01HL133504-02 REVISED 5R01HL134375-02 REVISED 5R01HL135486-02 REVISED 5R01HI 136942-02 REVISED 5R01HI 138578-02 5R01HL140580-02 5R01HL140580-02 5R01HS020270-06 5R01HS024296-02 5R01HS024516-03 5R01HS024930-04 5R01HS024945-02 5R01I M011297-06 5R011 M011962-0/ 5R01LM011962-04 5R01MD009217-06 5R01MD009561-04 REVISED 5R01MD011749-02 5R01MH071316-14 REVISED 5R01MH078064-12 REVISED 5R01MH097216-07 5R01MH100482-05 5R01MH100482-05 5R01MH101297-05 REVISED 5R01MH106511-02 REVISED 5R01MH106512-04 5R01MH107182-04 REVISED 5R01MH107652-03 REVISED 5R01MH107652-03 REVISED 5R01MH108837-03 5R01MH108837-03 5R01MH109466-03 REVISED 5R01MH110556-02 REVISED 5R01MH110556-02 5R01MH110626-03 5R01MH111610-02 5R01MH112545-02 5R01MH113189-03 5R01NR012745-05 5R01NR015444-02 5R01NS034696-22 5R01NS0340595-22 5R01NS047726-12 5R01NS053603-10 5R01NS053603-12 REVISED 5R01NS053792-16 REVISED 5R01NS057499-11 REVISED 5R01NS059934-09 REVISED 5R01NS061963-10 5R01NS064135-09 REVISED 5R01NS064135-09 5R01NS067299-09 5R01NS069777-07 5R01NS072381-09 5R01NS076054-06 5R01NS076054-08 5R01NS077863-05 5R01NS077863-05 5R01NS0778287-04 5R01NS078287-04 5R01NS080598-05 REVISED 5R01NS080619-05 5R01NS082351-05 5R01NS084959-05 5R01NS085002-05 REVISED 5R01NS085161-05 5R01NS085770-05 5R01NS086859-05 REVISED 5R01NS086945-04 5R01NS086973-05 5R01NS087575-03 5R01NS087990-05 REVISED 5R01NS089313-05 REVISED 5R01NS089313-05 REVISED 5R01NS090993-04 5R01NS092823-04 5R01NS092950-03 5R01NS093079-04 5R01NS093585-04 REVISED 5R01NS093843-04 5R01NS093903-04 5R01NS093903-04 5R01NS094011-04 REVISED 5R01NS094748-03 5R01NS095251-03 5R01NS095634-04 5R01NS095634-04 5R01NS095642-03 REVISED 5R01NS096240-03 REVISED 5R01NS096240-03 REVISED 5R01NS096746-04 REVISED 5R01NS096746-04 REVISED 5R01NS097851-03 5R01NS09701-03 5R01NS099064-02 REVISED 5R01NS099064-02 REVISED 5R01NS099210-03 5R01NS099623-03 5R01NS099638-03 5R01NS100785-03 5R01NS100785-02 5R01NS102669-02 5R01OH010469-04 5R03Al125813-02

Schedule of Findings and Questioned Costs

Table of Award Numbers Year ended August 31, 2018

Name of Federal Program or Cluster (CFDA #)

Research and Development Cluster (Various)

Award Number 5R03AI126090-02 5R03Al126090-02 5R03AR061593-03 5R03AR065800-03 5R03AR066543-03 REVISED 5R03CA194643-02 REVISED 5R03DC013841-03 5R03DC014553-03 REVISED 5R03DC014565-03 5R03DK109243-02 REVISED 5R03DR109243-02 5R03HD082558-02 5R03HD087111-02 5R03HS025267-02 5R03MH107834-02 5R13HD063248-07 5R13TR000046-05 5R18DK0830/1-06 5R18DK083941-06 5R18DK110741-02 5R18FD005292-02 ADDENDUM 5R18HS023459-03 5R18HS023921-03 5R21AG047510-02 5R21AG049218-02 5R21AG049218-02 5R21AG050897-02 REVISED 5R21AG057383-02 5R21AI11018-02 5R21AI111018-02 5R21AI11708-02 5R21AI11708-02 5R21AI117262-02 REVISED 5R21AI119137-02 5R21Al119137-02 5R21Al120492-02 5R21Al120618-02 5R21Al121836-02 5R21Al123462-02 5R21Al129167-02 REVISED 5R21Al133984-02 5R21Al056041.02 5R21AR068041-02 5R21AR068041-02 5R21AR060041-02 5R21AR068500-02 5R21AR069867-03 REVISED 5R21CA182725-02 5R21CA187869-02 5R21CA202552-02 REVISED 5R21CA208329-02 5R21CA209345-02 5R21CA210904-02 5R21CA210904-02 5R21CA220625-02 5R21DA045507-02 5R21DK105865-02 5R21DK108104-02 5R21EB024315-02 5R21ES026776-02 5R21FY024050-02 5R21E1024050-02 5R21EY027502-02 REVISED 5R21HD077140-02 5R21HD077140-02 5R21HD077336-02 5R21HD082781-02 5R21HL129930-02 5R21HL130969-02 5R21HI 132357-02 5R21HL132357-02 5R21LM012578-02 5R21MD011320-02 5R21MH098793-02 5R21MH104471-02 5R21MH104808-02 5R21MH108444-03 REVISED 5R21MH108444-03 REVISED 5R21MH108863-02 REVISED 5R21MH110374-02 REVISED 5R21MH115231-02 5R21NR016745-02 REVISED 5R21NS084069-02 5R21NS084069-02 5R21NS088916-02 5R21NS090346-02 REVISED 5R21NS092034-02 5R21NS092034-02 5R21NS094999-02 5R21NS096424-02 REVISED 5R21NS096572-02 REVISED 5R21NS09962-02 REVISED 5R21NS101150-02 5R21NS101150-02 5R21NS103138-02 REVISED 5R25EB013060-05 5R256M079300-12 REVISED 5R256M079300-12 REVISED 5R256M121231-02 5R25HL116372//5R25HL116372-03 5R25NS070695-09 5R25OD020222-02 5R33Al094584-05 5R33DC013115-05 5R33MH103231-04 5R33MH103231-05 5R34DA044752-02 5R34DK113541-02 REVISED 5R34HL122558-03 5R34HH100393-03 5R34MH101265-03 5R35CA197450-04 5R35CA197532-03 5R35CA197569-04 5R35CA197569-04 5R35CA197725-05 5R35GM118035-03 REVISED 5R35GM118108-02

5R35GM118144-03 5R35GM118184-03 REVISED 5R37AG008796-27 REVISED 5R37AG026647-13 5R37AI033493-24 5R37Al094595-07 5R37AR043380-23 5R37HD038691-19 5R37HD038691-19 5R37HL048129-23 5R37HL068546-35 5R37NS039395-17 5R37NS041280-20 5R37NS096241-03 5R50CA211271-03 5R50CA211428-03 5R50CA211534-03 5R50CA211534-03 5T32AG020506-17 5T32AI007476-22 5T32AI083216-09 5T32AI095207-07 REVISED 5T32AR007611-17 5T32CA009560-32 5T32CA009560-32 5T32CA070085-22 5T32CA080621-14 5T32CA186897-03 5T32CA193193-03 5T32DK007169-36 5T32DK007169-39 5T32DK062716-13 5T32DK077662-12 5T32DK077662-12 5T32DK108738-03 REVISED 5T32EB009406-08 5T32EY025202-04 REVISED 5T32GM008482-26 5T32GM008489-25 5T32GM105538-05 REVISED 5T32UM005538-05 REVISED 5T32GM105538-05 REVISED 5T32HL009771-15 REVISED 5T32HL069771-15 REVISED 5T32HL09271-15 REVISED 5T32HL094293-08 5T32HL134633-02 5T32HL134633-02 5T32LM012203-04 5T32NS041234-15 REVISED 5T32NS047987-10 5T32NS047987-10 5T32NS047987-12 5TL1TR001423-04 REVISED 5U01AA023176-03 5U01AI035039-26 5U01DK048380-25 REVISED 5U01DK082342-09 5U01DK099930-07 5U01EB020589-02 5U01HG008673-04 5U01HG008673-04 5U01HL128954-03 5U01HL131914-03 REVISED 5U01MD011281-03 REVISED 5U01MH082830-10 5U01MH109100-03 5U01NS080818-04 5U01TR001806-03 REVISED 5U10EY023207-05 5U10HL098096-07 5U10NS077271-07 5U10NS086608-05 5U18DP006120-04 5U54CA193419-04 REVISED 5U54CA193419-04 REVISED 5U54CA199091-03 5U54CA203000-04 5U54CA221205-02 5U54HD085601-04 5U54MD010723-03 REVISED 5UG1HD040512-19 5UG3ES029073-02 5UG3NS105562-02 5UG3N8105562-02 5UL17R001422-04 5UM1A1069471-12 REVISED 5UM1A120184-04 6 T91HP215420603 60045478 Amd 001 // R01GM120582 60046917/R050A150365-02 60060542 Amd 001 // R01GM120923 60060542 Amd 001 // R016M120923 60064759//SR01HL128857-03 REVISED 60088-12935-NWU//1R01AI127302-02 61526610-125216//1R01HL136390-01 61867865-128280//7R01DA037222-03 REVISED 618K165///P01A6020166 619-2 // DE-EE0007728 630K475 Amd 3 // CHE-1503408 6304475 Am3 3 // CHE-1503408 6317//90IFRE0007-01-00 63501087/SR34DA037516-03 REVISED 636K694//4R01A6041888-04 6455091 NOR-181797-02//5U01CA089600-13 6501622/05//W911NF-11-0297 65105010617-NWU//P50HL120163 65904754 Am4 // INNA13A92A 66102690414-04NWU/HISN268201300047C 652706//ED01NE004780 06 66122690414-041WW0/HH31 662706//5R01NS084288-05 667381//5R01DA040756-03 676K001//R24EY022883 693JJ31845009

693.1.131845043 693JJ31845043 6NU58DP006138-02-02 6UH1HP29963-03-01 7 R40MC30751-01-00 7(GG007619-04)//5R01HL093081-08 7/225/29/NU-02//D43TW010140-02 706K6611/5UE4GM119023-03 70NANB14H012 Amd 6 70NANB17H088 TONANB17H088 TONANB17H283 TONANB18H075-1 71(GG009393) // OCE-1450528-2 7201//SR01HD075777-05 7-312-0214047-52577L//1U10HL119991 7-312-0214047-525772/1/1010HL1199 7336107 Mod. 1// 2P01CA092584-16 7503// AID-OAA-A-16-00032 75689162//U19AG010483-25R 76091-11011/W911NF-15-1-0447 761K946/R01NS100510-01A1 76380016E//SNU38DP005367-03-00 730/023 // 4DA/5Y020000.05 76380016E//SNU38DP005387-03-00 770K973 // #242FV02288-3-05 776K031 // W911NF-17-1-0575 7800 Amd 2 // R01HL130760-03 / R01HL130760 790K182//R35GM19627 7955/06/1725625 7965409/17256625 79654993/WE12015-01/2U19A602490411 7965406/17256625 798K081//W911NF-18-2-0036 7DP2GM110838-02 7DP50D021356-03 7DP5OD021356-03 7K01MH098902-06 7K08HL135348-02 7R01AR064850-06 7R01CA176659-06 7R01CA191317-04 7R01CA202948-03 7R01CA204021-03 7R01CA208246-02 7R01CA208246-02 7R01DK095207-06 7R01EY012162-17 REVISED 7R01HL114529-05 7R01NS077388-05 7R03DC013373-03 7R03EB024705-02 7R03EB024705-02 7R21DC015880-03 7R21HD078946-02 7R21HD078946-02 7R21NR016377-02 7R21NS089802-03 7R21NS089802-03 7R21NS093439-03 80776-11044//FA9550-18-1-0136 80776-11044//FA9550-18-80NSSC17K0052 80NSSC17K0192-P00001 80NSSC17K0245 80NSSC18K0189 80NSSC18K0196-P00001 80NSSC18K0221 80NSSC18K0276 80NSSC18K0575 80NSSC18K0575 80NSSC18K1445 81421/901F0093-01-00 81454 Letter 7/12/16 //IIS-1552706 81464/CL5296//1632259 81622655//6R01AG047992-02 8231sc//5R01HD078748-03 8231sc//5R01HD078748-03 8244sc//5R01DA033854-05 834K352//1U19AG051426-01A1 851-SUB//5U01HL125177-04 85596622//R01DK110669-02 857-548 Amd 1 // U54HL119810-05 86380016F 8696sc//R01HL093009 8696s.//R011L093009 869-SUB/SU011H.123009 8729s-(/SR01NR015223-05 888-15-16-12//1101H.119991-01) 8725GM129223-04 9009627-009_Northwestern/3/010CA180 900527-09_Northwestern/3/010CA180 9015249 (130129-26)//5U01H.128954-03 9015249 (130129-26)//5U01H.128954-03 9012549 (130129-26)//5U011H.128954-03 9012549 (130129-21//5U01H.128954-03 9012549 (130129-26)//5U01HL128954-03 901501-NU /md 01//5U01HD084046-04 901507-NU//5U01HL133704-02 901513-NU//5U01HL133704-02 901526-NU//R21A1135702-01 901527 NU//K20HL14050 14 901527-NU//1K08HL140152-01 908468 NU//4P01AG043362-05 908468_NU//4P0 90AR5010-02-00 90AR5015-02-00 90AR5019-03-00 90AR5019-04-00 90AR5031-02-02 90AR5031-02-02 90AR5031-03-00 90ARPO0001-02-00 90HG1002-01-01 90HG1002-02-00 90HG1002-02-00 90YR0073-04-00 90YR0073-04-00 90YR0073-05-01 Amd 1

915377-NU//PTCL102002438850/UM1Al068632 915377-NU//PTCL10200243 9254sc//5U01Al118594-03 94701//5-U01CA202177-03 94743768//UG3OD023287 9487sc//5R01NR015223-05 9500012803//Job13765353/W911NE-09-2-0053 Mod. 13 9500080215//U10CA180886 9500080215///10CA180886 95047693//R21AC067395-01 965-SUB // 3U54HL119810-0551 97986868 // 1R01HL139001-01 999-SUB/SU01HL123009-05 999-SUB/SU01HL123009-05 9920180010//R21AG057396 9R01AG056258-06 REVISED 9R01AG056258-06 REVISED A002181204//N00014-11-1-0690 9 A003127002 Amd 6 // DE-SC0008688 A004088505 Amd. 1 // CHE-1413862 A004527502 // DE-SC0012702 Amd 05 A004527502 // DE-SC0012702 Amd 05 A00540701/J2801HD034294-23 A005958004 Amd 1/ HR0011-16-C-0134 A10-PO14-164103//RQ13-235R07//DE-EE0005764 A12761 Amd 01 // ACI-1640840 A12769 001 // W911NF-16-1-0524 A15-031-5S0C1-A02//DE-FE0024054 A15-031-5001-402//DE-FE0024054 A15-031-5001//W0911SR-17-C-0007 A15-0215-D014//W0911SR-17-2-0007 A18-0471-S001//N00014-17-1-2836-1 AAC6717//7R01DC014519-04 ACI-1450374 ACI-1450374 ACI-1450871 ACI-1535112 ACI-1541457 ACI-1550481 ACI-1550481 AEV-6-52063-01//DE-AC36-08GO28308 Agmnt 12/6/2017 // FA9550-14-1-0030 P00007 Agmt 03/27/18//2R44AR065886-02A1 Agmt 04/02/019//R414118072-01 Agmt 04/21/17 // N00014-16-1-2247 Agmt 04/21/18 Agmt 04/30/17//HHSP233201600230A Agmt 06/07/18 Agmt 08/31/2017 Agmt 08/31/2017 Agmt 1/16/2018 Agmt 1/31/2018 // 5R01NS- 0538139-09 REVISED Agmt 10/10/2017 // W56KGY-17-C-0010 Agmt 10/12/2017 Agmt 10/12/2017 // N00253-17-C-0024 Agmt 10/31/16/H30MC24052 Agmt 10/31/2017 Agmt 11/21/2017 // W911NF-17-P-0017 Agmt 11/21/2017 // W911NF-17-P-0017 Agmt 12/31/21 // U10 EY14231 Agmt 12/19/16//W81XWH-16-1-0788 Agmt 12/4/15 Amd 1/W912HZ-15-C-0004 Agmt 21/61/2018 // 1R43QBM121130-01A1 Agmt 21/6/18 // 1R43QB02023025-01A1 Agmt 21/6/2018 Agmt 02/16/20 Agmt 2/19/13 Agmt 2/7/18 Agmt 217/18 Agmt 31/10/2017 // 400-72-04-33-15F1 Amd 2 AGMT 3/14/18/1R44CA224658-01 Agmt 3/26/2013 / 01 // FA8651-13-C-0018 Agmt 3/3/17//IR4AAG051299-01 Agmt 3/3/17//IR4AAS100173-01 REVISED Agmt 3/5/17//IR41AG064337-01 Agmt 3/5/1///K41AG054337-01 Agmt 3/7/2018 // N68936-17-C-0063 Agmt 4/13/18 Agmt 4/24/17//5U01NS090259-03 Agmt 4/25/14//U10HD036801 Agmt 4/3/2017 Agmt 5/22/2018 Agmt 5/22/2018 Agmt 5/30/16 // NNX16CM03C Agmt 57/30/16 // NIXX16CM03C Agmt 62/71/2 // DE-AC022-07CH11359 Rev 5 Agmt 67/17//R01HL098354 Agmt 7//7//R01HL098354 Agmt 81/16//DE-SC0015106 Agmt 81/3/12 / U01CA021115 Agmt 81/5/21/17 // IIP-1721594 Agmt 82/4/16 // 1R43HD085317-01 Agmt 82/4/16 // 1R43HD085317-01 Agmt 8/30/16-001 // 2R44Al118086-02 Agmt 8/31/2017 Agmt 8/31/2017 Agmt 8/9/2016//IIP-1622842 Agmt 9/13/2017 Agmt 9/13/2017 Agmt 9/13/2017 // W911NF-17-P-0059 Agmt 9/14/2017 Agmt 31/22/15 Agmt 31/22/15 Agmt 31/26/2017 Agmt 31/26/2017/S-IS400-16-GR-0042 Agmt 31/26/2017/S-IS400-16-GR-0042 Agmt 31/26/2017/12/10/INS095388 Agmt 51/26/27/12/10/INS095388 Agmt 51/26/27/12/10/INS095388 Agmt 51/26/18 Agmt 51/26/18 Agmt 51/26/18 Agmt 06/26/18 Agmt 06/26/18 Agmt 02/14 Agmt 02/14 Agmt 10/13/2017 (537/151) Aamt 9/23/15

Schedule of Findings and Questioned Costs

Table of Award Numbers Year ended August 31, 2018

Name of Federal Program or Cluster (CFDA #)

Research and Development Cluster (Various)

Award Number AGMT00000 775//11/01N104326-01 AGMT00000 775//10111011104326-01 AGMT-4/975/IS/PF01CA108671-08 Agr. 10/06/2015//SR44AR061920-03 Agr. 41/9/2016 //HISN27601500744P Agr. 87/14 // U01HL107407 AGREEMENT 3/0/16/ I H07HA288010100 Agreement 3/22/13/ 0/1/FA8651-13-C-0011 Agreement 3/26/13 / 01//FA8651-13-C-0011 Agreement 4/19/7018 Agreement 4/19/71/2012-VF-GX-K022 Agreement 8/27/18 //z R44 AT009156-02 Agreement 8/4/2017 // R44DC013093-03 AGREEMENT 8/18/16 Agreement signed 11/9/10 // 1U01NS026835-01A1 Agr/21/17/15/12705sub1/R01HS024273 AH000527//5R01DK100304-04 Amard 007/2014 Amouds27//SR01Dk100304-04 Amend. 005//SR44AA022265-03 Amgt. 08/31/17//1647888 ASI//2R44Al092952-02A1 AST-1109753/002 AST-1343381 AST-1352369 AST-1359462-003 AST-1/12836 AST-1412836 AST-1517246 002 AST-1517491 002 AST-1517753 AST-1547328 AST-1652522 AST-1715216 AST-1716762 AST-1716762 ASUB00000017/2017-ST-061-QA001-01 ASUB22/2018-68001-27550 ATHN2015-VW-1-5530 1 NU27DD001155-03-00 Award Letter 4/516 // 510560060562-06 BBN Ref ID 14303 PO #9500012297//CNS-1346688 BC 14303 PO #9500012297//CNS-1346688 BCS - 1749580 BCS-1251345 BCS-1251345 BCS-1423917 BCS-1424025 BCS-1430400 BCS-1440564 BCS-1455804 BCS-1461088 002 BCS-1461088 BCS-1528569 BCS-1533512 BCS-1546972 BCS-1613340 BCS-1630141 BCS-1634118 BCS-1647219 BCS-1728173 BCS-1728173 BCS-1729720 BCS-1732129 BCS-1734217 BCS-1734981 BCS-1806248 BCS-1812764 BCS-1823543 BI -4831218-NWUC//IIS-1636893 BL-4831218-IW/0C//IIS-1030693 BL-4831222-NU//BCS-1734853 BMC ID 6610//1R01CA224911-01A1 BMSSA-006 // 80NSSC17M0054 BOA 3J-30081 // 3J-30081-0066B BWH 09/22/16//U01AI063594 C00045065-5//W911NF-14-1-0359 C0045055-5/W911NF-14-1-C2015.0008 // DE-AR0000495 C2017.0013//DE-AR0000813 CBET-0835800 CBET-1055379 CBET-1264963 CBET-1265029 CBFT-1403036 CBET-1403058 CBET-1403058 CBET-1435228 CBET-1438721 CBET-1452549-003 CBET-1452576 CBET-1453576 CBET-1511450 CBET-1604890 CBET-1604890 CBET-1637764 CBET-16537164 CBET-1653315 CBET-1701105 CBET-1704996 CBET-1706125 CBET-1706642 001 CBET-1806007 CC 81347 3024//R01MH103910 CC 81347 3024//R01MH103910 CC 81765 CL 2910/90RE5010-03-00 CC# 81353 3037/90ER5013-01-00 CC# 81383 CL 4442//1R01HD082216-03 CC# 81394 CL 4811 // 1544741 CC# 81920 CL 3919/JCR01EB019406-03 CC#81730/CK01HD072080 CC#81930 CL 40980/JSR01HD081525-04 -04177 CC70HD07MC000 Ld 20 cc81478 6323//90SIMS0001-01-00 CCE-1216006 CCF-1216006 CCF-1409601 CCF-1422489/001 CCF-1423040

CCF-1453853 002 CCF-1453853 002 CCF-1526109 CCF-1533560 001 CCF-1533656 CCF-1618065-001 CCF-1618502 CCF-1619253 CCF-1637585 CCF-1652491 001 CCF-1652491 CCF-1733860 CCF-1814706 CCF-1834324 CCF-1834701 CDT-2013-6 Amd 4 // R33DC011174-02 CHE-1266201 CHE-1308107 CHE-1308107 CHE-1308504 CHE-1351598 CHE-1361173 CHE-1363007 CHE-1400596 CHE-1455017 CHE-1455017 CHE-1464488 CHE-1464916 CHE-1465045 CHE-1465201 CHE-1506683 CHE-1507790 CHE-1565925 CHE-1607640 CHE-1607640 CHE-1655187 CHE-1665184 CHE-1665021 CHE-1665141 CHE-1665255 CHE-1709888 CHE-1760537 CITR Agmt 4/22/2013 CL 4346 CC 81345 //5U01EB015410-02 CL3802, CC81039//90RT5027-01-00 CL5253/1R01HD083314 CMMI-1130948 CMMI-1234491 CMMI-1265786 CMMI-1324834 CMMI-1324834 CMMI-1334609 CMMI-1334929 CMMI-1335014 CMMI-1335585 CMMI-1351534-005 CMMI-1361942 CMMI-1400169 CMMI-1400618 CMMI-1400618 CMMI-1404489 CMMI-1405231 CMMI-1434834 CMMI-1434876 CMMI-1435065 CMMI-1435358 CMMI-1435950 CMMI-1436297 CMMI-1436518 CMMI-1436574 CMMI-1436658 CMMI-1462633 001 CMMI-1462850 CMMI-1463411 CMMI-1463489 CMMI-1463489 CMMI-1536503 CMMI-1537060 CMMI-1537641 CMMI-1562941 CMMI-1563244 CMMI-1603060 CMMI-1634982 CMMI-1634982 CMMI-1646592-002 CMMI-1654469 CMMI-1662233 CMMI-1662435 CMMI-1662606 CMMI-1663196 CMMI-1727744 CMMI-1727744 CMMI-1740011 CMMI-1742849 CMMI-1743691 CMMI-1743886 CMMI-1748049 CMMI-1762035 CMMI-1763100 CMMI-1763100 CMMI-1829101 CMMI-1833195 CNS-1228357 CNS-1314620 CNS-1319086 CNS-1329891 CNS-1405756 001 CNS-1408790 CNS-1408790 CNS-1419138 CNS-1441695 CNS-1526052

CNS-1615837 DMR-1610367.002 CNS-1615837 CNS-1619317 CNS-1651695 001 CNS-1701921 CNS-1718670 CNS-1821362 CONTRACT NO. 11841
 CONTRACT NO. 11841
 DMR-1629383

 CONTRACT PO #42045/236320/50105365//US2602000: DMR-17108254
 CMR-25355.15-004659//H14502602000
 DMR-17101824

 CTAPSS-S-15-004659//H145N261200800
 DMR-1710104
 CTAFYN067//AUH3TR000967-02
 DMR-1710104

 CTAINI067//REFIAG041845
 DMR-1720139
 D14PC00005/0001
 DMR-1720139

 D14PC00005/0001
 DMR-1729016
 DMR-1729016
 DMR-1729017

 DA2-17-62986-1//59-0210-2-160
 DMR-1729477
 DMR-1729477

 D011-05CH02
 DMR-1729478
 DMR-1729478

 D011-05CH02
 DMR-1729478
 DMR-1729478
 DBI-1256188 DBI-1256188 DBI-1353682 DBI-1353952/002 DBI-1757973 DD7-18096A // NAS8-03060 DD8-19101A//NAS8-03060 DE-AR0000702 DE-AR0000702 DE-E0008077 DE-EE0006082 // PO# TCS67912-001 DE-EE0006449-0008 DE-EE0008079 DE-EE0008089 DE-FE00200ER45610/0020 DE-FC0200ER45610/0020 DE-EG02-01ER45945 0018 DE-FG02-01ER45945 0018 DE-FG02-02ER15457 0015 DE-FG02-04ER156120013 DE-FG02-05ER46246 0014 DE-FG02-05ER46346 0012 DE-FG02-06ER46346 0012 DE-FG02-08ER15967-0008 DE-FG02-08ER15967-0008 DE-EG02-87ER13808/0033 DE-EG02-87ER25047/0030 DE-FG02-87ER25047/0030 DE-FG02-87ER40344 0039 DE-FG02-96ER14684-0020 DE-FG02-99ER14999-0019 DE-FG02-99ER45782-0019 DE-NA0002522 DE-NE0008409-0001 DE-NE0008409-0001 DE-SC0000989 0006 DE-SC0001059/0008 DE-SC0004752-0008 DE-SC0007456 DE-SC0010265 0004 DE-SC0010594 0003 DE-SC0012130-0004 DF-SC0012161 0004 DE-SC0012531/0001 DE-SC0012531/0001 DE-SC0014330 0002 DE-SC0014424-0003 DE-SC0014520-0002 DE-SC0015910 0002 DE-SC0015973 0002 DE-SC0016284-0002 DE-SC0016965 DE-SC0018985 DE-SC0017615 DE-SC0018092 DE-SC0018093 DE-SC0018249-P0001 DGE - 1842165 DGE-1324585 009 DGE-1450006-003 DGE-1450006-003 DGE-1723805 DMR-0907068 DMR-0907639 DMR-1121262 Amd 009 DMR-1207282 DMR-1207539/ Amd 003 DMR-1307698 DMR-1307698 DMR-1308654 Amd 002 DMR-1308799 DMR-1310292 DMR-133335 002 DMR-1334928 DMR-1334928 DMR-1351959 004 DMR-1351959 004 DMR-1408901-003 DMR-1410169 DMR-1410968 DMR-1454688 004 DMR-1505103 004 DMR-1505849 DMR-1506925-002 DMR-1507058 DMR-1507058 DMR-1507101 001 DMR-1507810-001 DMR-1508323 002 DMR-1508399-002 DMR-1508730-003 DMR-1508731/003 DMR-1539724 DMR-1600837 DMR-1600837 DMR-1602542 DMR-1608218 DMR-1608258

DMR-1610367 002 DMR-1610796-001 DMR-1611076 No. 001 DMR-1611308 DMR-1611341 DMR-1612876 DMR-1629383 DMR-1729487-001 DMR-1756245 DMR-1801632 DMR-1806912 DMR-1822422 DMS 1502632 003 DMS -1833295 DMS-0636574/005 DMS-1043080 DMS-1043080 DMS-1312935 DMS-1352173-004 DMS-1405516-002 DMS-1406024 DMS-1406164 DMS-1413786 DMS-1418672 DMS-1449300 DMS-1449300 DMS-1500670 DMS-1506591-001 DMS-1508040-002 DMS-1514698 DMS-1517080 DMS-1522747 DMS-1522981-001 DMS-1522981 DMS-1547394 DMS-1600023 DMS-1600654 DMS-1600718-001 DMS-1610278-002 DMS-1612437 DMS-1619748 DMS-1619748 DMS-1620022 DMS-1647351 DMS-1653552 DMS-1700147 DMS-1700819 DMS-1702019 DMS-1708503 DMS-1708303 DMS-1709544 DMS-1709894 DMS-1710481 DMS-1716114 DMS-1720433 DMS-1744209-001 DMS-1747457 DMS-1764421 DMS-1800544 DMS-18000344 DMS-1802037 DMS-1809011 DMS-1810644 DMS-1812057 DRI -1020316 Amd 005 DRL-1020316 A DRL-1251516 DRL-1252121 DRL-1252372 DRL-1344266/00 DRL-1348800 DRL-1418020 DRI -1420599 DRI -1433724/001 DRL-1433724/001 DRL-1451762 003 DRL-1515788-002 DRL-1612619 DRL-1614745 DRL-1623550-01 DRL-1640201 003 DRI -1657438 DRL-1657438 DRL-1661089 DRL-1661264 002 DRL-1713368 DRL-1723750 DRL-1759360 DRL-1824551 DUE-1504952 DUE-1525725 DUE-1525725 DUE-1644555 EAR-1338312-005 EAR-1344280 EAR-1452344-002 EAR-1541891 EAR-1550108 FAR-1613359 EAR-1013339 EAR-1734300 ECCS-1505409 ECCS-1542205 ECCS-1607838

105

Schedule of Findings and Questioned Costs

Table of Award Numbers Year ended August 31, 2018

Name of Federal Program or Cluster (CFDA #)

Research and Development Cluster (Various):

Award Number ECCS-1611356 ECCS-1748339 EDSR 1/23/2018 EDSR 5/11/18 EEC-1530734 FFMA-1830961 EFRI/EFMA-1240416-004 EFRUEFMA-1240416-004 EFRU-1433510 EH13-344-52//SR21H100915-04 REVISED EH14-410-52//SR21H126015-02 Revised EH15-160-7.52//SR21H126015-02 EH15-160-11/SR01H1160575-03 EH15-6011-S1 Amd 3//SR01GM112715-03 EH15-6011-S1 Amd 3//SR01GM112715-03 EH17-147-S1//1R01HI 137920-01A1 EH17-256-S2//1R01HD092446-01A1 EH17-256-52//1R01HD092446-017 F0276-01 // CBET-1706562 F720161001s1 // DE-FE0027584 F8568sc//5U54NS092089 F8595-01 02 // W911NF-16-1-0262 FA2386-13-1-4124 Mod. P00003 FA8650-15-2-5518 P00008 P000011 P000012 FA8650-15-2-5518 P00008 FA8650-18-1-7810 FA9550-12-1-0141/P00003 FA9550-12-1-0280/P00005 FA9550-13-1-0192 FA9550-14-1-003-P00006 FA9550-14-1-003-P00006 FA9550-14-1-0032-P00003 FA9550-14-1-0274 P00003 FA9550-14-1-0358 FA9550-14-1-0368 FA9550-15-1-0031/P00002 FA9550-15-1-0044 P00002 FA9550-15-1-0247 P00002 FA9550-15-1-0377 P00002 FA9550-16-1-0138 P00002 FA9550-16-1-0150 P00002 FA9550-16-1-0236 FA9550-16-1-0379-P00001 FA9550-16-1-0379-P00001 FA9550-17-1-0089 P00001 FA9550-17-1-0247-P00001 FA9550-17-1-0271 FA9550-17-1-0348 P00001 FA9550-17-1-0352 FA9550-18-1-0159 FA9550-18-1-0159 FA9550-18-1-0252 FA9550-18-1-0252 FA9550-18-1-0259 FA9550-18-1-0401 FDP2R01DC012288-06 FP00000825_SA003//7R01HL128173-02 FP035726-02-H//5P30DK020595-40 FP037911//5T32HS000084-20 FP038885//R01NS62771 FP038885//R01NS62771 FP052801-C//SR01MH100155-05S1 FP052975//1R01DA035430-03 FP053700-3//P01HD076816 FP055658//5R01DK103014-04 FP058473/7R01ES015024 FP059116-B // FA9550-15-1-0162 FP060024 Amd 1 // 1R01EY025957-01A1 FP060211//R01NS095162 FP060211//K01NS093162 FP061138//1U01CE002712-01 FP063753 // DMS-1639761 Amd 1 FP063797-1//R01NS093908 FP064388-02//1R34HL136991-01A1 FP064397//R21MD011439 FP06439///X21MDU11439 FP06439//X216-ULFX-0002 FP06459//U01CA217078 FP065282-E///UL1TR002389-01 REVISED FP066297-02-PR-B//1R01CA223662-01A1 FP066297-02-PR-B//1R01CA223662-01A1 FP06629-70-2PR-B//1R01A136056-01 FP06835-A/I R01A136056-01 FUly-executed 11/13/13 FX-ATRAC-NWU-04/AP50HL120163-04 FX-ATRAC-NWU-05/SP50HL120163-05 FY14TN011/10UM1A109565-05 FY17.090.001/I5UH2AR067681-03 FY17TN165//5UM1A109565-05 FY18TN193//5UM1A109565-05 FY18TN193//5UM1A109565-05 FY18ITN158//5UM1AI109565-05 FY19.954.001//7R01HI 133504-03 FY19.954.001/778011L133504-03 G001534-7505 // HR0011-16-C-0028 Amd No. 1 G08-19025X //NAS8-03060 G08-19047A//NAS8-03060 G8110253 15553//SU01NS069498-07 GC12107-149595//U01NS069498 GENFD0007484300//1R01HG010004-01A1 GMO160216//5U01DK058369-18 GMO-161131//5U01DK058369-1 GMO-161131//5U01DK058369-17 GMO-170910//5U01DK058369-18 GO5-16059A//NAS8-03060 GO6-17052A//NAS8-03060 GO6-17054A//NAS8-03060 GO6-17054A//NAS8-03060 GO7-10462/MAS8-03060 GO7-18046A//NAS8-03060 GO7-18057X // NAS8-03060 GO8-19044X // NAS8-03060 GO8-19044X // NAS8-03060 GR101471 CON-8000 1218//DE-AR000087 HAA-258799-18

HDTRA1-14-1-0014 P00005 HDTRA1-14-1-0014 P00005 HDTRA1-15-1-0052 P00006 HDTRA11810003 heGO5-16064A//NAS8-03060 HHSF223201510126C//0004 HHSR261200800001E/11XS088 HHSN261201200035I/HHSN26100007 HHSN261201500013C HHSN261201700003C HHSN261201700003C HHSN268201300027C HHSN268201800003I HHSN271201700289P HHSN271201800190F HHSN271201800279P HHSN272201200026C HISN2722013-15-0045 Task B HHSN2722013-15-0045 Task B HHSN272201600016C HHSN272201700060C HHSN275201300013C HHSP233201500035l/50525S05679 HR0011-15-C-0084
 IRIO01175-C-0064

 HR0011170005

 HR0011172-20044-P00003

 HR01147146

 HST-AR-13910.001-A/INAS5-26555

 HST-AR-14292.001-A

 HST-AR-14292.001-A/INAS5-26555

 HST-AR-14552.001-A/INAS5-26555

 HST-AR-14562.001-A/INAS5-26555

 HST-AR-14562.001-A/INAS5-26555

 HST-CO-14681.011-A/INAS5-26555

 HST-CO-14681.011-A/INAS5-26555

 HST-CO-14685.007-A/INAS5-26555

 HST-GO-14685.007-A/INAS5-26555

 HST-GO-14685.007-A/INAS5-26555

 HST-GO-14685.007-A/INAS5-26555

 HST-GO-14685.007-A/INAS5-26555

 ICO-14680.007-A/INAS5-26555

 ICO-14691.011-A/INAS5-26555

 ICO-14691.011-A/INAS5-26555

 ICO-14690.001-A/INAS5-26555

 ICO-14690.001-A/INAS5-26555

 ICO-14690.001-A/INAS5-26555

 ICO-14690.001-A/INAS5-26555

 ICO-14690.001-A/INAS5-26555

 ILA-14600.31

 ILA-14600.13
 HR00111710005 IIA-1460143 IIA-1460143 IIP-1500222 001 IIP-1500314 001 IIP-1534120-002 IIP-1534138 IIP-1624823 IIP-1640736 IIP-1640736 IIP-1764312 IIS-1208118 IIS-1217143/005 IIS-1217225 IIS-1217302/001 IIS-1239599 IIS-1302422 IIS-1351029 005 IIS-1417819 IIS-1417819 IIS-1420971 IIS-1426961 IIS-1427419-005 IIS-1438813 IIS-1441552 IIS-1453192 IIS-1464315 IIS-1464315 IIS-1514427 IIS-1518602 003 IIS-1522921 IIS-1527921 IIS-1530833 IIS-1530837 IIS-1545751 IIS-1545751 IIS-1547880-002 IIS-1550051 IIS-1551574/002 IIS-1555805 IIS-1617387 001 IIS-1617468 IIS-1617497 IIS-1617497 IIS-1618096 IIS-1619078 IIS-1623635 IIS-1636909 IIS-1702440 IIS-1707296 002 IIS-1707319 IIS-1707319 IIS-1717330 IIS-1717951 IIS-1735977 IIS-1745399 IIS-1748375 IIS-1755628 IIS-1755873 IIS-1824536 IIS-1824536 IIS-182254 JJNWU-STAMINA-NU 03//5DW43TW010130-03 IN-4370124-NU // LG-96-18-0044-18 IN4681903NW//5R011502318-02 IN4684739NWU/1821CA198409-02 IN4687739NU//5U01HG007762-03 IN4687826NW//2R01HL111656-06 IN4688176NW//5R01AG0542493-02 N4689683NW//5R01Al114435-02 IOS-1456623 IOS-1456830

IOS-1456837 IOS-1456837 IOS-1516235-001 IOS-1557495 IOS-1558068 IOS-1708518 ICS-1708518 IPA Agmt - 578/151 IPA Agmt Signed 01/25/18 IPA Agmt Signed 02/10/17 IPA Agmt Signed 04/12/2017 IPA Agmt Signed 05/31/2017 (578/151) IPA Agmt Signed 05/31/2017 IPA Agmt Signed 08/28/2017 IPA Agmt Signed 10/06/2016 IPA Agmt Signed 11/06/2016 IPA Agmt Signed 10/06/2016 IPA Agmt Signed 11/09/2017 IPA Agmt Signed 11/09/2017 IPA Agmt Signed 11/09/2017 IPA Agmt Signed 11/13/2017 IPA Agmt Signed 04/12/2017 IPA Agmt Signed 04/12/2017 IPA Agmt Signed 04/12/2017 IPA Agmt. Signed 05/09/18 (537/151) IPA Agmt. Signed 07/06/2016 IPA Agmt. Signed 09/19/2017 (YR 02) IPA Agmt. Signed 19/09/27/2016 IPA Agmt. Signed 11/09/17 IPA Agmt. Signed 11/09/17 IPA Agmt. Signed 11/09/17 IPA Agmt. Signed 12/06/17 (537/151) KK150200 (2011) (537/151) KK150200 (2011) (537/151) KK1623 03 // W911NF-15-1-0577 KK1804 // DE-SC0012541 KK1804 // DE-SC0012541 Letter 10/14/14 MAPS2-14-029 //AID-OAA-A-14-00010 MAPS2-15-056//AID-OAA-A-14-00010 MASter JS-056//AID-OAA-A-14-00010 Master Agmmt 2/27/12/ U10NS077271 MCB-1121872 MCD-410560 MCB-1413563 MCB-1515981 001 MCB-1515981 001 MCB-1614953 MCB-1650040 002 MCB-1716766 MCB-1745753 MCB-1748307 MCW Signed 11/09/17/11U24NS100648-0 MED0035/W9110Y-12-C-0039 Mod 11/2UM140058058-10 Mod. 4/PS425707/IU01HL123338-05 MUSC14-024//5T15HD074546-07 MUSC16-102-8A028 // FS010K089222-05 MUSC16-102-8A028 // FS010K089222-05 MUSC16-102-8A028 // FS010K08922-05 MUSC16-102-8A028 // FS010K08922-05 MUSC16-102-8A028 // FS010K08922-05 MUSC16-102-8A028 // FS010K08922-05 MCB-1748307 MUSC18-033-8D222/2R25HD074566-07 N00014-13-10331-P00002 N00014-14-10331-P00002 N00014-14-10594 // N00014-16-1-2132-P00002 N00014-15-10594 // N00014-16-1-2132-P00002 N00014-15-1046/P00002 N00014-15-1046/P00002 N00014-15-1-2443-P00002 N00014-15-1-2443-P00002 N00014-15-1-2701-P00005 N00014-15-1-2735 P00002 N00014-16-1-2106-P00001 N00014-16-1-2177 P00002 N00014-16-1-2251 P00005 N00014-16-1-2280-P00007//N00014-16-1-2280 N00014-16-1-2400 P00001 N00014-16-1-2400 P00001 N00014-16-1-2402 P00003 N00014-16-1-2613-P00002/N00014-13-1-0470 N00014-16-1-2715 P00002 N00014-16-1-2838 P00002 N00014-16-1-3802 P00002 N00014-16-1-3802 P00002 N00014-16-1-3055 N00014-16-1-3117-P00001//N00014-15-1-0043 N00014-16-1-3117-P00001/ N00014-16-1-3175 P00003 N00014-16-1-3179 N00014-17-1-2092 P00003 N00014-17-1-2231 P00004 N00014-17-1-22319 N00014-17-1-22319 N00014-17-1-24309-P00002 N00014-17-1-2425 P00003 N00014-17-1-2425 P00003 N00014-17-1-2482 P00002 N00014-17-1-2688 N00014-17-1-2670 P00002 N00014-17-1-2870 N00014-17-1-2993 P00002 N00014-17-1-3023 N00014-17-1-3024 N00014-17-1-3024 N00014-18-1-2089-P00001 N00014-18-1-2097 P00001 N00014-18-1-2098 P00001 N00014-18-1-2102 N00014-18-1-2131 N00014-18-1-2131 N00014-18-1-2135 N00014-18-1-2316 P00001 N00014-18-1-2508 N00014-18-1-2594 N00014-18-1-2594 N00014-18-1-2651 N000266389 // DE-NA0002839 N00244-16-2-0002

N002854801//1U01AI1102463-01 N002854801/1001A11024634 N004761502//1U01A1120130-04 M660011824026-P00002 NIAMS//1R41AR069416-01A1 NN104//U01NS088312 NNX13AM10G/000003 NNX14AD21G 000005 NNX14AH26G-000005 NNX14AH26G-000005 NNX14AP92G/000005 NNX15AB22G-000002 NNX15AL05G 000010 NNX15AM08G 000002 NNX15AM32G 000008 NNX15AR24G 000007 NNX16AE02G 000003 NNY1641784 NNX16AL/8A NNX16AL31G-000001 NNX16AL94G-000001 NNX16AT51G NNX16AT58G NNX16AT81G NNX17AC09G NNX17AC09G NNX17AC44G-000002 NNX17AD48G 000002 NNX17AD82G NNX17AD89G NNX17AE10G-000001 NNX17AG80G NNX17AI13G No 634049//DE-AC02-07CH11359 No. 634049//DE-AC02-07CH11359 No. 86101156 Amd 1 // FA8650-17-C-9112 No.EL-1007-01-01//R01FD005396 NRC-HQ-60-14-G-0003 M0007 NRC-HQ-60-14-G-0003 M0007 NRC000-18-C-0098 NU-2017-001//DQL-09FS-15-C-0060 NU-2017-001//DQL-09FS-15-C-0060 NWU025865-2565//5R01DE025865-02 NWU-182824/PO#65461505//U54DK083908 NWU-182824/PO465461505/U54DK NWU-187276-02//5U01NS080168-03 NWUHL098115 // 5U10HL098115 NWUHL098115 // 5U10HL098115 NXS-17-001 // AID-OAA-A-17-00014 OAC-1740142 OAC-1811605 0058-0743748 0058/030239NUCS113726//1R56ES028121-0 058/2018042//1R01DK115890-01 P.0. 1210/N00014-14-C-0050 P010178624017FH611-22-00050 P010178624017FH611-22-00050 P010178624041/07FH6116D00030 P010198023 NO. R3 // DTFH6116D00030 P010198023 R1 // DTFH6116D00030 P010198023 R0 R3 // DTFH6116D000 OISE-1743748 Pape 0020//W81XWH-14-1-0568 Pape-0024//W81XWH-15-1-0516 PHY-1307020/002 PHY-1404455-002 PHY-1520916-002 PHY-1550658-002 PHY-1607709 0002 PHY-1708153 PHY-1734332 PHY-1734332 PHY-1806671 PHY-1806686 PHY-1809730 PHY-1826505 PLR-1304675 PLR-1304686/002 PI R-1454734 PNU-001//1534743 PNU-001///534743 PO 12743/W912H217C0027 PO 12909/W912H217C0027 PO 3100545485 135408-CT1-OMEGA//5U54AI117804-04 PO 3100545486 135409//5U54AI117804-04 PO 3880/2/PO1AI048240-12A1 PO 505026677 00001 // FA8550-15-C-7561 PO 2090020677 00001 // FA8550-15-C-7561 PO 8200206547 01 // W911NF-17-C-0024 PO No. 622384-1 PO No. 631010 Rev 1 // DE-AC02--07CH11359 PO No. 63303 // DE-AC02-07CH11359 PO No. 637604 // E939-6264-02 PO No. 64721 // DE-AC02-07CH11359 PO No. 64727 // DE-AC02-07CH11359 PO No. 64727 // DE-AC02-07CH11359 PO No. 64727 // DE-AC02-07CH11359 PO No. 400620170 // OSP2017053 Amd 1 // 5U54DK11 POF 640728 // B935-5264-02 PO# LBN9510212-0034 // W911NF-09-2-005 PO#424012056 (1) 0520 PO#424012056 (1) 0520 PO#424012056 (1) 0520 PO#63288/6156/TA-CA-15-008-06 PO2630356/JMDE-AR0000498 PO653386-31103A // 5U19A1103461-06 PR-258900-18 PO 8200206547 01 // W911NF-17-C-0024 PO659386-31103A // 5U19A1 PR-258900-18 R01834 // R324A160193 R-17-0021 // 7R01GM115632 R24NS086549-NU Amd 2 R284/1R21AR068035-02

Schedule of Findings and Questioned Costs

Table of Award Numbers Year ended August 31, 2018

Name of Federal Program or Cluster (CFDA #)

Research and Development Cluster (Various):

Award Number R305A120531-15-7 R305A120531-15-7 R305A160013 -17 R305B100027 - 14 R305B140029 - 16 R305B140042 - 17 Mod 4 R305B170016 R305D170041 - 17A R33CA225323 R33CA225323 R924//SR01 DC009972-09 RC103138NW//DUE-1347605 RC105782NU//SR01CA193706-03 RC106479NU//1632051 RC107136NU//1654929 Require5P30AR072579-02 RES126034 Amd 2//R01HI 124245 RES509477//DP3DK104438 RES50947///DF3DK104438 RES511132//4U01DK094157-06S1 RES511975/JRR01CA211762-02 RES512231/2U01DK094157-07 REVISED RES512302//1U01AR071168-01A1 REVISE RES512393//5U01NS090407-04 RES512561//2U01DK094157-07 REVISED RE5512561//2U01DK094157-07 REVISED RE5512878/2U01DK094157-07 REVISED RE5512878/2U01DK094157-07 REVISED RE5513371//2R01NS082007-07 RG884-G2 Amd 1/ R01HL130619 RNG20027-05//R01DK106201 RQ15-018R02 Mod 2//DE-EE00068867 RR211-536/S001474/1R01Al128924-01A1 RR376-410/4708620 Amd 3 // 2R01HD03058820A1 RR376-428/4945376 Amd 6 // 2P30DA027827-06 RR376-428/4945376 Amd 6 // 2P30DA02782 RSA No. 1594471 // NNNH2AA01C S-00014999 // R305A170165 S-000700 Amd 6 // USAF FA9550-15-1-009 S002//2R01NS047567-13A1 S140181-2 Amd. 3 // SR01A1112009-04 S2014000026205// 5R01MD007723-03 S4526-PO176307//1R03HD092676-01 S4326+70176307/// IROSHD092676-1 S51110000040313//7R01HL125089 SA17-0018-S001//1618244 SC160072//W81XWH-17-1-0340 SES-0750621/003 SES-1129475 SES-1151410/003 SES-1254380-005 SES-1260949 SES-1260949 SES-1324778 SES-1356899 SES-1359610 001 SES-1427035 SES-1456984 SES-1530534 SES-1530608 SES-1530748 SES-1530748 SES-1556343 SES-1628057 SES-1628126 SES-1637182 SES-1655382 SES-1702602 SES-1703056 SES-1703036 SES-1730079 SES-1730483 SES-1738297 SES-1824463 SES-1840443 SMA(SBE)-1451416-006 SMA(SBE)-1451416-006 SMA-1419324 SOF 05-0081 Santos // NAS2-97001 SOFIA 05-0133 01 // NAS2-97001 SOFIA 05-0133 01 // NAS2-97001 SP00012129-01// IR01GM115763 SP0031902-60041063//1D43TW010134-03 SPC-000246//5R01NS084288-05 SPC-000886//7R01Al28782-03 Study# 2222/0003//1U01HL117006-01A1 SUB 5.22.17//5U01HL130163-02

Sub No. 4471 CC81932//W81XWH-15-2-0035 Sub No. 44/1 CC81932//W81XWH-15 Sub# 12305-52//3P30CA006927-50SB Sub#00003339//HHSN261201200034I Sub#00003350//HHSN261201200034I Sub#2002749092//5U10EY024527-04 Sub#3003585891//5R01EB013198-09 REVISED SUB#567266//5UM1HL116886-03 REVISED SUB#S67266//SUM1HL116886-03 REVISEL SUB: 10009/SUM1A1068636-12 SUB0000078 Amd. 5 // W911NF1510421 SUB00000853/RC5-1519120 SUB-01/IHSHQDC-14-R-B0009 Subk No. 1478794 Mod 14 // NNN12AA01C T539496//R21NR014544 T652681//4U01NS038455-15 T733841//5R01NS088528-04 T745243//1P01AG054079-01 1745243//1R01AG054079-01 T811257//5U01DA036233-05 T897810//1R01AG057714-01 Revised T91HP215420502 TM6-17005X//NAS8-03060 TM7-18007X//NAS8-03060 TO#2 P0#10203492 //D5EH6116D00053 TO#2 P0#10203492 //D5FH6116D00055 TUL-HSC-558811-71/H1/U01HD052104 U10CA180820-01-NWU2 U10CA180820-01-NWU2 UFDSP00010117//R01HL121023 UFDSP00010117//R01HL121023 UFDSP00010414 // R01GM107227-03 UFDSP00010684//U01AG022376 UEDSP00011459//R01CA200867(2) LIEDSP00011851//U01AG050499 UFDSP00011851/1001AG050499 UFDSP00011999/U54AR052646 UFDSP00011947//U01NS102038 UFDSP00012107//R01CA187109/16122063 UFDSP00012338//W912HQ18C0039 UFDSP0011905//U54AR052646 UNIV59587//5R01DK050203-20 USTTB/NU/1R01Al1110386-02-2016 USTTB/NU//R01AI110386-02-2016 UTA16-000087 Amd. 1// R01HD083613-01A1 UWSC10113//838300001-0 UWSC8225/BPO2840/5R01NS085331-03 UWSC8429 / K01A1095060 UW206200/D01UW20620 01 UWSC8533//1R01HL127659-01 UWSC8539//HHSN268201500003 UWSC8539//HISN268201500003 UWSC8836//2R01FD003704-03A1 UWSC9381//5R01HL096875-06 UWSC9610//5R01AI128782-02 VUMC 57993//5R01CA202936-04 VUMC 588371/5R25TW009337-06 VUMC 59440//5R01HL133860-02 VUMC60724//5U2COD023196-02 VUMC60724//5U2COD023196-02 VUMC62776//1001Al32004-01 VUMC64676//7R01MH106511-03 VUMC65034/5U2COD023196-02 VUMC66624//2U01HG008672-04S1 W000941480/1R01EY026817-01A1 W81XWH-13-1-0319 W81XWH-13-2-0100 W81XWH-14-2-0193 W81XWH-14-2-0193 W81XWH-15-1-0214 W81XWH-15-1-0215 W81XWH-15-1-0335 W81XWH-15-1-0534 W81XWH-15-1-0708 W81XWH-15-1-0708 W81XWH-16-1-0708 W81XWH-16-1-0169 W81XWH-16-1-0375 W81XWH-16-1-0375 W81XWH-16-1-0379 W81XWH-16-1-0733 W81XWH-16-1-0733 W81XWH-16-1-0763 W81XWH-16-C-0012 W81XWH-17-1-008

W81XWH-17-1-0141

W81XWH-17-1-0230 W81XWH-17-1-0230 W81XWH-17-1-0362 W81XWH-17-1-0405 W81XWH-17-1-0406 W81XWH-17-1-0411 W81XWH-17-1-0578 W81XWH-17-1-0608 W81XWH-17-1-0642 W81XWH-17-1-0642 W81XWH-17-1-0679 W81XWH-17-1-8426 W81XWH1810053 W81XWH1810257 W81XWH1810594 W911NF-11-1-0390 P00011 W911NF-11-1-0445/P00004 W911NE-12-1-0542/P00008 W911NF-12-1-0542/P0008 W911NF-13-1-0229 P00010 W911NF-13-1-0412/P00002 W911NF-14-1-0168/P00008 W911NF-14-1-0259-P00004 W911NF-14-1-0461-P00006 W911NF-14-1-0461-P00006 W911NF-15-1-0017 P00004 W911NF-15-1-0017 P00006 W911NF-15-1-0081P00006 W911NF-15-1-0091 P00006 W911NF-15-1-0151 P00006 W911NF-15-1-0240 P00004 W911NF-15-1-0272-P00003 W911NF-15-1-0569 P00001 W911NF-15-1-0569 P00001 W911NF-16-1-0138 P00003 W911NF-16-1-0159 P00004 W911NF-16-1-0372 P00002 W911NF-16-1-0372 P00002 W911NF-16-1-0410 P00005 W911NF-16-1-0458 W911NF-16-1-0458 W911NF-16-1-0464-P00004 W911NF-16-1-0464-P00004 W911NF-16-1-0584 P00001 W911NF-17-1-0184 W911NF-17-1-0233 P00001 W911NF-17-1-0436 P00002 W911NF-17-1-0430 P00001 W911NF-17-2-0054-P00002 W911NF-18-1-0006 P00001 W911NF-18-1-0035 W911NF-18-1-0035 W911NF-18-1-0050 W911NF-18-1-0129 W911NF1810181 W911NF1810200 W911NF1810394 W911NF1810429 W911NF-18-2-0074 W911NE-18-2-0074 W91YTZ-13-C-0015/3004730431 WA00368827/RFA2015095 WA00406355-RFS2015140//5R01HL125089-02 WFUHS141462/R01CA218398 WFUHS141462/R01CA218398 WFUHS41012 SR-02/W81XWH-13-2-0054 WFUHS441082CF129W81XWH1420004 wFUHS441082CF129W81XWH1420004 Work Order No. 3J-30081-0067A Rev No. 0067B Work Order No. 3J-30081-0067A Rev No. 0067B WU-10-154 Amendment 04 //R01AR055176-02 WU-16-153-MOD-1//5R01NS091439-02 WU-18-261/UG3HL138325 WU-19-11//IR01MH113883-01A1 WU-HT-11-05-MOD-9 Amd 9 // DE-SC0001035 XEJ-6-62151-01-1 Mod. 3 // DE-AC36-08GO28308 Yale 2.23.2017//R01HL125918

Northwestern FINANCIAL OPERATIONS

SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS NORTHWESTERN UNIVERSITY For Year Ended August 31, 2018

2017-001 Enrollment Reporting

Corrective Action Plan:

Management notes that there was an error in the submission of graduate degrees to the Clearinghouse. As a result, a student was missed in the submission of conferred degrees. In response to this finding, management has created a query that is run weekly on newly conferred graduates. This file ensures no graduates are missed and all data is appropriately reported to the Clearinghouse.

Expected Implementation Date: October 18, 2017

Fully	Partially	Not	Change in	No Further
Corrected	Corrected	Corrected	Plan	Action/Other
Х				

Explanation (if required): N/A

Northwestern

Federal Award Findings and Questions Costs Corrective Action Plan Year Ended August 31, 2018

Finding No. 2018-001: Inadequate Process for Updating Property Management Records

CFDA Numbers: Various Program: Research and Development Cluster

Corrective Action: Exceptions noted during external audit interim fieldwork were corrected for fiscal year end close. Additional efforts to identify and record potential missing disposals for the fiscal year 2018 re-inventory process were also implemented (as described below in steps 1-4).

In fiscal year 2019, Accounting Services shall reiterate proper procedures to department Unit Representatives regarding the disposition of equipment, including timely submission of disposal requests.

In addition, Accounting Services shall continue the following steps introduced in summer 2018 designed to enhance controls around completeness and accuracy of disposals:

- 1. Department representatives submit individual asset disposal requests through NU Financials.
- 2. Department representatives submit biennial re-inventory sheets to Accounting Services.
- 3. Accounting Services compares disposals per the biennial re-inventory sheets to requests per NU Financials for completeness and accuracy.
- 4. Accounting Services then follows up on discrepancies with department representatives as necessary. Note: Previously, Accounting Services made the disposal entries based on the biennial re-inventory sheets alone.

Further in fiscal year 2019, Accounting Services shall perform its own audit of the re-inventories prepared by the department Unit Representatives. This entails judgmentally selecting assets from the re-inventory sheets, and verifying the existence of assets and accuracy of the information (e.g., location, custodian, etc.) through observation. Accounting Services will judgmentally gear its sample towards higher risk items, including higher dollar values and older assets. In addition, Accounting Services' audit sample size shall increase to address risks highlighted from this control activity observation.

Contact Person:Nicole Van LaanExpected Implementation:August 31, 2019

Finding No. 2018-002: Untimely Completion of Subrecipient Single Audit Desk Reviews

CFDA Numbers: Various Program: Research and Development Cluster

Corrective Action: The University has implemented necessary steps to ensure that the desk reviews, and issuance of management decisions, if necessary, will be made within 6 months of the audit report acceptance date from the Federal Audit Clearinghouse (FAC).

Contact Person:Jennifer MitchellExpected Implementation:May 31, 2019